[
  {
    "chunk_id": "402a36df_0000",
    "doc_id": "402a36df",
    "filename": "amoxicillin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "AMOXICILLIN - Complete Medication Guide",
    "drug_name": "Amoxicillin",
    "chunk_index": 0,
    "text": "AMOXICILLIN - Complete Medication Guide\n\nGENERIC NAME: Amoxicillin\nBRAND NAMES: Amoxil, Moxatag, Trimox\n\nDRUG CLASS: Penicillin Antibiotic (Aminopenicillin)\n\nMECHANISM OF ACTION:\nAmoxicillin is a bactericidal antibiotic that works by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) inside the bacterial cell wall, inhibiting the transpeptidation step of peptidoglycan synthesis. This weakens the cell wall and leads to osmotic lysis and death of susceptible bacteria. Amoxicillin is effective against gram-positive and some gram-negative bacteria.\n\nINDICATIONS AND USAGE:\n- Upper respiratory infections: Pharyngitis, tonsillitis, sinusitis, otitis media\n- Lower respiratory infections: Bronchitis, pneumonia\n- Skin and skin structure infections\n- Urinary tract infections (UTI)\n- Helicobacter pylori eradication (with other medications)\n- Lyme disease (early stages)\n- Prophylaxis for bacterial endocarditis (dental procedures)\n- Anthrax exposure (post-exposure prophylaxis)\n\nCOMMON BACTERIA COVERED:\n- Streptococcus pneumoniae\n- Streptococcus pyogenes\n- Haemophilus influenzae\n- Escherichia coli\n- Proteus mirabilis\n- Salmonella species\n- Enterococcus faecalis\n- Helicobacter pylori\n\nDOSAGE GUIDELINES:\nAdults:\n- Mild to moderate infections: 250-500 mg every 8 hours\n- Severe infections: 875 mg every 12 hours\n- Maximum dose: 2-3 grams per day\n\nChildren (based on weight):\n- 20-40 mg/kg/day in divided doses every 8 hours\n- 25-45 mg/kg/day in divided doses every 12 hours\n- Maximum: 2-3 grams per day\n\nSpecial populations:\n- Renal impairment: Dose adjustment required for CrCl <30 mL/min\n- Hemodialysis: Administer after dialysis\n- Elderly: Use normal adult dosing unless renal impairment\n\nCONTRAINDICATIONS:\n- Known hypersensitivity to penicillins or beta-lactam antibiotics\n- History of severe allergic reaction to cephalosporins (cross-sensitivity)\n- Infectious mononucleosis (increased risk of rash)\n\nWARNINGS AND PRECAUTIONS:\n- Anaphylaxis: Serious allergic reactions can occur (0.01-0.05% of courses)\n- Cross-sensitivity: 10% cross-sensitivity with cephalosporins\n- Clostridium difficile-associated diarrhea: Can occur during or after treatment\n- Superinfection: Prolonged use may cause fungal or bacterial overgrowth\n- Jarisch-Herxheimer reaction: In treatment of Lyme disease or syphilis\n- False-positive urine glucose tests (copper reduction method)\n\nCOMMON SIDE EFFECTS:\n- Diarrhea (most common, 5-10%)\n- Nausea and vomiting\n- Abdominal pain\n- Rash (especially in patients with mononucleosis)\n- Vaginal yeast infection\n- Headache\n- Altered taste",
    "word_count": 351,
    "metadata": {
      "doc_id": "402a36df",
      "filename": "amoxicillin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "AMOXICILLIN - Complete Medication Guide",
      "drug_name": "Amoxicillin",
      "source": "medical_document",
      "word_count": 702,
      "char_count": 5180
    }
  },
  {
    "chunk_id": "402a36df_0001",
    "doc_id": "402a36df",
    "filename": "amoxicillin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "AMOXICILLIN - Complete Medication Guide",
    "drug_name": "Amoxicillin",
    "chunk_index": 1,
    "text": "SERIOUS SIDE EFFECTS (seek medical attention):\n- Severe allergic reaction (anaphylaxis): difficulty breathing, hives, swelling\n- Clostridium difficile diarrhea: watery/bloody diarrhea, abdominal cramping\n- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis\n- Seizures (especially with high doses or renal impairment)\n- Hepatitis or cholestatic jaundice (rare)\n- Interstitial nephritis (rare)\n\nDRUG INTERACTIONS:\n1. Probenecid: Increases amoxicillin levels (used intentionally)\n2. Methotrexate: Decreased methotrexate elimination, increased toxicity\n3. Oral contraceptives: Possibly reduced contraceptive efficacy (use backup method)\n4. Allopurinol: Increased risk of rash\n5. Warfarin: May increase INR (monitor closely)\n6. Typhoid vaccine: Reduced vaccine efficacy\n7. Tetracyclines: May interfere with bactericidal action\n\nPREGNANCY AND LACTATION:\n- Pregnancy Category B: Generally considered safe\n- Crosses placenta but no evidence of fetal harm\n- Excreted in breast milk in small amounts\n- Generally compatible with breastfeeding (may cause diarrhea in infant)\n\nPHARMACOKINETICS:\n- Absorption: Rapidly and well absorbed (75-90% bioavailability)\n- Food effect: Not significantly affected by food\n- Peak levels: 1-2 hours after oral dose\n- Distribution: Widely distributed; crosses placental barrier\n- Protein binding: 17-20%\n- Metabolism: Partial hepatic metabolism\n- Half-life: 60-90 minutes (prolonged in renal impairment)\n- Excretion: 60-80% excreted unchanged in urine\n\nSPECTRUM OF ACTIVITY:\nGood activity against:\n- Streptococcus species\n- Enterococcus faecalis\n- Listeria monocytogenes\n- E. coli (non-ESBL producing)\n- Proteus mirabilis\n- Salmonella species\n- Helicobacter pylori\n\nLimited activity (resistance common):\n- Staphylococcus aureus (many strains resistant)\n- Klebsiella species\n- Pseudomonas aeruginosa\n- Anaerobes (better coverage with ampicillin-sulbactam)\n\nRESISTANCE MECHANISMS:\n- Beta-lactamase production (most common)\n- Altered penicillin-binding proteins\n- Reduced permeability\n- Efflux pumps\n\nSTORAGE:\n- Store at room temperature 20-25°C (68-77°F)\n- Keep away from moisture and heat\n- Oral suspension: Refrigerate after reconstitution, discard after 14 days\n- Protect from light\n\nPATIENT EDUCATION:\n- Take at evenly spaced intervals to maintain blood levels\n- Complete entire course even if feeling better\n- Do not share antibiotics with others\n- Report any rash or signs of allergic reaction\n- Use alternative contraception if on birth control pills\n- Probiotics may help prevent diarrhea\n- Shake oral suspension well before use",
    "word_count": 351,
    "metadata": {
      "doc_id": "402a36df",
      "filename": "amoxicillin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "AMOXICILLIN - Complete Medication Guide",
      "drug_name": "Amoxicillin",
      "source": "medical_document",
      "word_count": 702,
      "char_count": 5180
    }
  },
  {
    "chunk_id": "b814d355_0000",
    "doc_id": "b814d355",
    "filename": "ibuprofen.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "IBUPROFEN - Complete Medication Guide",
    "drug_name": "Ibuprofen",
    "chunk_index": 0,
    "text": "IBUPROFEN - Complete Medication Guide\n\nGENERIC NAME: Ibuprofen\nBRAND NAMES: Advil, Motrin, Nurofen, Caldolor\n\nDRUG CLASS: Nonsteroidal Anti-inflammatory Drug (NSAID)\n\nMECHANISM OF ACTION:\nIbuprofen works by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These enzymes are responsible for producing prostaglandins, which are chemical messengers that cause inflammation, pain, and fever in the body. By blocking these enzymes, ibuprofen reduces the production of prostaglandins, leading to decreased pain and inflammation.\n\nINDICATIONS AND USAGE:\n- Mild to moderate pain relief (headache, toothache, backache)\n- Fever reduction\n- Inflammation reduction (arthritis, muscle strains)\n- Menstrual cramps (dysmenorrhea)\n- Minor aches and pains\n\nDOSAGE GUIDELINES:\nAdults and children over 12 years:\n- 200-400mg every 4-6 hours as needed\n- Do not exceed 1200mg per day without doctor supervision\n- Take with food or milk to reduce stomach upset\n\nChildren (under 12):\n- Weight-based dosing: 5-10mg/kg every 6-8 hours\n- Maximum: 40mg/kg per day\n\nCONTRAINDICATIONS:\n- Known hypersensitivity to ibuprofen or other NSAIDs\n- History of asthma attacks after taking NSAIDs\n- Active peptic ulcer disease or GI bleeding\n- Severe heart failure (NYHA class III-IV)\n- Late pregnancy (third trimester, can cause premature closure of ductus arteriosus)\n- Coronary artery bypass graft (CABG) surgery perioperative pain\n\nWARNINGS AND PRECAUTIONS:\n- Cardiovascular risk: May increase risk of serious cardiovascular thrombotic events\n- Gastrointestinal risk: Can cause GI bleeding, ulceration, and perforation\n- Renal effects: Can reduce renal blood flow, risk in elderly or dehydrated patients\n- Hepatic effects: Rare cases of severe liver injury\n- Anaphylactoid reactions: Can occur in patients with aspirin triad\n\nCOMMON SIDE EFFECTS:\n- Nausea and vomiting\n- Heartburn and dyspepsia\n- Diarrhea or constipation\n- Dizziness and headache\n- Drowsiness\n\nSERIOUS SIDE EFFECTS (seek medical attention):\n- Signs of stomach bleeding: black/bloody stools, coffee-ground vomit\n- Signs of heart attack: chest pain, shortness of breath\n- Signs of stroke: sudden numbness, confusion, vision changes\n- Signs of allergic reaction: rash, hives, difficulty breathing\n- Signs of liver problems: dark urine, yellowing skin/eyes",
    "word_count": 333,
    "metadata": {
      "doc_id": "b814d355",
      "filename": "ibuprofen.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "IBUPROFEN - Complete Medication Guide",
      "drug_name": "Ibuprofen",
      "source": "medical_document",
      "word_count": 468,
      "char_count": 3271
    }
  },
  {
    "chunk_id": "b814d355_0001",
    "doc_id": "b814d355",
    "filename": "ibuprofen.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "IBUPROFEN - Complete Medication Guide",
    "drug_name": "Ibuprofen",
    "chunk_index": 1,
    "text": "DRUG INTERACTIONS:\n1. Warfarin (Coumadin): SEVERE - Increased bleeding risk\n2. Aspirin: MODERATE - Increased GI side effects, reduced cardioprotection\n3. Lisinopril (ACE inhibitors): MODERATE - Reduced blood pressure effect\n4. Metformin: MODERATE - Possible increased metformin levels\n5. Furosemide (diuretics): MODERATE - Reduced diuretic effect\n6. Lithium: MODERATE - Increased lithium levels, risk of toxicity\n7. Methotrexate: MODERATE - Increased methotrexate toxicity\n8. SSRIs (antidepressants): MILD - Increased bleeding risk\n\nPHARMACOKINETICS:\n- Absorption: Well absorbed orally (80-85% bioavailability)\n- Onset of action: 30-60 minutes\n- Peak plasma levels: 1-2 hours\n- Protein binding: 90-99% bound to plasma proteins\n- Metabolism: Hepatic via CYP2C9\n- Half-life: 2-4 hours\n- Excretion: Urine (primarily as metabolites, <1% unchanged)\n\nSTORAGE:\n- Store at room temperature 20-25°C (68-77°F)\n- Keep away from moisture and heat\n- Protect from light",
    "word_count": 135,
    "metadata": {
      "doc_id": "b814d355",
      "filename": "ibuprofen.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "IBUPROFEN - Complete Medication Guide",
      "drug_name": "Ibuprofen",
      "source": "medical_document",
      "word_count": 468,
      "char_count": 3271
    }
  },
  {
    "chunk_id": "0ad3d062_0000",
    "doc_id": "0ad3d062",
    "filename": "warfarin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "WARFARIN - Complete Medication Guide",
    "drug_name": "Warfarin",
    "chunk_index": 0,
    "text": "WARFARIN - Complete Medication Guide\n\nGENERIC NAME: Warfarin\nBRAND NAMES: Coumadin, Jantoven\n\nDRUG CLASS: Anticoagulant (Vitamin K Antagonist)\n\nMECHANISM OF ACTION:\nWarfarin inhibits the enzyme vitamin K epoxide reductase. This enzyme is responsible for recycling vitamin K, which is essential for the synthesis of clotting factors II, VII, IX, and X in the liver. By blocking this enzyme, warfarin reduces the production of these clotting factors, leading to a decreased ability for blood to clot. The full anticoagulant effect takes 3-5 days because existing clotting factors must naturally degrade.\n\nINDICATIONS AND USAGE:\n- Prophylaxis and treatment of venous thrombosis (deep vein thrombosis, DVT)\n- Prophylaxis and treatment of pulmonary embolism (PE)\n- Prevention of thromboembolic events in atrial fibrillation\n- Prevention of thromboembolic events after heart valve replacement\n- Reduction of risk of recurrent myocardial infarction\n- Prevention of stroke in patients with mechanical heart valves\n\nDOSAGE GUIDELINES:\n- Initial dose: 2-5 mg daily (based on patient factors)\n- Maintenance dose: 2-10 mg daily (individualized based on INR)\n- Dose adjustments based on International Normalized Ratio (INR)\n- Target INR depends on indication:\n  * Most indications: 2.0-3.0\n  * Mechanical heart valves: 2.5-3.5\n- Take at same time each day (usually evening)\n\nCONTRAINDICATIONS:\n- Active bleeding or hemorrhagic tendencies\n- Pregnancy (warfarin embryopathy, especially first trimester)\n- Recent or upcoming surgery (including dental surgery)\n- Severe uncontrolled hypertension\n- Pericarditis or pericardial effusion\n- Lumbar puncture or regional anesthesia\n- Inability to comply with monitoring requirements\n\nWARNINGS AND PRECAUTIONS:\n- Bleeding risk: Most serious adverse effect\n- Monitoring: Regular INR testing required (initially weekly, then monthly)\n- Dietary consistency: Vitamin K intake should be consistent\n- Drug interactions: Hundreds of drugs interact with warfarin\n- Genetic factors: CYP2C9 and VKORC1 variants affect metabolism\n- \"Warfarin necrosis\": Rare skin necrosis complication\n\nCOMMON SIDE EFFECTS:\n- Bleeding (epistaxis, gum bleeding, easy bruising)\n- Purplish toes (cholesterol microembolization)\n- Hair loss (reversible)\n- Skin rash\n- Nausea and vomiting\n- Abdominal pain\n\nSERIOUS SIDE EFFECTS (seek immediate medical attention):\n- Severe bleeding (internal, intracranial)\n- Signs of bleeding: black stools, blood in urine, coffee-ground vomit\n- Sudden severe headache (possible intracranial bleed)\n- Unexplained bruising or swelling\n- Warfarin-induced skin necrosis\n- Purple toe syndrome",
    "word_count": 371,
    "metadata": {
      "doc_id": "0ad3d062",
      "filename": "warfarin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "WARFARIN - Complete Medication Guide",
      "drug_name": "Warfarin",
      "source": "medical_document",
      "word_count": 696,
      "char_count": 4954
    }
  },
  {
    "chunk_id": "0ad3d062_0001",
    "doc_id": "0ad3d062",
    "filename": "warfarin.txt",
    "source_folder": "medical-documents",
    "file_type": ".txt",
    "title": "WARFARIN - Complete Medication Guide",
    "drug_name": "Warfarin",
    "chunk_index": 1,
    "text": "DRUG INTERACTIONS (SIGNIFICANT):\nSEVERE INTERACTIONS:\n1. Ibuprofen and other NSAIDs: Increased bleeding risk\n2. Aspirin: Significantly increased bleeding risk\n3. Amiodarone: Increased warfarin effect (monitor INR closely)\n4. Fluconazole (antifungals): Increased warfarin effect\n5. Metronidazole: Increased warfarin effect\n6. Trimethoprim-sulfamethoxazole: Increased warfarin effect\n\nMODERATE INTERACTIONS:\n1. Acetaminophen (high doses, regular use): Increased INR\n2. Amoxicillin: Increased warfarin effect (disrupts gut flora)\n3. Ciprofloxacin: Increased warfarin effect\n4. Omeprazole: Possible increased warfarin effect\n5. Simvastatin: Possible increased warfarin effect\n6. Phenytoin: Complex bidirectional interaction\n7. Alcohol (chronic heavy use): Variable effects\n\nINTERACTIONS THAT DECREASE WARFARIN EFFECT:\n1. Vitamin K (dietary supplements)\n2. Rifampin\n3. Barbiturates\n4. Carbamazepine\n5. Cholestyramine\n6. Oral contraceptives\n\nDIETARY CONSIDERATIONS:\n- Consistent vitamin K intake is crucial\n- Vitamin K rich foods: leafy greens (kale, spinach, broccoli, Brussels sprouts)\n- Do not eliminate these foods, but keep intake consistent\n- Avoid cranberry juice (may increase warfarin effect)\n- Avoid alcohol (especially binge drinking)\n- Avoid herbal supplements: St. John's wort, ginseng, ginkgo, coenzyme Q10\n\nPHARMACOKINETICS:\n- Absorption: Rapid and complete oral absorption\n- Bioavailability: >95%\n- Protein binding: 99% bound to albumin\n- Metabolism: Hepatic via CYP2C9\n- Half-life: 20-60 hours (average 40 hours)\n- Onset of action: 24-72 hours\n- Duration of action: 2-5 days\n- Monitoring: INR (International Normalized Ratio)\n\nLABORATORY MONITORING:\n- INR target: Individualized (typically 2-3)\n- Frequency: Initially daily to weekly, then every 4 weeks when stable\n- Check INR before any surgical procedure\n- Pregnancy: Warfarin contraindicated (heparin used instead)\n\nPATIENT EDUCATION POINTS:\n- Take exactly as prescribed at same time daily\n- Missed dose: Take if remembered same day, otherwise skip\n- Never double up doses\n- Report any unusual bleeding or bruising\n- Use soft toothbrush and electric razor\n- Avoid contact sports\n- Carry medical alert identification\n- Inform all healthcare providers of warfarin use\n- Keep all appointments for INR testing\n- Do not start or stop any medication without consulting prescriber",
    "word_count": 325,
    "metadata": {
      "doc_id": "0ad3d062",
      "filename": "warfarin.txt",
      "source_folder": "medical-documents",
      "file_type": ".txt",
      "title": "WARFARIN - Complete Medication Guide",
      "drug_name": "Warfarin",
      "source": "medical_document",
      "word_count": 696,
      "char_count": 4954
    }
  },
  {
    "chunk_id": "72326959_0000",
    "doc_id": "72326959",
    "filename": "common-meds.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Medication Knowledge Base for RAG Application (1–100)",
    "drug_name": "Common Meds",
    "chunk_index": 0,
    "text": "Medication Knowledge Base for RAG Application (1–100)\nNo.\nGeneric Name\nAbbrev.\nCommon Names / Brands\nDrug Class\nUsed For (User-Friendly)\nCommon Side Effects\nMajor Interaction Warning\n1\nParacetamol (Acetaminophen)\nAPAP\nPanadol, Tylenol\nAnalgesic\nReduces fever and relieves mild to moderate pain\nNausea, liver strain\nAvoid alcohol overdose\n2\nIbuprofen\nIBU\nBrufen, Advil\nNSAID\nRelieves pain and swelling\nStomach irritation\nAvoid other NSAIDs\n3\nAspirin\nASA\nDisprin\nNSAID / Antiplatelet\nPain relief and blood clot prevention\nStomach bleeding\nAvoid blood thinners\n4\nAmoxicillin\nAMX\nAmoxil\nAntibiotic\nTreats bacterial infections\nDiarrhea, rash\nPenicillin allergy\n5\nAzithromycin\nAZM\nZithromax\nAntibiotic\nTreats chest infections\nNausea\nHeart rhythm drugs\n6\nMetformin\nMET\nGlucophage\nAntidiabetic\nControls blood sugar\nStomach upset\nAvoid excess alcohol\n7\nOmeprazole\nOMP\nLosec\nPPI\nTreats acid reflux\nHeadache\nReduced drug absorption\n8\nAtorvastatin\nATV\nLipitor\nStatin\nLowers cholesterol\nMuscle pain\nAvoid grapefruit\n9\nSimvastatin\nSIM\nZocor\nStatin\nLowers cholesterol\nWeakness\nAntibiotic interaction\n10\nLosartan\nLOS\nCozaar\nARB\nLowers blood pressure\nDizziness\nAvoid potassium\n11\nAmlodipine\nAML\nNorvasc\nCalcium Channel Blocker\nTreats hypertension\nSwollen ankles\nBP meds caution\n12\nLisinopril\nLIS\nZestril\nACE Inhibitor\nControls BP\nDry cough\nAvoid potassium salts\n13\nHydrochlorothiazide\nHCTZ\nMicrozide\nDiuretic\nRemoves excess fluid\nFrequent urination\nElectrolyte imbalance\n14\nFurosemide\nFRU\nLasix\nLoop Diuretic\nTreats swelling\nDehydration\nMonitor potassium\n15\nSalbutamol\nSABA\nVentolin\nBronchodilator\nAsthma relief\nTremor\nAvoid overuse\n16\nPrednisone\nPRED\nDeltasone\nSteroid\nReduces inflammation\nWeight gain\nDo not stop suddenly\n17\nDexamethasone\nDEX\nDecadron\nSteroid\nSevere inflammation\nHigh sugar\nInfection risk\n18\nInsulin\nINS\nHumulin\nHormone\nControls diabetes\nLow sugar\nMonitor glucose\n19\nCeftriaxone\nCRO\nRocephin\nAntibiotic\nSerious infections\nInjection pain\nCalcium interaction\n20\nCiprofloxacin\nCIP\nCipro\nAntibiotic\nUTI treatment\nTendon pain\nAvoid antacids\n21\nFluconazole\nFLU\nDiflucan\nAntifungal\nFungal infections\nNausea\nLiver risk\n22\nMetronidazole\nMTZ\nFlagyl\nAntibiotic\nStomach infections\nMetallic taste\nNo alcohol\n23\nClotrimazole\nCLO\nCanesten\nAntifungal\nSkin infections\nIrritation\nMinimal interactions\n24\nDiclofenac\nDIC\nVoltaren\nNSAID\nJoint pain relief\nStomach pain\nAvoid NSAIDs combo\n25\nTramadol\nTRM\nUltram\nOpioid\nModerate pain\nDrowsiness\nAvoid alcohol",
    "word_count": 332,
    "metadata": {
      "doc_id": "72326959",
      "filename": "common-meds.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Medication Knowledge Base for RAG Application (1–100)",
      "drug_name": "Common Meds",
      "source": "medical_document",
      "word_count": 1232,
      "char_count": 9105
    }
  },
  {
    "chunk_id": "72326959_0001",
    "doc_id": "72326959",
    "filename": "common-meds.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Medication Knowledge Base for RAG Application (1–100)",
    "drug_name": "Common Meds",
    "chunk_index": 1,
    "text": "No.\nGeneric Name\nAbbrev.\nCommon Names / Brands\nDrug Class\nUsed For (User-Friendly)\nCommon Side Effects\nMajor Interaction Warning\n26\nMorphine\nMOR\nMS Contin\nOpioid\nSevere pain\nSleepiness\nRespiratory risk\n27\nCodeine\nCOD\nCodeine Phosphate\nOpioid\nPain & cough\nConstipation\nAvoid sedatives\n28\nCetirizine\nCTZ\nZyrtec\nAntihistamine\nAllergy relief\nSleepiness\nAlcohol sedation\n29\nLoratadine\nLOR\nClaritin\nAntihistamine\nAllergy relief\nHeadache\nFew interactions\n30\nDiphenhydramine\nDPH\nBenadryl\nAntihistamine\nAllergy & sleep aid\nDrowsiness\nAvoid driving\n31\nPantoprazole\nPAN\nProtonix\nPPI\nAcid reflux\nHeadache\nLong-term caution\n32\nWarfarin\nWAR\nCoumadin\nAnticoagulant\nPrevents clots\nBleeding\nMany interactions\n33\nHeparin\nHEP\nHep-Lock\nAnticoagulant\nClot prevention\nBleeding\nMonitor closely\n34\nClopidogrel\nCLOP\nPlavix\nAntiplatelet\nPrevents stroke\nBruising\nAvoid NSAIDs\n35\nNitroglycerin\nNTG\nNitrostat\nVasodilator\nChest pain relief\nHeadache\nED meds interaction\n36\nPropranolol\nPRO\nInderal\nBeta Blocker\nBP & anxiety\nFatigue\nAsthma caution\n37\nAtenolol\nATN\nTenormin\nBeta Blocker\nHypertension\nSlow pulse\nDo not stop suddenly\n38\nSertraline\nSER\nZoloft\nSSRI\nDepression\nNausea\nMAOI interaction\n39\nFluoxetine\nFLX\nProzac\nSSRI\nDepression\nInsomnia\nSerotonin syndrome\n40\nAmitriptyline\nAMT\nElavil\nTCA\nNerve pain\nDry mouth\nAvoid alcohol\n41\nDiazepam\nDZP\nValium\nBenzodiazepine\nAnxiety relief\nSleepiness\nDependence risk\n42\nAlprazolam\nALP\nXanax\nBenzodiazepine\nAnxiety\nDrowsiness\nAvoid alcohol\n43\nCarbamazepine\nCBZ\nTegretol\nAnticonvulsant\nSeizures\nDizziness\nMany interactions\n44\nSodium Valproate\nVPA\nEpilim\nAnticonvulsant\nSeizures\nWeight gain\nPregnancy warning\n45\nLevothyroxine\nLEVO\nSynthroid\nHormone\nLow thyroid\nPalpitations\nEmpty stomach use\n46\nOndansetron\nOND\nZofran\nAntiemetic\nStops nausea\nHeadache\nQT prolongation\n47\nLoperamide\nLOP\nImodium\nAntidiarrheal\nStops diarrhea\nConstipation\nAvoid overdose\n48\nORS\nORS\nDioralyte\nElectrolyte\nPrevents dehydration\nRare\nGenerally safe\n49\nZinc Sulfate\nZN\nZinc tablets\nSupplement\nSupports immunity\nNausea\nTake after meals\n50\nAmoxicillin + Clavulanate\nAMC\nAugmentin\nAntibiotic\nResistant infections\nDiarrhea\nPenicillin allergy\n51\nTenofovir\nTDF\nViread\nARV (NRTI)\nControls HIV\nKidney effects\nMonitor kidneys\n52\nLamivudine\n3TC\nEpivir\nARV (NRTI)\nHIV treatment\nHeadache\nMissed dose resistance\n53\nEfavirenz\nEFV\nSustiva\nARV (NNRTI)\nReduces HIV virus\nDizziness\nAvoid alcohol",
    "word_count": 321,
    "metadata": {
      "doc_id": "72326959",
      "filename": "common-meds.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Medication Knowledge Base for RAG Application (1–100)",
      "drug_name": "Common Meds",
      "source": "medical_document",
      "word_count": 1232,
      "char_count": 9105
    }
  },
  {
    "chunk_id": "72326959_0002",
    "doc_id": "72326959",
    "filename": "common-meds.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Medication Knowledge Base for RAG Application (1–100)",
    "drug_name": "Common Meds",
    "chunk_index": 2,
    "text": "No.\nGeneric Name\nAbbrev.\nCommon Names / Brands\nDrug Class\nUsed For (User-Friendly)\nCommon Side Effects\nMajor Interaction Warning\n54\nDolutegravir\nDTG\nTivicay\nARV (INSTI)\nStops HIV replication\nInsomnia\nAntacid interaction\n55\nZidovudine\nAZT\nRetrovir\nARV (NRTI)\nHIV therapy\nFatigue\nBone marrow risk\n56\nAbacavir\nABC\nZiagen\nARV (NRTI)\nCombination HIV therapy\nAllergic reaction\nScreen before use\n57\nNevirapine\nNVP\nViramune\nARV (NNRTI)\nReduces HIV load\nRash\nLiver monitoring\n58\nRitonavir\nRTV\nNorvir\nProtease Inhibitor\nBoosts ARVs\nNausea\nMany interactions\n59\nLopinavir/Ritonavir\nLPV/r\nKaletra\nProtease Inhibitor\nHIV combination therapy\nDiarrhea\nInteraction heavy\n60\nEmtricitabine\nFTC\nEmtriva\nARV (NRTI)\nControls HIV\nHeadache\nResistance risk\n61\nDoxycycline\nDOX\nVibramycin\nAntibiotic\nTreats acne and infections\nSun sensitivity\nAvoid antacids\n62\nClarithromycin\nCLR\nBiaxin\nAntibiotic\nRespiratory infections\nNausea\nStatin interaction\n63\nErythromycin\nERY\nErythrocin\nAntibiotic\nBacterial infections\nStomach upset\nQT prolongation\n64\nGentamicin\nGEN\nGaramycin\nAntibiotic\nSerious infections\nKidney toxicity\nMonitor levels\n65\nVancomycin\nVAN\nVancocin\nAntibiotic\nResistant infections\nFlushing\nKidney monitoring\n66\nInsulin Glargine\nGLA\nLantus\nLong■acting insulin\nLong-term glucose control\nLow sugar\nMonitor glucose\n67\nGlimepiride\nGLM\nAmaryl\nAntidiabetic\nLowers blood sugar\nHypoglycemia\nMeal timing important\n68\nGliclazide\nGLZ\nDiamicron\nAntidiabetic\nControls diabetes\nLow sugar\nAvoid missed meals\n69\nSpironolactone\nSPI\nAldactone\nDiuretic\nHeart failure & BP\nHigh potassium\nAvoid potassium supplements\n70\nEnalapril\nENA\nVasotec\nACE Inhibitor\nTreats hypertension\nDry cough\nPotassium risk\n71\nValsartan\nVAL\nDiovan\nARB\nLowers BP\nDizziness\nAvoid potassium\n72\nHydralazine\nHYD\nApresoline\nVasodilator\nSevere hypertension\nHeadache\nMonitor BP\n73\nIsosorbide Mononitrate\nISMN\nImdur\nNitrate\nPrevents chest pain\nHeadache\nAvoid ED meds\n74\nEscitalopram\nESC\nLexapro\nSSRI\nDepression & anxiety\nNausea\nSerotonin syndrome\n75\nVenlafaxine\nVEN\nEffexor\nSNRI\nDepression\nSweating\nWithdrawal risk\n76\nQuetiapine\nQUE\nSeroquel\nAntipsychotic\nMood disorders\nSleepiness\nWeight gain\n77\nRisperidone\nRIS\nRisperdal\nAntipsychotic\nSchizophrenia\nWeight gain\nHormone changes\n78\nOlanzapine\nOLA\nZyprexa\nAntipsychotic\nPsychosis treatment\nWeight gain\nMetabolic risk\n79\nHaloperidol\nHAL\nHaldol\nAntipsychotic\nSevere agitation\nStiff muscles\nMovement disorders\n80\nLithium\nLIT\nLithobid\nMood stabilizer\nBipolar disorder\nTremor\nMonitor blood levels\n81\nTopiramate\nTOP\nTopamax\nAnticonvulsant\nSeizures & migraine\nTingling\nKidney stones",
    "word_count": 340,
    "metadata": {
      "doc_id": "72326959",
      "filename": "common-meds.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Medication Knowledge Base for RAG Application (1–100)",
      "drug_name": "Common Meds",
      "source": "medical_document",
      "word_count": 1232,
      "char_count": 9105
    }
  },
  {
    "chunk_id": "72326959_0003",
    "doc_id": "72326959",
    "filename": "common-meds.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Medication Knowledge Base for RAG Application (1–100)",
    "drug_name": "Common Meds",
    "chunk_index": 3,
    "text": "No.\nGeneric Name\nAbbrev.\nCommon Names / Brands\nDrug Class\nUsed For (User-Friendly)\nCommon Side Effects\nMajor Interaction Warning\n82\nGabapentin\nGAB\nNeurontin\nNeuropathic agent\nNerve pain\nDrowsiness\nSedation risk\n83\nPregabalin\nPGB\nLyrica\nNeuropathic agent\nNerve pain\nDizziness\nAvoid alcohol\n84\nMeloxicam\nMEL\nMobic\nNSAID\nJoint pain\nStomach upset\nAvoid NSAIDs combo\n85\nCelecoxib\nCEL\nCelebrex\nCOX■2 inhibitor\nArthritis pain\nHeart risk\nAvoid heart disease\n86\nAllopurinol\nALLO\nZyloprim\nAnti■gout\nPrevents gout attacks\nRash\nKidney caution\n87\nColchicine\nCOL\nColcrys\nAnti■gout\nTreats gout flare\nDiarrhea\nDose toxicity risk\n88\nSildenafil\nSIL\nViagra\nPDE5 inhibitor\nErectile dysfunction\nHeadache\nAvoid nitrates\n89\nTamsulosin\nTAM\nFlomax\nAlpha blocker\nImproves urine flow\nDizziness\nBP drop risk\n90\nFinasteride\nFIN\nProscar\nHormonal\nProstate enlargement\nReduced libido\nPregnancy warning\n91\nLevofloxacin\nLEV\nLevaquin\nAntibiotic\nRespiratory infections\nTendon risk\nAvoid steroids\n92\nMoxifloxacin\nMOX\nAvelox\nAntibiotic\nSevere infections\nQT prolongation\nHeart rhythm risk\n93\nRifaximin\nRIF\nXifaxan\nAntibiotic\nTraveler’s diarrhea\nNausea\nMinimal absorption\n94\nBudesonide\nBUD\nPulmicort\nSteroid inhaler\nAsthma control\nHoarseness\nRinse mouth\n95\nMontelukast\nMON\nSingulair\nLeukotriene blocker\nAllergy asthma control\nHeadache\nMood changes\n96\nIpratropium\nIPR\nAtrovent\nBronchodilator\nCOPD relief\nDry mouth\nAvoid overuse\n97\nTiotropium\nTIO\nSpiriva\nBronchodilator\nLong-term COPD control\nDry mouth\nInhaler technique\n98\nHydrocortisone\nHC\nCortef\nSteroid\nAllergic reactions\nWeight gain\nDo not stop abruptly\n99\nMethotrexate\nMTX\nTrexall\nImmunosuppressant\nAutoimmune diseases\nNausea\nAvoid pregnancy\n100\nAdalimumab\nADA\nHumira\nBiologic agent\nAutoimmune conditions\nInfection risk\nAvoid live vaccines",
    "word_count": 239,
    "metadata": {
      "doc_id": "72326959",
      "filename": "common-meds.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Medication Knowledge Base for RAG Application (1–100)",
      "drug_name": "Common Meds",
      "source": "medical_document",
      "word_count": 1232,
      "char_count": 9105
    }
  },
  {
    "chunk_id": "dcb90cee_0000",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 0,
    "text": "Pharmacotherapy \nHandbook\nNinth Edition\n\nNOTICE\nMedicine is an ever-changing science. As new research and clinical experience \nbroaden our knowledge, changes in treatment and drug therapy are required. \nThe authors of this work have checked with sources believed to be reliable in \ntheir efforts to provide information that is complete and generally in accord \nwith the standards accepted at the time of publication. However, in view of the \npossibility of human error or changes in medical sciences, neither the authors \nnor the publisher nor any other party who has been involved in the preparation \nor publication of this work warrants that the information contained herein is in \nevery respect accurate or complete, and they disclaim all responsibility for any \nerrors or omissions or the results obtained from use of the information contained \nin this work. Readers are encouraged to confirm the information contained \nherein with other sources. For example and in particular, readers are advised to \ncheck the product information sheet included in the package of each drug they \nplan to administer to be certain that the information contained in this work is \naccurate and that changes have not been made in the recommended dose or in \nthe contraindications for administration. This recommendation is of particular \nimportance in connection with new or infrequently used drugs.\n\nNew Y ork  Chicago  San Francisco  Athens  Lisbon  London  Madrid \nMexico City  Milan  New Delhi  Singapore  Sydney  Toronto\nPharmacotherapy \nHandbook\nNinth Edition\nBarbara G. Wells, PharmD, FASHP , FCCP\nDean Emeritus and Professor Emeritus \nExecutive Director Emeritus, Research Institute of Pharmaceutical Sciences \nSchool of Pharmacy, The University of Mississippi \nOxford, Mississippi\nJoseph T. DiPiro, PharmD, FCCP\nProfessor and Dean \nArchie O. McCalley Chair \nSchool of Pharmacy \nVirginia Commonwealth University \nRichmond, Virginia\nTerry L. Schwinghammer, PharmD, FCCP , FASHP , FAPhA, BCPS\nProfessor and Chair, Department of Clinical Pharmacy \nSchool of Pharmacy, West Virginia University \nMorgantown, West Virginia\nCecily V. DiPiro, PharmD\nConsultant Pharmacist \nRichmond, Virginia",
    "word_count": 319,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0001",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 1,
    "text": "Copyright © 2015 by McGraw-Hill Education. All rights reserved. Except as permitted \nunder the United States Copyright Act of 1976, no part of this publication may be re-\nproduced or distributed in any form or by any means, or stored in a database or retrieval \nsystem, without the prior written permission of the publisher.\nISBN: 978-0-07-182129-2\nMHID: 0-07-182129-5\nThe material in this eBook also appears in the print version of this title: ISBN: 978-0-07-182128-5,\nMHID: 0-07-182128-7.\neBook conversion by codeMantra\nVersion 1.0\nAll trademarks are trademarks of their respective owners. Rather than put a  \ntrademark symbol after every occurrence of a trademarked name, we use names in an \neditorial fashion only, and to the benefit of the trademark owner, with no intention of  \ninfringement of the trademark. Where such designations appear in this book, they have \nbeen printed with initial caps.\nMcGraw-Hill Education eBooks are available at special quantity discounts to use as \npremiums and sales promotions or for use in corporate training programs. To contact a \nrepresentative, please visit the Contact Us page at www.mhprofessional.com.\nPrevious edition copyright © 2012, 2006, 2003, 2000, by The McGraw-Hill  \nCompanies, Inc.; copyright © 1998 by Appleton & Lange.\nTERMS OF USE\nThis is a copyrighted work and McGraw-Hill Education and its licensors reserve \nall rights in and to the work. Use of this work is subject to these terms. Except as  \npermitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the \nwork, you may not decompile, disassemble, reverse engineer, reproduce, modify, create  \nderivative works based upon, transmit, distribute, disseminate, sell, publish or sublicense \nthe work or any part of it without McGraw-Hill Education’s prior consent. You may use the \nwork for your own noncommercial and personal use; any other use of the work is strictly  \nprohibited. Your right to use the work may be terminated if you fail to comply with \nthese terms.\nTHE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND \nITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE  \nACCURACY , ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE \nOBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION \nTHAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR  \nOTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY , EXPRESS \nOR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRAN-\nTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.",
    "word_count": 392,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0002",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 2,
    "text": "Your right to use the work may be terminated if you fail to comply with \nthese terms.\nTHE WORK IS PROVIDED “AS IS.” McGRAW-HILL EDUCATION AND \nITS LICENSORS MAKE NO GUARANTEES OR WARRANTIES AS TO THE  \nACCURACY , ADEQUACY OR COMPLETENESS OF OR RESULTS TO BE \nOBTAINED FROM USING THE WORK, INCLUDING ANY INFORMATION \nTHAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR  \nOTHERWISE, AND EXPRESSLY DISCLAIM ANY WARRANTY , EXPRESS \nOR IMPLIED, INCLUDING BUT NOT LIMITED TO IMPLIED WARRAN-\nTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.  \nMcGraw-Hill Education and its licensors do not warrant or guarantee that the  \nfunctions contained in the work will meet your requirements or that its operation will be  \nuninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be \nliable to you or anyone else for any inaccuracy, error or omission, regardless of cause, \nin the work or for any damages resulting therefrom. McGraw-Hill Education has no \nresponsibility for the content of any information accessed through the work. Under \nno circumstances shall McGraw-Hill Education and/or its licensors be liable for any \nindirect, incidental, special, punitive, consequential or similar damages that result from \nthe use of or inability to use the work, even if any of them has been advised of the  \npossibility of such damages. This limitation of liability shall apply to any claim or cause \nwhatsoever whether such claim or cause arises in contract, tort or otherwise.",
    "word_count": 238,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0003",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 3,
    "text": "v\nFM_H1Contents\nPreface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix\nAcknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x\nSECTION 1: BONE AND JOINT DISORDERS\nEdited by Terry L. Schwinghammer\n1. Gout and Hyperuricemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1\n2. Osteoarthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9\n3. Osteoporosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16\n4. Rheumatoid Arthritis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26\nSECTION  2: CARDIOvASCul AR DISORDERS\nEdited by Terry L. Schwinghammer\n 5. Acute Coronary Syndromes . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0004",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 4,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . .37\n 6. Arrhythmias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .48\n 7. Cardiac Arrest  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .59\n 8.  Dyslipidemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .65\n 9.  Heart Failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .75\n10. Hypertension  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .87\n11. Ischemic Heart Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .102\n12. Shock . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0005",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 5,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .111\n13. Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120\n14. Venous Thromboembolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .125\nSECTION 3: DERMATO l OGIC DISORDERS\nEdited by Terry L. Schwinghammer\n15. Acne Vulgaris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .135\n16. Dermatologic Drug Reactions and Common Skin Conditions  . . . . . . . . . . . . . .141\n17. Psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .147\nSECTION 4: E NDOCRINO l OGIC DISORDERS\nEdited by Terry L. Schwinghammer\n18. Adrenal Gland Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .155\n19.  Diabetes Mellitus . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0006",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 6,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .161\n20. Thyroid Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .176\nSECTION  5: GASTROINTESTINA l  DISORDERS\nEdited by Joseph T. DiPiro and Terry L. Schwinghammer\n21. Cirrhosis and Portal Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .185\n22. Constipation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .194\n23. Diarrhea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .200\n24. Gastroesophageal Reflux Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .206\n25. Hepatitis, Viral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213",
    "word_count": 367,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0007",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 7,
    "text": "vi\nContents\n26. Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .221\n27. Nausea and Vomiting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .231\n28. Pancreatitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244\n29. Peptic Ulcer Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .251\nSECTION 6: GYNECO l OGIC AND OBSTETRIC DISORDERS  \nEdited by Barbara G. Wells\n30. Contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257\n31. Menopausal, Perimenopausal, and Postmenopausal Hormone Therapy . . . . . . .276\n32. Pregnancy and Lactation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .291\nSECTION 7: HEMATO l OGIC DISORDERS\nEdited by Cecily V . DiPiro\n33. Anemias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0008",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 8,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . .301\n34. Sickle Cell Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .308\nSECTION 8: INFECTIO u S DISEASES\nEdited by Joseph T. DiPiro\n35. Antimicrobial Regimen Selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .313\n36. Central Nervous System Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .323\n37. Endocarditis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .333\n38. Fungal Infections, Invasive . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .347\n39. Gastrointestinal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .361\n40. Human Immunodeficiency Virus Infection  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .368\n41. Influenza . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0009",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 9,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .387\n42. Intraabdominal Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .394\n43. Respiratory Tract Infections, Lower . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .405\n44. Respiratory Tract Infections, Upper . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .418\n45.  Sepsis and Septic Shock  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .427\n46. Sexually Transmitted Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .433\n47. Skin and Soft-Tissue Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .448\n48.  Surgical Prophylaxis  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .466\n49. Tuberculosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0010",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 10,
    "text": ". . . . . . . . . . . . . . . . . . . . . . .476\n50. Urinary Tract Infections  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .490\n51. Vaccines, Toxoids, and Other Immunobiologics. . . . . . . . . . . . . . . . . . . . . . . . . . .500\nSECTION 9: N Eu ROl OGIC DISORDERS\nEdited by Barbara G. Wells\n52. Alzheimer’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .511\n53. Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .518\n54. Headache: Migraine and Tension-Type . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .543\n55. Pain Management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .557\n56. Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .578\n57. Status Epilepticus . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0011",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 11,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .587",
    "word_count": 39,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0012",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 12,
    "text": "vii\nContents\nSECTION 10: N u TRITION S u PPORT\nEdited by Cecily V . DiPiro\n58. Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .599\n59. Nutrition Evaluation and Support . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .605\nSECTION 11: ONCO l OGIC DISORDERS\nEdited by Cecily V . DiPiro\n60. Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .619\n61. Colorectal Cancer  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .631\n62. Lung Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .642\n63. Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .647\n64. Prostate Cancer  . . . . . . . . . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0013",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 13,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . .654\nSECTION 12: OPHTHA l MIC DISORDERS\nEdited by Cecily V . DiPiro\n65. Glaucoma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .665\nSECTION 13: PSYCHIATRIC DISORDERS\nEdited by Barbara G. Wells\n66. Anxiety Disorders  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .673\n67. Bipolar Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .694\n68. Major Depressive Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .712\n69. Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .731\n70. Sleep-Wake Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .747\n71. Substance-Related Disorders . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0014",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 14,
    "text": ". . . . . . . . . . . . . . . . . . . . . . . . . . . .755\nSECTION 14: RENA l  DISORDERS  \nEdited by Cecily V . DiPiro \n72. Acid–Base Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .771\n73. Acute Kidney Injury  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .779\n74. Chronic Kidney Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .787\n75. Electrolyte Homeostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .798\nSECTION 15: RESPIRATORY DISORDERS  \nEdited by Terry L. Schwinghammer \n76. Allergic Rhinitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .813\n77. Asthma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .821\n78. Chronic Obstructive Pulmonary Disease . . . . . . . . . . . . . . . . . . .",
    "word_count": 400,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0015",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 15,
    "text": ". . . . . . . . . . . . . . .835\nSECTION 16: u ROl OGIC DISORDERS  \nEdited by Cecily V . DiPiro \n79. Benign Prostatic Hyperplasia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .845\n80. Erectile Dysfunction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .850\n81. Urinary Incontinence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .865",
    "word_count": 179,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0016",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 16,
    "text": "viii\nAPPENDICES\nEdited by Barbara G. Wells\nAppendix 1. Allergic and Pseudoallergic Drug Reactions  . . . . . . . . . . . . . . . . . . . . . .873\nAppendix 2. Geriatrics  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .877\nAppendix 3. Drug-Induced Hematologic Disorders  . . . . . . . . . . . . . . . . . . . . . . . . . .882\nAppendix 4. Drug-Induced Liver Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .887\nAppendix 5. Drug-Induced Pulmonary Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .889\nAppendix 6. Drug-Induced Kidney Disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .898\nIndex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .903\nContents",
    "word_count": 303,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0017",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 17,
    "text": "ix\nFM_H1Preface\nThe pocket companion to Pharmacotherapy: A Pathophysiologic Approach, 9th edition, \nis designed to provide practitioners and students with critical information that can be \neasily used to guide drug therapy decision making in the clinical setting. To ensure \nbrevity and portability, the bulleted format provides the user with essential textual \ninformation, key tables and figures, and treatment algorithms. In order to reduce the \nnumber of pages and thus allow it to fit more easily in a pocket, the publisher under -\ntook a slight redesign to save space, and the authors made every effort to write as clearly \nand succinctly as possible.\nCorresponding to the major sections in the main text, disorders are alphabetized \nwithin the following sections: Bone and Joint Disorders, Cardiovascular Disorders, \nDermatologic Disorders, Endocrinologic Disorders, Gastrointestinal Disorders, \nGynecologic and Obstetric Disorders, Hematologic Disorders, Infectious Diseases, \nNeurologic Disorders, Nutritional Disorders, Oncologic Disorders, Ophthalmic \nDisorders, Psychiatric Disorders, Renal Disorders, Respiratory Disorders, and Urologic \nDisorders. Drug-induced conditions associated with allergic and pseudoallergic reac-\ntions, hematologic disorders, liver diseases, pulmonary disorders, and kidney disease \nappear in five tabular appendices. Information on the management of pharmacothera-\npy in the elderly is also included as an appendix.\nEach chapter is organized in a consistent format:\n•\tDisease state definition \n•\tPathophysiology\n•\tClinical presentation\n•\tDiagnosis\n•\tTreatment\n•\tEvaluation of therapeutic outcomes\nThe treatment section may include goals of treatment, general approach to treat-\nment, nonpharmacologic therapy, drug selection guidelines, dosing recommendations, \nadverse effects, pharmacokinetic considerations, and important drug-drug interac-\ntions. When more in-depth information is required, the reader is encouraged to refer to \nthe primary text, Pharmacotherapy: A Pathophysiologic Approach, 9th edition.\nIt is our sincere hope that students and practitioners find this book helpful as they \ncontinuously strive to deliver highest-quality patient-centered care. We invite your \ncomments on how we may improve subsequent editions of this work.\nBarbara G. Wells\nJoseph T. DiPiro\nTerry L. Schwinghammer\nCecily V . DiPiro\nPlease provide your comments about this book—Wells et al, Pharmacotherapy \nHandbook, 9th edition—to its authors and publisher by writing to pharmacotherapy@\nmcgraw-hill.com. Please indicate the author and title of this handbook in the subject \nline of your e-mail.",
    "word_count": 359,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0018",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 18,
    "text": "x\nFM_H1Acknowledgments\nThe editors wish to express their sincere appreciation to the authors whose chapters in \nthe 9th edition of Pharmacotherapy: A Pathophysiologic Approach served as the basis \nfor this book. The dedication and professionalism of these outstanding practitioners, \nteachers, and clinical scientists are evident on every page of this work. The authors \nof the chapters from the 9th edition are acknowledged at the end of each respective \nhandbook chapter.",
    "word_count": 70,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0019",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 19,
    "text": "1\nSECTION 1\nBONE AND JOINT DISORDERS\nEdited by Terry L.",
    "word_count": 11,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0020",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 20,
    "text": "1\nSECTION 1\nBONE AND JOINT DISORDERS\nEdited by Terry L. Schwinghammer\n•\tGout\t involves\t hyperuricemia, \t recurrent\t attacks\t of\t acute\t arthritis\t with\t mono­\nsodium\turate\t(MSU)\tcrystals \tin\tsynovial\tfluid\tleukocytes, \tdeposits\tof\tMSU\tcrystals \t\nin\t tissues\t in\t and\t around\t joints\t (tophi),\t interstitial\t renal\t disease,\t and\t uric\t acid\t\nnephrolithiasis.\nPATHOPHYSIOLOGY\n•\tUric\tacid\tis\tthe\tend\tproduct\tof\tpurine\tdegradation.\tAn\tincreased\turate\tpool\tin\tindi­\nviduals\twith\tgout\tmay\tresult\tfrom\toverproduction\tor\tunderexcretion.\n•\tPurines\t originate\t from\t dietary\t purine,\t conversion\t of\t tissue\t nucleic\t acid\t to\t purine\t\nnucleotides,\tand\tde\tnovo\tsynthesis\tof\tpurine\tbases.\n•\tOverproduction\tof\turic\tacid\tmay\tresult\tfrom\tabnormalities\tin\tenzyme\tsystems\tthat\t\nregulate\tpurine\tmetabolism\t(eg,\tincreased\tactivity\tof\tphosphoribosyl\tpyrophosphate\t\n[PRPP]\tsynthetase\tor\tdeficiency\tof\thypoxanthine­guanine\tphosphoribosyl\ttransferase\t\t\n[HGPRT]).\n•\tUric\tacid\tmay\tbe\toverproduced\tbecause\tof\tincreased\tbreakdown\tof\ttissue\tnucleic\tacids,\t\nas\t with\t myeloproliferative\t and\t lymphoproliferative\t disorders.\t Cytotoxic\t drugs\t can\t\nresult\tin\toverproduction\tof\turic\tacid\tdue\tto\tlysis\tand\tthe\tbreakdown\tof\tcellular\tmatter.\n•\tDietary\t purines\t are\t insignificant\t in\t generation\t of\t hyperuricemia\t without\t some\t\nderangement\tin\tpurine\tmetabolism\tor\telimination.\n•\tTwo\t thirds\t of\t uric\t acid\t produced\t daily\t is\t excreted\t in\t urine.\t The\t remainder\t is\t\neliminated\tthrough\tgastrointestinal\t(GI)\ttract\tafter\tdegradation\tby\tcolonic\tbacteria.\t\nDecline\tin\turinary\texcretion\tto\ta\tlevel\tbelow\trate\tof\tproduction\tleads\tto\thyperurice­\nmia\tand\tincreased\tpool\tof\tsodium\turate.\n•\tDrugs\tthat\tdecrease\trenal\turic\tacid\tclearance\tinclude\tdiuretics,\tnicotinic\tacid,\tsalicy­\nlates\t (<2\t g/day),\t ethanol,\t pyrazinamide,\t levodopa,\t ethambutol,\t cyclosporine,\t and\t\ncytotoxic\tdrugs.\n•\tDeposition\tof\turate\tcrystals\tin\tsynovial\tfluid\tresults\tin\tinflammation,\tvasodilation,\t\nincreased\t vascular\t permeability,\t complement\t activation,\t and\t chemotactic\t activity\t\nfor\t polymorphonuclear\t leukocytes.\t Phagocytosis\t of\t urate\t crystals\t by\t leukocytes\t\nresults\tin\trapid\tlysis\tof\tcells\tand\tdischarge\tof\tproteolytic\tenzymes\tinto\tcytoplasm.\t\nThe\t ensuing\t inflammatory\t reaction\t causes\t intense\t joint\t pain,\t erythema,\t warmth,\t\nand\tswelling.\n•\tUric\tacid\tnephrolithiasis\toccurs\tin\t10%\tto\t25%\tof\tpatients\twith\tgout.\tPredisposing\t\nfactors\t include\t excessive\t urinary\t excretion\t of\t uric\t acid,\t acidic\t urine,\t and\t highly\t\nconcentrated\turine.\n•\tIn\tacute\turic\tacid\tnephropathy,\tacute\trenal\tfailure\toccurs\tbecause\tof\tblockage\tof\turine\t\nflow\tfrom\tmassive\tprecipitation\tof\turic\tacid\tcrystals\tin\tcollecting\tducts\tand\tureters.\t\nChronic\turate\tnephropathy\tis\tcaused\tby\tlong­term\tdeposition\tof\turate\tcrystals\tin\tthe\t\nrenal\tparenchyma.\n•\tT ophi\t(urate\tdeposits)\tare\tuncommon\tand\tare\ta\tlate\tcomplication\tof\thyperuricemia.\t\nMost\t common\t sites\t are\t the\t base\t of\t the\t fingers,\t olecranon\t bursae,\t ulnar\t aspect\t of\t\nforearm,\tAchilles\ttendon,\tknees,\twrists,\tand\thands.\nGout and Hyperuricemia\n1\nC H A P T E R",
    "word_count": 423,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0021",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 21,
    "text": "2\nSECTION 1     Bone and Joint Disorders\nCLINICAL PRESENTATION\n•\tAcute\t gout\t attacks\t are\t characterized\t by\t rapid\t onset\t of\t excruciating\t pain,\t swelling,\t\nand\tinflammation.\tThe\tattack\tis\ttypically\tmonoarticular,\tmost\toften\taffecting\tthe\tfirst\t\nmetatarsophalangeal\t joint\t (podagra),\t and\t then,\t in\t order\t of\t frequency,\t the\t insteps,\t\nankles,\t heels,\t knees,\twrists,\t fingers,\t and\t elbows.\t Attacks\tcommonly\t begin\t at\t night,\t\nwith\tthe\tpatient\tawakening\twith\texcruciating\tpain.\tAffected\tjoints\tare\terythematous,\t\nwarm,\tand\tswollen.\tFever\tand\tleukocytosis\tare\tcommon.\tUntreated\tattacks\tlast\tfrom\t\n3\tto\t14\tdays\tbefore\tspontaneous\trecovery.\n•\tAcute\t attacks\t may\t occur\t without\t provocation\t or\t be\t precipitated\t by\t stress,\t trauma,\t\nalcohol\t ingestion,\t infection,\t surgery,\t rapid\t lowering\t of\t serum\t uric\t acid\t by\t uric\t\nacid–lowering\t agents,\t and\t ingestion\t of\t drugs\t known\t to\t elevate\t serum\t uric\t acid\t\nconcentrations.\nDIAGNOSIS\n•\tDefinitive\t diagnosis\t requires\t aspiration\t of\t synovial\t fluid\t from\t the\t affected\t joint\t\nand\t identification\t of\t intracellular\t crystals\t of\t MSU\t monohydrate\t in\t synovial\t fluid\t\nleukocytes.\n•\tWhen\tjoint\taspiration\tis\tnot\tfeasible,\ta\tpresumptive\tdiagnosis\tis\tbased\ton\tpresence\tof\t\ncharacteristic\tsigns\tand\tsymptoms,\tas\twell\tas\tthe\tresponse\tto\ttreatment.\nTREATMENT\n•\tGoals\tof\tTreatment:\tT erminate\tthe\tacute\tattack,\tprevent\trecurrent\tattacks,\tand\tpre­\nvent\tcomplications\tassociated\twith\tchronic\tdeposition\tof\turate\tcrystals\tin\ttissues.\nACUTE GOUTY ARTHRITIS (F IG.",
    "word_count": 207,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0022",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 22,
    "text": "  Bone and Joint Disorders\nCLINICAL PRESENTATION\n•\tAcute\t gout\t attacks\t are\t characterized\t by\t rapid\t onset\t of\t excruciating\t pain,\t swelling,\t\nand\tinflammation.\tThe\tattack\tis\ttypically\tmonoarticular,\tmost\toften\taffecting\tthe\tfirst\t\nmetatarsophalangeal\t joint\t (podagra),\t and\t then,\t in\t order\t of\t frequency,\t the\t insteps,\t\nankles,\t heels,\t knees,\twrists,\t fingers,\t and\t elbows.\t Attacks\tcommonly\t begin\t at\t night,\t\nwith\tthe\tpatient\tawakening\twith\texcruciating\tpain.\tAffected\tjoints\tare\terythematous,\t\nwarm,\tand\tswollen.\tFever\tand\tleukocytosis\tare\tcommon.\tUntreated\tattacks\tlast\tfrom\t\n3\tto\t14\tdays\tbefore\tspontaneous\trecovery.\n•\tAcute\t attacks\t may\t occur\t without\t provocation\t or\t be\t precipitated\t by\t stress,\t trauma,\t\nalcohol\t ingestion,\t infection,\t surgery,\t rapid\t lowering\t of\t serum\t uric\t acid\t by\t uric\t\nacid–lowering\t agents,\t and\t ingestion\t of\t drugs\t known\t to\t elevate\t serum\t uric\t acid\t\nconcentrations.\nDIAGNOSIS\n•\tDefinitive\t diagnosis\t requires\t aspiration\t of\t synovial\t fluid\t from\t the\t affected\t joint\t\nand\t identification\t of\t intracellular\t crystals\t of\t MSU\t monohydrate\t in\t synovial\t fluid\t\nleukocytes.\n•\tWhen\tjoint\taspiration\tis\tnot\tfeasible,\ta\tpresumptive\tdiagnosis\tis\tbased\ton\tpresence\tof\t\ncharacteristic\tsigns\tand\tsymptoms,\tas\twell\tas\tthe\tresponse\tto\ttreatment.\nTREATMENT\n•\tGoals\tof\tTreatment:\tT erminate\tthe\tacute\tattack,\tprevent\trecurrent\tattacks,\tand\tpre­\nvent\tcomplications\tassociated\twith\tchronic\tdeposition\tof\turate\tcrystals\tin\ttissues.\nACUTE GOUTY ARTHRITIS (F IG. 1–1)\nNonpharmacologic Therapy\n•\tLocal\tice\tapplication\tis\tthe\tmost\teffective\tadjunctive\ttreatment.\tDietary\tsupplements\t\n(eg,\tflaxseed,\tcelery\troot)\tare\tnot\trecommended.\nPharmacologic Therapy\n•\tMost\tpatients\tmay\tbe\ttreated\tsuccessfully\twith\tnonsteroidal\tanti­inflammatory\tdrugs\t\n(NSAIDs),\tcorticosteroids,\tor\tcolchicine.\nNSAIDS\n•\tNSAIDs\t have\t excellent\t efficacy \t and\t minimal\t toxicity\t with\t short­term\t use.\t\nIndomethacin,\tnaproxen,\tand\tsulindac\thave\tFood\tand\tDrug\tAdministration\t(FDA)\t\napproval\tfor\tgout,\tbut\tothers\tare\tlikely\tto\tbe\teffective\t(Table 1–1).\n•\tStart\ttherapy\twithin\t24\thours\tof\tattack\tonset\tand\tcontinue\tuntil\tcomplete\tresolution\t\n(usually\t5–8\tdays).\tTapering\tmay\tbe\tconsidered\tafter\tresolution,\tespecially\tif\tcomor­\nbidities\tsuch\tas\thepatic\tor\trenal\tinsufficiency\tmake\tprolonged\ttherapy\tundesirable.\n•\tThe\tmost\tcommon\tadverse\teffects\tinvolve\tthe\tGI\ttract\t(gastritis,\tbleeding,\tperforation),\t\nkidneys\t(renal\tpapillary\tnecrosis,\treduced\tcreatinine\tclearance\t[CLcr]),\tcardiovascular\t\nsystem\t (increased\t blood\t pressure,\t sodium\t and\t fluid\t retention),\t and\t central\t nervous\t\nsystem\t(CNS)\t(impaired\tcognitive\tfunction,\theadache,\tdizziness).\n•\tSelective\tcyclooxygenase­2\t(COX­2)\tinhibitors\t(eg,\tcelecoxib)\tmay\tbe\tan\toption\tfor\t\npatients\t unable\t to\t take\t nonselective\t NSAIDs,\t but\t the\t risk­to­benefit\t ratio\t in\t acute\t\ngout\tis\tunclear,\tand\tcardiovascular\trisk\tmust\tbe\tconsidered.\nCORTICOSTEROIDS\n•\tCorticosteroid\t efficacy\t is\t equivalent\t to\t NSAIDs;\t they\t can\t be\t used\t systemically\t\nor\t by\t intra­articular\t (IA)\t injection.\t Systemic\t therapy\t is\t necessary\t if\t an\t attack\t is\t\npolyarticular.",
    "word_count": 414,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0023",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 23,
    "text": "3\nGout and Hyperuricemia  |  CHAPTER 1\nPain intensity\nTreatment outcome Treatment Outcome\nInadequate\nresponsed\nSuccessful\naEvidence Grade Level A: Supported by multiple randomized clinical trials or meta-analysesbEvidence Grade Level B: Derived from a single randomized trial, or nonrandomized studiescEvidence Grade Level C: Consensus opinion of experts, case studies, or standard-of-cared‘Inadequate Response’ is defined as <20% improvement in pain score within 24 hours or <50% at ≥ 24 hourseColchicine is recommended only if started within 36 hours of symptom onset\nSwitch to Alternative Monotherapyc\nOff-Label Therapies in Development\n• Interleukin-1 Inhibitor Therapy\nMild/Moderate\nInitiate Monotherapy:a\n• NSAIDa \n• Colchicinea,e\n• Systemic corticosteroida\n Inadequate responseSuccessful d\nPrevent Recurrent Attacks\n• Recommend dietary modifications to\nprevent hyperuricemiab\n• Educate patient about the role of uric \nacid excess in gout attacksb\n• Develop plan for patient to promptly self-\ntreat any future attacksb\n• Initiate urate-lowering therapy if indicated\n(see textbook Fig. 74-6 for further detail on\nurate-lowering therapy)\nc\nSevere\nInitiate Combination Therapy:c\n• Colchicine + NSAID\n• Colchicine + Oral corticosteroid\n• NSAID + Intra-articular corticosteroid\n• Colchicine + Intra-articular corticosteroid\n• Oral corticosteroid + Intra-articular corticosteroid\nFIGURE 1–1.  Algorithm for management of an acute gout attack.",
    "word_count": 196,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0024",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 24,
    "text": "4\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0025",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 25,
    "text": "4\nSECTION 1     Bone and Joint Disorders\n•\tPrednisone\tor\tprednisolone\toral\tdosing\tstrategies:\t(1)\t0.5\tmg/kg\tdaily\tfor\t5\tto\t10\t\ndays\tfollowed\tby\tabrupt\tdiscontinuation;\tor\t(2)\t0.5\tmg/kg\tdaily\tfor\t2\tto\t5\tdays\tfol­\nlowed\tby\ttapering\tfor\t7\tto\t10\tdays.\tTapering\tis\toften\tused\tto\treduce\tthe\thypothetical\t\nrisk\tof\ta\trebound\tattack\tupon\tsteroid\twithdrawal.\n•\tMethylprednisolone dose pack\tis\ta\t6­day\tregimen\tstarting\twith\t24\tmg\ton\tday\t1\tand\t\ndecreasing\tby\t4\tmg\teach\tday.\n•\tTriamcinolone acetonide\t 20–40\t mg\t given\t by\t IA\t injection\t may\t be\t used\t if\t gout\t is\t\nlimited\t to\t one\t or\t two\t joints.\t IA\t corticosteroids\t should\t generally\t be\t used\t with\t oral\t\nNSAID,\tcolchicine,\tor\tcorticosteroid\ttherapy.\n•\tMethylprednisolone\t (a\t long­acting\t corticosteroid)\t given\t by\t a\t single\t intramuscu­\nlar\t (IM)\t injection\t followed\t by\t oral\t corticosteroid\t therapy\t is\t another\t reasonable\t\napproach.\t Alternatively,\t IM\t corticosteroid\t monotherapy\t may\t be\t considered\t in\t\npatients\twith\tmultiple\taffected\tjoints\twho\tcannot\ttake\toral\ttherapy.\t\n•\tShort­term\tcorticosteroid\tuse\tis\tgenerally\twell\ttolerated.\tUse\twith\tcaution\tin\tpatients\t\nwith\tdiabetes,\tGI\tproblems,\tbleeding\tdisorders,\tcardiovascular\tdisease,\tand\tpsychi­\natric\tdisorders.\tAvoid\tlong­term\tuse\tbecause\tof\trisk\tfor\tosteoporosis,\thypothalamic–\npituitary–adrenal\taxis\tsuppression,\tcataracts,\tand\tmuscle\tdeconditioning.\n•\tAdrenocorticotropic hormone (ACTH) \t gel\t 40\t to\t 80\t USP\t units\t may\t be\t given\t IM\t\nevery\t6\tto\t8\thours\tfor\t2\tor\t3\tdays\tand\tthen\tdiscontinued.\tLimit\tuse\tfor\tpatients\twith\t\ncontraindications\tto\tfirst­line\ttherapies\t(eg,\theart\tfailure,\tchronic\trenal\tfailure,\this­\ntory\tof\tGI\tbleeding)\tor\tpatients\tunable\tto\ttake\toral\tmedications.\nCOLCHICINE\n•\tColchicine\tis\thighly\teffective\tin\trelieving\tacute\tgout\tattacks;\twhen\tit\tis\tstarted\twithin\t\nthe\tfirst\t24\thours\tof\tonset,\tabout\ttwo\tthirds\tof\tpatients\trespond\twithin\thours.\tUse\t\nonly\twithin\t36\thours\tof\tattack\tonset\tbecause\tthe\tlikelihood\tof\tsuccess\tdecreases\tsub­\nstantially\tif\ttreatment\tis\tdelayed.\n TABLE 1–1   Dosage Regimens of Oral Nonsteroidal Anti-inflammatory Drugs for \nTreatment of Acute Gout\nGeneric Name Initial Dose Usual Range\nEtodolac 300 mg twice daily 300–500 mg twice daily\nFenoprofen 400 mg three times daily 400–600 mg three to four times \ndaily\nIbuprofen 400 mg three times daily 400–800 mg three to four times \ndaily\nIndomethacin 50 mg three times daily 50 mg three times daily initially \nuntil pain is tolerable then rapidly \nreduce to complete cessation\nKetoprofen 75 mg three times daily or 50 mg \nfour times daily\n50–75 mg three to four times daily\nNaproxen 750 mg followed by 250 mg every \n8 h until the attack has subsided\n—\nPiroxicam 20 mg once daily or 10 mg twice \ndaily\n—\nSulindac 150 mg twice daily 150–200 mg twice daily for 7–10 \ndays\nCelecoxib 800 mg followed by 400 mg on \nday 1, then 400 mg twice daily \nfor 1 week\n—",
    "word_count": 457,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0026",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 26,
    "text": "5\nGout and Hyperuricemia     CHAPTER 1\n•\tColchicine\tcauses\tdose­dependent\tGI\tadverse\teffects\t(nausea,\tvomiting,\tand\tdiarrhea).\t\t\nNon­GI\teffects\tinclude\tneutropenia\tand\taxonal\tneuromyopathy,\twhich\tmay\tbe\twors­\nened\t in\tpatients\t taking\t other\t myopathic\t drugs\t (eg,\t statins)\t or\t in\trenal\t insufficiency.\t\t\nDo\t not\t use\t concurrently\t with\t P­glycoprotein\t or\t strong\t CYP450\t 3A4\t inhibitors\t\t\n(eg,\t clarithromycin)\tbecause\t reduced\tbiliary\t excretion\tmay\tlead\t to\tincreased\tplasma\t\ncolchicine\tlevels\tand\ttoxicity.\tUse\twith\tcaution\tin\trenal\tor\thepatic\tinsufficiency.\n•\tColcrys\tis\tan\tFDA­approved\tcolchicine\tproduct\tavailable\tin\t0.6\tmg\toral\ttablets.\tThe\t\nrecommended\tdose\tis\t1.2\tmg\t(two\ttablets)\tinitially,\tfollowed\tby\t0.6\tmg\t(one\ttablet)\t\n1\t hour\t later.\t Although\t not\t an\t FDA­approved\t regimen,\t the\t American\t College\t of\t\nRheumatology\t(ACR)\tgout\ttreatment\tguidelines\tsuggest\tthat\tcolchicine\t0.6\tmg\tonce\t\nor\ttwice\tdaily\tcan\tbe\tstarted\t12\thours\tafter\tthe\tinitial\t1.2\tmg\tdose\tand\tcontinued\tuntil\t\nthe\tattack\tresolves.\nHYPERURICEMIA IN GOUT \n•\tRecurrent\t gout\t attacks\t can\t be\t prevented\t by\t maintaining\t low\t uric\t acid\t levels,\t but\t\nadherence\twith\tnonpharmacologic\tand\tpharmacologic\ttherapies\tis\tpoor.\nNonpharmacologic Therapy\n•\tPatient\teducation\t should\t address\tthe\trecurrent\tnature\t of\t gout\t and\t the\t objective\tof\t\neach\tlifestyle/dietary\tmodification\tand\tmedication.\n•\tPromote\tweight\tloss\tthrough\tcaloric\trestriction\tand\texercise\tin\tall\tpatients\tto\tenhance\t\nrenal\turate\texcretion.\n•\tAlcohol\trestriction\tis\timportant\tbecause\t consumption\tcorrelates\twith\tgout\tattacks.\t\nACR\tguidelines\trecommend\tlimiting\talcohol\tuse\tin\tall\tgout\tpatients\tand\tavoidance\t\nof\tany\talcohol\tduring\tperiods\tof\tfrequent\tgout\tattacks\tand\tin\tpatients\twith\tadvanced\t\ngout\tunder\tpoor\tcontrol.\n•\tDietary\trecommendations\tinclude\tlimiting\tconsumption\tof\thigh­fructose\tcorn\tsyrup\t\nand\tpurine­rich\tfoods\t(organ\tmeats\tand\tsome\tseafood)\tand\tencouraging\tconsump­\ntion\tof\tvegetables\tand\tlow­fat\tdairy\tproducts.\n•\tEvaluate\tthe\tmedication\tlist\tfor\tpotentially\tunnecessary\tdrugs\tthat\tmay\televate\turic\t\nacid\tlevels.\tGout\tis\tnot\tnecessarily\ta\tcontraindication\tto\tuse\tof\tthiazide\tdiuretics\tin\t\nhypertensive\t patients.\t Low­dose\t aspirin\t for\t cardiovascular\t prevention\t should\t be\t\ncontinued\tin\tpatients\twith\tgout\tbecause\taspirin\thas\ta\tnegligible\teffect\ton\televating\t\nserum\turic\tacid.\nPharmacologic Therapy (Fig.",
    "word_count": 333,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0027",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 27,
    "text": "  CHAPTER 1\n•\tColchicine\tcauses\tdose­dependent\tGI\tadverse\teffects\t(nausea,\tvomiting,\tand\tdiarrhea).\t\t\nNon­GI\teffects\tinclude\tneutropenia\tand\taxonal\tneuromyopathy,\twhich\tmay\tbe\twors­\nened\t in\tpatients\t taking\t other\t myopathic\t drugs\t (eg,\t statins)\t or\t in\trenal\t insufficiency.\t\t\nDo\t not\t use\t concurrently\t with\t P­glycoprotein\t or\t strong\t CYP450\t 3A4\t inhibitors\t\t\n(eg,\t clarithromycin)\tbecause\t reduced\tbiliary\t excretion\tmay\tlead\t to\tincreased\tplasma\t\ncolchicine\tlevels\tand\ttoxicity.\tUse\twith\tcaution\tin\trenal\tor\thepatic\tinsufficiency.\n•\tColcrys\tis\tan\tFDA­approved\tcolchicine\tproduct\tavailable\tin\t0.6\tmg\toral\ttablets.\tThe\t\nrecommended\tdose\tis\t1.2\tmg\t(two\ttablets)\tinitially,\tfollowed\tby\t0.6\tmg\t(one\ttablet)\t\n1\t hour\t later.\t Although\t not\t an\t FDA­approved\t regimen,\t the\t American\t College\t of\t\nRheumatology\t(ACR)\tgout\ttreatment\tguidelines\tsuggest\tthat\tcolchicine\t0.6\tmg\tonce\t\nor\ttwice\tdaily\tcan\tbe\tstarted\t12\thours\tafter\tthe\tinitial\t1.2\tmg\tdose\tand\tcontinued\tuntil\t\nthe\tattack\tresolves.\nHYPERURICEMIA IN GOUT \n•\tRecurrent\t gout\t attacks\t can\t be\t prevented\t by\t maintaining\t low\t uric\t acid\t levels,\t but\t\nadherence\twith\tnonpharmacologic\tand\tpharmacologic\ttherapies\tis\tpoor.\nNonpharmacologic Therapy\n•\tPatient\teducation\t should\t address\tthe\trecurrent\tnature\t of\t gout\t and\t the\t objective\tof\t\neach\tlifestyle/dietary\tmodification\tand\tmedication.\n•\tPromote\tweight\tloss\tthrough\tcaloric\trestriction\tand\texercise\tin\tall\tpatients\tto\tenhance\t\nrenal\turate\texcretion.\n•\tAlcohol\trestriction\tis\timportant\tbecause\t consumption\tcorrelates\twith\tgout\tattacks.\t\nACR\tguidelines\trecommend\tlimiting\talcohol\tuse\tin\tall\tgout\tpatients\tand\tavoidance\t\nof\tany\talcohol\tduring\tperiods\tof\tfrequent\tgout\tattacks\tand\tin\tpatients\twith\tadvanced\t\ngout\tunder\tpoor\tcontrol.\n•\tDietary\trecommendations\tinclude\tlimiting\tconsumption\tof\thigh­fructose\tcorn\tsyrup\t\nand\tpurine­rich\tfoods\t(organ\tmeats\tand\tsome\tseafood)\tand\tencouraging\tconsump­\ntion\tof\tvegetables\tand\tlow­fat\tdairy\tproducts.\n•\tEvaluate\tthe\tmedication\tlist\tfor\tpotentially\tunnecessary\tdrugs\tthat\tmay\televate\turic\t\nacid\tlevels.\tGout\tis\tnot\tnecessarily\ta\tcontraindication\tto\tuse\tof\tthiazide\tdiuretics\tin\t\nhypertensive\t patients.\t Low­dose\t aspirin\t for\t cardiovascular\t prevention\t should\t be\t\ncontinued\tin\tpatients\twith\tgout\tbecause\taspirin\thas\ta\tnegligible\teffect\ton\televating\t\nserum\turic\tacid.\nPharmacologic Therapy (Fig. 1–2)\n•\tAfter\tthe\tfirst\tattack\tof\tacute\tgout,\tprophylactic\tpharmacotherapy\tis\trecommended\t\nif\tpatients\thave\ttwo\tor\tmore\tattacks\tper\tyear,\teven\tif\tserum\turic\tacid\tis\tnormal\tor\t\nonly\tminimally\televated.\tOther\tindications\tinclude\tpresence\tof\ttophi,\tchronic\tkidney\t\ndisease,\tor\thistory\tof\turolithiasis.\n•\tUrate­lowering\t therapy\t can\t be\t started\t during\t an\t acute\t attack\t if\t anti­inflammatory\t\nprophylaxis\thas\tbeen\tinitiated.\n•\tThe\tgoal\tof\turate­lowering\ttherapy\tis\tto\tachieve\tand\tmaintain\tserum\turic\tacid\tless\t\nthan\t6\tmg/dL\t(357\tµmol/L),\tand\tpreferably\tless\tthan\t5\tmg/dL\t(297\tµmol/L)\tif\tsigns\t\nand\tsymptoms\tof\tgout\tpersist.\n•\tUrate\tlowering\tshould\tbe\tprescribed\tfor\tlong­term\tuse.\tSerum\turate\tcan\tbe\treduced\t\nby\t decreasing\t synthesis\t of\t uric\t acid\t (xanthine\t oxidase\t inhibitors)\t or\t by\t increasing\t\nrenal\texcretion\tof\turic\tacid\t(uricosurics).\t\n•\tApply\ta\tstep­wise\tapproach\tto\thyperuricemia\t(see\tFig.\t1–2).\tXanthine\toxidase\tinhibi­\ntors\tare\trecommended\tfirst­line\ttherapy;\tthe\turicosuric\tagent\tprobenecid\tis\trecom­\nmended\tas\talternative\ttherapy\tin\tpatients\twith\ta\tcontraindication\tor\tintolerance\tto\t\nxanthine\toxidase\tinhibitors.\tIn\trefractory\tcases,\tcombination\ttherapy\twith\ta\txanthine\t\noxidase\t inhibitor\t plus\t a\t drug\t with\t uricosuric\t properties\t (probenecid,\t losartan,\t or\t\nfenofibrate)\tis\tsuggested.\tPegloticase\tmay\tbe\tused\tin\tsevere\tcases\tin\twhich\tthe\tpatient\t\ncannot\ttolerate\tor\tis\tnot\tresponding\tto\tother\ttherapies.",
    "word_count": 539,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0028",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 28,
    "text": "6\nSECTION 1  |  Bone and Joint Disorders\nDoes patient have an indication for Urate-Lowering Therapy (ULT)?a\nAchieved\nurate target?\nContinue all measures needed to maintain serum\nurate <6 mg/dL indefinitelyd\naIndications for ULT include: (1) presence of tophus, (2) ≥2 gout attacks per year, (3) CKD stage 2 or worse, or (4) past urolithiasis\nbEvidence Grade Level A: Supported by multiple randomized clinical trials or meta-analyses\ncEvidence Grade Level B: Derived from a single randomized trial, or nonrandomized studies\ndEvidence Grade Level C: Consensus opinion of experts, case studies, or standard-of-care\nYes\nContinue prophylactic therapy\nTophus present?No Yes\nYes\nYes\nNo\nNo\nNonpharmacologic Urate-Lowering Strategiesd\nDietary Modifications\n• Reduce/avoid alcohol and organ meats\n• Increase vegetable and dairy consumption\nEliminate Urate-Elevating Medications if Unnecessary\n• Diuretics\n• Niacin\n• Calcineurin inhibitors \nDiscontinue prophylactic\ntherapy after the greater of:\n1)  6 monthsb\n             OR\n2)  3 months following\n     achievement of urate\n     targetc\nTitrate ULT to\nmaximum dose\nDiscontinue\nprophylactic\ntherapy after\n6 months\nfollowing\nachievement of\nurate targetd\nYes\nNo\nNo\nNo\nYes\nAntiinflammatory Gout Prophylaxis During ULT Initiation\nFirst-Line\n• Low-dose colchicineb\n• Low-dose NSAIDd\nSecond-Line\n• Low-dose prednisone or prednisoloned\nEvidence of gout activity\nwhile taking ULT?\nULT Initiation\nFirst-Line\n• Xanthine Oxidase Inhibitor (XOI)b\n• Allopurinol\n• Febuxostat\nAlternative\n• Probenecidc\nAchieved\nurate target?\nIf using XOI,\nadd uricosuric therapy\n• Probenecid\n• Fenofibrate\n• Losartan\nAchieved\nUrate Target?\nSwitch to\npegloticase\nFIGURE 1–2.  Algorithm for management of hyperuricemia in gout.",
    "word_count": 243,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0029",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 29,
    "text": "7\nGout and Hyperuricemia  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0030",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 30,
    "text": "7\nGout and Hyperuricemia     CHAPTER 1\nXANTHINE  OXIDASE INHIb ITORS\n•\tXanthine\t oxidase\t inhibitors\t reduce\t uric\t acid\tby\timpairing\t conversion\t of\t hypoxan­\nthine\tto\txanthine\tand\txanthine\tto\turic\tacid.\tBecause\tthey\tare\teffective\tin\tboth\tover­\nproducers\tand\tunderexcretors\tof\turic\tacid,\tthey\tare\tthe\tmost\twidely\tprescribed\tagents\t\nfor\tlong­term\tprevention\tof\trecurrent\tgout\tattacks.\n•\tAllopurinol\t lowers\t uric\t acid\t levels\t in\t a\t dose­dependent\t manner.\t ACR\t guidelines\t\nrecommend\ta\tstarting\tdose\tno\tgreater\tthan\t100\tmg\tdaily\tand\tthen\tgradually\ttitrating\t\nevery\t2\tto\t5\tweeks\tup\tto\ta\tmaximum\tdose\tof\t800\tmg/day\tuntil\tthe\tserum\turate\ttarget\t\nis\tachieved.\tPatients\twith\tchronic\tkidney\tdisease\t(stage\t4\tor\tworse)\tshould\tstart\tat\ta\t\ndose\tno\tgreater\tthan\t50\tmg\tper\tday.\tConservative\tdosing\tis\tintended\tto\tavoid\tallo­\npurinol\thypersensitivity\t syndrome\tand\tprevent\t acute\t gout\t attacks\tcommon\t during\t\ninitiation\tof\turate­lowering\ttherapy.\t\n•\tMild\t adverse\t effects\t of\t allopurinol\t include\t skin\t rash,\t leukopenia,\t GI\t problems,\t\nheadache,\t and\t urticaria.\t More\t severe\t adverse\t reactions\t include\t severe\t rash\t (toxic\t\nepidermal\tnecrolysis,\terythema\tmultiforme,\tor\texfoliative\tdermatitis)\tand\tallopurinol\t\nhypersensitivity\tsyndrome\tcharacterized\tby\tfever,\teosinophilia,\tdermatitis,\tvasculitis,\t\nand\t renal\t and\t hepatic\t dysfunction\t that\t occurs\t rarely\t but\t is\t associated\t with\t a\t 20%\t\nmortality\trate.\n•\tFebuxostat\t(Uloric)\talso\tlowers\tserum\turic\tacid\tin\ta\tdose­dependent\tmanner.\tThe\t\nrecommended\tstarting\tdose\tis\t40\tmg\tonce\tdaily.\tIncrease\tthe\tdose\tto\t80\tmg\tonce\tdaily\t\nfor\tpatients\twho\tdo\tnot\tachieve\ttarget\tserum\turic\tacid\tconcentrations\tafter\t2 weeks\tof\t\ntherapy.\tFebuxostat\tis\twell\ttolerated,\twith\tadverse\tevents\tof\tnausea,\tarthralgias,\tand\t\nminor\thepatic\ttransaminase\televations.\tFebuxostat\tdoes\tnot\trequire\tdose\tadjustment\t\nin\tmild\tto\tmoderate\thepatic\tor\trenal\tdysfunction.\tDue\tto\trapid\tmobilization\tof\turate\t\ndeposits\tduring\tinitiation,\tgive\tconcomitant\ttherapy\twith\tcolchicine\tor\tan\tNSAID\tfor\t\nat\tleast\tthe\tfirst\t8\tweeks\tof\ttherapy\tto\tprevent\tacute\tgout\tflares.\nURICOSURICS\n•\tProbenecid\t increases\t renal\t clearance\t of\t uric\t acid\t by\t inhibiting\t the\t postsecretory\t\nrenal\t proximal\t tubular\t reabsorption\t of\t uric\t acid.\t Patients\t with\t a\t history\t of\t uroli­\nthiasis\tshould\tnot\treceive\turicosurics.\tStart\ttherapy\twith\turicosurics\tat\ta\tlow\tdose\tto\t\navoid\tmarked\turicosuria\tand\tpossible\tstone\tformation.\tMaintaining\tadequate\turine\t\nflow\tand\talkalinization\tof\tthe\turine\tduring\tthe\tfirst\tseveral\tdays\tof\ttherapy\tmay\talso\t\ndecrease\tlikelihood\tof\turic\tacid\tstone\tformation.\n•\tInitial\tprobenecid\tdose\tis\t250\tmg\ttwice\tdaily\tfor\t1\tto\t2\tweeks,\tthen\t500\tmg\ttwice\tdaily\t\nfor\t2\tweeks.\tIncrease\tthe\tdaily\tdose\tthereafter\tby\t500­mg\tincrements\tevery\t1\tto\t2\tweeks\t\nuntil\tsatisfactory\tcontrol\tis\tachieved\tor\ta\tmaximum\tdose\tof\t2\tg/day\tis\treached.\n•\tMajor\t side\t effects\t of\t probenecid\t include\t GI\t irritation,\t rash\t and\t hypersensitivity,\t\nprecipitation\tof\tacute\tgouty\tarthritis,\tand\tstone\tformation.\tContraindications\tinclude\t\nimpaired\t renal\t function\t (CLcr\t <50\t mL/min\t or\t <0.84\t mL/s)\t and\t overproduction\t of\t\nuric\tacid.\nPEGLOTICASE\n•\tPegloticase\t (Krystexxa)\t is\t a\t pegylated\t recombinant\t uricase\t that\t reduces\t serum\t\nuric\tacid\tby\tconverting\turic\tacid\tto\tallantoin,\twhich\tis\twater\tsoluble.\tPegloticase\tis\t\nindicated\tfor\tantihyperuricemic\ttherapy\tin\tadults\trefractory\tto\tconventional\ttherapy.\t\n•\tThe\t dose\t is\t 8\t mg\t by\t IV\t infusion\t over\t at\t least\t 2\t hours\t every\t 2\t weeks.\t Because\t of\t\npotential\t infusion­related\t allergic\t reactions,\t patients\t must\t be\t pretreated\t with\t anti­\nhistamines\t and\t corticosteroids.\t Pegloticase\t is\t substantially\t more\t expensive\t than\t\nfirst­line\turate­lowering\ttherapies.\n•\tThe\tideal\tduration\tof\tpegloticase\ttherapy\tis\tunknown.\tDevelopment\tof\tpegloticase\t\nantibodies\tresulting\tin\tloss\tof\tefficacy\tmay\tlimit\tthe\tduration\tof\teffective\ttherapy.\t\n•\tBecause\tof\tits\tlimitations,\treserve\tpegloticase\tfor\tpatients\twith\trefractory\tgout\twho\t\nare\tunable\tto\ttake\tor\thave\tfailed\tall\tother\turate­lowering\ttherapies.",
    "word_count": 589,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0031",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 31,
    "text": "8\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0032",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 32,
    "text": "8\nSECTION 1     Bone and Joint Disorders\nANTIIFLAMMATORY PROPHYLAXIS DURING INITIATION  \nOF URATE-LOWERING THERAPY\n•\tInitiation\tof\turate­lowering\ttherapy\tcan\tprecipitate\tan\tacute\tgout\tattack\tdue\tto\tremod­\neling\t of\t urate\t crystal\t deposits\t in\t joints\t after\t rapid\t lowering\t of\t urate\t concentrations.\t\nProphylactic\tantiinflammatory\ttherapy\tshould\tbe\tused\tto\tprevent\tsuch\tgout\tattacks.\n•\tThe\tACR\tguidelines\trecommend\tlow­dose\toral\tcolchicine\t(0.6\tmg\ttwice\tdaily)\tand\t\nlow­dose\tNSAIDs\t(eg,\tnaproxen\t250\tmg\ttwice\tdaily)\tas\tfirst­line\tprophylactic\tthera­\npies,\twith\tstronger\tevidence\tsupporting\tuse\tof\tcolchicine.\tFor\tpatients\ton\tlong­term\t\nNSAID\t prophylaxis,\t a\t proton\t pump\t inhibitor\t or\t other\t acid­suppressing\t therapy\t is\t\nindicated\tto\tprotect\tfrom\tNSAID­induced\tgastric\tproblems.\t\n•\tLow­dose\t corticosteroid\t therapy\t (eg,\t prednisone\t ≤10\t mg/day)\t is\t an\t alternative\t for\t\npatients\twith\tintolerance,\tcontraindication,\tor\tlack\tof\tresponse\tto\tfirst­line\ttherapy.\t\nThe\t potential\t severe\t adverse\t effects\t of\t prolonged\t corticosteroid\t therapy\t preclude\t\ntheir\tuse\tas\tfirst­line\ttherapy.\n•\tContinue\tprophylaxis\tfor\tat\tleast\t6\tmonths\tor\t3\tmonths\tafter\tachieving\ttarget\tserum\t\nuric\t acid,\t whichever\t is\t longer.\t For\t patients\t with\t one\t or\t more\t tophi,\t continue\t pro­\nphylactic\ttherapy\tfor\t6\tmonths\tafter\tachieving\tthe\tserum\turate\ttarget\t(see\tFig.\t1–2).\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tCheck\tthe\tserum\turic\tacid\tlevel\tin\tpatients\tsuspected\tof\thaving\tan\tacute\tgout\tattack,\t\nparticularly\tif\tit\tis\tnot\tthe\tfirst\tattack,\tand\ta\tdecision\tis\tto\tbe\tmade\tabout\tstarting\tpro­\nphylaxis.\tHowever,\tacute\tgout\tcan\toccur\twith\tnormal\tserum\turic\tacid\tconcentrations.\n•\tMonitor\tpatients\twith\tacute\tgout\tfor\tsymptomatic\trelief\tof\tjoint\tpain,\tas\twell\tas\tpoten­\ntial\t adverse\t effects\t and\t drug\t interactions\t related\t to\t drug\t therapy.\t Acute\t pain\t of\t an\t\ninitial\t gout\t attack\t should\tbegin\t to\tease\t within\tabout\t8\thours\tof\ttreatment\t initiation.\t\t\nComplete\tresolution\tof\tpain,\terythema,\tand\tinflammation\tusually\toccurs\twithin\t48\tto\t\n72\thours.\n•\tFor\t patients\t receiving\t urate­lowering\t therapy,\t obtain\t baseline\t assessment\t of\t renal\t\nfunction,\thepatic\tenzymes,\tcomplete\tblood\tcount,\tand\telectrolytes.\tRecheck\tthe\ttests\t\nevery\t6\tto\t12\tmonths\tin\tpatients\treceiving\tlong­term\ttreatment.\n•\tDuring\t titration\t of\t urate­lowering\t therapy,\t monitor\t serum\t uric\t acid\t every\t 2\t to\t 5\t\nweeks;\tafter\tthe\turate\ttarget\tis\tachieved,\tmonitor\turic\tacid\tevery\t6\tmonths.\n•\tBecause\t of\t the\t high\t rates\t of\t comorbidities\t associated\t with\t gout\t (diabetes,\t chronic\t\nkidney\t disease,\t hypertension,\t obesity,\t myocardial\t infarction,\t heart\t failure,\t stroke),\t\nelevated\tserum\turic\tacid\tlevels\tor\tgout\tshould\tprompt\tevaluation\tfor\tcardiovascular\t\ndisease\t and\t the\t need\t for\t appropriate\t risk\t reduction\t measures.\t Clinicians\t should\t\nalso\tlook\tfor\tpossible\tcorrectable\tcauses\tof\thyperuricemia\t(eg,\tmedications,\tobesity,\t\nmalignancy,\talcohol\tabuse).\nSee Chapter 74, Gout and Hyperuricemia, authored by Michelle A.",
    "word_count": 424,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0033",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 33,
    "text": "  Bone and Joint Disorders\nANTIIFLAMMATORY PROPHYLAXIS DURING INITIATION  \nOF URATE-LOWERING THERAPY\n•\tInitiation\tof\turate­lowering\ttherapy\tcan\tprecipitate\tan\tacute\tgout\tattack\tdue\tto\tremod­\neling\t of\t urate\t crystal\t deposits\t in\t joints\t after\t rapid\t lowering\t of\t urate\t concentrations.\t\nProphylactic\tantiinflammatory\ttherapy\tshould\tbe\tused\tto\tprevent\tsuch\tgout\tattacks.\n•\tThe\tACR\tguidelines\trecommend\tlow­dose\toral\tcolchicine\t(0.6\tmg\ttwice\tdaily)\tand\t\nlow­dose\tNSAIDs\t(eg,\tnaproxen\t250\tmg\ttwice\tdaily)\tas\tfirst­line\tprophylactic\tthera­\npies,\twith\tstronger\tevidence\tsupporting\tuse\tof\tcolchicine.\tFor\tpatients\ton\tlong­term\t\nNSAID\t prophylaxis,\t a\t proton\t pump\t inhibitor\t or\t other\t acid­suppressing\t therapy\t is\t\nindicated\tto\tprotect\tfrom\tNSAID­induced\tgastric\tproblems.\t\n•\tLow­dose\t corticosteroid\t therapy\t (eg,\t prednisone\t ≤10\t mg/day)\t is\t an\t alternative\t for\t\npatients\twith\tintolerance,\tcontraindication,\tor\tlack\tof\tresponse\tto\tfirst­line\ttherapy.\t\nThe\t potential\t severe\t adverse\t effects\t of\t prolonged\t corticosteroid\t therapy\t preclude\t\ntheir\tuse\tas\tfirst­line\ttherapy.\n•\tContinue\tprophylaxis\tfor\tat\tleast\t6\tmonths\tor\t3\tmonths\tafter\tachieving\ttarget\tserum\t\nuric\t acid,\t whichever\t is\t longer.\t For\t patients\t with\t one\t or\t more\t tophi,\t continue\t pro­\nphylactic\ttherapy\tfor\t6\tmonths\tafter\tachieving\tthe\tserum\turate\ttarget\t(see\tFig.\t1–2).\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tCheck\tthe\tserum\turic\tacid\tlevel\tin\tpatients\tsuspected\tof\thaving\tan\tacute\tgout\tattack,\t\nparticularly\tif\tit\tis\tnot\tthe\tfirst\tattack,\tand\ta\tdecision\tis\tto\tbe\tmade\tabout\tstarting\tpro­\nphylaxis.\tHowever,\tacute\tgout\tcan\toccur\twith\tnormal\tserum\turic\tacid\tconcentrations.\n•\tMonitor\tpatients\twith\tacute\tgout\tfor\tsymptomatic\trelief\tof\tjoint\tpain,\tas\twell\tas\tpoten­\ntial\t adverse\t effects\t and\t drug\t interactions\t related\t to\t drug\t therapy.\t Acute\t pain\t of\t an\t\ninitial\t gout\t attack\t should\tbegin\t to\tease\t within\tabout\t8\thours\tof\ttreatment\t initiation.\t\t\nComplete\tresolution\tof\tpain,\terythema,\tand\tinflammation\tusually\toccurs\twithin\t48\tto\t\n72\thours.\n•\tFor\t patients\t receiving\t urate­lowering\t therapy,\t obtain\t baseline\t assessment\t of\t renal\t\nfunction,\thepatic\tenzymes,\tcomplete\tblood\tcount,\tand\telectrolytes.\tRecheck\tthe\ttests\t\nevery\t6\tto\t12\tmonths\tin\tpatients\treceiving\tlong­term\ttreatment.\n•\tDuring\t titration\t of\t urate­lowering\t therapy,\t monitor\t serum\t uric\t acid\t every\t 2\t to\t 5\t\nweeks;\tafter\tthe\turate\ttarget\tis\tachieved,\tmonitor\turic\tacid\tevery\t6\tmonths.\n•\tBecause\t of\t the\t high\t rates\t of\t comorbidities\t associated\t with\t gout\t (diabetes,\t chronic\t\nkidney\t disease,\t hypertension,\t obesity,\t myocardial\t infarction,\t heart\t failure,\t stroke),\t\nelevated\tserum\turic\tacid\tlevels\tor\tgout\tshould\tprompt\tevaluation\tfor\tcardiovascular\t\ndisease\t and\t the\t need\t for\t appropriate\t risk\t reduction\t measures.\t Clinicians\t should\t\nalso\tlook\tfor\tpossible\tcorrectable\tcauses\tof\thyperuricemia\t(eg,\tmedications,\tobesity,\t\nmalignancy,\talcohol\tabuse).\nSee Chapter 74, Gout and Hyperuricemia, authored by Michelle A. Fravel, Michael E.",
    "word_count": 424,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0034",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 34,
    "text": "Fravel, Michael E. \nErnst, and Elizabeth C. Clark, for a more detailed discussion of this topic.",
    "word_count": 16,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0035",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 35,
    "text": "9\nChapter_Title\n00\nChapter\n•\tOsteoarthritis\t (OA)\t is\t a\t common,\t progressive\t disorder\t affecting\t primarily\t weight-\t\nbearing\tdiarthrodial\tjoints,\tcharacterized\tby\tprogressive\tdeterioration\tand\tloss\tof\tarticu-\nlar\tcartilage,\tosteophyte\tformation,\tpain,\tlimitation\tof\tmotion,\tdeformity,\tand\tdisability.\t\nPATHOPHYSIOLOGY\n•\tPrimary (idiopathic) OA,\tthe\tmost\tcommon\ttype,\thas\tno\tknown\tcause.\t\n•\tSecondary OA\tis\tassociated\twith\ta\tknown\tcause,\tsuch\tas\ttrauma,\tmetabolic\tor\tendo-\ncrine\tdisorders,\tand\tcongenital\tfactors.\n•\tOA\t usually\t begins\t with\t damage\t to\t articular\t cartilage\t through\t injury,\t excessive\t joint\t\nloading\tfrom\tobesity\tor\tother\treasons,\tor\tjoint\tinstability\tor\tinjury.\tDamage\tto\tcartilage\t\nincreases\tactivity\tof\tchondrocytes\tin\tattempt\tto\trepair\tdamage,\tleading\tto\tincreased\tsyn-\nthesis\tof\tmatrix\tconstituents\twith\tcartilage\tswelling.\tNormal\tbalance\tbetween\t\tcartilage\t\nbreakdown\tand\tresynthesis\tis\tlost,\twith\tincreasing\tdestruction\tand\tcartilage\tloss.\n•\tSubchondral\t bone\t adjacent\t to\t articular\t cartilage\t undergoes\t pathologic\t changes\t and\t\nreleases\tvasoactive\tpeptides\tand\tmatrix\tmetalloproteinases\t(MMPs).\tNeovascularization\t\nand\t increased\t permeability\t of\t adjacent\t cartilage\t occur,\t which\t contribute\t to\t cartilage\t\nloss\tand\tchondrocyte\tapoptosis.\n•\tCartilage\tloss\tcauses\tjoint\tspace\tnarrowing\tand\tpainful,\tdeformed\tjoints.\tRemaining\t\ncartilage\t softens\t and\t develops\t fibrillations,\t followed\t by\t further\t cartilage\t loss\t and\t\nexposure\t of\t underlying\t bone.\tNew\t bone\tformations\t (osteophytes)\t at\t joint\tmargins\t\ndistant\tfrom\tcartilage\tdestruction\tare\tthought\tto\thelp\tstabilize\taffected\tjoints.\n•\tInflammatory\tchanges\tcan\toccur\tin\tthe\tjoint\tcapsule\tand\tsynovium.\tCrystals\tor\tcar-\ntilage\tshards\tin\tsynovial\tfluid\tmay\tcontribute\tto\tinflammation.\tInterleukin-1,\tprosta-\nglandin\tE2,\ttumor\tnecrosis\tfactor-α\t(TNF-α),\tand\tnitric\toxide\tin\tsynovial\tfluid\tmay\t\nalso\tplay\ta\trole.\tInflammatory\tchanges\tresult\tin\tsynovial\teffusions\tand\tthickening.\n•\tPain\tmay\tresult\tfrom\tdistention\tof\tthe\tsynovial\tcapsule\tby\tincreased\tjoint\tfluid;\tmicro-\nfracture;\tperiosteal\tirritation;\tor\tdamage\tto\tligaments,\tsynovium,\tor\tthe\tmeniscus.\nCLINICAL PRESENTATION\n•\tRisk\t factors\t include\t increasing\t age,\t obesity,\t repetitive\t use\t through\t work\t or\t leisure\t\nactivities,\tjoint\ttrauma,\tand\tgenetic\tpredisposition.\n•\tPredominant\tsymptom\tis\tdeep,\taching\tpain\tin\taffected\tjoints.\tPain\taccompanies\tjoint\t\nactivity\tand\tdecreases\twith\trest.\n•\tJoints\t most\t commonly\t affected\t are\t the\t distal\t interphalangeal\t (DIP)\t and\t proximal\t\ninterphalangeal\t (PIP)\t joints\t of\t the\t hand,\t first\t carpometacarpal\t joint,\t knees,\t hips,\t\ncervical\tand\tlumbar\tspine,\tand\tfirst\tmetatarsophalangeal\t(MTP)\tjoint\tof\tthe\ttoe.\n•\tLimitation\t of\t motion,\t stiffness,\t crepitus,\t and\t deformities\t may\t occur.\t Patients\t with\t\nlower\textremity\tinvolvement\tmay\treport\tweakness\tor\tinstability.\n•\tUpon\tarising,\tjoint\tstiffness\ttypically\tlasts\tless\tthan\t30\tminutes\tand\tresolves\twith\tmotion.\n•\tPresence\tof\twarm,\tred,\tand\ttender\tjoints\tsuggests\tinflammatory\tsynovitis.\n•\tPhysical\t examination\t of\t affected\t joints\t reveals\t tenderness,\t crepitus,\t and\t possibly\t\nenlargement.\tHeberden\tand\tBouchard\tnodes\tare\tbony\tenlargements\t(osteophytes)\tof\t\nthe\tDIP\tand\tPIP\tjoints,\trespectively.\nDIAGNOSIS\n•\tDiagnosis\tis\tmade\tthrough\tpatient\thistory,\tphysician\texamination,\tradiologic\tfind-\nings,\tand\tlaboratory\ttesting.\n•\tAmerican\t College\t of\t Rheumatology\t (ACR)\t criteria\t for\t classification\t of\t OA\t of\t the\t\nhips,\t knees,\t and\t hands\t include\t presence\t of\t pain,\t bony\t changes\t on\t examination,\t\nOsteoarthritis\n2\nC h a p t e r",
    "word_count": 484,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0036",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 36,
    "text": "10\nSeCt ION 1     Bone and Joint Disorders\nnormal\terythrocyte\tsedimentation\trate\t(ESR),\tand\tradiographs\tshowing\tosteophytes\t\nor\tjoint\tspace\tnarrowing.\n•\tFor\thip\tOA,\tpatient\tmust\thave\thip\tpain\tand\ttwo\tof\tthe\tfollowing:\t(1)\tESR\tless\tthan\t\t\n20\tmm/h,\t(2)\tradiographic\tfemoral\tor\tacetabular\tosteophytes,\tand/or\t(3)\tradiographic\t\njoint\tspace\tnarrowing.\n•\tFor\tknee\tOA,\tpatient\tmust\thave\tknee\tpain\tand\tradiographic\tosteophytes\tin\taddition\t\nto\tone\tor\tmore\tof\tthe\tfollowing:\t(1)\t age\tmore\tthan\t50\tyears,\t(2)\tmorning\tstiffness\t\nlasting\t 30\t minutes\t or\t less,\t(3)\t crepitus\t on\t motion,\t (4)\t bony\t enlargement,\t(6)\t bony\t\ntenderness,\tand/or\t(7)\tpalpable\tjoint\twarmth.\n•\tESR\tmay\tbe\tslightly\televated\tif\tinflammation\tis\tpresent.\tRheumatoid\tfactor\tis\tnegative.\t\nAnalysis\t of\t synovial\t fluid\t reveals\t high\t viscosity\t and\t mild\t leukocytosis\t (<2000\t white\t\nblood\tcells/mm3\t[<2\t×\t109/L])\twith\tpredominantly\tmononuclear\tcells.\nTREATMENT\n•\tGoals\tof\tTreatment:\t(1)\teducate\tpatient,\tfamily\tmembers,\tand\tcaregivers;\t(2)\trelieve\t\npain\tand\tstiffness;\t(3)\tmaintain\tor\timprove\tjoint\tmobility;\t(4)\tlimit\tfunctional\timpair-\nment;\tand\t(5)\tmaintain\tor\timprove\tquality\tof\tlife.\nNONPHARMACOLOGIC THERAPY\n•\tEducate\tpatient\tabout\tdisease\tprocess\tand\textent,\tprognosis,\tand\ttreatment.\tPromote\t\ndietary\tcounseling,\texercise,\tand\tweight\tloss\tprogram\tfor\toverweight\tpatients.\n•\tPhysical\t therapy—with\t heat\t or\t cold\t treatments\t and\t an\t exercise\t program—helps\t\nmaintain\trange\tof\tmotion\tand\treduce\tpain\tand\tneed\tfor\tanalgesics.\n•\tAssistive\tand\torthotic\tdevices\t(canes,\twalkers,\tbraces,\theel\tcups,\tinsoles)\tcan\tbe\tused\t\nduring\texercise\tor\tdaily\tactivities.\n•\tSurgical\tprocedures\t(eg,\tosteotomy,\tarthroplasty,\tjoint\tfusion)\tare\tindicated\tfor\tfunc-\ntional\tdisability\tand/or\tsevere\tpain\tunresponsive\tto\tconservative\ttherapy.\nPHARMACOLOGIC THERAPY (T Ab LE 2–1)\nGeneral Approach\n•\tDrug\t therapy\t is\t targeted\t at\t relief\t of\t pain.\t A\t conservative\t approach\t is\t warranted\t\nbecause\tOA\toften\toccurs\tin\tolder\tindividuals\twith\tother\tmedical\tconditions.\n•\tApply\tan\tindividualized\tapproach\t(Figs.",
    "word_count": 299,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0037",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 37,
    "text": "  Bone and Joint Disorders\nnormal\terythrocyte\tsedimentation\trate\t(ESR),\tand\tradiographs\tshowing\tosteophytes\t\nor\tjoint\tspace\tnarrowing.\n•\tFor\thip\tOA,\tpatient\tmust\thave\thip\tpain\tand\ttwo\tof\tthe\tfollowing:\t(1)\tESR\tless\tthan\t\t\n20\tmm/h,\t(2)\tradiographic\tfemoral\tor\tacetabular\tosteophytes,\tand/or\t(3)\tradiographic\t\njoint\tspace\tnarrowing.\n•\tFor\tknee\tOA,\tpatient\tmust\thave\tknee\tpain\tand\tradiographic\tosteophytes\tin\taddition\t\nto\tone\tor\tmore\tof\tthe\tfollowing:\t(1)\t age\tmore\tthan\t50\tyears,\t(2)\tmorning\tstiffness\t\nlasting\t 30\t minutes\t or\t less,\t(3)\t crepitus\t on\t motion,\t (4)\t bony\t enlargement,\t(6)\t bony\t\ntenderness,\tand/or\t(7)\tpalpable\tjoint\twarmth.\n•\tESR\tmay\tbe\tslightly\televated\tif\tinflammation\tis\tpresent.\tRheumatoid\tfactor\tis\tnegative.\t\nAnalysis\t of\t synovial\t fluid\t reveals\t high\t viscosity\t and\t mild\t leukocytosis\t (<2000\t white\t\nblood\tcells/mm3\t[<2\t×\t109/L])\twith\tpredominantly\tmononuclear\tcells.\nTREATMENT\n•\tGoals\tof\tTreatment:\t(1)\teducate\tpatient,\tfamily\tmembers,\tand\tcaregivers;\t(2)\trelieve\t\npain\tand\tstiffness;\t(3)\tmaintain\tor\timprove\tjoint\tmobility;\t(4)\tlimit\tfunctional\timpair-\nment;\tand\t(5)\tmaintain\tor\timprove\tquality\tof\tlife.\nNONPHARMACOLOGIC THERAPY\n•\tEducate\tpatient\tabout\tdisease\tprocess\tand\textent,\tprognosis,\tand\ttreatment.\tPromote\t\ndietary\tcounseling,\texercise,\tand\tweight\tloss\tprogram\tfor\toverweight\tpatients.\n•\tPhysical\t therapy—with\t heat\t or\t cold\t treatments\t and\t an\t exercise\t program—helps\t\nmaintain\trange\tof\tmotion\tand\treduce\tpain\tand\tneed\tfor\tanalgesics.\n•\tAssistive\tand\torthotic\tdevices\t(canes,\twalkers,\tbraces,\theel\tcups,\tinsoles)\tcan\tbe\tused\t\nduring\texercise\tor\tdaily\tactivities.\n•\tSurgical\tprocedures\t(eg,\tosteotomy,\tarthroplasty,\tjoint\tfusion)\tare\tindicated\tfor\tfunc-\ntional\tdisability\tand/or\tsevere\tpain\tunresponsive\tto\tconservative\ttherapy.\nPHARMACOLOGIC THERAPY (T Ab LE 2–1)\nGeneral Approach\n•\tDrug\t therapy\t is\t targeted\t at\t relief\t of\t pain.\t A\t conservative\t approach\t is\t warranted\t\nbecause\tOA\toften\toccurs\tin\tolder\tindividuals\twith\tother\tmedical\tconditions.\n•\tApply\tan\tindividualized\tapproach\t(Figs. 2–1 and 2–2).\tContinue\tappropriate\tnon-\ndrug\ttherapies\twhen\tinitiating\tdrug\ttherapy.\nKnee and Hip OA\n•\tAcetaminophen\tis\ta\tpreferred\tfirst-line\ttreatment;\tit\tmay\tbe\tless\teffective\tthan\toral\t\nnonsteroidal\tanti-inflammatory\tdrugs\t(NSAIDs)\tbut\thas\tless\trisk\tof\tserious\tgastroin-\ntestinal\t(GI)\tand\tcardiovascular\tevents.\n•\tIf\ta\tpatient\tfails\tacetaminophen,\tnonselective NSAIDs or cyclooxygenase-2 (COX-2) \nselective inhibitors (eg,\t celecoxib)\t are\t recommended.\t COX-2\t inhibitors\t pose\t less\t\nrisk\tfor\tadverse\tGI\tevents\tthan\tnonselective\tNSAIDs,\tbut\tthis\tadvantage\tmay\tnot\tbe\t\nsustained\t beyond\t6\t months\t and\tis\t substantially\treduced\tfor\t patients\t taking\taspirin.\t\nProton\tpump\tinhibitors\t(PPIs)\tand\tmisoprostol\treduce\tadverse\tGI\tevents\tin\tpatients\t\ntaking\tNSAIDs.\n•\tFor\t knee\t OA,\t topical NSAIDs \t are\t recommended\t if\t acetaminophen\t fails\t and\t are\t\npreferred\tover\toral\tNSAIDs\tin\tpatients\tolder\tthan\t75\tyears.\tT opical\tNSAIDs\tprovide\t\nsimilar\tpain\trelief\twith\tfewer\tadverse\tGI\tevents\tthan\toral\tNSAIDs\tbut\tmay\tbe\tassoci-\nated\twith\tadverse\tevents\tat\tthe\tapplication\tsite.\n•\tIntra-articular (IA) corticosteroid injections \t are\t recommended\t for\t both\t hip\t and\t\nknee\tOA\twhen\tanalgesia\twith\tacetaminophen\tor\tNSAIDs\tis\tsuboptimal.\tInjections\t\ncan\t be\t given\t with\t concomitant\t oral\t analgesics\t for\t additional\t pain\t control.\t Do\t\nnot\t administer\t injections\t more\t frequently\t than\t once\t every\t 3\t months\t to\t minimize\t\n\tsystemic\tadverse\teffects.",
    "word_count": 501,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0038",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 38,
    "text": "11\nOsteoarthritis  |  Chapter  2\n TABLE 2–1  Medications for the Treatment of Osteoarthritis\nDrug Starting Dose Usual Range\nOral analgesics\nAcetaminophen 325–500 mg 3 times \na day\n325–650 mg every 4–6 h or 1 g 3–4 times/\nday\nTramadol 25 mg in the morning Titrate dose in 25-mg increments to reach a  \nmaintenance dose of 50–100 mg 3 times \na day.\nTramadol ER 100 mg daily Titrate to 200–300 mg daily\nHydrocodone/ \nacetaminophen\n5 mg/325 mg 3 times \ndaily\n2.5–10 mg/325–650 mg 3–5 times daily\nOxycodone/ \nacetaminophen\n5 mg/325 mg 3 times \ndaily\n2.5–10 mg/325–650 mg 3–5 times daily\nTopical analgesics\nCapsaicin 0.025% or \n0.075%\nApply to affected joint 3–4 times per day.\nDiclofenac 1% gel Apply 2 or 4 g per site as prescribed, 4 \ntimes daily.\nDiclofenac 1.3% \npatch\nApply one patch twice daily to the site to \nbe treated, as directed. \nDiclofenac 1.5% \nsolution\nApply 40 drops to the affected knee, apply -\ning and rubbing in 10 drops at a time. \nRepeat for a total of 4 times daily.\nIntra-articular cortico-\nsteroids\nTriamcinolone 5–15 mg per joint 10–40 mg per large joint (knee, hip, shoul-\nder)\nMethylprednisolone \nacetate\n10–20 mg per joint 20–80 mg per large joint (knee, hip, shoul-\nder) \nNSAIDs\nAspirin (plain, buff-\nered, or enteric-\ncoated)\n325 mg 3 times a day 325–650 mg 4 times a day\nCelecoxib 100 mg daily 100 mg twice daily or 200 mg daily\nDiclofenac IR 50 mg twice a day 50–75 mg twice a day\nDiclofenac XR 100 mg daily 100–200 mg daily\nDiflunisal 250 mg twice a day 500–750 mg twice a day\nEtodolac 300 mg twice a day 400 to 500 mg twice a day\nFenoprofen 400 mg 3 times a day 400–600 mg 3–4 times a day\nFlurbiprofen 100 mg twice a day 200–300 mg/day in 2–4 divided doses\nIbuprofen 200 mg 3 times a day 1200–3200 mg/day in 3–4 divided doses\nIndomethacin 25 mg twice a day Titrate dose by 25–50 mg/day until pain  \ncontrolled or maximum dose of 50 mg  \n3 times a day\n(continued)",
    "word_count": 344,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0039",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 39,
    "text": "12\nSeCt ION 1  |  Bone and Joint Disorders\n TABLE 2–1   Medications for the Treatment of Osteoarthritis (Continued)\nDrug Starting Dose Usual Range\nIndomethacin SR 75 mg SR once daily Can titrate to 75 mg SR twice daily if \nneeded\nKetoprofen 50 mg 3 times a day 50–75 mg 3–4 times a day\nMeclofenamate 50 mg 3 times a day 50–100 mg 3–4 times a day\nMefenamic acid 250 mg 3 times a day 250 mg 4 times a day\nMeloxicam 7.5 mg daily 15 mg daily\nNabumetone 500 mg daily 500–1000 mg 1–2 times a day\nNaproxen 250 mg twice a day 500 mg twice a day\nNaproxen sodium 220 mg twice a day 220–550 mg twice a day\nNaproxen sodium CR 750–1000 mg once \ndaily\n500–1500 mg once daily \nOxaprozin 600 mg daily 600–1200 mg daily\nPiroxicam 10 mg daily 20 mg daily\nSalsalate 500 mg twice a day 500–1000 mg 2–3 times a day\nCR, controlled-release; ER, extended-release; IR, immediate-release; SR, sustained-release; XR, \nextended-release.\nPatient requires\npharmacologic treatment\n Is acetaminophen\ncontraindicated?\nAcetaminophena\nMaximum 4 g/day\nContinue treatment\nNote: Selection of a medication should consider patient-specific characteristics.\naThe patient must be counseled regarding all acetaminophen-containing products.\nbWhen used for chronic management of OA, consider addition of a proton pump inhibitor.\nIs treatment effective?\nNo Yes\nseYoN\nAlternative second-line\nagents\n• Opioid analgesics\n• Surgery\n• Duloxetine (knee only)\n• Intra-articular hyaluronan\nAlternative /f_irst-line\nagents\n• Topical NSAIDs\n (knee only)\n• Intra-articular\n c orticosteroids\n• Tramadol\n• Oral NSAIDs\n (if <75 years or\n low CV and GI risk)b \nFIGURE 2–1.  Treatment recommendations for hip and knee osteoarthritis (OA). \n(CV, cardiovascular; GI, gastrointestinal; NSa ID, nonsteroidal anti-inflammatory drug.)",
    "word_count": 278,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0040",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 40,
    "text": "13\nOsteoarthritis  |  Chapter  2\n•\tTramadol\tis\trecommended\tfor\thip\tand\tknee\tOA\tin\tpatients\twho\thave\tfailed\tsched-\nuled\tfull-dose\tacetaminophen\tand\ttopical\tNSAIDs,\twho\tare\tnot\tappropriate\tcandi-\ndates\tfor\toral\tNSAIDs,\tand\twho\tare\tnot\table\tto\treceive\tIA\tcorticosteroids.\tTramadol\t\ncan\tbe\tadded\tto\tpartially\teffective\tacetaminophen\tor\toral\tNSAID\ttherapy.\n•\tOpioids\tshould\tbe\tconsidered\tin\tpatients\tnot\tresponding\tadequately\tto\tnonpharma-\ncologic\tand\tfirst-line\tpharmacologic\ttherapies.\tPatients\twho\tare\tat\thigh\tsurgical\trisk\t\nand\tcannot\tundergo\tjoint\tarthroplasty\tare\talso\tcandidates\tfor\topioid\ttherapy.\tAdverse\t\nevents\tlimit\troutine\tuse\tof\topioids\tfor\ttreatment\tof\tOA\tpain.\n•\tDuloxetine\tcan\tbe\tused\tas\tadjunctive\ttreatment\tin\tpatients\twith\tpartial\tresponse\tto\t\nfirst-line\tanalgesics\t(acetaminophen,\toral\tNSAIDs).\tIt\tmay\tbe\ta\tpreferred\tsecond-line\t\nmedication\tin\tpatients\twith\tboth\tneuropathic\tand\tmusculoskeletal\tOA\tpain.\t\n•\tIA hyaluronic acid\tis\tnot\troutinely\trecommended\tfor\tknee\tOA\tpain.\tInjections\tdo\t\nnot\tprovide\tclinically\tmeaningful\timprovement\tand\tmay\tbe\tassociated\twith\tserious\t\nadverse\tevents\t(eg,\tincreased\tpain,\tjoint\tswelling,\tand\tstiffness).\t\n•\tGlucosamine and/or chondroitin and topical rubefacients ( eg, methyl salicy-\nlate, trolamine salicylate) \tlack\tuniform\tefficacy\tfor\thip\tand\tknee\tpain\tand\tare\tnot\t\n\tpreferred\ttreatment\toptions.\nPatient requires\npharmacologic treatment\nIs patient ≥75 years of\nage?\naSelection of a medication should consider patient-specific characteristics\nbWhen used for chronic management of OA, consider addition of a proton pump inhibitor\ncShould not combine topical NSAIDs and oral NSAIDs\nseYoN\noNoN\nFirst-line agents\nTopical NSAIDs \nor\nTopical capsaicin\nand/or\nTramadol\nFirst-line Agents\nOral NSAIDsb (if\nlow CV and GI risk) \nTopical NSAIDs\nor\nTopical capsaicin\nand/or\nTramadol\nAlternative regimens\nCombined therapy\nwith 2 first-line\nagentsc\nAlternative Regimens\nCombined therapy\nwith 2 first-line\nagentsc\n(ie, oral NSAIDs\nand topical capsaicin\nor tramadol)\nIs treatment\neffective?\nIs treatment\neffective?Continue treatment YesYes\nFIGURE 2–2.  Treatment recommendations for hand osteoarthritis (OA). (CV, car-\ndiovascular; GI, gastrointestinal; NSa ID, nonsteroidal anti-inflammatory drug.)",
    "word_count": 318,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0041",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 41,
    "text": "14\nSeCt ION 1  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0042",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 42,
    "text": "14\nSeCt ION 1     Bone and Joint Disorders\nHand OA\n•\tTopical NSAIDs are\ta\tfirst-line\toption\tfor\thand\tOA.\tDiclofenac\thas\tefficacy\tsimilar\t\nto\toral\tibuprofen\tand\toral\tdiclofenac\twith\tfewer\tadverse\tGI\tevents,\talbeit\twith\tsome\t\nlocal\tapplication\tsite\tevents.\n•\tOral NSAIDs are\tan\talternative\tfirst-line\ttreatment\tfor\tpatients\twho\tcannot\ttolerate\t\nthe\tlocal\tskin\treactions\tor\twho\treceived\tinadequate\trelief\tfrom\ttopical\tNSAIDs.\n•\tCapsaicin cream is\t an\t alternative\t first-line\t treatment\t and\t demonstrates\t modest\t\nimprovement\tin\tpain\tscores.\tIt\tis\ta\treasonable\toption\tfor\tpatients\tunable\tto\ttake\toral\t\nNSAIDs.\tAdverse\teffects\tare\tprimarily\tskin\tirritation\tand\tburning.\t\n•\tTramadol\tis\tan\talternative\tfirst-line\ttreatment\tand\tis\ta\treasonable\tchoice\tfor\tpatients\t\nwho\t do\t not\t respond\t to\t topical\t therapy\t and\t are\t not\t candidates\t for\t oral\t NSAIDs\t\nbecause\t of\t high\t GI,\t cardiovascular,\t or\t renal\t risks.\t Tramadol\t may\t also\t be\t used\t in\t\ncombination\twith\tpartially\teffective\tacetaminophen,\ttopical\ttherapy,\tor\toral\tNSAIDs.\nDrug Class Information\n•\tAcetaminophen\t is\t usually\t well\t tolerated,\t but\t potentially\t fatal\t hepatotoxicity\t with\t\noverdose\t is\t well\t documented.\t Avoid\t in\t chronic\t alcohol\t users\t or\t patients\t with\t\nliver\t disease.\t Renal\t toxicity\t is\t possible\t with\t long-term\t use;\t use\t of\t nonprescription\t\ncombination\t products\t containing\t acetaminophen\t and\t NSAIDs\t is\t discouraged\t\nbecause\tof\tincreased\trisk\tof\trenal\tfailure.\n•\tNSAIDs\tcause\tminor\tGI\tcomplaints\tsuch\tas\tnausea,\tdyspepsia,\tanorexia,\tabdominal\t\npain,\t flatulence,\t and\t diarrhea\t in\t 10%\t to\t 60%\t of\t patients.\t They\t may\t cause\t gastric\t\nand\t duodenal\t ulcers\t and\t bleeding\t through\t direct\t (topical)\t or\t indirect\t (systemic)\t\nmechanisms.\tRisk\tfactors\tfor\tNSAID-associated\tulcers\tand\tulcer\tcomplications\t(per-\nforation,\tgastric\toutlet\tobstruction,\tand\tGI\tbleeding)\tinclude\thistory\tof\tcomplicated\t\nulcer,\t concomitant\t use\t of\t multiple\t NSAIDs\t (including\t aspirin)\t or\t anticoagulants,\t\nuse\t of\t high-dose\t NSAIDs,\t and\t age\t more\t than\t 70\t years.\t Options\t for\t reducing\t the\t\nGI\trisk\tof\tnonselective\tNSAIDs\tinclude\tusing\t(1)\tthe\tlowest\tdose\tpossible\tand\tonly\t\nwhen\t needed,\t (2)\t misoprostol\t four\t times\t daily\t with\t the\t NSAID,\t (3)\t a\t PPI\t or\t full-\ndose\t H2-receptor\tantagonist\tdaily\twith\tthe\t NSAID.\t COX-2\tselective\tinhibitors\t (eg,\t\ncelecoxib)\t may\t reduce\t risk\t of\t GI\t events\t but\t increase\t risk\t of\t cardiovascular\t events.\t\nNSAIDs\t may\t also\t cause\t kidney\t diseases,\t hepatitis,\t hypersensitivity\t reactions,\t rash,\t\nand\tCNS\tcomplaints\tof\tdrowsiness,\tdizziness,\theadaches,\tdepression,\tconfusion,\tand\t\ntinnitus.\tAll\tnonselective\tNSAIDs\tinhibit\tCOX-1–dependent\tthromboxane\tproduc-\ntion\tin\tplatelets,\tthereby\tincreasing\tbleeding\trisk.\tAvoid\tNSAIDs\tin\tlate\tpregnancy\t\nbecause\tof\trisk\tof\tpremature\tclosure\tof\tductus\tarteriosus.\tThe\tmost\tpotentially\tseri-\nous\tdrug\tinteractions\tinclude\tuse\tof\tNSAIDs\twith\tlithium,\twarfarin,\toral\thypogly-\ncemics,\tmethotrexate,\tantihypertensives,\tangiotensin-converting\tenzyme\tinhibitors,\t\nβ-blockers,\tand\tdiuretics.\n•\tT opical\t NSAIDs\t are\t associated\t with\t fewer\t GI\t and\t other\t adverse\t events\t than\t oral\t\nNSAIDs\t except\t for\t local\t application\t site\t reactions\t (eg,\t dry\t skin,\t pruritus,\t rash).\t\nPatients\tusing\ttopical\tproducts\tshould\tavoid\toral\tNSAIDs\tto\tminimize\tthe\tpotential\t\nfor\tadditive\tside\teffects.\n•\tIA\tcorticosteroids\tcan\tprovide\texcellent\tpain\trelief,\tparticularly\twhen\tjoint\teffusion\t\nis\tpresent.\tAfter\taseptic\taspiration\tof\tthe\teffusion\tand\tcorticosteroid\tinjection,\tinitial\t\npain\t relief\t may\t occur\t within\t 24\t to\t 72\t hours,\t with\t peak\t relief\t occurring\t after\t 7\t to\t\t\n10\t days\t and\t lasting\t for\t 4\t to\t 8\t weeks.\t Local\t adverse\t effects\t can\t include\t infection,\t\nosteonecrosis,\ttendon\trupture,\tand\tskin\tatrophy\tat\tthe\tinjection\tsite.\tSystemic\tcorti-\ncosteroid\ttherapy\tis\tnot\trecommended\tin\tOA,\tgiven\tlack\tof\tproven\tbenefit\tand\twell-\nknown\tadverse\teffects\twith\tlong-term\tuse.\n•\tCapsaicin\tmust\tbe\tused\tregularly\tto\tbe\teffective,\tand\tit\tmay\trequire\tup\tto\t2\tweeks\tto\t\ntake\teffect.\tAdverse\teffects\tare\tprimarily\tlocal\twith\tone\tthird\tof\tpatients\texperiencing\t\nburning,\tstinging,\tand/or\terythema\tthat\tusually\tsubsides\twith\trepeated\tapplication.\t\nW arn\tpatients\tnot\tto\tget\tcream\tin\ttheir\teyes\tor\tmouth\tand\tto\twash\thands\tafter\tappli-\ncation.\tApplication\tof\tthe\tcream,\tgel,\tor\tlotion\tis\trecommended\tfour\ttimes\tdaily,\tbut\t\ntwice-daily\tapplication\tmay\tenhance\tlong-term\tadherence\twith\tadequate\tpain\trelief.",
    "word_count": 629,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0043",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 43,
    "text": "15\nOsteoarthritis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0044",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 44,
    "text": "15\nOsteoarthritis     Chapter  2\n•\tTramadol\tis\tassociated\twith\topioid-like\tadverse\teffects\tsuch\tas\tnausea,\tvomiting,\tdiz-\nziness,\tconstipation,\theadache,\tand\tsomnolence.\tHowever,\ttramadol\tis\tnot\tassociated\t\nwith\t life-threatening\t GI\tbleeding,\t cardiovascular\tevents,\t or\trenal\t failure.\tThe\tmost\t\nserious\tadverse\tevent\tis\tseizures.\tAlthough\tnot\tclassified\tas\ta\tcontrolled\tsubstance,\t\ndrug-seeking\tbehaviors\thave\tbeen\treported\twith\ttramadol\tuse.\tThere\tis\tincreased\trisk\t\nof\tserotonin\tsyndrome\twhen\ttramadol\tis\tused\twith\tother\tserotonergic\tmedications,\t\nincluding\tduloxetine.\n•\tStart\t opioid\t analgesics\t in\t low\t doses,\t allowing\t a\t sufficient\t duration\t between\t dose\t\nincreases\t to\t assess\t efficacy\t and\t safety.\t Sustained-release\t compounds\t usually\t offer\t\nbetter\t pain\t control\t throughout\t the\t day.\t Common\t adverse\t effects\t include\t nausea,\t\nsomnolence,\tconstipation,\tdry\tmouth,\tand\tdizziness.\tOpioid\tdependence,\taddiction,\t\ntolerance,\t hyperalgesia,\t and\t issues\t surrounding\t drug\t diversion\t may\t be\t associated\t\nwith\tlong-term\ttreatment.\n•\tDuloxetine\t may\t cause\t nausea,\t dry\t mouth,\t constipation,\t anorexia,\t fatigue,\t somno-\nlence,\tand\tdizziness.\tSerious\trare\tevents\tinclude\tStevens-Johnson\tsyndrome\tand\tliver\t\nfailure.\tConcomitant\tuse\twith\tother\tmedications\tthat\tincrease\tserotonin\tconcentra-\ntion\t(including\ttramadol)\tincreases\trisk\tof\tserotonin\tsyndrome.\n•\tHyaluronic\t acid\t (sodium\t hyaluronate)\t injections\t have\t limited\t benefit\t for\t patients\t\nwith\tknee\tOA\tand\thave\tnot\tbeen\tshown\tto\tbenefit\tpatients\twith\thip\tOA.\tInjections\t\nare\twell\ttolerated,\tbut\tacute\tjoint\tswelling,\teffusion,\tand\tstiffness,\tas\twell\tas\tlocal\tskin\t\nreactions\t(eg,\trash,\tecchymoses,\tor\tpruritus)\thave\tbeen\treported.\tSix\tintra-articular\t\npreparations\tand\tregimens\tare\tavailable\tfor\tOA\tknee\tpain:\n✓\tSodium hyaluronate 20 mg/2 mL\t(Hyalgan)\tonce\tweekly\tfor\tfive\tinjections\n✓\tSodium hyaluronate 20 mg/2 mL\t(Euflexxa)\tonce\tweekly\tfor\tthree\tinjections\n✓\tSodium hyaluronate 25 mg/2.5 mL\t(Supartz)\tonce\tweekly\tfor\tfive\tinjections\n✓\tHylan polymers 16 mg/2 mL\t(Synvisc)\tonce\tweekly\tfor\tthree\tinjections\n✓\t\tHylan polymers 48 mg/6 mL \t (Synvisc-One)\t single\t injection\t (with\t efficacy\t for\t\nup\tto\t26\tweeks)\n✓\tHyaluronan 30 mg/2 mL\t(Orthovisc)\tonce\tweekly\tfor\tthree\tinjections\n•\tGlucosamine\tadverse\teffects\tare\tmild\tand\tinclude\tflatulence,\tbloating,\tand\tabdominal\t\ncramps;\t do\t not\t use\t in\t patients\t with\t shellfish\t allergies.\t The\t most\t common\t adverse\t\neffect\tof\tchondroitin\tis\tnausea.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tT o\tmonitor\tefficacy,\tassess\tbaseline\tpain\twith\ta\tvisual\tanalog\tscale,\tand\tassess\trange\t\nof\tmotion\tfor\taffected\tjoints\twith\tflexion,\textension,\tabduction,\tor\tadduction.\n•\tDepending\ton\tthe\tjoint(s)\taffected,\tmeasurement\tof\tgrip\tstrength\tand\t50-ft\twalking\t\ntime\tcan\thelp\tassess\thand\tand\thip/knee\tOA,\trespectively.\n•\tBaseline\t radiographs\tcan\t document\textent\tof\t joint\tinvolvement\tand\t follow\tdisease\t\nprogression\twith\ttherapy.\n•\tOther\t measures\t include\t the\t clinician’ s\t global\tassessment\t based\ton\t patient’ s\t history\t\nof\t activities\t and\t limitations\t caused\t by\t OA,\t the\t W estern\t Ontario\t and\t McMaster\t\nUniversities\tArthrosis\tIndex,\tStanford\tHealth\tAssessment\tQuestionnaire,\tand\tdocu-\nmentation\tof\tanalgesic\tor\tNSAID\tuse.\n•\tAsk\t patients\t about\t adverse\t effects\t from\t medications.\t Monitor\t for\t signs\t of\t drug-\nrelated\teffects,\tsuch\tas\tskin\trash,\theadaches,\tdrowsiness,\tweight\tgain,\tor\thypertension\t\nfrom\tNSAIDs.\n•\tObtain\tbaseline\tserum\tcreatinine,\thematology\tprofile,\tand\tserum\ttransaminases\twith\t\nrepeat\tlevels\tat\t6-\tto\t12-month\tintervals\tto\tidentify\tspecific\ttoxicities\tto\tthe\tkidney,\t\nliver,\tGI\ttract,\tor\tbone\tmarrow.\nSee Chapter 71, Osteoarthritis, authored by Lucinda M.",
    "word_count": 513,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0045",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 45,
    "text": "  Chapter  2\n•\tTramadol\tis\tassociated\twith\topioid-like\tadverse\teffects\tsuch\tas\tnausea,\tvomiting,\tdiz-\nziness,\tconstipation,\theadache,\tand\tsomnolence.\tHowever,\ttramadol\tis\tnot\tassociated\t\nwith\t life-threatening\t GI\tbleeding,\t cardiovascular\tevents,\t or\trenal\t failure.\tThe\tmost\t\nserious\tadverse\tevent\tis\tseizures.\tAlthough\tnot\tclassified\tas\ta\tcontrolled\tsubstance,\t\ndrug-seeking\tbehaviors\thave\tbeen\treported\twith\ttramadol\tuse.\tThere\tis\tincreased\trisk\t\nof\tserotonin\tsyndrome\twhen\ttramadol\tis\tused\twith\tother\tserotonergic\tmedications,\t\nincluding\tduloxetine.\n•\tStart\t opioid\t analgesics\t in\t low\t doses,\t allowing\t a\t sufficient\t duration\t between\t dose\t\nincreases\t to\t assess\t efficacy\t and\t safety.\t Sustained-release\t compounds\t usually\t offer\t\nbetter\t pain\t control\t throughout\t the\t day.\t Common\t adverse\t effects\t include\t nausea,\t\nsomnolence,\tconstipation,\tdry\tmouth,\tand\tdizziness.\tOpioid\tdependence,\taddiction,\t\ntolerance,\t hyperalgesia,\t and\t issues\t surrounding\t drug\t diversion\t may\t be\t associated\t\nwith\tlong-term\ttreatment.\n•\tDuloxetine\t may\t cause\t nausea,\t dry\t mouth,\t constipation,\t anorexia,\t fatigue,\t somno-\nlence,\tand\tdizziness.\tSerious\trare\tevents\tinclude\tStevens-Johnson\tsyndrome\tand\tliver\t\nfailure.\tConcomitant\tuse\twith\tother\tmedications\tthat\tincrease\tserotonin\tconcentra-\ntion\t(including\ttramadol)\tincreases\trisk\tof\tserotonin\tsyndrome.\n•\tHyaluronic\t acid\t (sodium\t hyaluronate)\t injections\t have\t limited\t benefit\t for\t patients\t\nwith\tknee\tOA\tand\thave\tnot\tbeen\tshown\tto\tbenefit\tpatients\twith\thip\tOA.\tInjections\t\nare\twell\ttolerated,\tbut\tacute\tjoint\tswelling,\teffusion,\tand\tstiffness,\tas\twell\tas\tlocal\tskin\t\nreactions\t(eg,\trash,\tecchymoses,\tor\tpruritus)\thave\tbeen\treported.\tSix\tintra-articular\t\npreparations\tand\tregimens\tare\tavailable\tfor\tOA\tknee\tpain:\n✓\tSodium hyaluronate 20 mg/2 mL\t(Hyalgan)\tonce\tweekly\tfor\tfive\tinjections\n✓\tSodium hyaluronate 20 mg/2 mL\t(Euflexxa)\tonce\tweekly\tfor\tthree\tinjections\n✓\tSodium hyaluronate 25 mg/2.5 mL\t(Supartz)\tonce\tweekly\tfor\tfive\tinjections\n✓\tHylan polymers 16 mg/2 mL\t(Synvisc)\tonce\tweekly\tfor\tthree\tinjections\n✓\t\tHylan polymers 48 mg/6 mL \t (Synvisc-One)\t single\t injection\t (with\t efficacy\t for\t\nup\tto\t26\tweeks)\n✓\tHyaluronan 30 mg/2 mL\t(Orthovisc)\tonce\tweekly\tfor\tthree\tinjections\n•\tGlucosamine\tadverse\teffects\tare\tmild\tand\tinclude\tflatulence,\tbloating,\tand\tabdominal\t\ncramps;\t do\t not\t use\t in\t patients\t with\t shellfish\t allergies.\t The\t most\t common\t adverse\t\neffect\tof\tchondroitin\tis\tnausea.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tT o\tmonitor\tefficacy,\tassess\tbaseline\tpain\twith\ta\tvisual\tanalog\tscale,\tand\tassess\trange\t\nof\tmotion\tfor\taffected\tjoints\twith\tflexion,\textension,\tabduction,\tor\tadduction.\n•\tDepending\ton\tthe\tjoint(s)\taffected,\tmeasurement\tof\tgrip\tstrength\tand\t50-ft\twalking\t\ntime\tcan\thelp\tassess\thand\tand\thip/knee\tOA,\trespectively.\n•\tBaseline\t radiographs\tcan\t document\textent\tof\t joint\tinvolvement\tand\t follow\tdisease\t\nprogression\twith\ttherapy.\n•\tOther\t measures\t include\t the\t clinician’ s\t global\tassessment\t based\ton\t patient’ s\t history\t\nof\t activities\t and\t limitations\t caused\t by\t OA,\t the\t W estern\t Ontario\t and\t McMaster\t\nUniversities\tArthrosis\tIndex,\tStanford\tHealth\tAssessment\tQuestionnaire,\tand\tdocu-\nmentation\tof\tanalgesic\tor\tNSAID\tuse.\n•\tAsk\t patients\t about\t adverse\t effects\t from\t medications.\t Monitor\t for\t signs\t of\t drug-\nrelated\teffects,\tsuch\tas\tskin\trash,\theadaches,\tdrowsiness,\tweight\tgain,\tor\thypertension\t\nfrom\tNSAIDs.\n•\tObtain\tbaseline\tserum\tcreatinine,\thematology\tprofile,\tand\tserum\ttransaminases\twith\t\nrepeat\tlevels\tat\t6-\tto\t12-month\tintervals\tto\tidentify\tspecific\ttoxicities\tto\tthe\tkidney,\t\nliver,\tGI\ttract,\tor\tbone\tmarrow.\nSee Chapter 71, Osteoarthritis, authored by Lucinda M. Buys and Mary Elizabeth Elliott, \nfor a more detailed discussion of this topic.",
    "word_count": 524,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0046",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 46,
    "text": "16\n•\tOsteoporosis\t is\t a\t bone\t disorder\t characterized\t by\t low\t bone\t density,\t impaired\t bone\t\narchitecture,\tand\tcompromised\tbone\tstrength\tpredisposing\tto\tfracture.\nPATHOPHYSIOLOGY\n•\tBone\tloss\toccurs\twhen\tresorption\texceeds\tformation,\tusually\tfrom\thigh\tbone\tturn-\nover\t when\t number\t and/or\t depth\t of\t bone\t resorption\t sites\t greatly\t exceed\t ability\t of\t\nosteoblasts\tto\tform\tnew\tbone.\n•\tBone\tmineral\tdensity\t(BMD)\tis\treduced\tand\tbone\tstructural\tintegrity\tis\timpaired\tdue\t\nto\tincreased\timmature\tbone\tthat\tis\tnot\tyet\tadequately\tmineralized.\n•\tMen\t and\t women\t begin\t to\t lose\t bone\t mass\t starting\t in\t the\t third\t or\t fourth\t decade\t\nbecause\tof\treduced\tbone\tformation.\tEstrogen\tdeficiency\tduring\tmenopause\tincreases\t\nosteoclast\t activity,\t increasing\t bone\t resorption\t more\t than\t formation.\t Men\t do\t not\t\nundergo\t a\t period\t of\t accelerated\tbone\t resorption\tsimilar\t to\t menopause.\tSecondary\t\ncauses\tand\taging\tare\tthe\tmost\tcommon\tcontributing\tfactors\tto\tmale\tosteoporosis.\n•\tAge-related\tosteoporosis\tresults\tfrom\thormone,\tcalcium,\tand\tvitamin\tD\tdeficiencies\t\nleading\tto\taccelerated\tbone\tturnover\tand\treduced\tosteoblast\tformation.\n•\tDrug-induced\t osteoporosis\t may\t result\t from\t systemic\t corticosteroids,\t thyroid\t hor-\nmone\t replacement,\t antiepileptic\t drugs\t (eg,\t phenytoin\t and\t phenobarbital),\t depot\t\nmedroxyprogesterone\tacetate,\tand\tother\tagents.\nCLINICAL PRESENTATION\n•\tMany\tpatients\tare\tunaware\tthat\tthey\thave\tosteoporosis\tand\tonly\tpresent\tafter\tfrac-\nture.\t Fractures\t can\t occur\t after\t bending,\t lifting,\t or\t falling\t or\t independent\t of\t any\t\nactivity.\n•\tThe\t most\t common\t fractures\t involve\t vertebrae,\t proximal\t femur,\t and\t distal\t radius\t\n(wrist\tor\tColles\tfracture).\tV ertebral\tfractures\tmay\tbe\tasymptomatic\tor\tpresent\twith\t\nmoderate\t to\t severe\t back\t pain\t that\t radiates\t down\t a\t leg.\t Pain\t usually\t subsides\t after\t\n2\t to\t 4\t weeks,\t but\t residual\t low-back\t pain\t may\t persist.\t Multiple\t vertebral\t fractures\t\ndecrease\theight\tand\tsometimes\tcurve\tthe\tspine\t(kyphosis\tor\tlordosis)\twith\tor\twithout\t\nsignificant\tback\tpain.\n•\tPatients\t with\t a\tnonvertebral\t fracture\t frequently\t present\t with\tsevere\t pain,\t swelling,\t\nand\treduced\tfunction\tand\tmobility\tat\tthe\tfracture\tsite.\nDIAGNOSIS\n•\tThe\tW orld\tHealth\tOrganization\t(WHO)\tfracture\tprediction\tmodel\tfor\ttreatment\trisk\t\nstratification\tuses\tthese\trisk\tfactors\tto\tpredict\tthe\tpercent\tprobability\tof\tfracture\tin\t\nthe\tnext\t10\tyears:\tage,\trace/ethnicity,\tsex,\tprevious\tfragility\tfracture,\tparent\thistory\tof\t\nhip\tfracture,\tbody\tmass\tindex,\tglucocorticoid\tuse,\tcurrent\tsmoking,\talcohol\t(three\tor\t\nmore\tdrinks\tper\tday),\trheumatoid\tarthritis,\tand\tselect\tsecondary\tcauses\twith\tfemoral\t\nneck\tBMD\tdata\toptional.\n•\tPhysical\texamination\tfindings:\tbone\tpain,\tpostural\tchanges\t(ie,\tkyphosis),\tand\tloss\t\nof\theight\t(>1.5\tin\t[3.8\tcm]).\n•\tLaboratory\ttesting:\tcomplete\tblood\tcount,\tcreatinine,\tblood\turea\tnitrogen,\tcalcium,\t\nphosphorus,\talkaline\tphosphatase,\talbumin,\tthyroid-stimulating\thormone,\tfree\ttes-\ntosterone,\t25-hydroxyvitamin\tD,\tand\t24-hour\turine\tconcentrations\tof\tcalcium\tand\t\nphosphorus.\n•\tMeasurement\tof\tcentral\t(hip\tand\tspine)\tBMD\twith\tdual-energy\tx-ray\tabsorptiometry\t\n(DXA)\t is\t the\t diagnostic\t standard.\t Measurement\t at\t peripheral\t sites\t (forearm,\t heel,\t\nand\tphalanges)\twith\tultrasound\tor\tDXA\tis\tused\tonly\tfor\tscreening\tand\tfor\tdetermin-\ning\tneed\tfor\tfurther\ttesting.\nOsteoporosis\n3\nC H A P T E R",
    "word_count": 468,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0047",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 47,
    "text": "17\nOsteoporosis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0048",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 48,
    "text": "17\nOsteoporosis     CHAPTER 3\n•\tA\t T-score\t compares\t the\t patient’ s\t measured\t BMD\t to\t the\t mean\t BMD\t of\t a\t healthy,\t\nyoung\t(20-\tto\t29-year-old),\tgender-matched,\twhite\treference\tpopulation.\tThe\tT-score\t\nis\tthe\tnumber\tof\tstandard\tdeviations\tfrom\tthe\tmean\tof\tthe\treference\tpopulation.\n•\tDiagnosis\tof\tosteoporosis\tis\tbased\ton\tlow-trauma\tfracture\tor\tcentral\thip\tand/or\tspine\t\nDXA\t using\tWHO\tT-score\t thresholds.\t Normal\tbone\tmass\t is\tT-score\t above\t −1,\tlow\t\nbone\tmass\t(osteopenia)\tis\tT-score\tbetween\t−1\tand\t−2.4,\tand\tosteoporosis\tis\tT-score\t\nat\tor\tbelow\t−2.5.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\tprimary\tgoal\tof\tosteoporosis\tcare\tis\tprevention.\tOptimizing\t\npeak\tbone\tmass\twhen\tyoung\treduces\tthe\tfuture\tincidence\tof\tosteoporosis.\tAfter\tlow\t\nbone\t mass\t or\t osteoporosis\t develops,\t the\t objective\t is\t to\t stabilize\t or\t improve\t bone\t\nmass\t and\t strength\t and\t prevent\t fractures.\t Goals\t in\t patients\t with\t osteoporotic\t frac-\ntures\t include\t reducing\t pain\t and\t deformity,\t improving\t function,\t reducing\t falls\t and\t\nfractures,\tand\timproving\tquality\tof\tlife.\n•\tFigure 3–1 \t provides\t an\t osteoporosis\t management\t algorithm\t for\t postmenopausal\t\nwomen\tand\tmen\tages\t50\tand\tolder.\nNONPHARMACOLOGIC THERAPY\n•\tAll\t individuals\t should\t have\t a\t balanced\t diet\t with\t adequate\t intake\t of\t calcium\t and\t\nvitamin D \t (Table 3–1 ).\t Achieving\t daily\t calcium\t requirements\t from\t calcium-\ncontaining\tfoods\tis\tpreferred.\n✓\t\tConsumers\tcan\tcalculate\tthe\tamount\tof\tcalcium\tin\ta\tfood\tserving\tby\tadding\ta\tzero\t\nto\tthe\tpercentage\tof\tthe\tdaily\tvalue\ton\tfood\tlabels.\tOne\tserving\tof\tmilk\t(8\toz\tor\t\n240\tmL)\thas\t30%\tof\tthe\tdaily\tvalue\tof\tcalcium;\tthis\tconverts\tto\t300\tmg\tof\tcalcium\t\nper\tserving.\n✓\t\tT o\tcalculate\tthe\tamount\tof\tvitamin\tD\tin\ta\tfood\tserving,\tmultiply\tthe\tpercent\tdaily\t\nvalue\tof\tvitamin\tD\tlisted\ton\tthe\tfood\tlabel\tby\t4.\tFor\texample,\t20%\tvitamin\tD\t=\t\n80\tunits.\n•\tAlcohol\t consumption\t should\t not\t exceed\t one\t drink\t per\t day\t for\t women\t and\t two\t\ndrinks\tper\tday\tfor\tmen.\n•\tIdeally,\tcaffeine\tintake\tshould\tbe\tlimited\tto\ttwo\tor\tfewer\tservings\tper\tday.\n•\tSmoking\t cessation\t helps\t optimize\t peak\t bone\t mass,\t minimize\t bone\t loss,\t and\t ulti-\nmately\treduce\tfracture\trisk.\n•\tW eight-bearing\t aerobic\t and\t strengthening\t exercises\t can\t decrease\t risk\t of\t falls\t and\t\nfractures\tby\timproving\tmuscle\tstrength,\tcoordination,\tbalance,\tand\tmobility.\nPHARMACOLOGIC THERAPY\nANTIRESORPTIVE THERAPY\nCalcium Supplementation\n•\tCalcium\tincreases\tBMD,\tbut\tits\teffects\tare\tless\tthan\tthose\tof\tother\ttherapies.\tFracture\t\nprevention\tis\tonly\tdocumented\twith\tconcomitant\tvitamin\tD\ttherapy;\tcalcium\tshould\t\nbe\t combined\t with\tvitamin\t D\t and\tosteoporosis\t medications\t when\t needed.\tBecause\t\nthe\t fraction\t of\t calcium\t absorbed\t decreases\t with\t increasing\t dose,\t maximum\t single\t\ndoses\tof\t600\tmg\tor\tless\tof\telemental\tcalcium\tare\trecommended.\n•\tCalcium carbonate\tis\tthe\tsalt\tof\tchoice\tbecause\tit\tcontains\tthe\thighest\tconcentration\t\nof\telemental\tcalcium\t(40%)\tand\tis\tleast\texpensive.\tIt\tshould\tbe\tingested\twith\tmeals\t\nto\tenhance\tabsorption\tin\tan\tacidic\tenvironment.\n•\tCalcium citrate\tabsorption\tis\tacid\tindependent\tand\tneed\tnot\tbe\ttaken\twith\tmeals.\tIt\t\nmay\thave\tfewer\tGI\tside\teffects\t(eg,\tflatulence)\tthan\tcalcium\tcarbonate.\n•\tTricalcium phosphate \t contains\t 38%\t calcium,\t but\t calcium-phosphate\t complexes\t\ncould\tlimit\toverall\tcalcium\tabsorption.\tIt\tmight\tbe\thelpful\tin\tpatients\twith\thypophos-\nphatemia\tthat\tcannot\tbe\tresolved\twith\tincreased\tdietary\tintake.",
    "word_count": 521,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0049",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 49,
    "text": "18\nSECTION 1     Bone and Joint Disorders\nNO\nYES\nOsteoporosis or high fracture risk\nT-score ≤ –2.5 at femoral neck\nor spine or T-score –1.1 to –2.4 at\nfemoral neck, total hip, or spine and a\nFRAX 10-year probability of hip\nfracture ≥3% or all major\nosteoporosis-related fractures ≥20%h\nPresence of a low trauma fracture (vertebrae or hip)\n•    Woman ≥65 years of age\n•    Man ≥70 years of age\n•    Postmenopausal woman <65 years of age or man 50 to 69 years old with clinical risk\n  factors for fracturesa\n•    Abnormal peripheral BMD test\n•    Radiographic evidence of low bone mass\n•    Medical conditions or medications known to increase the risk for bone loss and fracture\n ( eg, rheumatoid arthritis, glucocorticoids ≥3 months)\n•   Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D at least 800 to 1000 units daily\n• Medication therapy:d\n • First line: alendronate, risedronate,\n  zoledronic acid or denosumab\n • Alternate therapy: Ibandronate, raloxifene,e\n  or teriparatidef\n • Last line: intranasal calcitoning\n Obtain baseline central BMD testing for\n monitoring response to therapy.\n Re-evaluate BMD using central DXA in 1–2 years \nNormal BMD T-score ≥ –1.0\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n Re-evaluate BMD using central\n DXA in 5 years or as appropriate\nYES\nLow bone mass (osteopenia)\nT-score –1.1 to –2.4 at femoral neck\nor spine and a FRAX 10-year probability\nof hip fracture <3% or of all major\nosteoporosis-related fractures <20%h\nSend for central DXA testing\n•   Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n• Medication therapy to prevent further bone loss\n can be considered if risk factors exist\n Re-evaluate BMD using central\n DXA in ≥2 years or as appropriate\naMajor clinical risk factors for fracture:  current smoker, low body weight or body mass index, history of osteoporosis/low trauma fracture in a first-degree relative,\npersonal history of fracture as an adult (after age 50 years), excessive alcohol intake\nbBone-healthy lifestyle includes smoking cessation, limit alcohol intake, well-balanced diet with adequate calcium and vitamin D intakes, weight-bearing/resistance exercises, and fall prevention\ncDietary calcium preferred.",
    "word_count": 373,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0050",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 50,
    "text": "  Bone and Joint Disorders\nNO\nYES\nOsteoporosis or high fracture risk\nT-score ≤ –2.5 at femoral neck\nor spine or T-score –1.1 to –2.4 at\nfemoral neck, total hip, or spine and a\nFRAX 10-year probability of hip\nfracture ≥3% or all major\nosteoporosis-related fractures ≥20%h\nPresence of a low trauma fracture (vertebrae or hip)\n•    Woman ≥65 years of age\n•    Man ≥70 years of age\n•    Postmenopausal woman <65 years of age or man 50 to 69 years old with clinical risk\n  factors for fracturesa\n•    Abnormal peripheral BMD test\n•    Radiographic evidence of low bone mass\n•    Medical conditions or medications known to increase the risk for bone loss and fracture\n ( eg, rheumatoid arthritis, glucocorticoids ≥3 months)\n•   Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D at least 800 to 1000 units daily\n• Medication therapy:d\n • First line: alendronate, risedronate,\n  zoledronic acid or denosumab\n • Alternate therapy: Ibandronate, raloxifene,e\n  or teriparatidef\n • Last line: intranasal calcitoning\n Obtain baseline central BMD testing for\n monitoring response to therapy.\n Re-evaluate BMD using central DXA in 1–2 years \nNormal BMD T-score ≥ –1.0\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n Re-evaluate BMD using central\n DXA in 5 years or as appropriate\nYES\nLow bone mass (osteopenia)\nT-score –1.1 to –2.4 at femoral neck\nor spine and a FRAX 10-year probability\nof hip fracture <3% or of all major\nosteoporosis-related fractures <20%h\nSend for central DXA testing\n•   Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n• Vitamin D 800 to 1000 units daily\n• Medication therapy to prevent further bone loss\n can be considered if risk factors exist\n Re-evaluate BMD using central\n DXA in ≥2 years or as appropriate\naMajor clinical risk factors for fracture:  current smoker, low body weight or body mass index, history of osteoporosis/low trauma fracture in a first-degree relative,\npersonal history of fracture as an adult (after age 50 years), excessive alcohol intake\nbBone-healthy lifestyle includes smoking cessation, limit alcohol intake, well-balanced diet with adequate calcium and vitamin D intakes, weight-bearing/resistance exercises, and fall prevention\ncDietary calcium preferred. If diet is inadequate, supplement as necessary\ndSometimes men with hypogonadism also receive testosterone replacement; sometimes women with menopausal symptoms receive low dose hormone therapy for a short time\neRaloxifene can be a good option in women at high risk for breast cancer\nfTeriparatide can be considered a first-line option in patients with a very high risk of fracture (eg, T-score <–3.5 or multiple low trauma fractures) or intolerant to other medications\ngCalitonin is last-line due to limited fracture data and a recent concern over possible slight increased cancer risk.\nhWHO absolute fracture risk assessment tool (FRAX) for osteoporotic fracture risk estimations\n• Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n•  Vitamin D at least 800 to 1000 units daily\n•  Medication therapyd:\n  • First line: alendronate, risedronate, zoledronic acid\n or denosumab\n  • Alternate therapy: ibandronate raloxifene,e\n or teriparatidef\n  • Last line: intranasal calcitoning\n     \n     Obtain baseline central BMD testing for\n     monitoring response to therapy.\n  Re-evaluate BMD using central\n  DXA in 1–2 years\nFIGURE 3–1.",
    "word_count": 543,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0051",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 51,
    "text": "If diet is inadequate, supplement as necessary\ndSometimes men with hypogonadism also receive testosterone replacement; sometimes women with menopausal symptoms receive low dose hormone therapy for a short time\neRaloxifene can be a good option in women at high risk for breast cancer\nfTeriparatide can be considered a first-line option in patients with a very high risk of fracture (eg, T-score <–3.5 or multiple low trauma fractures) or intolerant to other medications\ngCalitonin is last-line due to limited fracture data and a recent concern over possible slight increased cancer risk.\nhWHO absolute fracture risk assessment tool (FRAX) for osteoporotic fracture risk estimations\n• Evaluate for secondary causes\n• Bone healthy lifestyleb\n• Dietary calcium 1000 to 1200 mg dailyc\n•  Vitamin D at least 800 to 1000 units daily\n•  Medication therapyd:\n  • First line: alendronate, risedronate, zoledronic acid\n or denosumab\n  • Alternate therapy: ibandronate raloxifene,e\n or teriparatidef\n  • Last line: intranasal calcitoning\n     \n     Obtain baseline central BMD testing for\n     monitoring response to therapy.\n  Re-evaluate BMD using central\n  DXA in 1–2 years\nFIGURE 3–1.  Algorithm for management of osteoporosis in postmenopausal women and men ages 50 and older. BMD, bone mineral density; DXA, \ndual-energy x-ray absorptiometry.",
    "word_count": 195,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0052",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 52,
    "text": "19\nOsteoporosis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0053",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 53,
    "text": "19\nOsteoporosis     CHAPTER 3\n•\tConstipation\tis\tthe\tmost\tcommon\tadverse\treaction;\ttreat\twith\tincreased\twater\tintake,\t\ndietary\tfiber\t(given\tseparately\tfrom\tcalcium),\tand\texercise.\tCalcium\tcarbonate\tcan\t\nsometimes\tcause\tflatulence\tor\tupset\tstomach.\tCalcium\tcauses\tkidney\tstones\trarely.\nVitamin D Supplementation\n•\tVitamin D\tsupplementation\tmaximizes\tintestinal\tcalcium\tabsorption\tand\tBMD;\tit\t\nmay\talso\treduce\tfractures\tand\tfalls.\n•\tSupplementation\tis\tusually\tprovided\twith\tdaily\tnonprescription\tcholecalciferol\t(vita-\nmin\t D3)\t products.\t Higher-dose\t prescription\t ergocalciferol\t (vitamin\t D2)\t regimens\t\ngiven\tweekly,\tmonthly,\tor\tquarterly\tmay\tbe\tused\tfor\treplacement\tand\tmaintenance\t\ntherapy.\n•\tThe\trecommended\tdietary\tallowances\tin\tTable 3–1\tshould\tbe\tachieved\tthrough\tfood\t\nand\tsupplementation\twith\ta\tgoal\tto\tmaintain\tthe\t25\t(OH)\tvitamin\tD\tconcentration\t\nat\t30\tng/mL\t(75\tnmol/L)\tor\thigher.\n•\tBecause\tthe\thalf-life\tof\tvitamin\tD\tis\tabout\t1\tmonth,\trecheck\tthe\tvitamin\tD\tconcentra-\ntion\tafter\tabout\t3\tmonths\tof\ttherapy.\nBisphosphonates\n•\tBisphosphonates\t(Table 3–2)\tinhibit\tbone\tresorption\tand\tbecome\tincorporated\tinto\t\nthe\tbones,\tgiving\tthem\tlong\tbiologic\thalf-lives\tof\tup\tto\t10\tyears.\n•\tOf\tthe\tantiresorptive\tagents\tavailable,\tbisphosphonates\tprovide\tsome\tof\tthe\thigher\t\nBMD\tincreases\tand\tfracture\trisk\treductions.\tFracture\treductions\tare\tdemonstrated\t\nas\tearly\tas\t6\tmonths.\n•\tBMD\tincreases\tare\tdose\tdependent\tand\tgreatest\tin\tthe\tfirst\t6\tto\t12\tmonths\tof\ttherapy.\t\nAfter\t discontinuation,\tthe\tincreased\tBMD\tis\tsustained\tfor\ta\tprolonged\tperiod\tthat\t\nvaries\tdepending\ton\tthe\tbisphosphonate\tused.\n•\tAlendronate, risedronate,\tand\tIV zoledronic acid\tare\tFood\tand\tDrug\tAdministration\t\n(FDA)–indicated\tfor\tpostmenopausal,\tmale,\tand\tglucocorticoid-induced\tosteoporo-\nsis.\tIV and oral ibandronate\tare\tindicated\tonly\tfor\tpostmenopausal\tosteoporosis.\n•\tBisphosphonates\t must\t be\t administered\t carefully\t to\t optimize\t clinical\t benefit\t and\t\nminimize\tadverse\tGI\teffects.\tEach\toral\ttablet\tshould\tbe\ttaken\tin\tthe\tmorning\twith\t\nat\t least\t 6\t oz\t of\t plain\t tap\t water\t (not\t coffee,\t juice,\t mineral\t water,\t or\t milk)\t at\t least\t\t\n30\t minutes\t (60\t minutes\t for\t oral\t ibandronate)\t before\t consuming\t any\t food,\t supple-\nment,\tor\tmedication.\tAn\texception\tis\tdelayed-release\trisedronate,\twhich\tis\tadminis-\ntered\timmediately\tafter\tbreakfast\twith\tat\tleast\t4\toz\tof\tplain\twater.\tThe\tpatient\tshould\t\n TABLE 3–1   Calcium and Vitamin D: Recommended Dietary Allowances and Upper Limits\nGroup and Ages Elemental Calcium \n(mg) \nVitamin D (units)a \nInfants\n Birth to 6 months 200–1000 400–1000\n 6–12 months 260–1500 400–1500\nChildren\n 1–3 years 700–2500 600–2500\n 4–8 years 1000–2500 600–3000\n 9–18 years 1300–3000 600–4000\nAdults\n 19–50 years 1000–2500 600–4000b\n 51–70 years (men)\n 51–70 years (women)\n >70 years\n1000–2000\n1200–2000\n1200–200\n600–4000b\n600–4000b\n800–4000b\naOther guidelines recommend intake to achieve a 25(OH) vitamin D concentration of >30 ng/mL [75 \nnmol/L], which is higher than the Institute of Medicine goal of >20 ng/mL [50 nmol/L].\nb2010 National Osteoporosis Foundation Guidelines recommend 400–800 units for adults younger \nthan 50 years and 800–1000 units for adults 50 years and older.",
    "word_count": 460,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0054",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 54,
    "text": "20\nSECTION 1  |  Bone and Joint Disorders\n TABLE 3–2  Medications Used to Prevent and Treat Osteoporosis\nDrug Adult Dosages Pharmacokinetics Adverse Effects Drug Interactions\nCalcium Supplement dose is the difference \nbetween adequate daily intake, \nwhich varies by age (see Table 3–1), \nand dietary intake. Divided doses \nmay be needed.\nAbsorption—predominantly active \ntransport with some passive \ndiffusion, fractional absorption \n10%–60%, fecal elimination of \nunabsorbed and renal elimina-\ntion of absorbed calcium\nConstipation, gas, upset \nstomach, rare kidney \nstones\nCarbonate products—decreased absorption \nwith proton pump inhibitors\nDecreased absorption of iron, tetracycline, \nquinolones, bisphosphonates, phenytoin, \nand fluoride when given concomitantly\nAntagonist of verapamil\nMay induce hypercalcemia with thiazide \ndiuretics\nFiber laxatives, oxalates, phytates, and  \nsulfates can decrease calcium absorption if \ngiven concomitantly\nVitamin D3 (cholecal-\nciferol)\nAdequate intake (see Table 3–1); \nhigher doses may be required if \nmalabsorption or multiple anticon-\nvulsants.\nHepatic metabolism to 25(OH) \nvitamin D and then renal \nmetabolism to active compound \n1,25(OH)2 vitamin D, other active \nand inactive metabolites\nHypercalcemia, (weak-\nness, headache, \nsomnolence, nausea, \nand/or cardiac rhythm \ndisturbance), hyper-\ncalciuria\nPhenytoin, barbiturates, carbamazepine, and \nrifampin increase vitamin D metabolism\nVitamin D2 (ergocal-\nciferol)\nFor vitamin D deficiency, 50,000 units \norally once or twice weekly for \n8–12 weeks; repeat as needed until \ntherapeutic concentrations; occa-\nsionally, 50,000 units monthly for \nmaintenance\nCholestyramine, colestipol, orlistat, and min-\neral oil decrease vitamin D absorption\n1,25(OH)2 vitamin D \n(calcitriol, Rocaltrol \nPO, Calcijex IV)\n0.25–0.5 mcg orally or 1–2 mcg/mL \nIV daily for renal osteodystrophy, \nhypoparathyroidism, or refractory \nrickets\nMight induce hypercalcemia with thiazide \ndiuretics in hypoparathyroid patients",
    "word_count": 256,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0055",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 55,
    "text": "21\nOsteoporosis  |  CHAPTER 3\nBisphosphonates\nAlendronate (Fosamax, \nBinosto effervescent \ntablets)\nPrevention: 5 mg orally daily or 35 mg \norally weekly\nTreatment: 10 mg orally daily or 70 mg \norally weekly; 70-mg dose available \nas oral tablet, effervescent tablet, or \ncombination tablet  with vitamin D3 \n2800 or 5600 units\nPoorly absorbed—<1% decreasing \nto zero with food or beverage \nintake—long T 1/2 (<10 years); \nrenal elimination (of absorbed) \nand fecal elimination (unab-\nsorbed)\nTransient musculosk-\neletal pain, nausea, \ndyspepsia (oral); tran-\nsient flu-like illness \n(injectable)\nRare: GI perforation, \nulceration, and/or \nbleeding (oral); ONJ, \natypical femoral shaft \nfracture, severe mus-\nculoskeletal pain\nDo not coadminister with any other medica-\ntion or supplements (including calcium \nand vitamin D)\nIbandronate (Boniva) Prevention: 150 mg orally monthly\nTreatment: 150 mg orally monthly; \n3 mg  \nIV every 3 months\nRisedronate (Actonel, \nAtelvia delayed \nrelease)\nPrevention and Treatment: 5 mg orally \ndaily, 35 mg orally weekly, 150 mg \norally monthly\nRare: GI perforation, \nulceration, and/or \nbleeding (oral); mus-\nculoskeletal pain, ONJ, \natypical  \nfractures\nZoledronic acid \n(Reclast)\nPrevention: 5 mg IV infusion every 2 \nyears\nTreatment: 5 mg IV infusion yearly\n(continued )\n\n22\nSECTION 1  |  Bone and Joint Disorders\nRANK ligand inhibitor\nDenosumab (Prolia) Treatment: 60 mcg subcutaneously \nevery 6 months\nTmax 10 days, T1/2  25.4 days Flatulence, dermatitis, \neczema, rash \nRare: serious infections, \nONJ, atypical fractures,  \nhypocalcemia\nEstrogen agonist/antagonists\nRaloxifene (Evista) 60 mg orally daily Hepatic metabolism Hot flushes, leg cramps, \nvenous thromboem-\nbolism, peripheral \nedema\nRare: cataracts and \ngallbladder disease; \nblack-box warning for \nfatal stroke\nNone\nCalcitonin\nCalcitonin salmon \n(Miacalcin, Fortical)\n200 units (1 spray) intranasally daily, \nalternating nares every other day; \n100 units subcutaneously daily\nRenal elimination; 3% nasal  \navailability\nNasal: rhinitis, epistaxis\nInjection: nausea, flush-\ning, local inflammation\nNone\nRecombinant human parathyroid hormone (PTH 1–34 units)\nTeriparatide, (Forteo) 20 mcg subcutaneously daily for up \nto 2 years\n95% bioavailability\nTmax ~30 min\nT1/2 ~60 min\nHepatic metabolism\nPain at injection site, \nnausea, headache, \ndizziness, leg cramps\nRare: increase in uric \nacid, slightly increased \ncalcium\nNone\nGI, gastrointestinal; IV, intravenous; ONJ, osteonecrosis of the jaw; PO, by mouth; Tmax, time to maximum concentration; T1/2, half-life.\n TABLE 3–2  Medications Used to Prevent and Treat Osteoporosis (Continued)\nDrug Adult Dosages Pharmacokinetics Adverse Effects Drug Interactions",
    "word_count": 370,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0056",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 56,
    "text": "23\nOsteoporosis  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0057",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 57,
    "text": "23\nOsteoporosis     CHAPTER 3\nremain\t upright\t (sitting\t or\t standing)\t for\t at\t least\t 30\t minutes\t after\t alendronate\t and\t\nrisedronate\tand\t1\thour\tafter\tibandronate\tadministration\tto\tprevent\tesophageal\tirrita-\ntion\tand\tulceration.\n•\tW eekly\t alendronate,\t weekly\t and\t monthly\trisedronate,\tand\t monthly\t oral\t and\t quar-\nterly\t IV\t ibandronate\t therapy\t produce\t equivalent\t BMD\t changes\t to\t their\t respective\t\ndaily\tregimens.\tIf\ta\tpatient\tmisses\ta\tweekly\tdose,\tit\tcan\tbe\ttaken\tthe\tnext\tday.\tIf\tmore\t\nthan\t1\tday\thas\telapsed,\tthat\tdose\tis\tskipped\tuntil\tthe\tnext\tscheduled\tingestion.\tIf\ta\t\npatient\tmisses\ta\tmonthly\tdose,\tit\tcan\tbe\ttaken\tup\tto\t7\tdays\tbefore\tthe\tnext\tscheduled\t\ndose.\n•\tThe\tmost\tcommon\tbisphosphonate\tadverse\teffects\tinclude\tnausea,\tabdominal\tpain,\t\nand\t dyspepsia.\t Esophageal,\t gastric,\t or\t duodenal\t irritation,\t perforation,\t ulceration,\t\nor\t bleeding\t may\t occur.\t The\t most\t common\t adverse\t effects\t of\t IV\t bisphosphonates\t\ninclude\tfever,\tflu-like\tsymptoms,\tand\tlocal\tinjection-site\treactions.\n•\tRare\t adverse\t effects\t include\t osteonecrosis\t of\t the\t jaw\t (ONJ)\t and\t subtrochanteric\t\nfemoral\t (atypical)\t fractures.\t ONJ\t occurs\t more\t commonly\t in\t patients\t with\t cancer,\t\nchemotherapy,\t radiation,\t and\t glucocorticoid\t therapy\t receiving\t higher-dose\t IV\t\nbisphosphonate\ttherapy.\nDenosumab\n•\tDenosumab\t(Prolia)\tis\ta\tRANK\tligand\t inhibitor\tthat\tinhibits\tosteoclast\t formation\t\nand\t increases\t osteoclast\t apoptosis.\t It\t is\t indicated\t for\t treatment\t of\t osteoporosis\t in\t\nwomen\tand\tmen\tat\thigh\trisk\tfor\tfracture.\tIt\tis\talso\tapproved\tto\tincrease\tbone\tmass\tin\t\nmen\treceiving\tandrogen-deprivation\ttherapy\tfor\tnonmetastatic\tprostate\tcancer\tand\t\nin\twomen\treceiving\tadjuvant\taromatase\tinhibitor\ttherapy\tfor\tbreast\tcancer\twho\tare\t\nat\thigh\trisk\tfor\tfracture.\n•\tDenosumab\t is\t administered\t as\t a\t 60-mg\t subcutaneous\t injection\t in\t the\t upper\t arm,\t\nupper\tthigh,\tor\tabdomen\tonce\tevery\t6\tmonths.\n•\tAdverse\t reactions\t are\t included\t in\t Table 3–2 .\t Denosumab\t is\t contraindicated\t in\t\npatients\twith\thypocalcemia\tuntil\tthe\tcondition\tis\tcorrected.\nMixed Estrogen Agonists/Antagonists\n•\tRaloxifene\t is\t an\t estrogen\t agonist\t in\t bone\t but\t an\t antagonist\t in\t breast\t and\t uterine\t\ntissue.\tIt\tis\tapproved\tfor\tprevention\tand\ttreatment\tof\tpostmenopausal\tosteoporosis.\n•\tRaloxifene\tdecreases\tvertebral\tfractures\tand\tincreases\tspine\tand\thip\tBMD,\tbut\tto\ta\t\nlesser\textent\tthan\tbisphosphonates.\tAfter\tdiscontinuation,\tthe\tbeneficial\teffect\tis\tlost,\t\nand\tbone\tloss\treturns\tto\tage-\tor\tdisease-related\trates.\n•\tRaloxifene\tis\twell\ttolerated\toverall.\tHot\tflushes,\tleg\tcramps,\tand\tmuscle\tspasms\tare\t\ncommon.\tEndometrial\tbleeding\toccurs\trarely.\tThromboembolic\tevents\tare\tuncom-\nmon\tbut\tcan\tbe\tfatal.\tRaloxifene\tis\tcontraindicated\tin\twomen\twith\tan\tactive\tor\tpast\t\nhistory\tof\tvenous\tthromboembolic\tdisease.\tDiscontinue\ttherapy\tif\tpatient\tanticipates\t\nextended\timmobility.\tPrescribing\tinformation\tcontains\ta\tblack-box\twarning\turging\t\ncaution\tin\twomen\tat\trisk\tfor\tstroke.\nCalcitonin\n•\tCalcitonin\tis\tan\tendogenous\thormone\treleased\tfrom\tthe\tthyroid\tgland\twhen\tserum\t\ncalcium\tis\televated.\tSalmon\tcalcitonin\tis\tused\tclinically\tbecause\tit\tis\tmore\tpotent\tand\t\nlonger\tlasting\tthan\tthe\tmammalian\tform.\t\n•\tCalcitonin\t is\t indicated\t for\t osteoporosis\t treatment\t for\t women\t at\t least\t 5\t years\t past\t\nmenopause.\tIt\tis\treserved\tas\ta\tlast-line\ttreatment\tbecause\tefficacy\tis\tless\trobust\tthan\t\nwith\tother\tantiresorptive\ttherapies.\n•\tOnly\tvertebral\tfractures\thave\tbeen\tdocumented\tto\tdecrease\twith\tintranasal\tcalcitonin\t\ntherapy.\tCalcitonin\tdoes\tnot\tconsistently\taffect\thip\tBMD\tand\tdoes\tnot\tdecrease\thip\t\nfracture\trisk.\n•\tCalcitonin\t may\t provide\t some\t pain\t relief\t in\t patients\t with\t acute\t vertebral\t fractures.\t\nIf\tthe\tnasal\tproduct\tis\tused\tfor\tthis\tpurpose,\tit\tshould\tbe\tprescribed\tfor\tshort-term\t\ntreatment\t(4\tweeks)\tand\tshould\tnot\tbe\tused\tin\tplace\tof\tother\tmore\teffective\tand\tless",
    "word_count": 554,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0058",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 58,
    "text": "24\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0059",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 59,
    "text": "24\nSECTION 1     Bone and Joint Disorders\nexpensive\t analgesics,\t nor\t should\t it\t preclude\t use\t of\t more\t appropriate\t osteoporosis\t\ntherapy.\n•\tIntranasal\t dose\t is\t 200\t units\t daily,\t alternating\t nares\t every\t other\t day.\t Subcutaneous\t\nadministration\tof\t100\tunits\tdaily\tis\tavailable\tbut\trarely\tused\tbecause\tof\tadverse\teffects\t\nand\tcost.\nEstrogen Therapy\n•\tEstrogens\tare\tFDA-indicated\tfor\tprevention\tof\tosteoporosis\tin\twomen\tat\tsignificant\t\nrisk\tand\tfor\twhom\tother\tosteoporosis\tmedications\tcannot\tbe\tused.\t\n•\tHormone\t therapy\t (estrogen\t with\t or\t without\ta\t progestogen)\t significantly\tdecreases\t\nfracture\t risk.\t Increases\t in\t BMD\t are\t less\t than\t with\t bisphosphonates,\t denosumab,\t\nor\tteriparatide\tbut\tgreater\tthan\twith\traloxifene\tor\tcalcitonin.\tOral\tand\ttransdermal\t\nestrogens\tat\tequivalent\tdoses\tand\tcontinuous\tor\tcyclic\tregimens\thave\tsimilar\tBMD\t\neffects.\tEffect\ton\tBMD\tis\tdose\tdependent,\twith\tsome\tbenefit\tseen\twith\tlower\testrogen\t\ndoses.\tWhen\ttherapy\tis\tdiscontinued,\tbone\tloss\taccelerates\tand\tfracture\tprotection\t\nis\tlost.\n•\tUse\tthe\tlowest\teffective\tdose\tthat\tprevents\tand\tcontrols\tmenopausal\tsymptoms,\tand\t\ndiscontinue\ttherapy\tas\tsoon\tas\tpossible.\nTestosterone\n•\tT estosterone\tis\tnot\tFDA-indicated\tfor\tosteoporosis,\tbut\tthe\tmale\tosteoporosis\tguide-\nline\trecommends\ttestosterone\talone\tfor\tmen\twith\ttestosterone\tconcentrations\tof\tless\t\nthan\t200\tng/dL\t[6.9\tnmol/L]\tif\tlow\tfracture\trisk\tand\tin\tcombination\twith\tan\tosteo-\nporosis\tmedication\tif\thigh\tfracture\trisk.\tDo\tnot\tuse\ttestosterone\treplacement\tsolely\t\nfor\tprevention\tor\ttreatment\tof\tosteoporosis.\n•\tT estosterone\tmay\tincrease\tBMD\tin\tmen\twith\tlow\ttestosterone\tconcentrations\tbut\thas\t\nno\teffect\tif\ttestosterone\tconcentrations\tare\tnormal.\tNo\tfracture\tdata\tare\tavailable.\nANABOLIC THERAPIES\nTeriparatide\n•\tTeriparatide\t(Forteo)\tis\ta\trecombinant\tproduct\trepresenting\tthe\tfirst\t34\tamino\tacids\t\nin\thuman\tparathyroid\thormone\t(PTH).\tT eriparatide\tincreases\tbone\tformation,\tbone\t\nremodeling\trate,\tand\tosteoblast\tnumber\tand\tactivity.\n•\tT eriparatide\tis\tFDA-indicated\tfor\ttreatment\tof\tpostmenopausal\twomen\tat\thigh\trisk\t\nfor\tfracture,\tfor\tincrease\tin\tBMD\tin\tmen\twith\tidiopathic\tor\thypogonadal\tosteoporo-\nsis\tat\thigh\tfracture\trisk,\tfor\tmen\tor\twomen\tintolerant\tto\tother\tosteoporosis\tmedica-\ntions,\tand\tfor\tpatients\twith\tglucocorticoid-induced\tosteoporosis.\n•\tThe\tdrug\treduces\tfracture\trisk\tin\tpostmenopausal\twomen,\tbut\tno\tfracture\tdata\tare\t\navailable\tin\tmen\tor\tfor\tpatients\ttaking\tcorticosteroids.\tLumbar\tspine\tBMD\tincreases\t\nare\t higher\t than\t with\t other\t osteoporosis\t medications.\t Although\t wrist\t BMD\t is\t\ndecreased,\twrist\tfractures\tare\tnot\tincreased.\n•\tDiscontinuation\tof\ttherapy\tresults\tin\tdecreased\tBMD,\twhich\tcan\tbe\talleviated\twith\t\nsubsequent\tantiresorptive\ttherapy.\tDue\tto\tconcern\tover\tosteosarcoma,\tteriparatide\tis\t\napproved\tfor\tuse\tfor\tonly\tup\tto\t2\tyears.\n•\tThe\tteriparatide\tdose\tis\t20\tmcg\tsubcutaneously\tonce\tdaily\tin\tthe\tthigh\tor\tabdomen\t\nfor\tup\tto\t2\tyears\t(see\tTable 3–2).\tGive\tthe\tinitial\tdose\twith\tthe\tpatient\teither\tlying\t\nor\t sitting,\t in\t case\t orthostatic\t hypotension\t occurs.\t Each\t prefilled\t 3-mL\t pen\t device\t\ndelivers\ta\t20-mcg\tdose\teach\tday\tfor\tup\tto\t28\tdays;\tkeep\tthe\tpen\tdevice\trefrigerated.\n•\tTransient\thypercalcemia\trarely\toccurs.\tT eriparatide\tis\tcontraindicated\tin\tpatients\tat\t\nincreased\trisk\tfor\tosteosarcoma.\nGLUCOCORTICOID-INDUCED OSTEOPOROSIS\n•\tGlucocorticoids\t decrease\t bone\t formation\t through\t decreased\t proliferation\t and\t dif-\nferentiation,\t as\t well\t as\t enhanced\t apoptosis\t of\t osteoblasts.\t They\t also\t increase\t bone\t\nresorption,\tdecrease\tcalcium\tabsorption,\tand\tincrease\trenal\tcalcium\texcretion.",
    "word_count": 513,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0060",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 60,
    "text": "25\nOsteoporosis  |  CHAPTER 3\n•\tBone\t losses\t are\t rapid,\t with\t the\t greatest\t decrease\t occurring\t during\t the\t first\t 6\t to\t\t\n12\t months\t of\t therapy.\t Oral\t doses\t as\t low\t as\t 2.5\t mg\t prednisone\t or\t equivalent\t daily\t\nhave\t been\t associated\t with\t fractures.\t Glucocorticoid-induced\t osteoporosis\t has\t also\t\nbeen\tassociated\twith\tinhaled\tglucocorticoids,\talthough\tmost\tdata\tsuggest\tno\tmajor\t\nbone\teffects.\n•\tMeasure\t baseline\t BMD,\t using\t central\t DXA\t for\t all\t patients\t starting\t on\t prednisone\t\n5\tmg\tor\tmore\tdaily\t(or\tequivalent)\tfor\tat\tleast\t6\tmonths.\tConsider\tBMD\ttesting\tat\t\nbaseline\tin\tpatients\tbeing\tstarted\ton\tshorter\tdurations\tof\tsystemic\tglucocorticoids\tif\t\nthey\tare\tat\thigh\trisk\tfor\tlow\tbone\tmass\tand\tfractures.\tBecause\tbone\tloss\tcan\toccur\t\nrapidly,\trepeat\tcentral\tDXA\tevery\t6\tto\t12\tmonths\tif\tneeded.\n•\tAll\tpatients\tstarting\tor\treceiving\tsystemic\tglucocorticoid\ttherapy\t(any\tdose\tor\tdura-\ntion)\tshould\tpractice\ta\tbone-healthy\tlifestyle\tand\tingest\t1200\tto\t1500\tmg\telemental\t\ncalcium\t and\t 800\t to\t 1200\t units\t of\t vitamin\t D\t daily\t to\t achieve\t therapeutic\t 25(OH)\t\nvitamin\tD\tconcentrations.\tUse\tthe\tlowest\tpossible\tcorticosteroid\tdose\tand\tduration.\n•\tTreatment\t guidelines\t divide\t recommendations\t for\t prescription\t medication\t use\t by\t\nfracture\trisk,\tage,\tmenopause\tand\tchildbearing\tstatus,\tglucocorticoid\tdose\tand\tdura-\ntion,\tand\tfragility\tfracture.\tOral\talendronate\tand\trisedronate\tand\tIV\tzoledronic\tacid\t\nare\tFDA\tapproved\tfor\tglucocorticoid-induced\tosteoporosis.\tThe\tAmerican\tCollege\t\nof\tRheumatology\tguidelines\trecommend\tthat\tall\tpatients\tnewly\tstarting\ton\tsystemic\t\nglucocorticoids\t(≥5\tmg/day\tof\tprednisone\tequivalent)\tfor\tan\tanticipated\tduration\tof\t\nat\tleast\t3\tmonths\tshould\treceive\tpreventive\tbisphosphonate\ttherapy.\tT eriparatide\tcan\t\nbe\tused\tif\tbisphosphonates\tare\tnot\ttolerated\tor\tcontraindicated.\t\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tExamine\t patients\t receiving\t pharmacotherapy\t for\t low\t bone\t mass\t at\t least\t annually.\t\nAssess\tmedication\tadherence\tand\ttolerance\tat\teach\tvisit.\n•\tAsk\tpatients\tabout\tpossible\tfracture\tsymptoms\t(eg,\tbone\tpain\tor\tdisability)\tat\teach\t\nvisit.\tAssessment\tof\tfracture,\tback\tpain,\tand\theight\tloss\tcan\thelp\tidentify\tworsening\t\nosteoporosis.\n•\tObtain\tcentral\tDXA\tBMD\tmeasurements\tevery\t1\tto\t2\tyears\tafter\tinitiating\ta\tmedica-\ntion\tto\tmonitor\tresponse.\tMore\tfrequent\tmonitoring\tmay\tbe\twarranted\tin\tpatients\t\nwith\tconditions\tassociated\twith\thigher\trates\tof\tbone\tloss\t(eg,\tglucocorticoid\tuse).\nSee Chapter 73, Osteoporosis and Other Metabolic Bone Diseases, authored by Mary Beth \nO’Connell and Jill S. Borchert, for a more detailed discussion of this topic.",
    "word_count": 378,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0061",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 61,
    "text": "26\n•\tRheumatoid arthritis \t (RA)\t is\t a\t chronic,\t progressive\t inflammatory\t disorder\t of\t\nunknown\t etiology\t characterized\tby\tpolyarticular\tsymmetric\t joint\t involvement\tand\t\nsystemic\tmanifestations.\nPATHOPHYSIOLOGY\n•\tRA\tresults\tfrom\tdysregulation\tof\thumoral\tand\tcell-mediated\timmunity.\tMost\tpatients\t\nproduce\tantibodies\tcalled\trheumatoid factors;\tthese\tseropositive\tpatients\ttend\tto\thave\t\na\tmore\taggressive\tcourse\tthan\tseronegative\tpatients.\n•\tImmunoglobulins\t(Ig)\tactivate\tthe\tcomplement\tsystem,\twhich\tamplifies\tthe\timmune\t\nresponse\t by\t enhancing\t chemotaxis,\t phagocytosis,\t and\t release\t of\t lymphokines\t by\t\nmononuclear\t cells\t that\t are\t then\t presented\t to\t T\t lymphocytes.\t Processed\t antigen\t is\t\nrecognized\t by\t the\t major\t histocompatibility\t complex\t proteins\t on\t the\t lymphocyte\t\nsurface,\tresulting\tin\tactivation\tof\tT\tand\tB\tcells.\n•\tT umor\t necrosis\t factor-α\t (TNF-α),\t interleukin-1\t(IL-1),\t and\t IL-6\t are\tproinflamma-\ntory\tcytokines\timportant\tin\tinitiation\tand\tcontinuance\tof\tinflammation.\n•\tActivated\t T\t cells\t produce\t cytotoxins\t and\t cytokines,\t which\t stimulate\t further\t\nactivation\t of\t inflammatory\t processes\t and\t attract\t cells\t to\t areas\t of\t inflammation.\t\nMacrophages\tare\tstimulated\tto\trelease\tprostaglandins\tand\tcytotoxins.\tT-cell\tactiva-\ntion\trequires\tboth\tstimulation\tby\tproinflammatory\tcytokines\tas\twell\tas\tinteraction\t\nbetween\tcell\tsurface\treceptors,\tcalled\tcostimulation.\tOne\tsuch\tcostimulation\tinterac-\ntion\tis\tbetween\tCD28\tand\tCD80/86.\n•\tActivated\t B\t cells\t produce\t plasma\t cells,\t which\t form\t antibodies\t that,\t in\t combina-\ntion\t with\t the\t complement\t system,\t result\t in\t accumulation\t of\t polymorphonuclear\t\nleukocytes.\tThese\tleukocytes\trelease\tcytotoxins,\toxygen-free\tradicals,\tand\thydroxyl\t\nradicals\tthat\tpromote\tdamage\tto\tsynovium\tand\tbone.\n•\tSignaling\t molecules\t are\t important\t for\t activating\t and\t maintaining\t inflamma-\ntion.\t Janus\t kinase\t (JAK)\t is\t a\t tyrosine\t kinase\t responsible\t for\t regulating\t leukocyte\t\nmaturation\t and\t activation.\t JAK\t also\t has\t effects\t on\t production\t of\t cytokines\t and\t\nimmunoglobulins.\n•\tV asoactive\t substances\t (histamine,\t kinins,\t prostaglandins)\t are\t released\t at\t sites\t of\t\ninflammation,\tincreasing\tblood\tflow\tand\tvascular\tpermeability.\tThis\tcauses\tedema,\t\nwarmth,\terythema,\tand\tpain,\tand\tfacilitates\tgranulocyte\tpassage\tfrom\tblood\tvessels\t\nto\tsites\tof\tinflammation.\n•\tChronic\t inflammation\t of\t synovial\t tissue\t lining\t the\t joint\t capsule\t results\t in\t tissue\t\nproliferation\t(pannus\tformation).\tPannus\tinvades\tcartilage\tand\teventually\tthe\tbone\t\nsurface,\t producing\terosions\tof\tbone\tand\tcartilage\tand\t leading\tto\tjoint\tdestruction.\t\nEnd\tresults\tmay\tbe\tloss\tof\tjoint\tspace\tand\tjoint\tmotion,\tbony\tfusion\t(ankylosis),\tjoint\t\nsubluxation,\ttendon\tcontractures,\tand\tchronic\tdeformity.\nCLINICAL PRESENTATION\n•\tNonspecific\tprodromal\tsymptoms\tdeveloping\tover\tweeks\tto\tmonths\tinclude\tfatigue,\t\nweakness,\tlow-grade\tfever,\tanorexia,\tand\tjoint\tpain.\tStiffness\tand\tmyalgias\tmay\tpre-\ncede\tdevelopment\tof\tsynovitis.\n•\tJoint\tinvolvement\ttends\tto\tbe\tsymmetric\tand\taffect\tsmall\tjoints\tof\tthe\thands,\twrists,\t\nand\tfeet;\telbows,\tshoulders,\thips,\tknees,\tand\tankles\tmay\talso\tbe\taffected.\n•\tJoint\tstiffness\ttypically\tis\tworse\tin\tthe\tmorning,\tusually\texceeds\t30\tminutes,\tand\tmay\t\npersist\tall\tday.\n•\tOn\texamination,\tjoint\tswelling\tmay\tbe\tvisible\tor\tapparent\tonly\tby\tpalpation.\tTissue\t\nis\tsoft,\tspongy,\twarm,\tand\tmay\tbe\terythematous.\tJoint\tdeformities\tmay\tinvolve\tsub-\nluxations\tof\twrists,\tmetacarpophalangeal\tjoints,\tand\tproximal\tinterphalangeal\tjoints\t\n(swan\tneck\tdeformity,\tboutonnière\tdeformity,\tand\tulnar\tdeviation).\nRheumatoid Arthritis\n4\nC H A P T E R",
    "word_count": 482,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0062",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 62,
    "text": "27\nRheumatoid Arthritis     CHAPTER 4\n•\tExtra-articular\t involvement\t may\t include\t rheumatoid\t nodules,\t vasculitis,\t pleural\t\neffusions,\tpulmonary\tfibrosis,\tocular\tmanifestations,\tpericarditis,\tcardiac\tconduction\t\nabnormalities,\tbone\tmarrow\tsuppression,\tand\tlymphadenopathy.\nDIAGNOSIS\n•\tThe\t American\t College\t of\t Rheumatology\t (ACR)\t and\t the\t European\t League\t Against\t\nRheumatism\t (EULAR)\t revised\t criteria\t for\t diagnosis\t of\t RA\t in\t 2010.\t These\t criteria\t\nare\tintended\tfor\tpatients\tearly\tin\ttheir\tdisease\tand\temphasize\tearly\tmanifestations.\t\nLate\tmanifestations\t(bone\terosions,\tsubcutaneous\tnodules)\tare\tno\tlonger\tin\tthe\tdiag-\nnostic\tcriteria.\tPatients\twith\tsynovitis\tof\tat\tleast\tone\tjoint\tand\tno\tother\texplanation\t\nfor\tthe\tfinding\tare\tcandidates\tfor\tassessment.\tThe\tcriteria\tuse\ta\tscoring\tsystem\twith\t\na\tcombined\tscore\tof\t6\tor\tmore\tout\tof\t10\tindicating\tthat\tthe\tpatient\thas\tdefinite\tRA.\t\n•\tLaboratory\t abnormalities\t include\t normocytic,\t normochromic\t anemia;\t thrombo-\ncytosis\t or\t thrombocytopenia;\t leukopenia;\t elevated\t erythrocyte\t sedimentation\t rate\t\nand\tC-reactive\tprotein;\tpositive\trheumatoid\tfactor\t(60%–70%\tof\tpatients);\tpositive\t\nanticitrullinated\tprotein\tantibody\t(ACPA)\t(50%–85%\tof\tpatients);\tand\tpositive\tanti-\nnuclear\tantibodies\t(25%\tof\tpatients).\n•\tAspirated\t synovial\t fluid\t may\t reveal\t turbidity,\t leukocytosis,\t reduced\t viscosity,\t and\t\nnormal\tor\tlow\tglucose\trelative\tto\tserum\tconcentrations.\n•\tEarly\tradiologic\tfindings\tinclude\tsoft\ttissue\tswelling\tand\tosteoporosis\tnear\tthe\tjoint\t\n(periarticular\tosteoporosis).\tErosions\tlater\tin\tthe\tdisease\tcourse\tare\tusually\tseen\tfirst\t\nin\t the\t metacarpophalangeal\t and\t proximal\t interphalangeal\t joints\t of\t the\t hands\t and\t\nmetatarsophalangeal\tjoints\tof\tthe\tfeet.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\tultimate\tgoal\tis\tto\tinduce\tcomplete\tremission\tor\tlow\tdisease\t\nactivity.\tAdditional\tgoals\tare\tto\tcontrol\tdisease\tactivity\tand\tjoint\tpain,\tmaintain\tabil-\nity\tto\tfunction\tin\tdaily\tactivities,\tslow\tdestructive\tjoint\tchanges,\tand\tdelay\tdisability.\nNONPHARMACOLOGIC THERAPY\n•\tAdequate\trest,\tweight\treduction\tif\tobese,\toccupational\ttherapy,\tphysical\ttherapy,\tand\t\nuse\tof\tassistive\tdevices\tmay\timprove\tsymptoms\tand\thelp\tmaintain\tjoint\tfunction.\n•\tPatients\twith\tsevere\tdisease\tmay\tbenefit\tfrom\tsurgical\tprocedures\tsuch\tas\ttenosyno-\nvectomy,\ttendon\trepair,\tand\tjoint\treplacements.\n•\tPatient\teducation\tabout\tthe\tdisease\tand\tthe\tbenefits\tand\tlimitations\tof\tdrug\ttherapy\t\nis\timportant.\nPHARMACOLOGIC THERAPY\nGeneral Approach\n•\tStart\t disease-modifying\t antirheumatic\t drugs\t (DMARDs)\t as\t soon\t as\t possible\t after\t\ndisease\tonset\tbecause\tearly\ttreatment\tresults\tin\tmore\tfavorable\toutcomes.\n•\tDMARDs\t slow\t RA\t disease\t progression.\t Common\t nonbiologic\t DMARDs\t include\t\nmethotrexate (MTX) , hydroxychloroquine ,\t sulfasalazine ,\t and leflunomide \t\n(Fig.",
    "word_count": 371,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0063",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 63,
    "text": "  CHAPTER 4\n•\tExtra-articular\t involvement\t may\t include\t rheumatoid\t nodules,\t vasculitis,\t pleural\t\neffusions,\tpulmonary\tfibrosis,\tocular\tmanifestations,\tpericarditis,\tcardiac\tconduction\t\nabnormalities,\tbone\tmarrow\tsuppression,\tand\tlymphadenopathy.\nDIAGNOSIS\n•\tThe\t American\t College\t of\t Rheumatology\t (ACR)\t and\t the\t European\t League\t Against\t\nRheumatism\t (EULAR)\t revised\t criteria\t for\t diagnosis\t of\t RA\t in\t 2010.\t These\t criteria\t\nare\tintended\tfor\tpatients\tearly\tin\ttheir\tdisease\tand\temphasize\tearly\tmanifestations.\t\nLate\tmanifestations\t(bone\terosions,\tsubcutaneous\tnodules)\tare\tno\tlonger\tin\tthe\tdiag-\nnostic\tcriteria.\tPatients\twith\tsynovitis\tof\tat\tleast\tone\tjoint\tand\tno\tother\texplanation\t\nfor\tthe\tfinding\tare\tcandidates\tfor\tassessment.\tThe\tcriteria\tuse\ta\tscoring\tsystem\twith\t\na\tcombined\tscore\tof\t6\tor\tmore\tout\tof\t10\tindicating\tthat\tthe\tpatient\thas\tdefinite\tRA.\t\n•\tLaboratory\t abnormalities\t include\t normocytic,\t normochromic\t anemia;\t thrombo-\ncytosis\t or\t thrombocytopenia;\t leukopenia;\t elevated\t erythrocyte\t sedimentation\t rate\t\nand\tC-reactive\tprotein;\tpositive\trheumatoid\tfactor\t(60%–70%\tof\tpatients);\tpositive\t\nanticitrullinated\tprotein\tantibody\t(ACPA)\t(50%–85%\tof\tpatients);\tand\tpositive\tanti-\nnuclear\tantibodies\t(25%\tof\tpatients).\n•\tAspirated\t synovial\t fluid\t may\t reveal\t turbidity,\t leukocytosis,\t reduced\t viscosity,\t and\t\nnormal\tor\tlow\tglucose\trelative\tto\tserum\tconcentrations.\n•\tEarly\tradiologic\tfindings\tinclude\tsoft\ttissue\tswelling\tand\tosteoporosis\tnear\tthe\tjoint\t\n(periarticular\tosteoporosis).\tErosions\tlater\tin\tthe\tdisease\tcourse\tare\tusually\tseen\tfirst\t\nin\t the\t metacarpophalangeal\t and\t proximal\t interphalangeal\t joints\t of\t the\t hands\t and\t\nmetatarsophalangeal\tjoints\tof\tthe\tfeet.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\tultimate\tgoal\tis\tto\tinduce\tcomplete\tremission\tor\tlow\tdisease\t\nactivity.\tAdditional\tgoals\tare\tto\tcontrol\tdisease\tactivity\tand\tjoint\tpain,\tmaintain\tabil-\nity\tto\tfunction\tin\tdaily\tactivities,\tslow\tdestructive\tjoint\tchanges,\tand\tdelay\tdisability.\nNONPHARMACOLOGIC THERAPY\n•\tAdequate\trest,\tweight\treduction\tif\tobese,\toccupational\ttherapy,\tphysical\ttherapy,\tand\t\nuse\tof\tassistive\tdevices\tmay\timprove\tsymptoms\tand\thelp\tmaintain\tjoint\tfunction.\n•\tPatients\twith\tsevere\tdisease\tmay\tbenefit\tfrom\tsurgical\tprocedures\tsuch\tas\ttenosyno-\nvectomy,\ttendon\trepair,\tand\tjoint\treplacements.\n•\tPatient\teducation\tabout\tthe\tdisease\tand\tthe\tbenefits\tand\tlimitations\tof\tdrug\ttherapy\t\nis\timportant.\nPHARMACOLOGIC THERAPY\nGeneral Approach\n•\tStart\t disease-modifying\t antirheumatic\t drugs\t (DMARDs)\t as\t soon\t as\t possible\t after\t\ndisease\tonset\tbecause\tearly\ttreatment\tresults\tin\tmore\tfavorable\toutcomes.\n•\tDMARDs\t slow\t RA\t disease\t progression.\t Common\t nonbiologic\t DMARDs\t include\t\nmethotrexate (MTX) , hydroxychloroquine ,\t sulfasalazine ,\t and leflunomide \t\n(Fig. 4–1 ).\t The\t order\t of\t selection\t is\t not\t clearly\t defined,\t but\t MTX\t is\t often\t chosen\t\ninitially\t because\t long-term\t data\t suggest\t superior\t outcomes\t compared\t with\t other\t\nDMARDs\tand\tlower\tcost\tthan\tbiologic\tagents.\n•\tCombination\ttherapy\twith\ttwo\tor\tmore\tnonbiologic\tDMARDs\tmay\tbe\teffective\twhen\t\nsingle-DMARD\ttreatment\tis\tunsuccessful.\tRecommended\tcombinations\tinclude\t(1)\t\nMTX\tplus\thydroxychloroquine,\t(2)\tMTX\tplus\tleflunomide,\t(3)\tMTX\tplus\tsulfasala-\nzine,\tand\t(4)\tMTX\tplus\thydroxychloroquine\tplus\tsulfasalazine.\n•\tBiologic\t DMARDs\t include\t the\t anti-TNF\t agents\t etanercept, infliximab ,\t adalim-\numab,\tcertolizumab,\tand\tgolimumab;\tthe\tcostimulation\tmodulator\tabatacept;\tthe\t\nIL-6\t receptor\t antagonist\t tocilizumab;\t and\t rituximab,\t which\t depletes\t peripheral\t\nB\tcells.\tBiologic\tDMARDs\thave\tproven\teffective\tfor\tpatients\tfailing\ttreatment\twith\t\nnonbiologic\tDMARDs\t(Fig.",
    "word_count": 484,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0064",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 64,
    "text": "4–1 ).\t The\t order\t of\t selection\t is\t not\t clearly\t defined,\t but\t MTX\t is\t often\t chosen\t\ninitially\t because\t long-term\t data\t suggest\t superior\t outcomes\t compared\t with\t other\t\nDMARDs\tand\tlower\tcost\tthan\tbiologic\tagents.\n•\tCombination\ttherapy\twith\ttwo\tor\tmore\tnonbiologic\tDMARDs\tmay\tbe\teffective\twhen\t\nsingle-DMARD\ttreatment\tis\tunsuccessful.\tRecommended\tcombinations\tinclude\t(1)\t\nMTX\tplus\thydroxychloroquine,\t(2)\tMTX\tplus\tleflunomide,\t(3)\tMTX\tplus\tsulfasala-\nzine,\tand\t(4)\tMTX\tplus\thydroxychloroquine\tplus\tsulfasalazine.\n•\tBiologic\t DMARDs\t include\t the\t anti-TNF\t agents\t etanercept, infliximab ,\t adalim-\numab,\tcertolizumab,\tand\tgolimumab;\tthe\tcostimulation\tmodulator\tabatacept;\tthe\t\nIL-6\t receptor\t antagonist\t tocilizumab;\t and\t rituximab,\t which\t depletes\t peripheral\t\nB\tcells.\tBiologic\tDMARDs\thave\tproven\teffective\tfor\tpatients\tfailing\ttreatment\twith\t\nnonbiologic\tDMARDs\t(Fig. 4–2 ).",
    "word_count": 118,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0065",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 65,
    "text": "28\nSECTION 1  |  Bone and Joint Disorders\nDisease\nactivity\nMethotrexate,\nleflunomide,\nsulfasalazine,\nor combination\nDMARD\nMethotrexate,\nleflunomide,\nsulfasalazine,\nor combination\nDMARD\nCombination\nDMARD or \nTNF inhibitor \nwith or\nwithout MTX  \nHydroxychloroquine\nor minocycline\nPoor\nprognosis?\nPoor\nprognosis?\nLow\nYes No\nHigh\nYes No\n•\tAnti-TNF\tbiologics\tmay\talso\tbe\tused\tin\tpatients\twith\tearly\tdisease\tof\thigh\tactivity\tand\t\npoor\tprognostic\tfactors,\tregardless\tof\tprevious\tDMARD\tuse.\tFeatures\tof\tpoor\tprogno-\nsis\tinclude\tfunctional\tlimitation,\textra-articular\tdisease\t(eg,\trheumatoid\tnodules,\tvas-\nculitis)\tpositive\trheumatoid\tfactor\tor\tACP A,\tor\tbone\terosions.\tAnti-TNF\tbiologics\tcan\t\nbe\tused\tas\teither\tmonotherapy\tor\tin\tcombination\twith\tother\tDMARDs.\tUse\tof\tbiologics\t\nin\tcombination\twith\tMTX\tis\tmore\teffective\tthan\tbiologic\tmonotherapy.\t\n•\tDMARDs\t less\t frequently\t used\t include\t anakinra\t (IL-1\t receptor\t antagonist),\t azathio-\nprine,\t penicillamine,\t gold\t salts\t (including\t auranofin),\t minocycline,\t cyclosporine,\t\nand\tcyclophosphamide.\tThese\tagents\thave\teither\tless\tefficacy\tor\thigher\ttoxicity,\tor\tboth.\n•\tNonsteroidal\t anti-inflammatory\t drugs\t (NSAIDs)\t and/or\t corticosteroids\t may\t be\t\nused\t for\t symptomatic\t relief\t if\t needed.\t They\t provide\t relatively\t rapid\t improvement\t\ncompared\twith\tDMARDs,\twhich\tmay\ttake\tweeks\tto\tmonths\tbefore\tbenefit\tis\tseen.\t\nHowever,\tNSAIDs\thave\tno\timpact\ton\tdisease\tprogression,\tand\tcorticosteroids\thave\t\npotential\tfor\tlong-term\tcomplications.\n•\tSee\tTables 4–1 \tand\t4–2\tfor\tusual\tdosages\tand\tmonitoring\tparameters\tfor\tDMARDs\t\nand\tNSAIDs\tused\tin\tRA.\nFIGURE 4–1.  Algorithm for treatment of rheumatoid arthritis in early disease.  \nPoor prognosis is defined as limitation in function, extra-articular findings (rheumatoid \nnodules, vasculitis, Felty syndrome, Sjögren syndrome, rheumatoid lung findings, ero -\nsions on radiograph), bone erosions, and positive rheumatoid factor or anticitrullinated \nprotein antibody. (DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; \nNSAID, nonsteroidal anti-inflammatory drug; TNF, tumor necrosis factor.)\nNonbiologic\nDMARD\nLow High\nYes\nPoor response\nPoor response\nNo\nCombination nonbiologic\nDMARD or anti-TNF\nAnti-TNF, rituximab or\nabatacept\nDisease\nactivity\nAnti-TNF or\ncombination\nnonbiologic\nNonbiologic\nDMARD\nMethotrexate,\nleflunomide,\nnonbiologic\ncombination or\nanti-TNF\nPoor\nprognosis?\nFIGURE 4–2.  Algorithm for treatment of rheumatoid arthritis in established \ndisease  (>6 months).  (DMARD, disease-modifying antirheumatic drug; anti-TNF , \nanti-tumor necrosis factor.)",
    "word_count": 335,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0066",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 66,
    "text": "29\nRheumatoid Arthritis  |  CHAPTER 4\n TABLE 4–1   Usual Doses and Monitoring Parameters for Antirheumatic Drugs\nDrug Usual Dose Initial Monitoring Tests Maintenance Monitoring Tests\nNSAIDs See Table 4–3 Scr or BUN, CBC every 2–4 weeks after starting ther -\napy for 1–2 months; salicylates: serum salicylate \nlevels if therapeutic dose and no response\nSame as initial plus stool guaiac every 6–12 \nmonths\nCorticosteroids Oral, IV, IM, IA, and soft-tissue injections: variable Glucose; blood pressure every 3–6 months Same as initial\nMethotrexate Oral or IM: 7.5–15 mg/week Baseline: AST, ALT, ALK-P , albumin, total bilirubin,  \nhepatitis B and C studies, CBC with platelets, S cr\nCBC with platelets, AST, albumin every 1–2 \nmonths\nLeflunomide Oral: 100 mg daily for 3 days, then 10–20 mg \ndaily, or 10–20 mg daily without loading dose\nBaseline: ALT, CBC with platelets CBC with platelets and ALT monthly initially, \nthen every 6–8 weeks\nHydroxychloroquine Oral: 200–300 mg twice daily; after 1–2 months \nmay decrease to 200 mg once or twice daily\nBaseline: color fundus photography and automated \ncentral perimetric analysis\nOphthalmoscopy every 9–12 months and \nAmsler grid at home every 2 weeks\nSulfasalazine Oral: 500 mg twice daily, then increase to 1 g \ntwice daily\nBaseline: CBC with platelets, then every week for \n1 month\nSame as initial every 1–2 months\nMinocycline Oral: 100–200 mg daily None None\nEtanercept 50 mg SC once weekly or 25 mg twice weekly Tuberculin skin test None\nInfliximab 3 mg/kg IV at 0, 2, 6 weeks, then every 8 weeks Tuberculin skin test None\nAdalimumab 40 mg SC every 2 weeks Tuberculin skin test None\nCertolizumab 400 mg (2 doses of 200 mg) SC at weeks 0, 2, 4, \nthen 200 mg every 2 weeks\nTuberculin skin test None\nGolimumab 50 mg SC once monthly Tuberculin skin test None\nRituximab 1000-mg IV infusion given twice, 2 weeks apart Tuberculin skin test None\n(continued )",
    "word_count": 315,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0067",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 67,
    "text": "30\nSECTION 1  |  Bone and Joint Disorders\n TABLE 4–1   Usual Doses and Monitoring Parameters for Antirheumatic Drugs ( Continued )\nDrug Usual Dose Initial Monitoring Tests Maintenance Monitoring Tests\nAbatacept IV infusion: 30-min weight-based infusion: <60 \nkg = 500 mg; 60–100 kg = 750 mg; >100 kg \n= 1000 mg\nSC injection: 125 mg SC within 24 h after a single \nIV infusion loading dose of ~10 mg/kg; then \n125 mg SC every 7 days\nTuberculin skin test None\nTocilizumab 4–8 mg/kg IV every 4 weeks Tuberculin skin test, AST/ALT, CBC with platelets, \nlipids\nAST/ALT, CBC with platelets, lipids every 4–8 \nweeks\nAnakinra 100 mg SC daily Tuberculin skin test, neutrophil count Neutrophil count monthly for 3 months, then \nquarterly for up to 1 year\nTofacitinib Oral: 5 mg twice daily Tuberculin skin test, CBC with differential; hepatic \nenzymes, lipids\nCBC with differential after 4–8 weeks and every  \n3 months thereafter\nAuranofin Oral: 3 mg once or twice daily Baseline: UA, CBC with platelets Same as initial every 1–2 months\nGold thiomalate IM: 10 mg test dose, then weekly dosing 25–50 \nmg; after response may increase dosing interval\nBaseline and until stable: UA, CBC with platelets  \npreinjection\nSame as initial every other dose\nAzathioprine Oral: 50–150 mg daily CBC with platelets, AST every 2 weeks for 1–2 \nmonths\nSame as initial every 1–2 months\nPenicillamine Oral: 125–250 mg daily, may increase by 125–\n250 mg every 1–2 months; max 750 mg/day\nBaseline: UA, CBC with platelets, then every week \nfor  \n1 month\nSame as initial every 1–2 months, but every 2 \nweeks if dose changes\nCyclophosphamide Oral: 1–2 mg/kg/day UA, CBC with platelets every week for 1 month Same tests as initial but every 2–4 weeks\nCyclosporine Oral: 2.5 mg/kg/day divided twice daily Scr, blood pressure every month Same as initial\nALK-P , alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CBC, complete blood cell count; IA, intra-articular; IM, intramuscu-\nlar; IV, intravenous; NSAIDs, nonsteroidal anti-inflammatory drugs; SC, subcutaneous; S cr, serum creatinine; UA, urinalysis.",
    "word_count": 340,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0068",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 68,
    "text": "31\nRheumatoid Arthritis  |  CHAPTER 4\n TABLE 4–2   Clinical Monitoring of Drug Therapy in Rheumatoid Arthritis\nDrug Toxicities Requiring Monitoring\nSymptoms to Inquire \nAbouta\nNSAIDs and salicy-\nlates\nGI ulceration and bleeding, renal \ndamage\nBlood in stool, black stool, dys-\npepsia, nausea/vomiting, weak-\nness, dizziness, abdominal pain, \nedema, weight gain, shortness \nof breath\nCorticosteroids Hypertension, hyperglycemia,  \nosteoporosisb\nBlood pressure, polyuria, polydip-\nsia, edema, shortness of breath, \nvisual changes, weight gain, \nheadaches, broken bones or \nbone pain\nMethotrexate GI (stomatitis, nausea/vomiting, \ndiarrhea), myelosuppression \n(thrombocytopenia, leukopenia), \nhepatic (elevated enzymes, rarely \ncirrhosis), pulmonary (fibrosis, \npneumonitis), rash\nSymptoms of myelosuppression, \nshortness of breath, nausea/\nvomiting, lymph node swelling, \ncoughing, mouth sores, diar-\nrhea, jaundice\nLeflunomide Hepatotoxicity, myelosuppression,  \nGI distress, alopecia\nNausea/vomiting, gastritis, diar-\nrhea, hair loss, jaundice\nHydroxychloroquine GI (nausea/vomiting, diarrhea), \nocular (benign corneal deposits, \nblurred vision, scotomas, night \nblindness, preretinopathy), \ndermatologic (rash, alopecia, \npigmentation), neurologic (head-\nache, vertigo, insomnia)\nVisual changes, including a \ndecrease in night or peripheral \nvision, rash, diarrhea\nSulfasalazine GI (anorexia, nausea/vomiting, \ndiarrhea), dermatologic (rash, \nurticaria), myelosuppression (leu-\nkopenia, rarely agranulocytosis), \nelevated hepatic enzymes\nSymptoms of myelosuppression, \nphotosensitivity, rash, nausea/\nvomiting\nEtanercept, adali-\nmumab, certoli-\nzumab, golimum-\nab, tocilizumab, \nanakinra\nLocal injection site reactions, infec-\ntion\nSymptoms of infection\nInfliximab, rituximab, \nabatacept\nImmune reactions, infection Postinfusion reactions, symptoms \nof infection\nTofacitinib Infection, malignancy, GI perfora-\ntion, upper respiratory tract \ninfection, headache, diarrhea, \nnasopharyngitis, elevated hepatic \nenzymes and lipids\nSymptoms of infection or myelo-\nsuppression, shortness of \nbreath, blood in stool, black \nstool, dyspepsia\nGold (intramuscular \nor oral)\nMyelosuppression, proteinuria, rash, \nstomatitis\nSymptoms of myelosuppression, \nedema, rash, oral ulcers, diar-\nrhea\nAzathioprine Myelosuppression, hepatotoxicity, \nlymphoproliferative disorders\nSymptoms of myelosuppression \n(extreme fatigue, easy bleeding \nor bruising, infection), jaundice\n(continued )",
    "word_count": 278,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0069",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 69,
    "text": "32\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0070",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 70,
    "text": "32\nSECTION 1     Bone and Joint Disorders\nNonsteroidal Anti-inflammatory Drugs\n•\tNSAIDs\tinhibit\tprostaglandin\tsynthesis,\twhich\tis\tonly\ta\tsmall\tportion\tof\tthe\tinflam-\nmatory\tcascade.\tThey\tpossess\tboth\tanalgesic\tand\tanti-inflammatory\tproperties\tand\t\nreduce\tstiffness,\tbut\tthey\tdo\tnot\tslow\tdisease\tprogression\tor\tprevent\tbony\terosions\tor\t\njoint\tdeformity.\tCommon\tNSAID\tdosage\tregimens\tare\tshown\tin\tTable 4–3.\nNonbiologic DMARDs\nMETHOTRE x ATE\n•\tMethotrexate (MTX)\tinhibits\tcytokine\tproduction\tand\tpurine\tbiosynthesis,\tand\tmay\t\nstimulate\tadenosine\trelease,\tall\tof\twhich\tmay\tlead\tto\tanti-inflammatory\tproperties.\t\nOnset\tis\tas\tearly\tas\t2\tto\t3\tweeks,\tand\t45%\tto\t67%\tof\tpatients\tremained\ton\tit\tin\tstudies\t\nranging\tfrom\t5\tto\t7\tyears.\n•\tConcomitant\t folic\t acid\t may\t reduce\t some\t adverse\t effects\t without\t loss\t of\t efficacy.\t\nMonitor\t liver\t injury\t tests\t periodically,\t but\t a\t liver\t biopsy\t is\t recommended\t during\t\ntherapy\tonly\tin\tpatients\twith\tpersistently\televated\thepatic\tenzymes.\tMTX\tis\tterato-\ngenic,\tand\tpatients\tshould\tuse\tcontraception\tand\tdiscontinue\tthe\tdrug\tif\tconception\t\nis\tplanned.\n•\tMTX\t is\t contraindicated\t in\t pregnant\t and\t nursing\t women,\t chronic\t liver\t disease,\t\nimmunodeficiency,\t pleural\t or\t peritoneal\t effusions,\t leukopenia,\t thrombocytope-\nnia,\t preexisting\t blood\t disorders,\t and\t creatinine\t clearance\t of\t less\t than\t 40\t mL/min\t\t\n(0.67\tmL/s).\nLEf Lu NOMIDE\n•\tLeflunomide\t(Arava)\tinhibits\tpyrimidine\tsynthesis,\twhich\treduces\tlymphocyte\tpro-\nliferation\tand\tmodulation\tof\tinflammation.\tEfficacy\tfor\tRA\tis\tsimilar\tto\tthat\tof\tMTX.\n•\tA\tloading\tdose\tof\t100\tmg/day\tfor\t3\tdays\tmay\tresult\tin\ttherapeutic\tresponse\twithin\t\nthe\tfirst\tmonth.\tThe\tusual\tmaintenance\tdose\tof\t20\tmg/day\tmay\tbe\tlowered\tto\t10\tmg/\nday\tin\tcases\tof\tGI\tintolerance,\talopecia,\tor\tother\tdose-related\ttoxicity.\n•\tLeflunomide\tis\tcontraindicated\tin\tpatients\twith\tpreexisting\tliver\tdisease.\tIt\tis\tterato-\ngenic\tand\tmust\tbe\tavoided\tduring\tpregnancy.\n TABLE 4–2   Clinical Monitoring of Drug Therapy in Rheumatoid Arthritis ( Continued )\nDrug Toxicities Requiring Monitoring\nSymptoms to Inquire \nAbouta\nPenicillamine Myelosuppression, proteinuria, sto-\nmatitis, rash, dysgeusia\nSymptoms of myelosuppression, \nedema, rash, diarrhea, altered \ntaste perception, oral ulcers\nCyclophosphamide Alopecia, infertility, GI distress, \nhemorrhagic cystitis, myelosup-\npression, nephrotoxicity, cardio-\ntoxicity\nNausea/vomiting, gastritis, diar-\nrhea, hair loss, urination difficul-\nties, chest pain, rash, respiratory \ndifficulties\nCyclosporine Hepatotoxicity, nephrotoxicity, \nhypertension, headache, malig-\nnancy, infections, GI distress\nNausea/vomiting, diarrhea, symp-\ntoms of infection, symptoms of \nelevated blood pressure\nGI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs.\naAltered immune function increases infection, which should be considered particularly in patients \ntaking azathioprine, methotrexate, corticosteroids, or other drugs that may produce myelosup -\npression.\nbOsteoporosis is not likely to manifest early in treatment, but all patients should be taking appropri-\nate steps to prevent bone loss.",
    "word_count": 425,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0071",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 71,
    "text": "33\nRheumatoid Arthritis  |  CHAPTER 4\n TABLE 4–3   Dosage Regimens for Nonsteroidal Anti-inflammatory Drugs\nRecommended Total Daily Anti-inflammatory Dosage\nDrug Adult Children Dosing Schedule\nAspirin 2.6–5.2 g 60–100 mg/kg 4 times daily\nCelecoxib 200–400 mg – Once or twice daily\nDiclofenac 150–200 mg – 3 or 4 times daily; extended \nrelease: twice daily\nDiflunisal 0.5–1.5 g – Twice daily\nEtodolac 0.2–1.2 g (max 20 \nmg/kg)\n– 2–4 times daily\nFenoprofen 0.9–3 g – 4 times daily\nFlurbiprofen 200–300 mg – 2–4 times daily\nIbuprofen 1.2–3.2 g 20–40 mg/kg 3 or 4 times daily\nIndomethacin 50–200 mg 2–4 mg/kg (max \n200 mg)\n2–4 times daily; extended \nrelease: once daily\nMeclofenamate 200–400 mg – 3–4 times daily\nMeloxicam 7.5–15 mg – Once daily\nNabumetone 1–2 g – Once or twice daily\nNaproxen 0.5–1 g 10 mg/kg Twice daily; extended release: \nonce daily\nNaproxen sodium 0.55–1.1 g – Twice daily\nNonacetylated \nsalicylates\n1.2–4.8 g – 2–6 times daily\nOxaprozin 0.6–1.8 g (max 26 \nmg/kg)\n– 1–3 times daily\nPiroxicam 10–20 mg – Once daily\nSulindac 300–400 mg – Twice daily\nTolmetin 0.6–1.8 g 15–30 mg/kg 2–4 times daily\nHYDROx YCHLOROqu INE\n•\tHydroxychloroquine\t is\t often\t used\t in\t mild\t RA\t or\t as\t an\t adjuvant\t in\t combination\t\nDMARD\t therapy.\t It\t lacks\t the\t myelosuppressive,\t hepatic,\t and\t renal\t toxicities\t seen\t\nwith\tsome\tother\tDMARDs,\twhich\tsimplifies\tmonitoring.\tOnset\tmay\tbe\tdelayed\tfor\t\nup\tto\t6\tweeks,\tbut\tthe\tdrug\tshould\tnot\tbe\tconsidered\ta\ttherapeutic\tfailure\tuntil\tafter\t\n6\tmonths\tof\ttherapy\twith\tno\tresponse.\n•\tPeriodic\tophthalmologic\texaminations\tare\tnecessary\tfor\tearly\tdetection\tof\treversible\t\nretinal\ttoxicity.\nSu LfASALA z INE\n•\tSulfasalazine\tuse\tis\toften\tlimited\tby\tadverse\teffects.\tAntirheumatic\teffects\tshould\tbe\t\nseen\twithin\t2\tmonths.\n•\tGI\tsymptoms\tmay\tbe\tminimized\tby\tstarting\twith\tlow\tdoses,\tdividing\tthe\tdose\tevenly\t\nthroughout\tthe\tday,\tand\ttaking\tit\twith\tfood.\nMINOCYCLINE\n•\tMinocycline\t may\t inhibit\t metalloproteinases\t active\t in\t damaging\t articular\t cartilage.\t\nIt\tmay\tbe\tan\talternative\tfor\tpatients\twith\tmild\tdisease\tand\twithout\tfeatures\tof\tpoor\t\nprognosis.",
    "word_count": 332,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0072",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 72,
    "text": "34\nSECTION 1  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0073",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 73,
    "text": "34\nSECTION 1     Bone and Joint Disorders\nTOfACITINI b\n•\tTofacitinib\t(Xeljanz)\tis\ta\tnonbiologic\tJAK\tinhibitor\tindicated\tfor\tpatients\twith\tmod-\nerate\tto\tsevere\tRA\twho\thave\tfailed\tor\thave\tintolerance\tto\tMTX.\n•\tThe\t Food\t and\t Drug\t Administration\t (FDA)–approved\t dose\t is\t 5\t mg\t twice\t daily\t as\t\nmonotherapy\tor\tin\tcombination\twith\tother\tnonbiologic\tDMARDs.\n•\tLabeling\t includes\t black-box\t warnings\t about\t serious\t infections,\t lymphomas,\t and\t\nother\tmalignancies.\tLive\tvaccinations\tshould\tnot\tbe\tgiven\tduring\ttreatment.\n•\tLong-term\tsafety\tdata\tand\timpact\ton\tradiographic\tjoint\tdamage\tare\tneeded\tbefore\t\ntofacitinib’ s\tplace\tin\tthe\ttherapy\twill\tbe\tclear.\nBiologic DMARDs\n•\tBiologic\t DMARDs\t may\t be\t effective\t when\t nonbiologic\t DMARDs\t fail\t to\t achieve\t\nadequate\tresponses\tbut\tare\tconsiderably\tmore\texpensive.\n•\tOther\tthan\tanakinra\tand\ttocilizumab,\tthese\tagents\thave\tno\ttoxicities\trequiring\tlabo-\nratory\tmonitoring,\tbut\tthey\tdo\tcarry\ta\tsmall\tincreased\trisk\tfor\tinfection,\tincluding\t\ntuberculosis.\tT uberculin\tskin\ttesting\tshould\tbe\tperformed\tbefore\ttreatment\tto\tdetect\t\nlatent\ttuberculosis.\t\n•\tBiologic\tagents\tshould\tbe\tat\tleast\ttemporarily\tdiscontinued\tin\tpatients\twho\tdevelop\t\ninfections\twhile\ton\ttherapy\tuntil\tthe\tinfection\tis\tcured.\tLive\tvaccines\tshould\tnot\tbe\t\ngiven\tto\tpatients\ttaking\tbiologic\tagents.\nTNf - α I NHIb ITORS\n•\tInhibitors\t of\t TNF-α\t are\t generally\t the\t first\t biologic\t DMARDs\t used.\t About\t 30%\t of\t\npatients\teventually\tdiscontinue\tuse\towing\tto\tinadequate\tefficacy\tor\tadverse\teffects.\t\nIn\tsuch\tsituations,\taddition\tof\ta\tnonbiologic\tDMARD\tmay\tbe\tbeneficial\tif\tthe\tpatient\t\nis\tnot\talready\ttaking\tone.\tChoosing\tan\talternative\tTNF\tinhibitor\tmay\tbenefit\tsome\t\npatients;\ttreatment\twith\trituximab\tor\tabatacept\tmay\talso\tbe\teffective\tin\tpatients\tfail-\ning\t TNF\t inhibitors.\t Combination\t biologic\t DMARD\t therapy\t is\t not\t recommended\t\nbecause\tof\tincreased\tinfection\trisk.\n•\tCongestive\theart\tfailure\t(HF)\tis\ta\trelative\tcontraindication\tfor\tanti-TNF\tagents\tdue\tto\t\nreports\tof\tincreased\tcardiac\tmortality\tand\tHF\texacerbations.\tPatients\twith\tNew\tY ork\t\nHeart\tAssociation\tclass\tIII\tor\tIV\tand\tan\tejection\tfraction\tof\t50%\tor\tless\tshould\tnot\tuse\t\nanti-TNF\ttherapy.\tDiscontinue\tthe\tdrugs\tif\tHF\tworsens\tduring\ttreatment.\n•\tAnti-TNF\ttherapy\thas\tbeen\treported\tto\tinduce\ta\tmultiple\tsclerosis\t(MS)–like\tillness\t\nor\texacerbate\tMS\tin\tpatients\twith\tthe\tdisease.\tDiscontinue\ttherapy\tif\tpatients\tdevelop\t\nneurologic\tsymptoms\tsuggestive\tof\tMS.\n•\tTNF\t inhibitors\t are\t associated\t with\t increased\t risk\t of\t cancer,\t especially\t lympho-\nproliferative\t cancers.\t The\t drugs\t contain\t a\t black-box\t warning\t about\t increased\t risk\t\nof\t lymphoproliferative\t and\t other\t cancers\t in\t children\t and\t adolescents\t treated\t with\t\nthese\tdrugs.\n•\tSee\tTables\t4–1\tand\t4–2\tfor\tdosing\tand\tmonitoring\tinformation.\n✓  Etanercept\t(Enbrel)\tis\ta\tfusion\tprotein\tconsisting\tof\ttwo\tp75-soluble\tTNF\trecep-\ntors\t linked\t to\t an\t Fc\t fragment\t of\t human\t IgG1.\t It\t binds\t to\t and\t inactivates\t TNF ,\t\npreventing\t it\t from\t interacting\t with\t the\t cell-surface\t TNF\t receptors\t and\t thereby\t\nactivating\t cells.\t Clinical\t trials\t using\t etanercept\t in\t patients\t who\t failed\t DMARDs\t\ndemonstrated\t responses\t in\t 60%\t to\t 75%\t of\t patients.\t It\t slows\t erosive\t disease\t\nprogression\t more\t than\t oral\t MTX\t in\t patients\t with\t inadequate\t response\t to\t MTX\t\nmonotherapy.\n✓  Infliximab\t(Remicade)\tis\ta\tchimeric\t anti-TNF\t antibody\t fused\tto\t a\thuman\t con-\nstant-region\tIgG1.\tIt\tbinds\tto\tTNF\tand\tprevents\tits\tinteraction\twith\tTNF\treceptors\t\non\tinflammatory\tcells.\tT o\tprevent\tformation\tof\tan\tantibody\tresponse\tto\tthis\tfor-\neign\tprotein,\tMTX\tmust\tbe\tgiven\torally\tin\tdoses\tused\tto\ttreat\tRA\tfor\tas\tlong\tas\tthe\t\npatient\tcontinues\tinfliximab.\tIn\tclinical\ttrials,\tthe\tcombination\tof\tinfliximab\tand\t\nMTX\thalted\tprogression\tof\tjoint\tdamage\tand\twas\tsuperior\tto\tMTX\tmonotherapy.\t\nAn\tacute\tinfusion\treaction\twith\tfever,\tchills,\tpruritus,\tand\trash\tmay\toccur\twithin",
    "word_count": 580,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0074",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 74,
    "text": "35\nRheumatoid Arthritis  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0075",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 75,
    "text": "35\nRheumatoid Arthritis     CHAPTER 4\n1\tto\t2\thours\tafter\tadministration.\tAutoantibodies\tand\tlupus-like\tsyndrome\t have\t\nalso\tbeen\treported.\n✓  Adalimumab\t(Humira)\tis\ta\thuman\tIgG1\tantibody\tto\tTNF-α\tthat\tis\tless\tantigenic\t\nthan\tinfliximab.\tIt\thas\tresponse\trates\tsimilar\tto\tother\tTNF\tinhibitors.\t\n✓  Golimumab\t(Simponi)\tis\ta\thuman\tantibody\tto\tTNF-α\twith\tactivity\tand\tprecau-\ntions\tsimilar\tto\tother\tTNF-α\tinhibitors.\n✓  Certolizumab\t(Cimzia)\tis\ta\thumanized\tantibody\tspecific\tfor\tTNF-α\twith\tprecau-\ntions\tand\tside\teffects\tsimilar\tto\tother\tTNF-α\tinhibitors.\nAb ATACEPT\n•\tAbatacept\t(Orencia)\tis\ta\tcostimulation\tmodulator\tapproved\tfor\tpatients\twith\tmod-\nerate\tto\tsevere\tdisease\twho\tfail\tto\tachieve\tan\tadequate\tresponse\tfrom\tone\tor\tmore\t\nDMARDs.\tBy\tbinding\tto\tCD80/CD86\treceptors\ton\tantigen-presenting\tcells,\tabata-\ncept\tinhibits\tinteractions\tbetween\tthe\tantigen-presenting\tcells\tand\tT\tcells,\tpreventing\t\nT\tcells\tfrom\tactivating\tto\tpromote\tthe\tinflammatory\tprocess.\t\nRITux IMAb\n•\tRituximab\t(Rituxan)\tis\ta\tmonoclonal\tchimeric\tantibody\tconsisting\tof\thuman\tprotein\t\nwith\t the\t antigen-binding\t region\t derived\t from\t a\t mouse\t antibody\t to\t CD20\t protein\t\nfound\ton\tthe\tcell\tsurface\tof\tmature\tB\tlymphocytes.\tBinding\tof\trituximab\tto\tB\tcells\t\nresults\t in\t nearly\t complete\t depletion\t of\t peripheral\t B\t cells,\t with\t a\t gradual\t recovery\t\nover\tseveral\tmonths.\n•\tRituximab\t is\t useful\t in\t patients\t failing\t MTX\t or\t TNF\t inhibitors.\t Give\t methylpred-\nnisolone\t100\tmg\t30\tminutes\tprior\tto\trituximab\tto\treduce\tincidence\tand\tseverity\tof\t\ninfusion\treactions.\tAcetaminophen\tand\tantihistamines\tmay\talso\tbenefit\tpatients\twho\t\nhave\ta\thistory\tof\treactions.\tMTX\tshould\tbe\tgiven\tconcurrently\tin\tthe\tusual\tdoses\tfor\t\nRA\tto\tachieve\toptimal\ttherapeutic\toutcomes.\nTOCILIzu MAb\n•\tTocilizumab\t(Actemra)\tis\ta\thumanized\tmonoclonal\tantibody\tthat\tattaches\tto\tIL-6\t\nreceptors,\tpreventing\tthe\tcytokine\tfrom\tinteracting\twith\tIL-6\treceptors.\tIt\tis\tapproved\t\nfor\tadults\twith\tmoderately\tto\tseverely\tactive\tRA\twho\thave\tfailed\tto\trespond\tto\tone\tor\t\nmore\t anti-TNF\t biologic\t agents.\t It\t is\t used\t as\t either\t monotherapy\t or\t in\t combination\t\nwith\tMTX\tor\tanother\tDMARD.\t\nANAk INRA\n•\tAnakinra\t(Kineret)\tis\tan\tIL-1\treceptor\tantagonist;\tit\tis\tless\teffective\tthan\tother\tbio-\nlogic\tDMARDs\tand\tis\tnot\tincluded\tin\tthe\tcurrent\tACR\ttreatment\trecommendations.\t\nHowever,\tselect\tpatients\twith\trefractory\tdisease\tmay\tbenefit.\tIt\tcan\tbe\tused\talone\tor\t\nin\tcombination\twith\tany\tof\tthe\tother\tDMARDs\texcept\tTNF-α\tinhibitors.\nCorticosteroids\n•\tCorticosteroids\t have\t anti-inflammatory\t and\t immunosuppressive\t properties.\t They\t\ninterfere\t with\t antigen\t presentation\t to\t T\t lymphocytes,\t inhibit\t prostaglandin\t and\t\nleukotriene\t synthesis,\t and\t inhibit\t neutrophil\t and\t monocyte\t superoxide\t radical\t\ngeneration.\n•\tOral\tcorticosteroids\t(eg,\tprednisone\tand\tmethylprednisolone)\tcan\tbe\tused\tto\tcon-\ntrol\tpain\tand\tsynovitis\twhile\tDMARDs\tare\ttaking\teffect\t(“bridging\ttherapy”).\n•\tLow-dose,\t long-term\t corticosteroid\t therapy\t may\t be\t used\t to\t control\t symptoms\t in\t\npatients\t with\t difficult-to-control\t disease.\t Prednisone\t doses\t below\t 7.5\t mg/day\t (or\t\nequivalent)\tare\twell\ttolerated\tbut\tare\tnot\tdevoid\tof\tlong-term\tadverse\teffects.\tUse\tthe\t\nlowest\tdose\tthat\tcontrols\tsymptoms.\tAlternate-day\tdosing\tof\tlow-dose\toral\tcortico-\nsteroids\tis\tusually\tineffective\tin\tRA.\n•\tHigh-dose\toral\tor\tIV\tbursts\tmay\tbe\tused\tfor\tseveral\tdays\tto\tsuppress\tdisease\tflares.\t\nAfter\tsymptoms\tare\tcontrolled,\ttaper\tthe\tdrug\tto\tthe\tlowest\teffective\tdose.",
    "word_count": 505,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0076",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 76,
    "text": "36\nSECTION 1  |  Bone and Joint Disorders\n•\tThe\tintramuscular\troute\tis\tpreferable\tin\tnonadherent\tpatients.\tDepot\tforms\t(triam-\ncinolone acetonide,\ttriamcinolone hexacetonide,\tand methylprednisolone acetate)\t\nprovide\t 2\t to\t 6\t weeks\t of\t symptomatic\t control.\t Onset\t of\t effect\t may\t be\t delayed\t for\t\nseveral\tdays.\tThe\tdepot\teffect\tprovides\ta\tphysiologic\ttaper,\tavoiding\thypothalamic-\npituitary\taxis\tsuppression.\n•\tIntra-articular\t injections\t of\t depot\t forms\t may\t be\t useful\t when\t only\t a\t few\t joints\t are\t\ninvolved.\tIf\teffective,\tinjections\tmay\tbe\trepeated\tevery\t3\tmonths.\tDo\tnot\tinject\tany\t\none\tjoint\tmore\tthan\ttwo\tor\tthree\ttimes\tper\tyear.\n•\tAdverse\t effects\t of\t systemic\t glucocorticoids\t limit\t long-term\t use.\t Consider\t dosage\t\ntapering\tand\teventual\tdiscontinuation\tat\tsome\tpoint\tduring\tchronic\ttherapy.\nEv ALu ATION Of T HERAPE u TIC Ou TCOMES\n•\tClinical\tsigns\tof\timprovement\tinclude\treduction\tin\tjoint\tswelling,\tdecreased\twarmth\t\nover\tactively\tinvolved\tjoints,\tand\tdecreased\ttenderness\tto\tjoint\tpalpation.\n•\tSymptom\timprovement\tincludes\treduction\tin\tjoint\tpain\tand\tmorning\tstiffness,\tlon-\nger\ttime\tto\tonset\tof\tafternoon\tfatigue,\tand\timprovement\tin\tability\tto\tperform\tdaily\t\nactivities.\n•\tPeriodic\tjoint\tradiographs\tmay\tbe\tuseful\tin\tassessing\tdisease\tprogression.\n•\tLaboratory\tmonitoring\tis\tof\tlittle\tvalue\tin\tassessing\tresponse\tto\ttherapy\tbut\tis\tessen-\ntial\tfor\tdetecting\tand\tpreventing\tadverse\tdrug\teffects\t(see\tTable 4–2).\n•\tAsk\t patients\t about\t the\t presence\t of\t symptoms\t that\t may\t be\t related\t to\t adverse\t drug\t\neffects\t(see\tTable 4–3).\nSee Chapter 72, Rheumatoid Arthritis, authored by Kimberly Wahl and Arthur A. \nSchuna, for a detailed discussion of this topic.",
    "word_count": 251,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0077",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 77,
    "text": "37\nSection 2 \nCardiovas Cular d isorders\nEdited by Terry L.",
    "word_count": 11,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0078",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 78,
    "text": "37\nSection 2 \nCardiovas Cular d isorders\nEdited by Terry L. Schwinghammer\n•\tAcute coronary syndromes \t (ACSs)\t include\t all\t syndromes\t compatible\t with\t acute\t\nmyocardial\tischemia\tresulting\tfrom\timbalance\tbetween\tmyocardial\toxygen\tdemand\t\nand\tsupply.\n•\tACSs\t are\t classified\t according\t to\t electrocardiographic\t (ECG)\t changes\t into\t (1)\t\nST-segment-elevation\t (STE)\t myocardial\t infarction\t (MI)\t or\t (2)\t non–ST-segment-\nelevation\t(NSTE)\tACS,\twhich\tincludes\tNSTE\tMI\tand\tunstable\tangina\t(UA).\nPATHOPHYSIOLOGY\n•\tEndothelial\tdysfunction,\tinflammation,\tand\tformation\tof\tfatty\tstreaks\tcontribute\tto\t\ndevelopment\tof\tatherosclerotic\tcoronary\tartery\tplaques.\t\n•\tThe\tcause\tof\tACS\tin\tmore\tthan\t90%\tof\tpatients\tis\trupture,\tfissuring,\tor\terosion\tof\tan\t\nunstable\tatheromatous\tplaque.\tA\tclot\tforms\ton\ttop\tof\tthe\truptured\tplaque.\tExposure\t\nof\tcollagen\tand\ttissue\tfactor\tinduces\tplatelet\tadhesion\tand\tactivation,\twhich\tpromote\t\nrelease\tof\tadenosine\tdiphosphate\t(ADP)\tand\tthromboxane\tA2\tfrom\tplatelets\tproduc-\ning\tvasoconstriction\tand\tplatelet\tactivation.\tA\tchange\tin\tthe\tconformation\tof\tthe\tgly-\ncoprotein\t(GP)\tIIb/IIIa\tsurface\treceptors\tof\tplatelets\toccurs\tthat\tcross-links\tplatelets\t\nto\teach\tother\tthrough\tfibrinogen\tbridges.\n•\tSimultaneously,\tactivation\tof\tthe\textrinsic\tcoagulation\tcascade\toccurs\tas\ta\tresult\tof\t\nexposure\tof\tblood\tto\tthe\tthrombogenic\tlipid\tcore\tand\tendothelium,\twhich\tare\trich\t\nin\ttissue\tfactor.\tThis\tleads\tto\tformation\tof\ta\tfibrin\tclot\tcomposed\tof\tfibrin\tstrands,\t\ncross-linked\tplatelets,\tand\ttrapped\tred\tblood\tcells.\n•\tV entricular\tremodeling\toccurs\tafter\tMI\tand\tis\tcharacterized\tby\tleft\tventricular\tdila-\ntion\tand\treduced\tpumping\tfunction,\tleading\tto\tcardiac\tfailure.\t\n•\tComplications\tof\tMI\tinclude\tcardiogenic\tshock,\theart\tfailure\t(HF),\tvalvular\tdysfunc-\ntion,\t arrhythmias,\t pericarditis,\t stroke\t secondary\t to\t left\t ventricular\t (LV)\t thrombus\t\nembolization,\tvenous\tthromboembolism,\tand\tLV\tfree-wall\trupture.\nCLINICAL PRESENTATION\n•\tPredominant\tsymptom\tis\tmidline\tanterior\tchest\tdiscomfort\t(usually\tat\trest),\tsevere\t\nnew-onset\tangina,\tor\tincreasing\tangina\tthat\tlasts\tat\tleast\t20\tminutes.\tDiscomfort\tmay\t\nradiate\tto\tthe\tshoulder,\tdown\tthe\tleft\tarm,\tto\tthe\tback,\tor\tto\tthe\tjaw.\tAccompanying\t\nsymptoms\tmay\tinclude\tnausea,\tvomiting,\tdiaphoresis,\tand\tshortness\tof\tbreath.\t\n•\tNo\tspecific\tfeatures\tindicate\tACS\ton\tphysical\texamination.\tHowever,\tpatients\twith\t\nACS\tmay\tpresent\twith\tsigns\tof\tacute\tHF\tor\tarrhythmias.\nDIAGNOSIS\n•\tObtain\t 12-lead\t ECG\t within\t 10\t minutes\t of\t presentation.\t Key\t findings\t indicating\t\nmyocardial\tischemia\tor\tMI\tare\tSTE,\tST-segment\tdepression,\tand\tT-wave\tinversion.\t\nAppearance\tof\ta\tnew\tleft\tbundle-branch\tblock\twith\tchest\tdiscomfort\tis\thighly\tspe-\ncific\tfor\tacute\tMI.\tSome\tpatients\twith\tmyocardial\t ischemia\thave\t no\tECG\tchanges,\t\nso\t biochemical\t markers\t and\t other\t risk\t factors\t for\t coronary\t artery\t disease\t (CAD)\t\nshould\tbe\tassessed.\n•\tBiochemical\tmarkers\tof\tmyocardial\tcell\tdeath\tare\timportant\tfor\tconfirming\tdiagno-\nsis\tof\tacute\tMI.\tDiagnosis\tis\tconfirmed\twith\tdetection\tof\trise\tand/or\tfall\tof\tcardiac\t\na cute Coronary syndromes\n5\nc h a p t e r",
    "word_count": 445,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0079",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 79,
    "text": "38\nSection  2     c ardiovascular Disorders\nbiomarkers\t(cardiac\ttroponin\tpreferred)\twith\tat\tleast\tone\tvalue\tabove\tthe\t99th\tper-\ncentile\tof\tthe\tupper\treference\tlimit\tand\tat\tleast\tone\tof\tthe\tfollowing:\t(1)\tsymptoms\t\nof\t ischemia;\t (2)\t new\t significant\t ST-segment–T-wave\t changes\t or\t new\t left\t bundle-\nbranch\tblock;\t(3)\tpathological\tQ\twaves;\tor\t(4)\timaging\tevidence\tof\tnew\tloss\tof\tviable\t\nmyocardium\tor\tnew\tregional\twall\tmotion\tabnormality.\tTypically,\ta\tblood\tsample\tis\t\nobtained\tonce\tin\tthe\temergency\tdepartment,\tthen\t6\tto\t9\thours\tlater.\n•\tPatient\t symptoms,\t past\t medical\t history,\t ECG,\t and\t biomarkers\t are\t used\t to\t stratify\t\npatients\tinto\tlow,\tmedium,\tor\thigh\trisk\tof\tdeath,\tMI,\tor\tlikelihood\tof\tfailing\tphar-\nmacotherapy\tand\tneeding\turgent\tcoronary\tangiography\tand\tpercutaneous\tcoronary\t\nintervention\t(PCI).\nTREATMENT\n•\tGoals\tof\tTreatment:\tShort-term\tgoals\tinclude:\t(1)\tearly\trestoration\tof\tblood\tflow\tto\t\nthe\tinfarct-related\tartery\tto\tprevent\tinfarct\texpansion\t(in\tthe\tcase\tof\tMI)\tor\tprevent\t\ncomplete\tocclusion\tand\tMI\t(in\tUA),\t(2)\tprevention\tof\tdeath\tand\tother\tcomplications,\t\n(3)\tprevention\tof\tcoronary\tartery\treocclusion,\t(4)\trelief\tof\tischemic\tchest\tdiscomfort,\t\nand\t (5)\t resolution\t of\t ST-segment\t and\t T-wave\t changes\t on\t ECG.\t Long-term\t goals\t\ninclude\t control\t of\t cardiovascular\t (CV)\t risk\t factors,\t prevention\t of\t additional\t CV\t\nevents,\tand\timprovement\tin\tquality\tof\tlife.\nGENERAL APPROACH\n•\tGeneral\tmeasures\tinclude\thospital\tadmission,\toxygen\tif\tsaturation\tis\tlow,\tcontinuous\t\nmultilead\tST-segment\tmonitoring\tfor\tarrhythmias\tand\tischemia,\tfrequent\tmeasure-\nment\tof\tvital\tsigns,\tbedrest\tfor\t12\thours\tin\themodynamically\tstable\tpatients,\tuse\tof\t\nstool\tsofteners\tto\tavoid\tV alsalva\tmaneuver,\tand\tpain\trelief.\n•\tObtain\t serum\t potassium,\t magnesium,\t glucose,\t and\t creatinine;\t baseline\t complete\t\nblood\t cell\t count\t (CBC)\t and\t coagulation\t tests;\t and\t fasting\t lipid\t panel.\t Draw\t lipid\t\npanel\twithin\tthe\tfirst\t24\thours\tof\thospitalization\tbecause\tvalues\tfor\tcholesterol\t(an\t\nacute\tphase\treactant)\tmay\tbe\tfalsely\tlow\tafter\tthat\tperiod.\n•\tIt\tis\timportant\tto\ttriage\tand\ttreat\tpatients\taccording\tto\ttheir\trisk\tcategory\t(Fig.",
    "word_count": 315,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0080",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 80,
    "text": "  c ardiovascular Disorders\nbiomarkers\t(cardiac\ttroponin\tpreferred)\twith\tat\tleast\tone\tvalue\tabove\tthe\t99th\tper-\ncentile\tof\tthe\tupper\treference\tlimit\tand\tat\tleast\tone\tof\tthe\tfollowing:\t(1)\tsymptoms\t\nof\t ischemia;\t (2)\t new\t significant\t ST-segment–T-wave\t changes\t or\t new\t left\t bundle-\nbranch\tblock;\t(3)\tpathological\tQ\twaves;\tor\t(4)\timaging\tevidence\tof\tnew\tloss\tof\tviable\t\nmyocardium\tor\tnew\tregional\twall\tmotion\tabnormality.\tTypically,\ta\tblood\tsample\tis\t\nobtained\tonce\tin\tthe\temergency\tdepartment,\tthen\t6\tto\t9\thours\tlater.\n•\tPatient\t symptoms,\t past\t medical\t history,\t ECG,\t and\t biomarkers\t are\t used\t to\t stratify\t\npatients\tinto\tlow,\tmedium,\tor\thigh\trisk\tof\tdeath,\tMI,\tor\tlikelihood\tof\tfailing\tphar-\nmacotherapy\tand\tneeding\turgent\tcoronary\tangiography\tand\tpercutaneous\tcoronary\t\nintervention\t(PCI).\nTREATMENT\n•\tGoals\tof\tTreatment:\tShort-term\tgoals\tinclude:\t(1)\tearly\trestoration\tof\tblood\tflow\tto\t\nthe\tinfarct-related\tartery\tto\tprevent\tinfarct\texpansion\t(in\tthe\tcase\tof\tMI)\tor\tprevent\t\ncomplete\tocclusion\tand\tMI\t(in\tUA),\t(2)\tprevention\tof\tdeath\tand\tother\tcomplications,\t\n(3)\tprevention\tof\tcoronary\tartery\treocclusion,\t(4)\trelief\tof\tischemic\tchest\tdiscomfort,\t\nand\t (5)\t resolution\t of\t ST-segment\t and\t T-wave\t changes\t on\t ECG.\t Long-term\t goals\t\ninclude\t control\t of\t cardiovascular\t (CV)\t risk\t factors,\t prevention\t of\t additional\t CV\t\nevents,\tand\timprovement\tin\tquality\tof\tlife.\nGENERAL APPROACH\n•\tGeneral\tmeasures\tinclude\thospital\tadmission,\toxygen\tif\tsaturation\tis\tlow,\tcontinuous\t\nmultilead\tST-segment\tmonitoring\tfor\tarrhythmias\tand\tischemia,\tfrequent\tmeasure-\nment\tof\tvital\tsigns,\tbedrest\tfor\t12\thours\tin\themodynamically\tstable\tpatients,\tuse\tof\t\nstool\tsofteners\tto\tavoid\tV alsalva\tmaneuver,\tand\tpain\trelief.\n•\tObtain\t serum\t potassium,\t magnesium,\t glucose,\t and\t creatinine;\t baseline\t complete\t\nblood\t cell\t count\t (CBC)\t and\t coagulation\t tests;\t and\t fasting\t lipid\t panel.\t Draw\t lipid\t\npanel\twithin\tthe\tfirst\t24\thours\tof\thospitalization\tbecause\tvalues\tfor\tcholesterol\t(an\t\nacute\tphase\treactant)\tmay\tbe\tfalsely\tlow\tafter\tthat\tperiod.\n•\tIt\tis\timportant\tto\ttriage\tand\ttreat\tpatients\taccording\tto\ttheir\trisk\tcategory\t(Fig. 5–1).\n•\tPatients\twith\tSTE\tMI\tare\tat\thigh\trisk\tof\tdeath,\tso\tinitiate\timmediate\tefforts\tto\trees-\ntablish\tcoronary\tperfusion\tand\tadjunctive\tpharmacotherapy.\nNONPHARMACOLOGIC THERAPY\n•\tFor\tpatients\twith\tSTE\tMI\tpresenting\twithin\t12\thours\tof\tsymptom\tonset,\tthe\treperfu-\nsion\ttreatment\tof\tchoice\tis\tearly\treperfusion\twith\tprimary\tPCI\tof\tthe\tinfarct\tartery\t\nwithin\t90\tminutes\tof\tfirst\tmedical\tcontact.\n•\tFor\tpatients\twith\tNSTE\tACS,\tpractice\tguidelines\trecommend\tcoronary\tangiography\t\nwith\teither\tPCI\tor\tcoronary\tartery\tbypass\tgraft\t(CABG)\tsurgery\trevascularization\tas\t\nearly\ttreatment\tfor\thigh-risk\tpatients;\tsuch\tan\tapproach\tmay\talso\tbe\tconsidered\tfor\t\npatients\tnot\tat\thigh\trisk.\nEARLY PHARMACOTHERAPY FOR STE MI (F IG.",
    "word_count": 422,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0081",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 81,
    "text": "5–1).\n•\tPatients\twith\tSTE\tMI\tare\tat\thigh\trisk\tof\tdeath,\tso\tinitiate\timmediate\tefforts\tto\trees-\ntablish\tcoronary\tperfusion\tand\tadjunctive\tpharmacotherapy.\nNONPHARMACOLOGIC THERAPY\n•\tFor\tpatients\twith\tSTE\tMI\tpresenting\twithin\t12\thours\tof\tsymptom\tonset,\tthe\treperfu-\nsion\ttreatment\tof\tchoice\tis\tearly\treperfusion\twith\tprimary\tPCI\tof\tthe\tinfarct\tartery\t\nwithin\t90\tminutes\tof\tfirst\tmedical\tcontact.\n•\tFor\tpatients\twith\tNSTE\tACS,\tpractice\tguidelines\trecommend\tcoronary\tangiography\t\nwith\teither\tPCI\tor\tcoronary\tartery\tbypass\tgraft\t(CABG)\tsurgery\trevascularization\tas\t\nearly\ttreatment\tfor\thigh-risk\tpatients;\tsuch\tan\tapproach\tmay\talso\tbe\tconsidered\tfor\t\npatients\tnot\tat\thigh\trisk.\nEARLY PHARMACOTHERAPY FOR STE MI (F IG. 5–2)\n•\tIn\t addition\t to\t reperfusion\t therapy,\t American\t College\t of\t Cardiology\t Foundation/\nAmerican\tHeart\tAssociation\t(ACCF/AHA)\tguidelines\trecommend\tthat\tall\tpatients\t\nwith\t STE\t MI\t and\t without\t contraindications\t should\t receive\t within\t the\t first\t day\t of\t\nhospitalization\tand\t preferably\t in\t the\t emergency\t department:\t (1)\t intranasal\toxygen\t\n(if\t oxygen\t saturation\t is\t low),\t (2)\t sublingual\t (SL)\t nitroglycerin\t (NTG),\t (3)\t aspirin,\t\t\n(4)\ta\tP2Y12\tplatelet\tinhibitor,\t(5)\tand\tanticoagulation\twith\tbivalirudin,\tunfractionated\t\nheparin\t(UFH),\tor\tenoxaparin.\t\n•\tAdminister\ta\tGP\tIIb/IIIa\tinhibitor\twith\tUFH\tto\tpatients\tundergoing\tprimary\tPCI.\t\nGive\tIV\tβ-blockers\tand\tIV\tNTG\tto\tselect\tpatients.\tInitiate\toral\tβ-blockers\tthe\tfirst\tday\t\nin\tpatients\twithout\tcardiogenic\tshock.\tAdminister\tmorphine\tto\tpatients\twith\trefrac-\ntory\tangina\tas\tan\tanalgesic\tand\tvenodilator\tthat\tlowers\tpreload.\tStart\tan\tangiotensin-\nconverting\t enzyme\t (ACE)\t inhibitor\t within\t 24\t hours\t in\t patients\t who\t have\t either\t\nanterior\twall\tMI\tor\tLVEF\tof\t40%\tor\tless\tand\tno\tcontraindications.",
    "word_count": 257,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0082",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 82,
    "text": "39\na cute c oronary Syndromes  |  chapter  5\nFibrinolytic Therapy\n•\tA\tfibrinolytic\tagent\tis\tindicated\tin\tpatients\twith\tSTE\tMI\tpresenting\twithin\t12\thours\t\nof\tthe\tonset\tof\tchest\tdiscomfort\twho\thave\tat\tleast\t1\tmm\tof\tSTE\tin\ttwo\tor\tmore\tcon-\ntiguous\tECG\t leads\tand\tare\t unable\t to\t undergo\t primary\t PCI\twithin\t120\tminutes\t of\t\nmedical\tcontact.\tLimit\tuse\tof\tfibrinolytics\tbetween\t12\tand\t24\thours\tafter\tsymptom\t\nonset\tto\tpatients\twith\tongoing\tischemia.\n•\tIt\t is\t not\t necessary\t to\t obtain\t the\t results\t of\t biochemical\t markers\t before\t initiating\t\nfibrinolytic\ttherapy.\n•\tAbsolute\tcontraindications\tto\tfibrinolytic\ttherapy\tinclude:\t(1)\thistory\tof\themorrhagic\t\nstroke\t(at\tany\ttime),\t(2)\tischemic\tstroke\twithin\t3\tmonths,\t(3)\tactive\tinternal\tbleeding,\t\n(4)\t known\t intracranial\t neoplasm,\t (5)\t known\t structural\t cerebrovascular\t lesion,\t (6)\t\nFigure 5–1.  evaluation of the acute coronary syndrome patient.  aas described \nin textbook table 7-1. b“positive”: a bove the myocardial infarction decision limit. \nc“negative”: Below the myocardial infarction decision limit. ( ac S, acute coronary \nsyndrome; ca BG, coronary artery bypass graft; ca D, coronary artery disease; c K MB, \ncreatine kinase myocardial band; ecG, electrocardiogram; pci, percutaneous coronary \nintervention. (Modified with permission from Spinler S a . evolution of antithrombotic \ntherapy used in acute coronary syndromes. in: r ichardson MM, c hant c , c heng JWM, et \nal, eds. Pharmacotherapy Self-Assessment Program. Book 1: Cardiology, 7th ed. Lenexa, KS: \na merican c ollege of c linical pharmacy; 2010.)\nST-segment elevation\nRisk stratificationa; multilead continuous ST-segment\nmonitoring; obtain serial troponin and CK MBb,c\nNo ST-segment elevation\nIschemic chest discomfort symptoms, lasting at least 20 min; \nsuspect acute coronary syndrome\nInitiate adjunctive ST-segment elevation\nACS pharmacotherapy\nInitiate reperfusion therapy in appropriate\ncandidates (fibrinolysis or primary PCI)\nObtain serial troponin and CK MB as\nconfirmatory; results not needed before\nreperfusion therapy is initiated; multilead\ncontinuous ST-segment monitoring\nObtain and interpret a 12-lead ECG within 10 min\nDiagnosis of noncardiac\nchest pain syndrome\nNegative stress test\nLow-risk\nPositive stress test\nStress test to evaluate likelihood of CAD\nCoronary angiography with\nrevascularization (PCI or CABG)\nInitiate pharmacotherapy for non-ST-segment\nelevation ACS based on patient risk\nST-segment depression T-wave inversion No ECG changes\nModerate- and high-risk",
    "word_count": 361,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0083",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 83,
    "text": "40\nSection  2  |  c ardiovascular Disorders\nST-segment elevation myocardial infarction\nOxygen (if O2 saturation <90%)\nSL NTG, aspirin, morphine\nsulfated, IV NTGd\nSymptoms ≤ to 12 h\nSecondary PCI or CABG or fibrinolysis\nfor select patients; for secondary\nPCI during hospitalization, administer\nbivalirudinee alone or UFH or\nenoxaparinc or fondaparinux\n(plus UFH) with optional GP\nllb/Illa inhibitor at time of PCIf\nSymptoms >12 h\nReperfusion therapy\nBivalirudine alone or\nunfractionated heparin\nwith GP llb/Illa\nreceptor inhibitor\nPrimary PCI\nIV UFHa or IV and SC\nenoxaparinb,c\n(preferred; selected patients)\nor IV and SC fondaparinuxd\nFibrinolysis\nβ-Blocker, ACE inhibitor (or ARB), eplerenone (or spironolactone)d\nHigh-intensity statin\nClopidogrel, prasugrel,\nor ticagrelor Clopidogrel, statin\nFigure 5–2.  initial pharmacotherapy for ST-segment elevation myocardial \ninfarction. aFor at least 48 hours. bSee textbook table 24–2 for dosing and specific \ntypes of patients who should not receive enoxaparin. cFor the duration of hospitaliza-\ntion, up to 8 days. dFor select patients, see textbook table 24–2. eif pretreated with \nUFh, stop UFh infusion for 30 minutes prior to administration of bivalirudin (bolus plus \ninfusion). f increased risk of major bleeding and ich  if a G p iib/iiia inhibitor is added to \nan anticoagulant for pci following fibrinolysis, especially in the elderly; weigh risk ver -\nsus benefit ( ace , angiotensin-converting enzyme; ar B, angiotensin receptor blocker; \nca BG, coronary artery bypass graft surgery; G p, glycoprotein; nt G, nitroglycerin; pci, \npercutaneous coronary intervention; Sc , subcutaneous; SL, sublingual; UFh, unfraction-\nated heparin.) (Modified with permission from Spinler S a . evolution of antithrombotic \ntherapy used in acute coronary syndromes. in: r ichardson MM, c hant c . c heng JWM, \net al, eds. Pharmacotherapy Self-Assessment Program. 7th ed. Book 1: Cardiology. Lenexa, \nKS: a merican c ollege of c linical pharmacy; 2010.)",
    "word_count": 295,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0084",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 84,
    "text": "41\na cute c oronary Syndromes  ",
    "word_count": 6,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0085",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 85,
    "text": "41\na cute c oronary Syndromes     chapter  5\nsuspected\taortic\tdissection,\tand\t(7)\tsignificant\tclosed\thead\tor\tfacial\ttrauma\twithin\t3\t\nmonths.\tPrimary\tPCI\tis\tpreferred\tin\tthese\tsituations.\n•\tA\t fibrin-specific\t agent\t (alteplase,\t reteplase,\t or\t tenecteplase)\t is\t preferred\t over\t the\t\nnon–fibrin-specific\tagent\tstreptokinase.\t\n•\tTreat\teligible\tpatients\tas\tsoon\tas\tpossible,\tbut\tpreferably\twithin\t30\tminutes\tfrom\tthe\t\ntime\tthey\tpresent\tto\tthe\temergency\tdepartment,\twith\tone\tof\tthe\tfollowing\tregimens:\n✓  Alteplase:\t15\tmg\tIV\tbolus\tfollowed\tby\t0.75\tmg/kg\tinfusion\t(maximum\t50\tmg)\tover\t\n30\t minutes,\t followed\t by\t 0.5\t mg/kg\t infusion\t (maximum\t 35\t mg)\t over\t 60\t minutes\t\n(maximum\tdose\t100\tmg)\n✓  Reteplase:\t 10\t units\t IV\t over\t 2\t minutes,\t followed\t 30\t minutes\t later\t with\t another\t\n10\tunits\tIV\tover\t2\tminutes\n✓  Tenecteplase:\t A\t single\t IV\t bolus\t dose\t given\t over\t 5\t seconds\t based\t on\t patient\t\nweight:\t30\tmg\tif\tless\tthan\t60\tkg;\t35\tmg\tif\t60\tto\t69.9\tkg;\t40\tmg\tif\t70\tto\t79.9\tkg;\t\t\n45\tmg\tif\t80\tto\t89.9\tkg;\tand\t50\tmg\tif\t90\tkg\tor\tgreater\n✓  Streptokinase:\t1.5\tmillion\tunits\tin\t50\tmL\tof\tnormal\tsaline\tor\t5%\tdextrose\tin\twater\t\nIV\tover\t60\tminutes\n•\tIntracranial\t hemorrhage\t (ICH)\t and\t major\t bleeding\t are\t the\t most\t serious\t side\t\neffects.\tThe\trisk\tof\tICH\tis\thigher\twith\tfibrin-specific\tagents\tthan\twith\tstreptokinase.\t\nHowever,\tthe\trisk\tof\tsystemic\tbleeding\tother\tthan\tICH\tis\thigher\twith\tstreptokinase\t\nthan\twith\tfibrin-specific\tagents.\nAspirin\n•\tAdminister\taspirin\tto\tall\tpatients\twithout\tcontraindications\twithin\t24\thours\tbefore\t\nor\tafter\thospital\tarrival.\tIt\tprovides\tadditional\tmortality\tbenefit\tin\tpatients\twith\tSTE\t\nACS\twhen\tgiven\twith\tfibrinolytic\ttherapy.\n•\tIn\tpatients\texperiencing\tan\tACS,\tnon–enteric-coated\taspirin,\t160\tto\t325\tmg,\tshould\t\nbe\tchewed\tand\tswallowed\tas\tsoon\tas\tpossible\tafter\tthe\tonset\tof\tsymptoms\tor\timme-\ndiately\tafter\tpresentation\tto\tthe\temergency\tdepartment\tregardless\tof\tthe\treperfusion\t\nstrategy\t being\t considered.\t Patients\t undergoing\t PCI\t not\t previously\t taking\t aspirin\t\nshould\treceive\t325\tmg\tnon–enteric-coated\taspirin.\n•\tA\tdaily\tmaintenance\tdose\tof\t75\tto\t162\tmg\tis\trecommended\tthereafter\tand\tshould\tbe\t\ncontinued\tindefinitely.\tBecause\tof\tincreased\tbleeding\trisk\tin\tpatients\treceiving\taspi-\nrin\tplus\ta\tP2Y12\tinhibitor,\tlow-dose\taspirin\t(81\tmg\tdaily)\tis\tpreferred\tfollowing\tPCI.\n•\tDiscontinue\tother\tnonsteroidal\tanti-inflammatory\tdrugs\t(NSAIDs)\tand\tcyclooxygenase-2\t\n(COX-2)\tselective\t inhibitors\tat\tthe\ttime\t of\t STE\tMI\tdue\tto\tincreased\trisk\t of\tdeath,\t\nreinfarction,\tHF ,\tand\tmyocardial\trupture.\n•\tThe\t most\t frequent\t side\t effects\t of\t aspirin\t include\t dyspepsia\t and\t nausea.\t Inform\t\npatients\tabout\tthe\trisk\tof\tGI\tbleeding.\nPlatelet P2Y12 Inhibitors\n•\tClopidogrel,\tprasugrel,\tand\tticagrelor\tblock\ta\tsubtype\tof\tADP\treceptor\t(the\tP2Y12\t\nreceptor)\t on\t platelets,\t preventing\t binding\t of\t ADP\t to\t the\t receptor\t and\t subsequent\t\nexpression\tof\tplatelet\tGP\tIIb/IIIa\treceptors,\treducing\tplatelet\taggregation.\n•\tA\t P2Y12\t receptor\t inhibitor\t in\t addition\t to\t aspirin\t is\t recommended\t for\t all\t patients\t\nwith\tSTE\tMI.\tFor\tpatients\tundergoing\tprimary\tPCI,\tgive\tclopidogrel,\tprasugrel,\tor\t\nticagrelor,\tin\taddition\tto\taspirin,\tto\tprevent\tsubacute\tstent\t thrombosis\t and\tlonger-\nterm\tCV\tevents.\t\n•\tThe\trecommended\tduration\tof\tP2Y12\tinhibitors\tfor\ta\tpatient\tundergoing\tPCI\t(either\t\nSTE\tMI\tor\tNSTE\tACS)\tis\tat\tleast\t12\tmonths\tfor\tpatients\treceiving\teither\ta\tbare\tmetal\t\nor\tdrug-eluting\tstent.\n•\tIf\t CABG\t surgery\t is\t planned,\t withhold\t clopidogrel\t and\t ticagrelor\t for\t 5\t days,\t and\t\nprasugrel\tat\tleast\t7\tdays,\tto\treduce\trisk\tof\tpostoperative\tbleeding,\tunless\tthe\tneed\tfor\t\nrevascularization\toutweighs\tthe\tbleeding\trisk.\n•\tClopidogrel: 300\tmg\toral\tloading\tdose\tfollowed\tby\t75\tmg\torally\tdaily\tin\tpatients\treceiv-\ning\t a\t fibrinolytic\t or\t who\t do\t not\t receive\t reperfusion\t therapy.\t Avoid\t loading\t dose\t in\t\npatients\taged\t75\tyears\tor\tmore.\tA\t600-mg\toral\tloading\tdose\tis\trecommended\tbefore\tpri-\nmary\tPCI,\texcept\tthat\t300\tmg\tshould\tbe\tgiven\tif\twithin\t24\thours\tof\tfibrinolytic\ttherapy.",
    "word_count": 621,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0086",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 86,
    "text": "42\nSection  2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0087",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 87,
    "text": "42\nSection  2     c ardiovascular Disorders\n•\tPrasugrel:\t60\tmg\toral\tloading\tdose\tfollowed\tby\t10\tmg\torally\tonce\tdaily\tfor\tpatients\t\nweighing\t60\tkg\t(132\tlb)\tor\tmore.\n•\tTicagrelor: 180\tmg\toral\tloading\tdose\tin\tpatients\tundergoing\tPCI,\tfollowed\tby\t90\tmg\t\norally\ttwice\tdaily.\n•\tThe\tmost\tfrequent\tside\teffects\tof\tclopidogrel\tand\tprasugrel\tinclude\tnausea,\tvomiting,\t\nand\t diarrhea,\t (2%–5%\t of\t patients).\t Thrombotic\t thrombocytopenic\t purpura\t (TTP)\t\nhas\tbeen\treported\trarely\twith\tclopidogrel.\tTicagrelor\tis\tassociated\twith\tnausea\t(4%),\t\ndiarrhea\t(3%),\tdyspnea\t(14%),\tand,\trarely,\tventricular\tpauses\tand\tbradyarrhythmias.\t\n•\tIn\tpatients\twith\tSTE\tMI\treceiving\tfibrinolysis,\tearly\ttherapy\twith\tclopidogrel\t75\tmg\t\nonce\tdaily\tduring\thospitalization\tand\tup\tto\t28\tdays\treduces\tmortality\tand\treinfarc-\ntion\twithout\tincreasing\trisk\tof\tmajor\tbleeding.\tIn\tadults\tyounger\tthan\t75\tyears\treceiv-\ning\tfibrinolytics,\tthe\tfirst\tdose\tof\tclopidogrel\tcan\tbe\ta\t300-mg\tloading\tdose.\n•\tFor\tpatients\twith\tSTE\tMI\twho\tdo\tnot\tundergo\treperfusion\ttherapy\twith\teither\tpri-\nmary\tPCI\tor\tfibrinolysis,\tclopidogrel\tis\tthe\tpreferred\tP2Y12\tinhibitor\tadded\tto\taspirin\t\nand\tshould\tbe\tcontinued\tfor\tat\tleast\t14\tdays\t(and\tup\tto\t1\tyear).\tTicagrelor\tmay\talso\t\nbe\tan\toption\tin\tmedically\tmanaged\tpatients\twith\tACS.\nGlycoprotein IIb/IIIa Receptor Inhibitors\n•\tGP\tIIb/IIIa\treceptor\tinhibitors\tblock\tthe\tfinal\tcommon\tpathway\tof\tplatelet\taggrega-\ntion,\tnamely\tcross-linking\tof\tplatelets\tby\tfibrinogen\tbridges\tbetween\tthe\tGP\tIIb\tand\t\nIIIa\treceptors\ton\tthe\tplatelet\tsurface.\t\n•\tAbciximab\t (IV\t or\t intracoronary\t administration),\t eptifibatide,\t or\t tirofiban\t may\t be\t\nadministered\tin\tpatients\twith\tSTE\tMI\tundergoing\tprimary\tPCI\twho\tare\ttreated\twith\t\nUFH.\tDo\tnot\tadminister\tGP\tIIb/IIIa\tinhibitors\tto\tpatients\twith\tSTE\tMI\twho\twill\tnot\t\nbe\tundergoing\tPCI.\n•\tAbciximab:\t0.25\tmg/kg\tIV\tbolus\tgiven\t10\tto\t60\tminutes\tbefore\tthe\tstart\tof\tPCI,\tfol-\nlowed\tby\t0.125\tmcg/kg/min\t(maximum\t10\tmcg/min)\tfor\t12\thours.\n•\tEptifibatide:\t180\tmcg/kg\tIV\tbolus,\trepeated\tin\t10\tminutes,\tfollowed\tby\tinfusion\tof\t\n2\tmcg/kg/min\tfor\t18\tto\t24\thours\tafter\tPCI.\n•\tTirofiban:\t25\tmcg/kg\tIV\tbolus,\tthen\t0.15\tmcg/kg/min\tup\tto\t18\tto\t24\thours\tafter\tPCI.\t\n•\tRoutine\tuse\tof\ta\tGP\tIIb/IIIa\treceptor\tinhibitor\tis\tnot\trecommended\tin\tpatients\twho\t\nhave\t received\t fibrinolytics\t or\t in\t those\t receiving\t bivalirudin\t because\t of\t increased\t\nbleeding\trisk.\n•\tBleeding\tis\tthe\tmost\tsignificant\tadverse\teffect.\tDo\tnot\tuse\tGP\tIIb/IIIa\tinhibitors\tin\t\npatients\twith\ta\thistory\tof\themorrhagic\tstroke\tor\trecent\tischemic\tstroke.\tRisk\tof\tbleed-\ning\tis\tincreased\tin\tpatients\twith\tchronic\tkidney\tdisease;\treduce\tthe\tdose\tof\teptifiba-\ntide\t and\t tirofiban\t in\t renal\t impairment.\t An\t immune-mediated\t thrombocytopenia\t\noccurs\tin\tapproximately\t5%\tof\tpatients\twith\tabciximab\tand\tfewer\tthan\t1%\tof\tpatients\t\nreceiving\teptifibatide\tor\ttirofiban.\nAnticoagulants\n•\tEither\t UFH\t or\t bivalirudin\t is\t preferred\t for\t patients\t undergoing\t primary\t PCI,\t\nwhereas\tfor\tfibrinolysis,\teither\tUFH,\tenoxaparin,\tor\tfondaparinux\tmay\tbe\tused.\n•\tUFH\tinitial\tdose\tfor\tprimary\tPCI\tis\t50\tto\t70\tunits/kg\tIV\tbolus\tif\ta\tGP\tIIb/IIIa\tinhibi-\ntor\tis\tplanned\tand\t70\tto\t100\tU/kg\tIV\tbolus\tif\tno\tGP\tIIb/IIIa\tinhibitor\tis\tplanned;\tgive\t\nsupplemental\tIV\tbolus\tdoses\tto\tmaintain\tthe\ttarget\tactivated\tclotting\ttime\t(ACT).\n•\tUFH\tinitial\tdose\twith\tfibrinolytics\tis\t60\tU/kg\tIV\tbolus\t(maximum\t4000\tunits),\tfol-\nlowed\tby\tconstant\tIV\tinfusion\tof\t12\tU/kg/h\t(maximum\t1000\tU/h).\tAdjust\tthe\tUFH\t\ninfusion\tdose\tfrequently\tto\tmaintain\ta\ttarget\tactivated\tpartial\tthromboplastin\ttime\t\n(aPTT)\tof\t1.5\tto\t2\ttimes\tcontrol\t(50–70\tseconds).\tMeasure\tthe\tfirst\taPTT\tat\t3\thours\t\nin\tpatients\twith\tSTE\tACS\twho\tare\ttreated\twith\tfibrinolytics\tand\tat\t4\tto\t6\thours\tin\t\npatients\tnot\treceiving\tthrombolytics\tor\tundergoing\tprimary\tPCI.\n•\tEnoxaparin\tdose\tis\t1\tmg/kg\tsubcutaneous\t(SC)\tevery\t12\thours\t(creatinine\tclearance\t\n[Clcr]\t≥30\tmL/min)\tor\t24\thours\tif\timpaired\trenal\tfunction\t(Clcr\t15–29\tmL/min).\tFor\t\npatients\twith\tSTE\tMI\treceiving\tfibrinolytics,\tenoxaparin\t30\tmg\tIV\tbolus\tis\tfollowed\t\nimmediately\t by\t 1\t mg/kg\t SC\t every\t 12\t hours\t if\t younger\t than\t 75\t years.\t In\t patients",
    "word_count": 651,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0088",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 88,
    "text": "43\na cute c oronary Syndromes  ",
    "word_count": 6,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0089",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 89,
    "text": "43\na cute c oronary Syndromes     chapter  5\n75\tyears\tand\tolder,\tgive\tenoxaparin\t0.75\tmg/kg\tSC\tevery\t12\thours.\tContinue\tenoxa-\nparin\tthroughout\thospitalization\tor\tup\tto\t8\tdays.\n•\tBivalirudin\t dose\tfor\t PCI\t in\t STE\tMI\t is\t 0.75\t mg/kg\t IV\t bolus,\tfollowed\t by\t1.75\t mg/\nkg/h\tinfusion.\tDiscontinue\tat\tthe\tend\tof\tPCI\tor\tcontinue\tat\t0.25\tmg/kg/h\tif\tprolonged\t\nanticoagulation\tis\tnecessary.\n•\tFondaparinux\tdose\tis\t2.5\tmg\tIV\tbolus\tfollowed\tby\t2.5\tmg\tSC\tonce\tdaily\tstarting\ton\t\nhospital\tday\t2.\n•\tFor\t patients\t undergoing\t PCI,\t discontinue\t anticoagulation\t immediately\t after\t the\t\nprocedure.\tIn\tpatients\treceiving\tan\tanticoagulant\tplus\ta\tfibrinolytic,\tcontinue\tUFH\t\nfor\t a\t minimum\t of\t 48\t hours\t and\t enoxaparin\t and\t fondaparinux\t for\t the\t duration\t of\t\nhospitalization,\tup\tto\t8\tdays.\tIn\t patients\twho\tdo\t not\tundergo\treperfusion\ttherapy,\t\nanticoagulant\ttherapy\t may\tbe\t administered\t for\t up\t to\t48\t hours\t for\t UFH\t or\t for\t the\t\nduration\tof\thospitalization\tfor\tenoxaparin\tor\tfondaparinux.\nβ-Adrenergic Blockers\n•\tIf\tno\tcontraindications,\tadminister\ta\tβ-blocker\tearly\t(within\tthe\tfirst\t24\thours)\tand\t\ncontinue\tindefinitely.\n•\tBenefits\t result\t from\t blockade\t of\t β1\t receptors\t in\t the\t myocardium,\t which\t reduces\t\nheart\t rate,\t myocardial\t contractility,\t and\t BP ,\t thereby\t decreasing\t myocardial\t oxygen\t\ndemand.\tReduced\theart\trate\tincreases\tdiastolic\ttime,\tthus\timproving\tventricular\tfill-\ning\tand\tcoronary\tartery\tperfusion.\n•\tβ-Blockers\treduce\trisk\tfor\trecurrent\tischemia,\tinfarct\tsize,\treinfarction,\tand\tventricu-\nlar\tarrhythmias.\n•\tUsual\tdoses\tof\tβ-blockers,\twith\ttarget\tresting\theart\trate\tof\t50\tto\t60\tbeats/min:\n✓  Metoprolol:\t5\tmg\tby\tslow\t(over\t1–2\tminutes)\tIV\tbolus,\trepeated\tevery\t5\tminutes\t\nfor\ttotal\tinitial\tdose\tof\t15\tmg.\tIf\ta\tconservative\tregimen\tis\tdesired,\treduce\tinitial\t\ndoses\tto\t1\tto\t2\tmg.\tFollow\tin\t1\tto\t2\thours\tby\t25\tto\t50\tmg\torally\tevery\t6\thours.\tIf\t\nappropriate,\tinitial\tIV\ttherapy\tmay\tbe\tomitted.\n✓  Propranolol:\t0.5\tto\t1\tmg\tslow\tIV\tpush,\tfollowed\tin\t1\tto\t2\thours\tby\t40\tto\t80\tmg\t\norally\tevery\t6\tto\t8\thours.\tIf\tappropriate,\tthe\tinitial\tIV\ttherapy\tmay\tbe\tomitted.\n✓  Atenolol:\t5\tmg\tIV\tdose,\tfollowed\t5\tminutes\tlater\tby\ta\tsecond\t5\tmg\tIV\tdose,\tthen\t\n50\tto\t100\tmg\torally\tonce\tdaily\tbeginning\t1\tto\t2\thours\tafter\tthe\tIV\tdose.\tThe\tinitial\t\nIV\ttherapy\tmay\tbe\tomitted.\n•\tThe\t most\t serious\t side\t effects\t early\t in\t ACS\t include\t hypotension,\t acute\t HF ,\t brady-\ncardia,\tand\theart\tblock.\tInitial\tacute\tadministration\tof\tβ-blockers\tis\tnot\tappropriate\t\nfor\tpatients\tpresenting\twith\tacute\tHF\tbut\tmay\tbe\tattempted\tin\tmost\tpatients\tbefore\t\ndischarge\tafter\ttreatment\tof\tacute\tHF .\n•\tContinue\t β-blockers\t for\t at\t least\t 3\t years\t in\t patients\t with\t normal\t LV\t function\t and\t\nindefinitely\tin\tpatients\twith\tLV\tsystolic\tdysfunction\tand\tLVEF\tof\t40%\tor\tless.\nStatins\n•\tAdminister\ta\thigh-intensity\tstatin,\teither\tatorvastatin\t80\tmg\tor\trosuvastatin\t40\tmg,\t\nto\tall\tpatients\tprior\tto\tPCI\t(regardless\tof\tprior\tlipid-lowering\ttherapy)\tto\treduce\tthe\t\nfrequency\tof\tperiprocedural\tMI\tfollowing\tPCI.\nNitrates\n•\tNTG\tcauses\tvenodilation,\twhich\tlowers\tpreload\tand\tmyocardial\toxygen\tdemand.\tIn\t\naddition,\t arterial\t vasodilation\t may\t lower\t BP ,\t thereby\t reducing\t myocardial\t oxygen\t\ndemand.\t Arterial\t dilation\t also\t relieves\t coronary\t artery\t vasospasm\t and\t improves\t\nmyocardial\tblood\tflow\tand\toxygenation.\n•\tImmediately\t upon\t presentation,\t administer\t one\t SL NTG \t tablet\t (0.4\t mg)\t every\t\n5\tminutes\tfor\tup\tto\tthree\tdoses\tto\trelieve\tchest\tpain\tand\tmyocardial\tischemia.\n•\tIntravenous NTG\tis\tindicated\tfor\tpatients\twith\tan\tACS\twho\tdo\tnot\thave\ta\tcontrain-\ndication\tand\twho\thave\tpersistent\tischemia,\tHF ,\tor\tuncontrolled\thigh\tBP .\tThe\tusual\t\ndose\t is\t5\tto\t10\tmcg/min\tby\t continuous\tinfusion,\ttitrated\tup\t to\t 100\tmcg/min\tuntil\t\nrelief\tof\tsymptoms\tor\tlimiting\tside\teffects\t(eg,\theadache\tor\thypotension).\tContinue\t\ntreatment\tfor\tapproximately\t24\thours\tafter\tischemia\tis\trelieved.",
    "word_count": 619,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0090",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 90,
    "text": "44\nSection  2     c ardiovascular Disorders\n•\tOral\tnitrates\tplay\ta\tlimited\trole\tin\tACS\tbecause\tclinical\ttrials\thave\tfailed\tto\tshow\ta\t\nmortality\tbenefit\tfor\tIV\tfollowed\tby\toral\tnitrate\ttherapy\tin\tacute\tMI.\n•\tThe\tmost\tsignificant\tadverse\teffects\tof\tnitrates\tinclude\ttachycardia,\tflushing,\thead-\nache,\tand\thypotension.\tNitrates\tare\tcontraindicated\tin\tpatients\twho\thave\ttaken\tthe\t\noral\tphosphodiesterase-5\tinhibitors\tsildenafil\tor\tvardenafil\twithin\tthe\tprior\t24\thours\t\nor\ttadalafil\twithin\tthe\tprior\t48\thours.\nCalcium Channel Blockers\n•\tAfter\t STE\t MI,\t calcium\t channel\t blockers\t (CCBs)\t are\t used\t for\t relief\t of\t ischemic\t\nsymptoms\tin\tpatients\twho\thave\tcontraindications\tto\tβ-blockers.\tThere\tis\tlittle\tclini-\ncal\tbenefit\tbeyond\tsymptom\trelief,\tso\tavoid\tCCBs\tin\tacute\tmanagement\tof\tall\tACSs\t\nunless\tthere\tis\ta\tclear\tsymptomatic\tneed\tor\tcontraindication\tto\tβ-blockers.\n•\tA\tCCB\tthat\tlowers\theart\trate\t(diltiazem\tor\tverapamil)\tis\tpreferred\tunless\tthe\tpatient\t\nhas\tLV\tsystolic\tdysfunction,\tbradycardia,\tor\theart\tblock.\tIn\tthose\tcases,\teither\tamlo-\ndipine\t or\t felodipine\t is\t preferred.\t Avoid\t nifedipine\t because\t it\t causes\t reflex\t sympa-\nthetic\tactivation,\ttachycardia,\tand\tworsened\tmyocardial\tischemia.\n✓ Diltiazem:\t120\tto\t360\tmg\tsustained\trelease\torally\tonce\tdaily\n✓ Verapamil:\t180\tto\t480\tmg\tsustained\trelease\torally\tonce\tdaily\n✓ Amlodipine:\t5\tto\t10\tmg\torally\tonce\tdaily\nEARLY PHARMACOTHERAPY FOR NSTE ACS (F IG.",
    "word_count": 216,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0091",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 91,
    "text": "  c ardiovascular Disorders\n•\tOral\tnitrates\tplay\ta\tlimited\trole\tin\tACS\tbecause\tclinical\ttrials\thave\tfailed\tto\tshow\ta\t\nmortality\tbenefit\tfor\tIV\tfollowed\tby\toral\tnitrate\ttherapy\tin\tacute\tMI.\n•\tThe\tmost\tsignificant\tadverse\teffects\tof\tnitrates\tinclude\ttachycardia,\tflushing,\thead-\nache,\tand\thypotension.\tNitrates\tare\tcontraindicated\tin\tpatients\twho\thave\ttaken\tthe\t\noral\tphosphodiesterase-5\tinhibitors\tsildenafil\tor\tvardenafil\twithin\tthe\tprior\t24\thours\t\nor\ttadalafil\twithin\tthe\tprior\t48\thours.\nCalcium Channel Blockers\n•\tAfter\t STE\t MI,\t calcium\t channel\t blockers\t (CCBs)\t are\t used\t for\t relief\t of\t ischemic\t\nsymptoms\tin\tpatients\twho\thave\tcontraindications\tto\tβ-blockers.\tThere\tis\tlittle\tclini-\ncal\tbenefit\tbeyond\tsymptom\trelief,\tso\tavoid\tCCBs\tin\tacute\tmanagement\tof\tall\tACSs\t\nunless\tthere\tis\ta\tclear\tsymptomatic\tneed\tor\tcontraindication\tto\tβ-blockers.\n•\tA\tCCB\tthat\tlowers\theart\trate\t(diltiazem\tor\tverapamil)\tis\tpreferred\tunless\tthe\tpatient\t\nhas\tLV\tsystolic\tdysfunction,\tbradycardia,\tor\theart\tblock.\tIn\tthose\tcases,\teither\tamlo-\ndipine\t or\t felodipine\t is\t preferred.\t Avoid\t nifedipine\t because\t it\t causes\t reflex\t sympa-\nthetic\tactivation,\ttachycardia,\tand\tworsened\tmyocardial\tischemia.\n✓ Diltiazem:\t120\tto\t360\tmg\tsustained\trelease\torally\tonce\tdaily\n✓ Verapamil:\t180\tto\t480\tmg\tsustained\trelease\torally\tonce\tdaily\n✓ Amlodipine:\t5\tto\t10\tmg\torally\tonce\tdaily\nEARLY PHARMACOTHERAPY FOR NSTE ACS (F IG. 5–3)\n•\tEarly\tpharmacotherapy\tfor\tNSTE\tACS\tis\tsimilar\tto\tthat\tfor\tSTE\tACS.\t\n•\tIn\tabsence\tof\tcontraindications,\ttreat\tall\tpatients\tin\tthe\temergency\tdepartment\twith\t\nintranasal oxygen\t(if\toxygen\tsaturation\tis\tlow),\tSL NTG,\taspirin,\tand\tan\tanticoagu-\nlant\t(UFH,\tenoxaparin,\tfondaparinux,\tor\tbivalirudin).\n•\tHigh-risk\tpatients\tshould\tproceed\tto\tearly\tangiography\tand\tmay\treceive\ta\tGP\tIIb/\nIIIa\tinhibitor\t(optional\twith\teither\tUFH\tor\tenoxaparin\tbut\tshould\tbe\tavoided\twith\t\nbivalirudin).\n•\tAdminister\ta\tP2Y12 inhibitor\tto\tall\tpatients.\n•\tGive\tIV β-blockers \tand\tIV NTG\tto\tselect\tpatients.\n•\tInitiate\toral β-blockers\twithin\tthe\tfirst\t24\thours\tin\tpatients\twithout\tcardiogenic\tshock.\n•\tGive\tmorphine\tto\tpatients\twith\trefractory\tangina,\tas\tdescribed\tpreviously.\n•\tFibrinolytic\ttherapy\tis\tnever\tadministered\tin\tNSTE\tACS.\nAspirin\n•\tAspirin\treduces\trisk\tof\tdeath\tor\tMI\tby\tapproximately\t50%\tcompared\twith\tno\tanti-\nplatelet\ttherapy\tin\tpatients\twith\tNSTE\tACS.\tDosing\tof\taspirin\tis\tthe\tsame\tas\tfor\tSTE\t\nACS,\tand\taspirin\tis\tcontinued\tindefinitely.\nAnticoagulants\n•\tFor\tpatients\ttreated\tby\tan\tearly\tinvasive\tapproach\twith\tearly\tcoronary\tangiography\t\nand\tPCI,\tadminister\tUFH,\tenoxaparin,\tor\tbivalirudin.\n•\tIf\tan\tinitial\tconservative\tstrategy\tis\tplanned\t(no\tcoronary\tangiography\tor\trevascular-\nization),\tenoxaparin,\tUFH,\tor\tlow-dose\tfondaparinux\tis\trecommended.\n•\tContinue\ttherapy\tfor\tat\tleast\t48\thours\tfor\tUFH,\tuntil\tthe\tpatient\tis\tdischarged\tfrom\t\nthe\thospital\t(or\t8\tdays,\twhichever\tis\tshorter)\tfor\teither\tenoxaparin\tor\tfondaparinux,\t\nand\tuntil\tthe\tend\tof\tthe\tPCI\tor\tangiography\tprocedure\t(or\tup\tto\t72\thours\tafter\tPCI)\t\nfor\tbivalirudin.\n•\tFor\tNSTE\tACS,\tthe\tdose\tof\tUFH\tis\t60\tU/kg\tIV\tbolus\t(maximum\t4000\tunits),\tfol-\nlowed\tby\ta\tcontinuous\tIV\tinfusion\tof\t12\tU/kg/h\t(maximum\t1000\tU/h).\tTitrate\tthe\t\ndose\tto\tmaintain\taPTT\tbetween\t1.5\tand\t2\ttimes\tcontrol.\nP2Y12 Inhibitors\n•\tWhen\t an\t initial\t invasive\t strategy\t is\t selected,\t there\t are\t two\t initial\t options\t for\t dual\t\nantiplatelet\ttherapy\tdepending\ton\tchoice\tof\tP2Y12\tinhibitor:\n1.\t\tAspirin\tplus\tearly\tuse\tof\tclopidogrel\tor\tticagrelor\t(in\tthe\temergency\tdepartment)\n2.\t\t\tAspirin\tplus\tdouble-bolus\tdose\teptifibatide\tplus\tan\teptifibatide\tinfusion\tor\thigh-\ndose\ttirofiban\tbolus\tplus\tinfusion\tadministered\tat\tthe\ttime\tof\tPCI.",
    "word_count": 569,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0092",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 92,
    "text": "45\nacute coronary Syndromes     chapter 5\nFigure  5–3. initial pharmacotherapy for non–ST-segment elevation ACS. aFor selected patients. bpreferred in patients at high risk for bleeding. cif pretreated \nwith UFh, stop UF h infusion for 30 minutes prior to administration of bivalirudin bolus plus infusion. dMay require iV supplemental dose of enoxaparin. eDo \nnot use if prior history of stroke/ tia , age older than 75 years, or body weight 60 kg or less. fSc  enoxaparin or UF h can be continued at a lower dose for venous \nthromboembolism prophylaxis. (ac S, acute coronary syndrome; ace , angiotensin-converting enzyme; ar B, angiotensin receptor blocker; ca BG, coronary artery \nbypass graft; ca D, coronary artery disease; ch D, coronary heart disease; Gp, glycoprotein; iV, intravenous; nSte , non–St-segment elevation; nt G, nitroglycerin; pci, \npercutaneous coronary intervention; S c , subcutaneous; SL, sublingual; S te  Mi, St -segment-elevation myocardial infarction; tia , transient ischemic attack; UF h, \nunfractionated heparin.) (Modified with permission from Spinler Sa , de Denus S. a cute coronary syndromes. in: c hisholm-Burns M, Wells BG, Schwinghammer t L, \nMalone pM, Kolesar JM, Dipiro Jt, eds. Pharmacotherapy Principles and Practice. 3rd ed.",
    "word_count": 192,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0093",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 93,
    "text": "3rd ed. new York, nY: McGraw-h ill; 2013:133–167.)\nOptional initiate GP IIb/IIIa inhibitor\nor switch anticoagulant to bivalirudin;\nadminister additional loading dose of\nclopidogrel/ticagrelor prior to PCI\nEarly conservative strategy\nMedical management only planned\nIV UFH, Subcut enoxaparin, Subcut fondaparinuxb\nClopidogrel 300 mg or ticagrelor\nNo recurrent ischemia, heart failure, or arrhythmias\nβ-blocker, statin, ACE inhibitor\n(or ARB); Discontinue IV NTG\nand anticoagulantf\nStress testNo or noncritical CAD; Treat CHD\nrisk factors; Continue clopidogrel/\nticagrelor, aspirin if CAD Positive findings\nfor ischemia \nNegative findings\nfor ischemia\nTreat CHD\nrisk factors \nPCI\nCABG; continue/\nchange anticoagulant\nto UFH; discontinue\nclopidogrel/ticagrelor\nand GP IIb/IIIa inhibitor\nprior to surgery \nNon–ST-segment elevation ACS\nOxygen (if O2 saturation less than 90%[0.90]) Aspirin,\nSL NTG, IV NTGa Morphine sulfatea\nIV UFH, bivalirudinc, Subcut\nenoxaparind, or Subcut fondaparinux\nplus UFH administered at time of PCI \nOne of two options:\n(a) Either clopidogrel 600 mg or\nticagrelor or (b) GP IIb/IIIa inhibitor\nNo or noncritical CAD;\ndiscontinue\nanticoagulant; treat\nCHD risk factors; if\nCAD, continue P2Y12\ninhibitor, aspirin, and\nstatin; add β-blocker\nand ACE inhibitor (or ARB)\nPCI; consider prasugrele if\nclopidogrel/ticagrelor not\npreviously given; discontinue\nanticoagulant; continue GP\nIIb/IIIa inhibitor per guidelines;\ndiscontinue NTG; continue\nstatin and aspirin, add β-blocker\nand ACE inhibitor (or ARB) \nAngiography\nEarly Invasive Strategy\nEarly coronary angiography planned\nless than or equal to 12–24 hours from hospital presentation \nRecurrent ischemia,\nheart failure, or\narrhythmias\nContinue clopidogrel/ticagrelor; discontinue\nanticoagulant; continue GP IIb/IIIa inhibitor per\nguidelines; discontinue NTG; continue statin and\naspirin; add β-blocker and ACE inhibitor (or ARB) \nHigh-intensity statin Nonurgent angiography\nHigh-intensity statin\nprior to PCI\nUrgent\nangiography",
    "word_count": 266,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0094",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 94,
    "text": "46\nSection  2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0095",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 95,
    "text": "46\nSection  2     c ardiovascular Disorders\n•\tFor\tsubsequent\tantiplatelet\ttherapy\tin\tpatients\tundergoing\tPCI\tinitially\ttreated\twith\t\nregimen\t1\tabove,\ta\tGP\tIIb/IIIa\tinhibitor\t(abciximab,\teptifibatide,\tor\thigh-dose\ttirofi-\nban)\tcan\tbe\tadded,\tand\tthen\tclopidogrel\tcontinued\twith\tlow-dose\tASA.\n•\tFor\tpatients\tundergoing\tPCI\tinitially\ttreated\twith\toption\t2,\tclopidogrel,\tprasugrel,\tor\t\nticagrelor\tcan\tbe\tstarted\twithin\t1\thour\tafter\tPCI\tand\tthe\tP2Y12\tinhibitor\tcontinued\t\nwith\tlow-dose\taspirin.\tFollowing\tPCI,\tcontinue\tdual\toral\tantiplatelet\ttherapy\tfor\tat\t\nleast\t12\tmonths.\n•\tFor\tpatients\treceiving\tan\tinitial\tconservative\tstrategy,\teither\tclopidogrel\tor\tticagrelor\t\ncan\tbe\tadministered\tin\taddition\tto\taspirin.\tContinue\tdual\tantiplatelet\ttherapy\tfor\tat\t\nleast\t12\tmonths.\nGlycoprotein IIb/IIIa Receptor Inhibitors\n•\tThe\trole\tof\tGP\tIIb/IIIa\tinhibitors\tin\tNSTE\tACS\tis\tdiminishing\tas\tP2Y12\tinhibitors\tare\t\nused\tearlier,\tand\tbivalirudin\tis\toften\tselected\tas\tthe\tanticoagulant.\n•\tRoutine\t administration\t of\t eptifibatide\t (added\t to\t aspirin\t and\t clopidogrel)\t prior\t to\t\nangiography\tand\tPCI\tin\tNSTE\tACS\tdoes\tnot\treduce\tischemic\tevents\tand\tincreases\t\nbleeding\trisk.\tTherefore,\tthe\ttwo\tantiplatelet\tinitial\ttherapy\toptions\tdescribed\tin\tthe\t\nprevious\tsection\tare\tpreferred.\n•\tFor\t low-risk\t patients\t and\t a\t conservative\t management\t strategy,\t there\t is\t no\t role\t for\t\nroutine\tGP\tIIb/IIIa\tinhibitors\tbecause\tbleeding\trisk\texceeds\tthe\tbenefit.\t\nNitrates\n•\tAdminister\t SL\t NTG\t followed\t by\t IV\t NTG\t to\t patients\t with\t NSTE\t ACS\t and\t ongo-\ning\t ischemia,\t HF ,\t or\t uncontrolled\t high\t BP .\t Continue\t IV\t NTG\t for\t approximately\t\t\n24\thours\tafter\tischemia\trelief.\nβ-Blockers\n•\tIn\t the\t absence\t of\t contraindications,\tadminister\t oral\t β-blockers\t to\t all\tpatients\t with\t\nNSTE\tACS\twithin\t24\thours\tof\thospital\tadmission.\tBenefits\tare\tassumed\tto\tbe\tsimilar\t\nto\tthose\tseen\tin\tpatients\twith\tSTE\tMI.\n•\tContinue\tβ-blockers\tindefinitely\tin\tpatients\twith\tLVEF\tof\t40%\tor\tless\tand\tfor\tat\tleast\t\n3\tyears\tin\tpatients\twith\tnormal\tLV\tfunction.\nCalcium Channel Blockers\n•\tAs\t described\t previously\t for\t STE\t ACS,\t CCBs\t should\t not\t be\t administered\t to\t most\t\npatients\twith\tACS.\nSECONDARY PREVENTION FOLLOWING MI\n•\tGoals\t of\t Treatment:\t The\t long-term\t goals\t after\t MI\t are\t to:\t (1)\t control\t modifiable\t\ncoronary\theart\tdisease\t(CHD)\trisk\tfactors;\t(2)\tprevent\tdevelopment\tof\tsystolic\tHF;\t\t\n(3)\t prevent\t recurrent\t MI\t and\t stroke;\t (4)\t prevent\t death,\t including\t sudden\t cardiac\t\ndeath;\tand\t(5)\tprevent\tstent\tthrombosis\tafter\tPCI.\nPHARMACOTHERAPY\n•\tStart\tpharmacotherapy\tthat\thas\tbeen\tproven\tto\tdecrease\tmortality,\tHF ,\treinfarction\t\nor\tstroke,\tand\tstent\tthrombosis\tprior\tto\thospital\tdischarge\tfor\tsecondary\tprevention.\n•\tAfter\tMI\tfrom\teither\tSTE\tMI\tor\tNSTE\tACS,\tall\tpatients\t(in\tthe\tabsence\tof\tcontrain-\ndications)\tshould\treceive\tindefinite\ttreatment\twith\taspirin\t(or\tclopidogrel\tif\taspirin\t\ncontraindications),\t an\t ACE\t inhibitor,\t and\t a\t “high-intensity”\t statin\t for\t secondary\t\nprevention\tof\tdeath,\tstroke,\tor\trecurrent\tinfarction.\n•\tStart\tACE\tinhibitors\tand\tcontinue\tindefinitely\tin\tall\tpatients\tafter\tMI\tto\treduce\tmor-\ntality,\tdecrease\treinfarction,\tand\tprevent\tHF .\tMost\tpatients\twith\tCAD\t(not\tjust\tthose",
    "word_count": 471,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0096",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 96,
    "text": "47\na cute c oronary Syndromes  ",
    "word_count": 6,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0097",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 97,
    "text": "47\na cute c oronary Syndromes     chapter  5\nwith\tACS\tor\tHF)\tbenefit\tfrom\tan\tACE\tinhibitor.\tThe\tdose\tshould\tbe\tlow\tinitially\tand\t\ntitrated\tto\tthe\tdose\tused\tin\tclinical\ttrials\tif\ttolerated,\tfor\texample:\n✓ Captopril:\t6.25\tto\t12.5\tmg\tinitially;\ttarget\tdose\t50\tmg\ttwo\tor\tthree\ttimes\tdaily\n✓ Enalapril:\t2.5\tto\t5\tmg\tinitially;\ttarget\tdose\t10\tmg\ttwice\tdaily\n✓ Lisinopril:\t2.5\tto\t5\tmg\tinitially;\ttarget\tdose\t10\tto\t20\tmg\tonce\tdaily\n✓ Ramipril:\t1.25\tto\t2.5\tmg\tinitially;\ttarget\tdose\t5\tmg\ttwice\tdaily\tor\t10\tmg\tonce\tdaily\n✓ Trandolapril:\t1\tmg\tinitially;\ttarget\tdose\t4\tmg\tonce\tdaily\n•\tAn\tangiotensin\treceptor\tblocker\tmay\tbe\tprescribed\tfor\tpatients\twith\tACE\tinhibitor\t\ncough\tand\ta\tlow\tLVEF\tand\tHF\tafter\tMI:\n✓ Candesartan:\t4\tto\t8\tmg\tinitially;\ttarget\tdose\t32\tmg\tonce\tdaily\n✓ Valsartan:\t40\tmg\tinitially;\ttarget\tdose\t160\tmg\ttwice\tdaily\n•\tContinue\ta\tβ-blocker\tfor\tat\tleast\t3\tyears\tin\tpatients\twithout\tHF\tor\tan\tejection\tfrac-\ntion\tof\t40%\tor\tless\tand\tindefinitely\tin\tpatients\twith\tLV\tsystolic\tdysfunction\tor\tHF\t\nsymptoms.\tA\tCCB\tcan\tbe\tused\tto\tprevent\tanginal\tsymptoms\tin\tpatients\twho\tcannot\t\ntolerate\tor\thave\tcontraindications\tto\tβ-blockers\tbut\tshould\tnot\tbe\tused\troutinely\tin\t\nthe\tabsence\tof\tsuch\tfindings.\n•\tContinue\ta\tP2Y12\tinhibitor\tfor\tat\tleast\t12\tmonths\tfor\tpatients\tundergoing\tPCI\tand\tfor\t\npatients\twith\tNSTE\tACS\treceiving\ta\tmedical\tmanagement\tstrategy.\tContinue\tclopi-\ndogrel\tfor\tat\tleast\t14\tdays\tin\tpatients\twith\tSTE\tMI\tnot\tundergoing\tPCI.\n•\tT o\t reduce\t mortality,\t consider\t a\t mineralocorticoid\t receptor\t antagonist\t (eplerenone\t\nor\tspironolactone)\twithin\tthe\tfirst\t7\tdays\tafter\tMI\tin\tall\tpatients\talready\treceiving\tan\t\nACE\tinhibitor\t(or\tARB)\tand\ta\tβ-blocker\tand\thave\tan\tLVEF\tof\t40%\tor\tless\tand\teither\t\nHF\tsymptoms\tor\tdiabetes\tmellitus.\tThe\tdrugs\tare\tcontinued\tindefinitely.\n✓ Eplerenone:\t25\tmg\tinitially;\ttarget\tdose\t50\tmg\tonce\tdaily\n✓ Spironolactone:\t12.5\tmg\tinitially;\ttarget\tdose\t25\tto\t50\tmg\tonce\tdaily\n•\tAll\tpatients\twith\tCAD\tshould\treceive\tdietary\tcounseling\tand\ta\tstatin\tto\treach\tappro-\npriate\ttargets\tbased\ton\tcurrent\tpractice\tguidelines.\n•\tPrescribe\ta\tshort-acting\tSL\tNTG\tor\tlingual\tNTG\tspray\tfor\tall\tpatients\tto\trelieve\tangi-\nnal\tsymptoms\twhen\tnecessary.\tChronic\tlong-acting\tnitrates\thave\tnot\tbeen\tshown\tto\t\nreduce\tCHD\tevents\tafter\tMI\tand\tare\tnot\tused\tin\tACS\tpatients\twho\thave\tundergone\t\nrevascularization\tunless\tthe\tpatient\thas\tchronic\tstable\tangina\tor\tsignificant\tcoronary\t\nstenosis\tthat\twas\tnot\trevascularized.\n•\tFor\tall\tACS\tpatients,\ttreat\tand\tcontrol\tmodifiable\trisk\tfactors\tsuch\tas\thypertension\t\n(HTN),\tdyslipidemia,\tobesity,\tsmoking,\tand\tDM.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tMonitoring\tparameters\tfor\tefficacy\tfor\tboth\tSTE\tand\tNSTE\tACS\tinclude:\t(1)\trelief\t\nof\t ischemic\tdiscomfort,\t (2)\t return\tof\tECG\tchanges\t to\t baseline,\tand\t (3)\t absence\tor\t\nresolution\tof\tHF\tsigns\tand\tsymptoms.\n•\tMonitoring\t parameters\t for\t adverse\t effects\t are\t dependent\t on\t the\t individual\t drugs\t\nused.\t In\t general,\t the\t most\t common\t adverse\t reactions\t from\t ACS\t therapies\t include\t\nhypotension\tand\tbleeding.\nSee Chapter 7, Acute Coronary Syndromes, authored by Sarah A.",
    "word_count": 513,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0098",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 98,
    "text": "  chapter  5\nwith\tACS\tor\tHF)\tbenefit\tfrom\tan\tACE\tinhibitor.\tThe\tdose\tshould\tbe\tlow\tinitially\tand\t\ntitrated\tto\tthe\tdose\tused\tin\tclinical\ttrials\tif\ttolerated,\tfor\texample:\n✓ Captopril:\t6.25\tto\t12.5\tmg\tinitially;\ttarget\tdose\t50\tmg\ttwo\tor\tthree\ttimes\tdaily\n✓ Enalapril:\t2.5\tto\t5\tmg\tinitially;\ttarget\tdose\t10\tmg\ttwice\tdaily\n✓ Lisinopril:\t2.5\tto\t5\tmg\tinitially;\ttarget\tdose\t10\tto\t20\tmg\tonce\tdaily\n✓ Ramipril:\t1.25\tto\t2.5\tmg\tinitially;\ttarget\tdose\t5\tmg\ttwice\tdaily\tor\t10\tmg\tonce\tdaily\n✓ Trandolapril:\t1\tmg\tinitially;\ttarget\tdose\t4\tmg\tonce\tdaily\n•\tAn\tangiotensin\treceptor\tblocker\tmay\tbe\tprescribed\tfor\tpatients\twith\tACE\tinhibitor\t\ncough\tand\ta\tlow\tLVEF\tand\tHF\tafter\tMI:\n✓ Candesartan:\t4\tto\t8\tmg\tinitially;\ttarget\tdose\t32\tmg\tonce\tdaily\n✓ Valsartan:\t40\tmg\tinitially;\ttarget\tdose\t160\tmg\ttwice\tdaily\n•\tContinue\ta\tβ-blocker\tfor\tat\tleast\t3\tyears\tin\tpatients\twithout\tHF\tor\tan\tejection\tfrac-\ntion\tof\t40%\tor\tless\tand\tindefinitely\tin\tpatients\twith\tLV\tsystolic\tdysfunction\tor\tHF\t\nsymptoms.\tA\tCCB\tcan\tbe\tused\tto\tprevent\tanginal\tsymptoms\tin\tpatients\twho\tcannot\t\ntolerate\tor\thave\tcontraindications\tto\tβ-blockers\tbut\tshould\tnot\tbe\tused\troutinely\tin\t\nthe\tabsence\tof\tsuch\tfindings.\n•\tContinue\ta\tP2Y12\tinhibitor\tfor\tat\tleast\t12\tmonths\tfor\tpatients\tundergoing\tPCI\tand\tfor\t\npatients\twith\tNSTE\tACS\treceiving\ta\tmedical\tmanagement\tstrategy.\tContinue\tclopi-\ndogrel\tfor\tat\tleast\t14\tdays\tin\tpatients\twith\tSTE\tMI\tnot\tundergoing\tPCI.\n•\tT o\t reduce\t mortality,\t consider\t a\t mineralocorticoid\t receptor\t antagonist\t (eplerenone\t\nor\tspironolactone)\twithin\tthe\tfirst\t7\tdays\tafter\tMI\tin\tall\tpatients\talready\treceiving\tan\t\nACE\tinhibitor\t(or\tARB)\tand\ta\tβ-blocker\tand\thave\tan\tLVEF\tof\t40%\tor\tless\tand\teither\t\nHF\tsymptoms\tor\tdiabetes\tmellitus.\tThe\tdrugs\tare\tcontinued\tindefinitely.\n✓ Eplerenone:\t25\tmg\tinitially;\ttarget\tdose\t50\tmg\tonce\tdaily\n✓ Spironolactone:\t12.5\tmg\tinitially;\ttarget\tdose\t25\tto\t50\tmg\tonce\tdaily\n•\tAll\tpatients\twith\tCAD\tshould\treceive\tdietary\tcounseling\tand\ta\tstatin\tto\treach\tappro-\npriate\ttargets\tbased\ton\tcurrent\tpractice\tguidelines.\n•\tPrescribe\ta\tshort-acting\tSL\tNTG\tor\tlingual\tNTG\tspray\tfor\tall\tpatients\tto\trelieve\tangi-\nnal\tsymptoms\twhen\tnecessary.\tChronic\tlong-acting\tnitrates\thave\tnot\tbeen\tshown\tto\t\nreduce\tCHD\tevents\tafter\tMI\tand\tare\tnot\tused\tin\tACS\tpatients\twho\thave\tundergone\t\nrevascularization\tunless\tthe\tpatient\thas\tchronic\tstable\tangina\tor\tsignificant\tcoronary\t\nstenosis\tthat\twas\tnot\trevascularized.\n•\tFor\tall\tACS\tpatients,\ttreat\tand\tcontrol\tmodifiable\trisk\tfactors\tsuch\tas\thypertension\t\n(HTN),\tdyslipidemia,\tobesity,\tsmoking,\tand\tDM.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tMonitoring\tparameters\tfor\tefficacy\tfor\tboth\tSTE\tand\tNSTE\tACS\tinclude:\t(1)\trelief\t\nof\t ischemic\tdiscomfort,\t (2)\t return\tof\tECG\tchanges\t to\t baseline,\tand\t (3)\t absence\tor\t\nresolution\tof\tHF\tsigns\tand\tsymptoms.\n•\tMonitoring\t parameters\t for\t adverse\t effects\t are\t dependent\t on\t the\t individual\t drugs\t\nused.\t In\t general,\t the\t most\t common\t adverse\t reactions\t from\t ACS\t therapies\t include\t\nhypotension\tand\tbleeding.\nSee Chapter 7, Acute Coronary Syndromes, authored by Sarah A. Spinler and Simon De \nDenus, for a more detailed discussion of this topic.",
    "word_count": 520,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0099",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 99,
    "text": "48\n•\tArrhythmia\tis\tloss\tof\tcardiac\trhythm,\tespecially\tirregularity\tof\theartbeat.\nPATHOPHYSIOLOGY\nSUPRAVENTRICULAR ARRHYTHMIAS\n•\tCommon\tsupraventricular\ttachycardias\trequiring\tdrug\ttreatment\tare\tatrial\tfibrilla-\ntion\t(AF),\tatrial\tflutter,\tand\tparoxysmal\tsupraventricular\ttachycardia\t(PSVT).\tOther\t\narrhythmias\t that\t usually\t do\t not\t require\t drug\t therapy\t are\t not\t discussed\t here\t (eg,\t\npremature\tatrial\tcomplexes,\tsinus\tarrhythmia,\tsinus\ttachycardia).\nAtrial Fibrillation and Atrial Flutter\n•\tAF\thas\textremely\trapid\t(400–600\tatrial\tbeats/min)\tand\tdisorganized\tatrial\tactivation.\t\nThere\t is\t loss\tof\tatrial\t contraction\t(atrial\tkick),\tand\t supraventricular\t impulses\tpen-\netrate\tthe\tatrioventricular\t(A V)\tconduction\tsystem\tto\tvariable\tdegrees,\tresulting\tin\t\nirregular\tventricular\tactivation\tand\tirregularly\tirregular\tpulse\t(120–180\tbeats/min).\n•\tAtrial\t flutter\t has\t rapid\t (270–330\t atrial\t beats/min)\t but\t regular\t atrial\t activation.\t\nV entricular\t response\t usually\t has\t a\t regular\t pattern\t and\t a\t pulse\t of\t 300\t beats/min.\t\nThis\tarrhythmia\toccurs\tless\tfrequently\tthan\tAF\tbut\thas\tsimilar\tprecipitating\tfactors,\t\nconsequences,\tand\tdrug\ttherapy.\n•\tThe\t predominant\t mechanism\t of\t AF\t and\t atrial\t flutter\t is\t reentry,\t which\t is\t usually\t\nassociated\t with\t organic\t heart\t disease\t that\t causes\t atrial\t distention\t (eg,\t ischemia\t or\t\ninfarction,\thypertensive\theart\tdisease,\tand\tvalvular\tdisorders).\tAdditional\tassociated\t\ndisorders\t include\t acute\t pulmonary\t embolus\t and\t chronic\t lung\t disease,\t resulting\t in\t\npulmonary\thypertension\tand\tcor\tpulmonale,\tand\tstates\tof\thigh\tadrenergic\ttone\tsuch\t\nas\tthyrotoxicosis,\talcohol\twithdrawal,\tsepsis,\tand\texcessive\tphysical\texertion.\nParoxysmal Supraventricular Tachycardia Caused by Reentry\n•\tPSVT\t arising\t by\t reentrant\t mechanisms\t includes\t arrhythmias\t caused\t by\t A V\t nodal\t\nreentry,\tA V\treentry\tincorporating\tan\tanomalous\tA V\tpathway,\tsinoatrial\t(SA)\tnodal\t\nreentry,\tand\tintraatrial\treentry.\nVENTRICULAR ARRHYTHMIAS\nPremature Ventricular Complexes\n•\tPremature\tventricular\tcomplexes\t(PVCs)\tcan\toccur\tin\tpatients\twith\tor\twithout\theart\t\ndisease.\nVentricular Tachycardia\n•\tV entricular\ttachycardia\t(VT)\tis\tdefined\tby\tthree\tor\tmore\trepetitive\tPVCs\toccurring\t\nat\t a\t rate\t greater\t than\t 100\t beats/min.\t It\t is\t a\t wide\t QRS\t tachycardia\t that\t may\t result\t\nacutely\t from\t severe\t electrolyte\t abnormalities\t (hypokalemia\t or\t hypomagnesemia),\t\nhypoxia,\tdrug\ttoxicity\t(eg,\tdigoxin),\tor\t(most\tcommonly)\tduring\tan\tacute\tmyocardial\t\ninfarction\t(MI)\tor\tischemia\tcomplicated\tby\theart\tfailure\t(HF).\tThe\tchronic\trecurrent\t\nform\t is\t almost\t always\t associated\t with\t organic\t heart\t disease\t (eg,\t idiopathic\t dilated\t\ncardiomyopathy\tor\tremote\tMI\twith\tleft\tventricular\t[LV]\taneurysm).\n•\tSustained\tVT\tis\tthat\twhich\trequires\tintervention\tto\trestore\ta\tstable\trhythm\tor\tpersists\t\na\trelatively\tlong\ttime\t(usually\t>30\ts).\tNonsustained\tVT\tself-terminates\tafter\ta\tbrief\t\nduration\t(usually\t<30\ts).\tIncessant VT\trefers\tto\tVT\toccurring\tmore\tfrequently\tthan\t\nsinus\trhythm,\tso\tthat\tVT\tbecomes\tthe\tdominant\trhythm.\tMonomorphic\tVT\thas\ta\t\nconsistent\tQRS\tconfiguration,\twhereas\tpolymorphic\tVT\thas\tvarying\tQRS\tcomplexes.\t\nT orsade\tde\tpointes\t(T dP)\tis\ta\tpolymorphic\tVT\tin\twhich\tthe\tQRS\tcomplexes\tappear\t\nto\tundulate\taround\ta\tcentral\taxis.\nArrhythmias\n6\nC h a p t e r",
    "word_count": 449,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0100",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 100,
    "text": "49\na rrhythmias  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0101",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 101,
    "text": "49\na rrhythmias     Chapter  6\nVentricular Proarrhythmia\n•\tProarrhythmia\t refers\t to\t the\t development\t of\t a\t significant\t new\t arrhythmia,\t such\t as\t\nVT ,\t ventricular\t fibrillation\t (VF),\t or\t T dP ,\t or\t worsening\t of\t an\t existing\t arrhythmia.\t\nProarrhythmia\tresults\tfrom\tthe\t same\t mechanisms\t that\tcause\t other\tarrhythmias\tor\t\nfrom\tan\talteration\tin\tthe\tunderlying\tsubstrate\tdue\tto\tthe\tantiarrhythmic\tagent.\tT dP\t\nis\ta\trapid\tform\tof\tpolymorphic\tVT\tassociated\twith\tevidence\tof\tdelayed\tventricular\t\nrepolarization\tdue\tto\tblockade\tof\tpotassium\tconductance.\tT dP\tmay\tbe\thereditary\tor\t\nacquired.\t Acquired\t forms\t are\t associated\t with\t many\t clinical\t conditions\t and\t drugs,\t\nespecially\tclass\tIa\tand\tclass\tIII\tIKr\tblockers.\nVentricular Fibrillation\n•\tVF\t is\t electrical\t anarchy\t of\t the\t ventricle\t resulting\t in\t no\t cardiac\toutput\t and\t cardio-\nvascular\t collapse.\t Sudden\t cardiac\t death\t occurs\t most\t commonly\t in\t patients\t with\t\ncoronary\tartery\tdisease\tand\tthose\twith\tLV\tdysfunction.\tVF\tassociated\twith\tacute\tMI\t\nmay\tbe\tclassified\tas\teither\t(1)\tprimary\t(an\tuncomplicated\tMI\tnot\tassociated\twith\tHF)\t\nor\t(2)\tsecondary\tor\tcomplicated\t(an\tMI\tcomplicated\tby\tHF).\nBRADYARRHYTHMIAS\n•\tSinus\tbradyarrhythmias\t(heart\trate\t<60\tbeats/min)\tare\tcommon,\tespecially\tin\tyoung,\t\nathletically\tactive\tindividuals,\tand\tare\tusually\tasymptomatic\tand\tdo\tnot\trequire\tinter-\nvention.\tHowever,\tsome\tpatients\thave\tsinus\tnode\tdysfunction\t(sick\tsinus\tsyndrome)\t\nbecause\t of\t underlying\t organic\t heart\t disease\t and\t the\t normal\t aging\t process,\t which\t\nattenuates\tSA\tnodal\tfunction.\tSinus\tnode\tdysfunction\tis\tusually\trepresentative\tof\tdif-\nfuse\tconduction\tdisease,\twhich\tmay\tbe\taccompanied\tby\tA V\tblock\tand\tby\tparoxysmal\t\ntachycardias\t such\t as\t AF .\t Alternating\t bradyarrhythmias\t and\t tachyarrhythmias\t are\t\nreferred\tto\tas\tthe\ttachy–brady\tsyndrome.\n•\tA V\tblock\tor\tconduction\tdelay\tmay\toccur\tin\tany\tarea\tof\tthe\tA V\tconduction\tsystem.\t\nA V\tblock\tmay\tbe\tfound\tin\tpatients\twithout\tunderlying\theart\tdisease\t(eg,\ttrained\tath-\nletes)\tor\tduring\tsleep\twhen\tvagal\ttone\tis\thigh.\tIt\tmay\tbe\ttransient\twhen\tthe\tunderly-\ning\tetiology\tis\treversible\t(eg,\tmyocarditis,\tmyocardial\tischemia,\tafter\tcardiovascular\t\nsurgery,\t or\t during\t drug\t therapy).\t β-Blockers,\t digoxin,\t or\t nondihydropyridine\t cal-\ncium\tantagonists\tmay\tcause\tA V\tblock,\tprimarily\tin\tthe\tA V\tnodal\tarea.\tClass\tI\tanti-\narrhythmics\tmay\texacerbate\tconduction\tdelays\tbelow\tthe\tlevel\tof\tthe\tA V\tnode.\tA V\t\nblock\tmay\tbe\tirreversible\tif\tthe\tcause\tis\tacute\tMI,\trare\tdegenerative\tdiseases,\tprimary\t\nmyocardial\tdisease,\tor\tcongenital\theart\tdisease.\nCLINICAL PRESENTATION\n•\tSupraventricular\t tachycardias\t may\t cause\t clinical\t manifestations\t ranging\t from\t no\t\nsymptoms\tto\tminor\tpalpitations\tor\tirregular\tpulse\tto\tsevere\tand\teven\tlife-threatening\t\nsymptoms.\tPatients\tmay\texperience\tdizziness\tor\tacute\tsyncopal\tepisodes,\tsymptoms\t\nof\tHF ,\tanginal\tchest\tpain,\tor,\tmore\toften,\ta\tchoking\tor\tpressure\tsensation\tduring\tthe\t\ntachycardia\tepisode.\n•\tAF\t or\t atrial\t flutter\t may\t be\tmanifested\t by\t the\t entire\t range\t of\t symptoms\t associated\t\nwith\tother\tsupraventricular\ttachycardias,\tbut\tsyncope\tis\tuncommon.\tArterial\tembo-\nlization\tfrom\tatrial\tstasis\tand\tpoorly\tadherent\tmural\tthrombi\tmay\tresult\tin\tembolic\t\nstroke.\n•\tPVCs\t often\t cause\t no\t symptoms\t or\t only\t mild\t palpitations.\t The\t presentation\t of\t\nVT\t may\t vary\t from\t totally\t asymptomatic\t to\t pulseless\t hemodynamic\t collapse.\t\nConsequences\tof\tproarrhythmia\trange\tfrom\tno\tsymptoms\tto\tworsening\tof\tsymptoms\t\nto\tsudden\tdeath.\tVF\tresults\tin\themodynamic\tcollapse,\tsyncope,\tand\tcardiac\tarrest.\n•\tPatients\twith\tbradyarrhythmias\texperience\tsymptoms\tassociated\twith\thypotension,\t\nsuch\tas\tdizziness,\tsyncope,\tfatigue,\tand\tconfusion.\tIf\tLV\tdysfunction\texists,\tpatients\t\nmay\texperience\tworsening\tHF\tsymptoms.",
    "word_count": 544,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0102",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 102,
    "text": "50\nSeCt ION 2  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0103",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 103,
    "text": "50\nSeCt ION 2     Cardiovascular Disorders\nDIAGNOSIS\n•\tElectrocardiogram\t(ECG)\tis\tthe\tcornerstone\tof\tdiagnosis\tfor\tcardiac\trhythm\tdisturbances.\n•\tCardiac\tauscultation\tcan\treveal\tthe\tirregularly\tirregular\tpulse\tcharacteristic\tof\tAF .\n•\tProarrhythmia\tcan\tbe\tdifficult\tto\tdiagnose\tbecause\tof\tthe\tvariable\tnature\tof\tunderly-\ning\tarrhythmias.\n•\tT dP\tis\tcharacterized\tby\tlong\tQT\tintervals\tor\tprominent\tU\twaves\ton\tthe\tsurface\tECG.\n•\tSpecific\tmaneuvers\tmay\tbe\trequired\tto\tdelineate\tthe\tetiology\tof\tsyncope\tassociated\t\nwith\tbradyarrhythmias.\tDiagnosis\tof\tcarotid\tsinus\thypersensitivity\tcan\tbe\tconfirmed\t\nby\t performing\t carotid\t sinus\t massage\t with\t ECG\t and\t blood\t pressure\t monitoring.\t\nV asovagal\tsyncope\tcan\tbe\tdiagnosed\tusing\tthe\tupright\tbody-tilt\ttest.\n•\tBased\ton\tECG\tfindings,\tA V\tblock\tis\tusually\tcategorized\tas\tfirst-,\tsecond-,\tor\tthird-\ndegree\tA V\tblock.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\tdesired\toutcome\tdepends\ton\tthe\tunderlying\tarrhythmia.\tFor\t\nexample,\tthe\tgoals\tof\ttreating\tAF\tor\tatrial\tflutter\tare\trestoring\tsinus\trhythm,\tprevent-\ning\tthromboembolic\tcomplications,\tand\tpreventing\tfurther\trecurrences.\nGENERAL APPROACH\n•\tUse\t of\t antiarrhythmic\t drugs\t has\t declined\t because\t major\t trials\t showed\t increased\t\nmortality\twith\tuse\tin\tseveral\tsituations,\tthe\trealization\tof\tproarrhythmia\tas\ta\tsignifi-\ncant\tside\teffect,\tand\tthe\tadvancing\ttechnology\tof\tnondrug\ttherapies,\tsuch\tas\tablation\t\nand\tthe\timplantable\tcardioverter-defibrillator\t(ICD).\nCLASSIFICATION OF ANTIARRHYTHMIC DRUGS\n•\tDrugs\tmay\tdepress\tthe\tautomatic\tproperties\tof\tabnormal\tpacemaker\tcells\tby\tdecreas-\ning\tthe\tslope\tof\tphase\t4\tdepolarization\tand/or\tby\televating\tthreshold\tpotential.\tDrugs\t\nmay\talter\tconduction\tcharacteristics\tof\tthe\tpathways\tof\ta\treentrant\tloop.\n•\tThe\t V aughan\t Williams\t classification\t is\t most\t frequently\t used\t (Table 6–1).\t Class\t Ia\t\ndrugs\tslow\tconduction\tvelocity,\tprolong\trefractoriness,\tand\tdecrease\tthe\tautomatic\t\nproperties\tof\tsodium-dependent\t(normal\tand\tdiseased)\tconduction\ttissue.\tClass\tIa\t\ndrugs\tare\teffective\tfor\tboth\tsupraventricular\tand\tventricular\tarrhythmias.\n•\tAlthough\t categorized\t separately,\t class\t Ib\t drugs\t probably\t act\t similarly\t to\t class\t Ia\t\ndrugs,\texcept\tthat\tclass\tIb\tagents\tare\tconsiderably\tmore\teffective\tin\tventricular\tthan\t\nsupraventricular\tarrhythmias.\n•\tClass\tIc\tdrugs\tslow\tconduction\tvelocity\twhile\tleaving\trefractoriness\trelatively\tunal-\ntered.\tAlthough\teffective\tfor\tboth\tventricular\tand\tsupraventricular\tarrhythmias,\ttheir\t\nuse\tfor\tventricular\tarrhythmias\thas\tbeen\tlimited\tby\tthe\trisk\tof\tproarrhythmia.\n•\tClass\tI\tdrugs\tare\tsodium\tchannel\tblockers.\tAntiarrhythmic\tsodium\tchannel\treceptor\t\nprinciples\taccount\tfor\tdrug\tcombinations\tthat\tare\tadditive\t(eg,\tquinidine\tand\tmexi-\nletine)\tand\tantagonistic\t(eg,\tflecainide\tand\tlidocaine),\tas\twell\tas\tpotential\tantidotes\t\nto\texcess\tsodium\tchannel\tblockade\t(sodium\tbicarbonate).\n•\tClass\tII\tdrugs\tinclude\tβ-adrenergic antagonists ;\teffects\tresult\tfrom\tantiadrenergic\t\nactions.\tβ-Blockers\tare\tmost\tuseful\tin\ttachycardias\tin\twhich\tnodal\ttissues\tare\tabnor-\nmally\tautomatic\tor\tare\ta\tportion\tof\ta\treentrant\tloop.\tThese\tagents\tare\talso\thelpful\tin\t\nslowing\tventricular\tresponse\tin\tatrial\ttachycardias\t(eg,\tAF)\tby\teffects\ton\tthe\tA V\tnode.\n•\tClass\tIII\tdrugs\tprolong\trefractoriness\tin\tatrial\tand\tventricular\ttissue\tand\tinclude\tvery\t\ndifferent\tdrugs\tthat\tshare\tthe\tcommon\teffect\tof\tdelaying\trepolarization\tby\tblocking\t\npotassium\tchannels.\n✓\t\tAmiodarone\t and\t sotalol\t are\t effective\t in\t most\t supraventricular\t and\t ventricular\t\ntachycardias.\t Amiodarone\t displays\t electrophysiologic\t characteristics\t consistent\t\nwith\teach\ttype\tof\tantiarrhythmic\tdrug.\tIt\tis\ta\tsodium\tchannel\tblocker\twith\trelatively\t\nfast\ton-off\tkinetics,\thas\tnonselective\tβ-blocking\tactions,\tblocks\tpotassium\tchannels,\t\nand\thas\tslight\tcalcium-blocking\tactivity.\tSotalol\tinhibits\toutward\tpotassium\tmove-\nment\tduring\trepolarization\tand\talso\tpossesses\tnonselective\tβ-blocking\tactions.",
    "word_count": 543,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0104",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 104,
    "text": "51\na rrhythmias     Chapter  6\n✓\t\tDronedarone,\tibutilide,\tand\tdofetilide\tare\tindicated\tonly\tfor\ttreatment\tof\tsupra-\nventricular\tarrhythmias.\n•\tClass\t IV\t drugs\t inhibit\t calcium\t entry\t into\t cells,\t which\t slows\t conduction,\t prolongs\t\nrefractoriness,\t and\t decreases\t SA\t and\t A V\t nodal\t automaticity.\t Calcium channel \nantagonists\tare\teffective\tfor\tautomatic\tor\treentrant\ttachycardias\tthat\tarise\tfrom\tor\t\nuse\tthe\tSA\tor\tA V\tnodes.\n•\tSee\tTable 6–2\tfor\trecommended\tdoses\tof\toral\tantiarrhythmic\tdrugs,\tTable 6–3\tfor\t\nusual\tIV\tantiarrhythmic\tdoses,\tand\tTable 6–4\tfor\tcommon\tside\teffects.\nATRIAL FIBRILLATION OR ATRIAL FLUTTER\n•\tTreatment\t of\t AF\t involves\t several\t sequential\t goals.\t First,\t evaluate\t need\t for\t acute\t\ntreatment\t (usually\t with\t drugs\t that\t slow\t ventricular\t rate).\t Next,\t consider\t methods\t\nto\trestore\tsinus\trhythm,\tconsidering\trisks\tinvolved\t(eg,\tthromboembolism).\tLastly,\t\nconsider\tways\tto\tprevent\tlong-term\tcomplications,\tsuch\tas\trecurrent\tarrhythmia\tand\t\nthromboembolism\t(Fig.",
    "word_count": 139,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0105",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 105,
    "text": "  Chapter  6\n✓\t\tDronedarone,\tibutilide,\tand\tdofetilide\tare\tindicated\tonly\tfor\ttreatment\tof\tsupra-\nventricular\tarrhythmias.\n•\tClass\t IV\t drugs\t inhibit\t calcium\t entry\t into\t cells,\t which\t slows\t conduction,\t prolongs\t\nrefractoriness,\t and\t decreases\t SA\t and\t A V\t nodal\t automaticity.\t Calcium channel \nantagonists\tare\teffective\tfor\tautomatic\tor\treentrant\ttachycardias\tthat\tarise\tfrom\tor\t\nuse\tthe\tSA\tor\tA V\tnodes.\n•\tSee\tTable 6–2\tfor\trecommended\tdoses\tof\toral\tantiarrhythmic\tdrugs,\tTable 6–3\tfor\t\nusual\tIV\tantiarrhythmic\tdoses,\tand\tTable 6–4\tfor\tcommon\tside\teffects.\nATRIAL FIBRILLATION OR ATRIAL FLUTTER\n•\tTreatment\t of\t AF\t involves\t several\t sequential\t goals.\t First,\t evaluate\t need\t for\t acute\t\ntreatment\t (usually\t with\t drugs\t that\t slow\t ventricular\t rate).\t Next,\t consider\t methods\t\nto\trestore\tsinus\trhythm,\tconsidering\trisks\tinvolved\t(eg,\tthromboembolism).\tLastly,\t\nconsider\tways\tto\tprevent\tlong-term\tcomplications,\tsuch\tas\trecurrent\tarrhythmia\tand\t\nthromboembolism\t(Fig. 6–1).\n•\tIn\tpatients\twith\tnew-onset\tAF\tor\tatrial\tflutter\twith\tsigns\tand/or\tsymptoms\tof\themo-\ndynamic\t instability\t (eg,\t severe\t hypotension,\t angina,\t and/or\t pulmonary\t edema),\t\ndirect-current\tcardioversion\t(DCC)\tis\tindicated\tto\trestore\tsinus\trhythm\timmediately\t\n(without\tregard\tto\tthe\trisk\tof\tthromboembolism).\n•\tIf\tpatients\tare\themodynamically\tstable,\tthe\tfocus\tshould\tbe\tdirected\ttoward\tcontrol-\nling\tventricular\trate.\tUse\tdrugs\tthat\tslow\tconduction\tand\tincrease\trefractoriness\tin\t\nthe\tA V\tnode\tas\tinitial\ttherapy.\tIn\tpatients\twith\tnormal\tLV\tfunction\t(left\tventricular\t\nejection\t fraction\t [LVEF]\t >40%),\t IV\t β-blockers\t (propranolol,\t metoprolol,\t and\t\nesmolol),\tdiltiazem,\tor\tverapamil\tare\trecommended\tas\tfirst-line\ttherapy.\tIf\ta\thigh\t\nadrenergic\tstate\tis\tthe\tprecipitating\tfactor,\tIV\tβ-blockers\tcan\tbe\thighly\teffective\tand\t\nshould\t be\t considered\t first.\t In\tpatients\t with\t LVEF\t less\t than\tor\tequal\t to\t 40%,\tavoid\t\nIV\t diltiazem\t and\t verapamil,\t and\t use\t IV\t β-blockers\t with\t caution.\t In\t patients\t hav-\ning\t an\t exacerbation\t of\t HF\t symptoms,\t use\t IV\t digoxin\t or\t amiodarone\t as\t first-line\t\ntherapy\tfor\tventricular\trate\tcontrol.\tIV\tamiodarone\tcan\talso\tbe\tused\tin\tpatients\twho\t\n TABLE 6–1  Classification of Antiarrhythmic Drugs\nClass Drug\nConduction \nVelocitya\nRefractory \nPeriod Automaticity Ion Block\nIa Quinidine\nProcainamide\nDisopyramide\n↓ ↑ ↓ Sodium (intermediate)\nPotassium\nIb Lidocaine\nMexiletine\n0/↓ ↓ ↓ Sodium (fast on/off )\nIc Flecainide\nPropafenoneb\n↓↓ 0 ↓ Sodium (slow on/off )\nIIc β-Blockers ↓ ↑ ↓ Calcium (indirect)\nIII Amiodaroned\nDofetilide\nDronedaroned\nSotalolb\nIbutilide\n0 ↑↑ 0 Potassium\nIVc Verapamil\nDiltiazem\n↓ ↑ ↓ Calcium\n0, no change; ↑, increased; ↓, decreased.\na Variables for normal tissue models in ventricular tissue.\nb Also has β-blocking actions.\nc Variables for sinoatrial and atrioventricular nodal tissue only.\nd Also has sodium, calcium, and β-blocking actions.",
    "word_count": 414,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0106",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 106,
    "text": "52\nSeCt ION 2  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0107",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 107,
    "text": "52\nSeCt ION 2     Cardiovascular Disorders\nare\trefractory\tor\thave\tcontraindications\tto\tβ-blockers,\tnondihydropyridine\tcalcium\t\nchannel\tblockers,\tand\tdigoxin.\n•\tAfter\t treatment\t with\t A V\t nodal\tblocking\tagents\tand\t a\tsubsequent\tdecrease\tin\t ven-\ntricular\t response,\t assess\t the\t patient\t for\t the\t possibility\t of\t restoring\t sinus\t rhythm\t if\t\nAF\tpersists.\n•\tIf\t sinus\t rhythm\t is\t to\t be\t restored,\t initiate\t anticoagulation\t prior\t to\t cardioversion\t\nbecause\t return\t of\t atrial\t contraction\t increases\t risk\t of\t thromboembolism.\t Patients\t\nbecome\tat\tincreased\trisk\tof\tthrombus\tformation\tand\ta\tsubsequent\tembolic\tevent\tif\t\nthe\tduration\tof\tAF\texceeds\t48\thours.\n✓\t\tPatients\twith\tAF\tfor\tlonger\tthan\t48\thours\tor\tan\tunknown\tduration\tshould\treceive\t\nwarfarin\t(target\t international\tnormalized\tratio\t[INR]\t 2.0–3.0),\ta\t low-molecular-\nweight \theparin \t(subcutaneously \tat\ttreatment \tdoses), \tor\tdabigatran \tfor\tat\tleast\t\n3\tweeks\tprior\tto\tcardioversion.\tIf\tcardioversion\tis\tsuccessful,\tcontinue\tanticoagula-\ntion\twith\teither\twarfarin\tor\tdabigatran\tfor\tat\tleast\t4\tweeks.\t\n✓\t\tPatients\t with\t AF\t less\t than\t 48\t hours\t in\t duration\t do\t not\t require\t anticoagulation\t\nprior\t to\t cardioversion,\tbut\t they\t should\t receive\t either\t IV\t unfractionated\theparin\t\nor\t a\t low-molecular-weight\t heparin\t (subcutaneously\t at\t treatment\t doses)\t at\t pre-\nsentation\tprior\tto\tand\tproceeding\tto\tcardioversion.\tIf\tcardioversion\tis\tsuccessful,\t\ncontinue\tanticoagulation\twith\teither\twarfarin\tor\tdabigatran\tfor\tat\tleast\t4\tweeks.\n•\tAfter\t prior\t anticoagulation\t (or\t after\t transesophageal\t echocardiography\t demon-\nstrated\tabsence\tof\ta\tthrombus,\tobviating\tneed\tfor\twarfarin),\tmethods\tfor\trestoring\t\nsinus\t rhythm\t are\t pharmacologic\t cardioversion\t and\t DCC.\t DCC\t is\t quick\t and\t more\t\noften\tsuccessful,\tbut\tit\trequires\tprior\tsedation\tor\tanesthesia\tand\thas\ta\tsmall\trisk\tof\t\nserious\tcomplications,\tsuch\tas\tsinus\tarrest\tor\tventricular\tarrhythmias.\tAdvantages\tof\t\ninitial\tdrug\ttherapy\tare\tthat\tan\teffective\tagent\tmay\tbe\tdetermined\tin\tcase\tlong-term\t\ntherapy\tis\trequired.\tDisadvantages\tare\tsignificant\tside\teffects,\tsuch\tas\tdrug-induced\t\nTdP ,\t drug-drug \t interactions, \t and\t lower\t cardioversion \t rate\t for\t drugs \t compared\t\n TABLE 6–2  Typical Maintenance Doses of Oral Antiarrhythmic Drugs\nDrug Dose Dose Adjusted\nDisopyramide 100–150 mg every 6 h\n200–300 mg every 12 h (SR form)\nHEP , REN\nQuinidine 200–300 mg sulfate salt every 6 h\n324–648 mg gluconate salt every 8–12 h\nHEP\nMexiletine 200–300 mg every 8 h HEP\nFlecainide 50–200 mg every 12 h HEP , REN\nPropafenone 150–300 mg every 8 h\n225–425 mg every 12 h (SR form)\nHEP\nAmiodarone 400 mg 2 or 3 times daily until 10 g total, \nthen 200–400 mg daily a\nDofetilide 500 mcg every 12 h RENb\nDronedarone 400 mg every 12 h (with meals) c\nSotalol 80–160 mg every 12 h RENd\nHEP , hepatic disease; REN, renal dysfunction; SR, sustained-release.\naUsual maintenance dose for atrial fibrillation is 200 mg/day (may further decrease dose to 100 mg/\nday with long-term use if patient is clinically stable in order to decrease risk of toxicity); usual \nmaintenance dose for ventricular arrhythmias is 300 to 400 mg/day.\nbDose should be based on creatinine clearance; should not be used when creatinine clearance <20 \nmL/min  \n(<0.33 mL/s).\ncAvoid in severe hepatic impairment.\ndAvoid in atrial fibrillation when creatinine clearance less than 40 mL/min ( <0.67 mL/s).",
    "word_count": 506,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0108",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 108,
    "text": "53\na rrhythmias  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0109",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 109,
    "text": "53\na rrhythmias     Chapter  6\nwith\t DCC.\t There\t is\t good\t evidence\t for\t efficacy \t of\t class\t III\t pure\t Ik\t blockers\t\n(ibutilide\t and\t dofetilide),\t class\t Ic\t drugs\t (eg,\t flecainide\t and\t propafenone),\t and\t\namiodarone\t(oral\tor\tIV).\tWith\tthe\t“pill\tin\tthe\tpocket”\tapproach,\toutpatient,\tpatient-\ncontrolled\t self-administration\t of\t a\t single,\t oral\t loading\t dose\t of\t either\t flecainide\t or\t\npropafenone\tcan\tbe\trelatively\tsafe\tand\teffective\tfor\ttermination\tof\trecent-onset\tAF\t\nin\tselect\tpatients\twithout\tsinus\tor\tA V\tnode\tdysfunction,\tbundle-branch\tblock,\tQT\t\ninterval\tprolongation,\tBrugada’ s\tsyndrome,\tor\tstructural\theart\tdisease.\tIt\tshould\tonly\t\nbe\tconsidered\tfor\tpatients\twho\thave\tbeen\tsuccessfully\tcardioverted\twith\tthese\tdrugs\t\non\tan\tinpatient\tbasis.\n•\tLong-term\t antithrombotic\t therapy\t is\t recommended\t to\t prevent\t stroke.\t Patients\t\nwith\ta\tCHADS2\t(acronym\tderived\tfrom\tstroke\trisk\tfactors:\tcongestive\theart\tfailure,\t\nhypertension,\tage\t>75\tyears,\tdiabetes,\tand\tprior\tstroke\tor\ttransient\tischemic\tattack)\t\nscore\tof\t2\tor\tgreater,\t1,\tor\t0\tare\tconsidered\tto\tbe\tat\thigh\trisk,\tintermediate\trisk,\tand\t\nlow\trisk\tfor\tstroke,\trespectively.\tFor\tpatients\tat\thigh\tor\tintermediate\trisk\tfor\tstroke,\t\noral\tanticoagulation\tis\tpreferred\tover\taspirin\tor\taspirin\tplus\tclopidogrel;\tdabigatran\t\n TABLE 6–3  Intravenous Antiarrhythmic Dosing\nDrug Clinical Situation Dose\nAmiodarone Pulseless VT/VF\nStable VT (with a pulse)\nAF (termination)\n300 mg IV/IO push (can give additional 150 mg IV/\nIO push if persistent VT/VF), followed by infusion \nof 1 mg/min for 6 h, then 0.5 mg/min\n150 mg IV over 10 min, followed by infusion of 1 \nmg/min for 6 h, then 0.5 mg/min\n5 mg/kg IV over 30 min, followed by infusion of 1 \nmg/min for 6 h, then 0.5 mg/min\nDiltiazem PSVT; AF (rate control) 0.25 mg/kg IV over 2 min (may repeat with 0.35 \nmg/kg IV over 2 min), followed by infusion of 5 \nto 15 mg/h\nIbutilide AF (termination) 1 mg IV over 10 min (may repeat if needed)\nLidocaine Pulseless VT/VF\nStable VT (with a pulse)\n1–1.5 mg/kg IV/IO push (can give additional 0.5–0.75 \nmg/ kg IV/IO push every 5–10 min if persistent \nVT/VF [maximum cumulative dose = 3 mg/kg]), \nfollowed by infusion of 1 to 4 mg/min (1–2 mg/\nmin if liver disease or HF)\n1–1.5 mg/kg IV push (can give additional 0.5–0.75 \nmg/kg IV push every 5–10 min if persistent VT \n[maximum cumulative dose = 3 mg/kg]), fol-\nlowed by infusion of 1–4 mg/min (1–2 mg/min \nif liver disease or HF)\nProcainamide AF (termination); stable \nVT (with a pulse)\n15–18 mg/kg IV over 60 min, followed by infusion \nof 1–4 mg/min\nSotalola AF/AFl (SR mainte-\nnance) Ventricular \narrhythmias\n75–150 mg IV once or twice daily (infused over  \n5 h)b\nVerapamil PSVT; AF (rate control) 2.5–5 mg IV over 2 min (may repeat up to  \nmaximum cumulative dose of 20 mg); can follow \nwith infusion of 2.5–10 mg/h\nAF , atrial fibrillation; AFl, atrial flutter; HF , heart failure; IO, intraosseous; PSVT, paroxysmal supraven-\ntricular tachycardia; VF , ventricular fibrillation; VT, ventricular tachycardia.\naUse only when patients are unable to take sotalol orally.\nbAdminister IV sotalol at the same frequency as oral sotalol (based on creatinine clearance).",
    "word_count": 508,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0110",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 110,
    "text": "  Chapter  6\nwith\t DCC.\t There\t is\t good\t evidence\t for\t efficacy \t of\t class\t III\t pure\t Ik\t blockers\t\n(ibutilide\t and\t dofetilide),\t class\t Ic\t drugs\t (eg,\t flecainide\t and\t propafenone),\t and\t\namiodarone\t(oral\tor\tIV).\tWith\tthe\t“pill\tin\tthe\tpocket”\tapproach,\toutpatient,\tpatient-\ncontrolled\t self-administration\t of\t a\t single,\t oral\t loading\t dose\t of\t either\t flecainide\t or\t\npropafenone\tcan\tbe\trelatively\tsafe\tand\teffective\tfor\ttermination\tof\trecent-onset\tAF\t\nin\tselect\tpatients\twithout\tsinus\tor\tA V\tnode\tdysfunction,\tbundle-branch\tblock,\tQT\t\ninterval\tprolongation,\tBrugada’ s\tsyndrome,\tor\tstructural\theart\tdisease.\tIt\tshould\tonly\t\nbe\tconsidered\tfor\tpatients\twho\thave\tbeen\tsuccessfully\tcardioverted\twith\tthese\tdrugs\t\non\tan\tinpatient\tbasis.\n•\tLong-term\t antithrombotic\t therapy\t is\t recommended\t to\t prevent\t stroke.\t Patients\t\nwith\ta\tCHADS2\t(acronym\tderived\tfrom\tstroke\trisk\tfactors:\tcongestive\theart\tfailure,\t\nhypertension,\tage\t>75\tyears,\tdiabetes,\tand\tprior\tstroke\tor\ttransient\tischemic\tattack)\t\nscore\tof\t2\tor\tgreater,\t1,\tor\t0\tare\tconsidered\tto\tbe\tat\thigh\trisk,\tintermediate\trisk,\tand\t\nlow\trisk\tfor\tstroke,\trespectively.\tFor\tpatients\tat\thigh\tor\tintermediate\trisk\tfor\tstroke,\t\noral\tanticoagulation\tis\tpreferred\tover\taspirin\tor\taspirin\tplus\tclopidogrel;\tdabigatran\t\n TABLE 6–3  Intravenous Antiarrhythmic Dosing\nDrug Clinical Situation Dose\nAmiodarone Pulseless VT/VF\nStable VT (with a pulse)\nAF (termination)\n300 mg IV/IO push (can give additional 150 mg IV/\nIO push if persistent VT/VF), followed by infusion \nof 1 mg/min for 6 h, then 0.5 mg/min\n150 mg IV over 10 min, followed by infusion of 1 \nmg/min for 6 h, then 0.5 mg/min\n5 mg/kg IV over 30 min, followed by infusion of 1 \nmg/min for 6 h, then 0.5 mg/min\nDiltiazem PSVT; AF (rate control) 0.25 mg/kg IV over 2 min (may repeat with 0.35 \nmg/kg IV over 2 min), followed by infusion of 5 \nto 15 mg/h\nIbutilide AF (termination) 1 mg IV over 10 min (may repeat if needed)\nLidocaine Pulseless VT/VF\nStable VT (with a pulse)\n1–1.5 mg/kg IV/IO push (can give additional 0.5–0.75 \nmg/ kg IV/IO push every 5–10 min if persistent \nVT/VF [maximum cumulative dose = 3 mg/kg]), \nfollowed by infusion of 1 to 4 mg/min (1–2 mg/\nmin if liver disease or HF)\n1–1.5 mg/kg IV push (can give additional 0.5–0.75 \nmg/kg IV push every 5–10 min if persistent VT \n[maximum cumulative dose = 3 mg/kg]), fol-\nlowed by infusion of 1–4 mg/min (1–2 mg/min \nif liver disease or HF)\nProcainamide AF (termination); stable \nVT (with a pulse)\n15–18 mg/kg IV over 60 min, followed by infusion \nof 1–4 mg/min\nSotalola AF/AFl (SR mainte-\nnance) Ventricular \narrhythmias\n75–150 mg IV once or twice daily (infused over  \n5 h)b\nVerapamil PSVT; AF (rate control) 2.5–5 mg IV over 2 min (may repeat up to  \nmaximum cumulative dose of 20 mg); can follow \nwith infusion of 2.5–10 mg/h\nAF , atrial fibrillation; AFl, atrial flutter; HF , heart failure; IO, intraosseous; PSVT, paroxysmal supraven-\ntricular tachycardia; VF , ventricular fibrillation; VT, ventricular tachycardia.\naUse only when patients are unable to take sotalol orally.\nbAdminister IV sotalol at the same frequency as oral sotalol (based on creatinine clearance). Oral \nsotalol may be converted to IV sotalol as follows: 80 mg oral = 75 mg IV; 120 mg oral = 112.5 mg \nIV; 160 mg oral = 150 mg IV.",
    "word_count": 536,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0111",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 111,
    "text": "54\nSeCt ION 2  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0112",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 112,
    "text": "54\nSeCt ION 2     Cardiovascular Disorders\nshould\t be\t used\t rather\t than\t warfarin.\t For\t patients\t at\t low\t risk\t for\t stroke,\t either\t no\t\nantithrombotic\ttherapy\tor\taspirin\tis\trecommended;\thowever,\tno\ttherapy\tis\tpreferred.\t\nIf\tthe\tdecision\tis\tmade\tto\tinitiate\tantithrombotic\ttherapy\tin\tlow-risk\tpatients,\taspirin\t\n75–325\tmg/day\tcan\tbe\tused.\n•\tIn\tpatients\twith\tnonvalvular\tAF ,\twarfarin,\tdabigatran,\trivaroxaban,\tand\tapixaban\tare\t\nall\tindicated\tfor\tprevention\tof\tinitial\tand\trecurrent\tstrokes.\n✓\t\tDabigatran\t150\tmg\ttwice\tdaily\tis\tan\teffective\talternative\tto\twarfarin\tfor\tinitial\tor\t\nrecurrent\tstroke\tprevention\tin\tpatients\twith\tat\tleast\tone\tadditional\trisk\tfactor\tfor\t\nstroke\tand\ta\tCrCl\tgreater\tthan\t30\tmL/min\t(>0.50\tmL/s).\n✓\t\tRivaroxaban\t20\tmg\tdaily\tis\tan\talternative\tto\twarfarin\tin\tpatients\tat\tmoderate-to-\nhigh\trisk\tof\tstroke\t(eg,\tprior\thistory\tof\tTIA,\tstroke\tor\tsystemic\tembolism,\tor\tat\tleast\t\n2\tadditional\trisk\tfactors\tfor\tstroke).\n✓\t\tApixaban\t5\tmg\ttwice\tdaily\tis\tan\teffective\talternative\tto\twarfarin\tin\tpatients\twith\tat\t\nleast\tone\trisk\tfactor\tfor\tstroke.\tApixaban\tis\talso\tan\talternative\tto\taspirin\tin\tpatients\t\nwith\tat\tleast\t1\trisk\tfactor\tfor\tstroke\tand\twho\tare\tconsidered\tunsuitable\tcandidates\t\nfor\twarfarin.\n TABLE 6–4  Side Effects of Antiarrhythmic Drugs\nDisopyramide Anticholinergic symptoms (dry mouth, urinary retention, constipation, \nand blurred vision), nausea, anorexia, TdP , HF , conduction disturbances, \nventricular arrhythmias\nProcainamidea Hypotension, TdP , worsening HF , conduction disturbances, ventricular \narrhythmias\nQuinidine Cinchonism, diarrhea, abdominal cramps, nausea, vomiting, hypotension, \nTdP , worsening HF , conduction disturbances, ventricular arrhythmias, \nfever, hepatitis, thrombocytopenia, hemolytic anemia\nLidocaine Dizziness, sedation, slurred speech, blurred vision, paresthesia, muscle \ntwitching, confusion, nausea, vomiting, seizures, psychosis, sinus arrest, \nconduction disturbances\nMexiletine Dizziness, sedation, anxiety, confusion, paresthesia, tremor, ataxia, blurred \nvision,  \nnausea, vomiting, anorexia, conduction disturbances, ventricular \narrhythmias\nFlecainide Blurred vision, dizziness, dyspnea, headache, tremor, nausea, worsening HF ,  \nconduction disturbances, ventricular arrhythmias\nPropafenone Dizziness, fatigue, bronchospasm, headache, taste disturbances, nausea, \nvomiting, bradycardia or AV block, worsening HF , ventricular arrhythmias\nAmiodarone Tremor, ataxia, paresthesia, insomnia, corneal microdeposits, optic neu-\nropathy/neuritis, nausea, vomiting, anorexia, constipation, TdP (<1%), \nbradycardia or AV block (IV and oral use), pulmonary fibrosis, liver \nfunction test abnormalities, hepatitis, hypothyroidism, hyperthyroid-\nism, photosensitivity, blue-gray skin discoloration, hypotension (IV use), \nphlebitis (IV use)\nDofetilide Headache, dizziness, TdP\nDronedarone Nausea, vomiting, diarrhea, serum creatinine elevations, bradycardia, wors-\nening HF , liver toxicity, pulmonary fibrosis, TdP (<1%)\nIbutilide Headache, TdP , hypotension\nSotalol Dizziness, weakness, fatigue, nausea, vomiting, diarrhea, bradycardia, TdP , \nbronchospasm, worsening HF\nAV, atrioventricular; HF , heart failure; IV, intravenous; TdP , torsade de pointes.\naSide effects are listed for IV formulation only; oral formulations are no longer available.",
    "word_count": 434,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0113",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 113,
    "text": "55\na rrhythmias  |  Chapter  6\nAtrial /f_ibrillation/Flutter\nsmotpmys etaredom ro laminiMsmotpmys ereveS\nSlow ventricular rate\n(BB, CCB, or digoxin)\nRate control\n(leave in AF)\nRhythm control\n(restore sinus\nrhythm)\nWarfarin, LMWH, or\ndabigatran\n≥3 weeks or TEE\nto exclude\nthrombusa\nElective\ncardioversion\n(electrical or\npharmacologic)\nLong-term\nAADs?\nNo AADs\nIsolated episode\nChronic\nantithrombotic\ntherapy\nConsider\nadding AAD if\npatient remains\nsymptomatic\ndespite\nadequate\nventricular rate\ncontrol\nRecurrent episodes\nMay consider AAD (especially if patient\nremains symptomatic despite adequate\nventricular rate control)b\nMay also consider leaving in AF (and\nproviding rate control and antithrombotic therapy)\nConsider chronic antithrombotic therapy\nfor patients with risk factors for strokec\nDCC\nIf atrial /f_lutter\nonly\nConsider\nablation\nFIGURE 6–1.  Algorithm for the treatment of atrial fibrillation (AF) and atrial flutter. (BB, \nβ-blocker; CCB, calcium channel blocker [ie, verapamil or diltiazem]; DCC, direct-current \ncardioversion.) aIf a F less than 48 hours, anticoagulation prior to cardioversion is unnec-\nessary; may consider transesophageal echocardiogram ( tee ) if patient has risk factors \nfor stroke. bConsider ablation for patients who fail or do not tolerate one or more anti-\narrhythmic drugs (aa Ds). cConsider chronic antithrombotic therapy in all patients with \na F and risk factors for stroke regardless of whether or not they remain in sinus rhythm.",
    "word_count": 210,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0114",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 114,
    "text": "56\nSeCt ION 2     Cardiovascular Disorders\n•\tDual\tantiplatelet\ttherapy\twith\taspirin\tplus\tclopidogrel\tis\trecommended\tover\taspirin\t\nmonotherapy\tfor\tpatients\tat\thigh\tor\tintermediate\trisk\tfor\tstroke\twho\tare\tnot\tcandi-\ndates\tfor\toral\tanticoagulation\tfor\treasons\tother\tthan\tbleeding\t(ie,\tpatient\tpreference,\t\nunable\tto\tadhere\tto\tmonitoring\trequirements).\n•\tConsider\tchronic\tantithrombotic\ttherapy\tfor\tall\tpatients\twith\tAF\tand\trisk\tfactors\tfor\t\nstroke\tregardless\tof\twhether\tor\tnot\tthey\tremain\tin\tsinus\trhythm.\n•\tAF\t often\t recurs\t after\t initial\t cardioversion\t because\t most\t patients\t have\t irreversible\t\nunderlying\theart\tor\tlung\tdisease.\tA\tmeta-analysis\tconfirmed\tthat\tquinidine\tmain-\ntained\tsinus\trhythm\tbetter\tthan\tplacebo;\thowever,\t50%\tof\tpatients\thad\trecurrent\tAF\t\nwithin\t1\tyear,\tand\tquinidine\tincreased\tmortality,\tpresumably\tdue\tin\tpart\tto\tproar-\nrhythmia.\tClass\tIc\tor\tIII\tantiarrhythmic\tagents\tare\treasonable\talternatives\tto\tconsider\t\nfor\tmaintaining\tsinus\trhythm.\tBecause\tthe\tclass\tIc\tdrugs\tflecainide\tand\tpropafenone\t\nincrease\tthe\trisk\tof\tproarrhythmia,\tthey\tshould\tbe\tavoided\tin\tpatients\twith\tstructural\t\nheart\t disease.\t Amiodarone\t is\tthe\tmost\teffective\tand\t most\tfrequently\t used\t class\t III\t\nagent\tfor\tpreventing\tAF\trecurrences\tdespite\tits\tpotential\tfor\tsignificant\torgan\ttoxicity.\nPAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA\n•\tThe\t choice\t between\t pharmacologic\t and\t nonpharmacologic\t methods\t for\t treating\t\nPSVT\t depends\t on\t symptom\t severity\t (Fig. 6–2 ).\t Treatment\t measures\t are\t directed\t\nfirst\tat\tterminating\tthe\tacute\tepisode\tand\tthen\tat\tpreventing\trecurrences.\tFor\tpatients\t\nwith\tsevere\tsymptoms\t(eg,\tsyncope,\tnear\tsyncope,\tanginal\tchest\tpain,\tor\tsevere\tHF),\t\nsynchronized\t DCC\t is\t the\t treatment\t of\t choice.\t If\t symptoms\t are\t mild\t to\t moderate,\t\nnondrug\t measures\t that\t increase\t vagal\t tone\t to\t the\t A V\t node\t (eg,\t unilateral\t carotid\t\nsinus\t massage\t and\t V alsalva\t maneuver)\t can\t be\t used\t initially.\t If\t these\t methods\t fail,\t\ndrug\ttherapy\tis\tthe\tnext\toption.\nAcute\ntermination\nChronic\nprevention\nWide QRS, irregular\nAF with AP?\nProcainamide or\namiodarone\nSevere or frequent\nepisodes\nAVN modification or\nAP ablation\nDefinitive diagnosis\n(ECG, EPS)\nAdenosine or\nprocainamide\nAVNRT or AVRT\nPRN AAD\nVT or antidromic\nAVRT?\nWide QRS, regular\nMild\nSymptoms\nNarrow QRS, regular\nAVNRT or orthodromic\nAVRT?\nAdenosine, verapamil,\nor diltiazem\nMild and infrequent\nepisodes\nNo therapy\nDCC\nSevere\nFIGURE 6–2.  Algorithm for the treatment of acute  (top portion ) paroxysmal supraventricular \ntachycardia and chronic prevention of recurrences (bottom portion).",
    "word_count": 367,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0115",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 115,
    "text": " Algorithm for the treatment of acute  (top portion ) paroxysmal supraventricular \ntachycardia and chronic prevention of recurrences (bottom portion). Note: For empiric bridge \ntherapy prior to radiofrequency ablation procedures, do not use calcium channel block-\ners (or other atrioventricular [ aV] nodal blockers) if the patient has aV reentry with an \naccessory pathway. (aa D, antiarrhythmic drugs; a F, atrial fibrillation; ap, accessory path-\nway; aVN, atrioventricular nodal; aVNrt , atrioventricular nodal reentrant tachycardia; \naVrt , atrioventricular reentrant tachycardia; DCC, direct-current cardioversion; eCG, \nelectrocardiographic monitoring; epS, electrophysiologic studies; pr N, as needed; V t, \nventricular tachycardia.)",
    "word_count": 96,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0116",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 116,
    "text": "57\na rrhythmias     Chapter  6\n•\tThe\tchoice\tamong\tdrugs\tis\tbased\ton\tthe\tQRS\tcomplex\t(see\tFig.",
    "word_count": 18,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0117",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 117,
    "text": "  Chapter  6\n•\tThe\tchoice\tamong\tdrugs\tis\tbased\ton\tthe\tQRS\tcomplex\t(see\tFig. 6–2 ).\tDrugs\tcan\tbe\t\ndivided\tinto\tthree\tbroad\tcategories:\t(1)\tthose\tthat\tdirectly\tor\tindirectly\tincrease\tvagal\t\ntone\tto\tthe\tA V\tnode\t(eg,\tdigoxin);\t(2)\tthose\tthat\tdepress\tconduction\tthrough\tslow,\t\ncalcium-dependent\ttissue\t(eg,\tadenosine,\tβ-blockers ,\tand\tnondihydropyridine cal-\ncium channel blockers);\tand\t(3)\tthose\tthat\tdepress\tconduction\tthrough\tfast,\tsodium-\ndependent\ttissue\t(eg,\tquinidine,\tprocainamide,\tdisopyramide,\tand\tflecainide).\n•\tAdenosine\thas\tbeen\trecommended\tas\tthe\tdrug\tof\tfirst\tchoice\tfor\tpatients\twith\tPSVT\t\nbecause\tits\tshort\tduration\tof\taction\twill\tnot\tcause\tprolonged\themodynamic\tcompro-\nmise\tin\tpatients\twith\twide\tQRS\tcomplexes\twho\tactually\thave\tVT\trather\tthan\tPSVT .\n•\tAfter\t acute\t PSVT\t is\t terminated,\t long-term\t prophylaxis\t is\t indicated\t if\t frequent\t\nepisodes\t necessitate\t therapeutic\t intervention\t or\t if\t episodes\t are\t infrequent\t but\t\nseverely\t symptomatic.\t Serial\t testing\t of\t antiarrhythmic\t agents\t can\t be\t performed\t\nvia\t ambulatory\t ECG\t recordings\t (Holter\t monitors)\t or\t telephonic\t transmissions\t of\t\ncardiac\trhythm\t(event\tmonitors)\tor\tby\tinvasive\telectrophysiologic\ttechniques\tin\tthe\t\nlaboratory.\n•\tConsider\t transcutaneous\t catheter\t ablation\t using\t radiofrequency\t current\t on\t the\t\nPSVT\t substrate\t in\t any\t patient\t who\t would\t have\t previously\t been\t considered\t for\t\nchronic\t antiarrhythmic\t drug\t treatment.\t It\t is\t highly\t effective\t and\t curative,\t rarely\t\nresults\tin\tcomplications,\tobviates\tneed\tfor\tchronic\tantiarrhythmic\tdrug\ttherapy,\tand\t\nis\tcost\teffective.\nPREMATURE VENTRICULAR COMPLEXES\n•\tIn\tapparently\thealthy\tindividuals,\tdrug\ttherapy\tis\tunnecessary\tbecause\tPVCs\twithout\t\nassociated\theart\tdisease\tcarry\tlittle\tor\tno\trisk.\tIn\tpatients\twith\trisk\tfactors\tfor\tarrhyth-\nmic\tdeath\t(recent\tMI,\tLV\tdysfunction,\tor\tcomplex\tPVCs),\tlimit\tchronic\ttherapy\tto\t\nβ-blockers \tbecause\tonly\tthey\thave\tbeen\tproven\tto\tprevent\tmortality\tin\tthese\tpatients.\nVENTRICULAR TACHYCARDIA\nAcute Ventricular Tachycardia\n•\tIf\tsevere\tsymptoms\tare\tpresent,\tinstitute\tsynchronized\tDCC\timmediately\tto\trestore\t\nsinus\trhythm\tand\tcorrect\tprecipitating\tfactors\tif\tpossible.\tIf\tVT\tis\tan\tisolated\telectri-\ncal\tevent\tassociated\twith\ta\ttransient\tinitiating\tfactor\t(eg,\tacute\tmyocardial\tischemia\t\nor\t digitalis\t toxicity),\t there\t is\t no\t need\t for\t long-term\t antiarrhythmic\t therapy\t after\t\nprecipitating\tfactors\tare\tcorrected.\n•\tPatients\t with\t mild\t or\t no\t symptoms\t can\t be\t treated\t initially\t with\t antiarrhythmic\t\ndrugs.\tIV\tprocainamide,\tamiodarone,\tor\tsotalol\tmay\tbe\tconsidered\tin\tthis\tsituation;\t\nlidocaine\t is\t an\t alternative\t agent.\t Deliver\t synchronized\t DCC\t if\t the\t patient’ s\t status\t\ndeteriorates,\tVT\tdegenerates\tto\tVF ,\tor\tdrug\ttherapy\tfails.\nSustained Ventricular Tachycardia\n•\tPatients\t with\t chronic\t recurrent\t sustained\t VT\t are\t at\t high\t risk\t for\t death;\t trial-and-\nerror\tattempts\tto\tfind\teffective\ttherapy\tare\tunwarranted.\tNeither\telectrophysiologic\t\nstudies\tnor\tserial\tHolter\tmonitoring\twith\tdrug\ttesting\tis\tideal.\tThese\tfindings\tand\tthe\t\nside\teffect\tprofiles\tof\tantiarrhythmic\tagents\thave\tled\tto\tnondrug\tapproaches.\n•\tThe\tautomatic\tICD\tis\ta\thighly\teffective\tmethod\tfor\tpreventing\tsudden\tdeath\tdue\tto\t\nrecurrent\tVT\tor\tVF .\nVentricular Proarrhythmia\n•\tThe\ttypical\tform\tof\tproarrhythmia\tcaused\tby\tthe\tclass\tIc\tantiarrhythmic\tdrugs\tis\ta\t\nrapid,\tsustained,\tmonomorphic\tVT\twith\ta\tcharacteristic\tsinusoidal\tQRS\tpattern\tthat\t\nis\toften\tresistant\tto\tresuscitation\twith\tcardioversion\tor\toverdrive\tpacing.\tIV\tlidocaine\t\n(competes\t for\t the\t sodium\t channel\t receptor)\t or\t sodium bicarbonate (reverses\t the\t\nexcessive\tsodium\tchannel\tblockade)\thave\tbeen\tused\tsuccessfully\tby\tsome\tclinicians.\nTorsade de Pointes\n•\tFor\tan\tacute\tepisode\tof\ttorsade\tde\tpointes\t(T dP),\tmost\tpatients\trequire\tand\trespond\t\nto\tDCC.\tHowever,\tT dP\ttends\tto\tbe\tparoxysmal\tand\toften\trecurs\trapidly\tafter\tDCC.",
    "word_count": 551,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0118",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 118,
    "text": "58\nSeCt ION 2  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0119",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 119,
    "text": "58\nSeCt ION 2     Cardiovascular Disorders\n•\tIV\t magnesium sulfate \t is\t the\t drug\t of\t choice\t for\t preventing\t recurrences\t of\t T dP .\t If\t\nineffective,\tinstitute\tstrategies\tto\tincrease\theart\trate\tand\tshorten\tventricular\trepolar-\nization\t (ie,\t temporary\t transvenous\t pacing\t at\t 105–120\t beats/min\t or\t pharmacologic\t\npacing\twith\tisoproterenol\tor\tepinephrine\tinfusion).\tDiscontinue\tagents\tthat\tprolong\t\nthe\tQT\tinterval\tand\tcorrect\texacerbating\tfactors\t(eg,\thypokalemia\tand\thypomagne-\nsemia).\tDrugs\tthat\tfurther\tprolong\trepolarization\t(eg,\tIV\tprocainamide)\tare\tcontra-\nindicated.\tLidocaine\tis\tusually\tineffective.\nVentricular Fibrillation\n•\tManage\t patients\t with\t pulseless\t VT\t or\t VF\t (with\t or\t without\t associated\t myocardial\t\nischemia)\taccording\tto\tAmerican\tHeart\tAssociation\tguidelines\tfor\tcardiopulmonary\t\nresuscitation\tand\temergency\tcardiovascular\tcare\t(see\tChap.\t7).\nBRADYARRHYTHMIAS\n•\tTreatment\tof\tsinus\tnode\tdysfunction\tinvolves\telimination\tof\tsymptomatic\tbradycar-\ndia\tand\tpossibly\tmanaging\talternating\ttachycardias\tsuch\tas\tAF .\tAsymptomatic\tsinus\t\nbradyarrhythmias\tusually\tdo\tnot\trequire\ttherapeutic\tintervention.\n•\tIn\tgeneral,\ta\tpermanent\tventricular\tpacemaker\tis\tthe\tlong-term\ttherapy\tof\tchoice\tfor\t\npatients\twith\tsignificant\tsymptoms.\n•\tDrugs\t commonly\t employed\t to\t treat\t supraventricular\t tachycardias\t should\t be\t used\t\nwith\tcaution,\tif\tat\tall,\tin\tthe\tabsence\tof\ta\tfunctioning\tpacemaker.\n•\tSymptomatic\t carotid\t sinus\t hypersensitivity\t also\t should\t be\t treated\t with\t permanent\t\npacemaker\ttherapy.\tPatients\twho\tremain\tsymptomatic\tmay\tbenefit\tfrom\tadding\tan\t\nα-adrenergic\tstimulant\tsuch\tas\tmidodrine.\n•\tV asovagal\t syncope\t has\t traditionally\t been\t treated\t successfully\t with\t oral\t β-blockers\t\n(eg,\t metoprolol)\t to\t inhibit\t the\t sympathetic\t surge\t that\t causes\t forceful\t ventricular\t\ncontraction\tand\tprecedes\tthe\tonset\tof\thypotension\tand\tbradycardia.\tOther\tdrugs\tthat\t\nhave\t been\t used\t successfully\t (with\t or\t without\t β-blockers)\t include\t fludrocortisone,\t\nanticholinergics\t (scopolamine patches \t and\t disopyramide),\t α-adrenergic\t agonists\t\n(midodrine),\tadenosine\tanalogues\t(theophylline\tand\tdipyridamole),\tand\tselective\t\nserotonin\treuptake\tinhibitors\t(sertraline\tand\tparoxetine).\nAtrioventricular Block\n•\tIf\t patients\t with\t Mobitz\t II\t or\t third-degree\t A V\t block\t develop\t signs\t or\t symptoms\t of\t\npoor\t perfusion\t (eg,\t altered\t mental\t status,\t chest\t pain,\t hypotension,\t and/or\t shock)\t\nadminister\t atropine\t (0.5\t mg\t IV\t given\t every\t 3–5\t minutes,\t up\t to\t 3\t mg\t total\t dose).\t\nTranscutaneous\t pacing\t can\t be\t initiated\t in\t patients\t unresponsive\t to\t atropine.\t\nInfusions\tof\tepinephrine\t(2–10\tmcg/min)\tor\tdopamine\t(2–10\tmcg/kg/min)\tcan\talso\t\nbe\tused\tin\tthe\tevent\tof\tatropine\tfailure.\tThese\tagents\tusually\tdo\tnot\thelp\tif\tthe\tsite\tof\t\nthe\tA V\tblock\tis\tbelow\tthe\tA V\tnode\t(Mobitz\tII\tor\ttrifascicular\tA V\tblock).\n•\tChronic\t symptomatic\t A V\t block\t warrants\t insertion\t of\t a\t permanent\t pacemaker.\t\nPatients\twithout\tsymptoms\tcan\tsometimes\tbe\tfollowed\tclosely\twithout\tthe\tneed\tfor\t\na\tpacemaker.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tThe\tmost\timportant\tmonitoring\tparameters\tinclude:\t(1)\tmortality\t(total\tand\tdue\tto\t\narrhythmic\tdeath),\t(2)\tarrhythmia\trecurrence\t(duration,\tfrequency,\tand\tsymptoms),\t\n(3)\themodynamic\tconsequences\t(rate,\tblood\tpressure,\tand\tsymptoms),\tand\t(4)\ttreat-\nment\tcomplications\t(side\teffects\tor\tneed\tfor\talternative\tor\tadditional\tdrugs,\tdevices,\t\nor\tsurgery).\nSee Chapter 8, The Arrhythmias, authored by Cynthia A.",
    "word_count": 464,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0120",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 120,
    "text": "  Cardiovascular Disorders\n•\tIV\t magnesium sulfate \t is\t the\t drug\t of\t choice\t for\t preventing\t recurrences\t of\t T dP .\t If\t\nineffective,\tinstitute\tstrategies\tto\tincrease\theart\trate\tand\tshorten\tventricular\trepolar-\nization\t (ie,\t temporary\t transvenous\t pacing\t at\t 105–120\t beats/min\t or\t pharmacologic\t\npacing\twith\tisoproterenol\tor\tepinephrine\tinfusion).\tDiscontinue\tagents\tthat\tprolong\t\nthe\tQT\tinterval\tand\tcorrect\texacerbating\tfactors\t(eg,\thypokalemia\tand\thypomagne-\nsemia).\tDrugs\tthat\tfurther\tprolong\trepolarization\t(eg,\tIV\tprocainamide)\tare\tcontra-\nindicated.\tLidocaine\tis\tusually\tineffective.\nVentricular Fibrillation\n•\tManage\t patients\t with\t pulseless\t VT\t or\t VF\t (with\t or\t without\t associated\t myocardial\t\nischemia)\taccording\tto\tAmerican\tHeart\tAssociation\tguidelines\tfor\tcardiopulmonary\t\nresuscitation\tand\temergency\tcardiovascular\tcare\t(see\tChap.\t7).\nBRADYARRHYTHMIAS\n•\tTreatment\tof\tsinus\tnode\tdysfunction\tinvolves\telimination\tof\tsymptomatic\tbradycar-\ndia\tand\tpossibly\tmanaging\talternating\ttachycardias\tsuch\tas\tAF .\tAsymptomatic\tsinus\t\nbradyarrhythmias\tusually\tdo\tnot\trequire\ttherapeutic\tintervention.\n•\tIn\tgeneral,\ta\tpermanent\tventricular\tpacemaker\tis\tthe\tlong-term\ttherapy\tof\tchoice\tfor\t\npatients\twith\tsignificant\tsymptoms.\n•\tDrugs\t commonly\t employed\t to\t treat\t supraventricular\t tachycardias\t should\t be\t used\t\nwith\tcaution,\tif\tat\tall,\tin\tthe\tabsence\tof\ta\tfunctioning\tpacemaker.\n•\tSymptomatic\t carotid\t sinus\t hypersensitivity\t also\t should\t be\t treated\t with\t permanent\t\npacemaker\ttherapy.\tPatients\twho\tremain\tsymptomatic\tmay\tbenefit\tfrom\tadding\tan\t\nα-adrenergic\tstimulant\tsuch\tas\tmidodrine.\n•\tV asovagal\t syncope\t has\t traditionally\t been\t treated\t successfully\t with\t oral\t β-blockers\t\n(eg,\t metoprolol)\t to\t inhibit\t the\t sympathetic\t surge\t that\t causes\t forceful\t ventricular\t\ncontraction\tand\tprecedes\tthe\tonset\tof\thypotension\tand\tbradycardia.\tOther\tdrugs\tthat\t\nhave\t been\t used\t successfully\t (with\t or\t without\t β-blockers)\t include\t fludrocortisone,\t\nanticholinergics\t (scopolamine patches \t and\t disopyramide),\t α-adrenergic\t agonists\t\n(midodrine),\tadenosine\tanalogues\t(theophylline\tand\tdipyridamole),\tand\tselective\t\nserotonin\treuptake\tinhibitors\t(sertraline\tand\tparoxetine).\nAtrioventricular Block\n•\tIf\t patients\t with\t Mobitz\t II\t or\t third-degree\t A V\t block\t develop\t signs\t or\t symptoms\t of\t\npoor\t perfusion\t (eg,\t altered\t mental\t status,\t chest\t pain,\t hypotension,\t and/or\t shock)\t\nadminister\t atropine\t (0.5\t mg\t IV\t given\t every\t 3–5\t minutes,\t up\t to\t 3\t mg\t total\t dose).\t\nTranscutaneous\t pacing\t can\t be\t initiated\t in\t patients\t unresponsive\t to\t atropine.\t\nInfusions\tof\tepinephrine\t(2–10\tmcg/min)\tor\tdopamine\t(2–10\tmcg/kg/min)\tcan\talso\t\nbe\tused\tin\tthe\tevent\tof\tatropine\tfailure.\tThese\tagents\tusually\tdo\tnot\thelp\tif\tthe\tsite\tof\t\nthe\tA V\tblock\tis\tbelow\tthe\tA V\tnode\t(Mobitz\tII\tor\ttrifascicular\tA V\tblock).\n•\tChronic\t symptomatic\t A V\t block\t warrants\t insertion\t of\t a\t permanent\t pacemaker.\t\nPatients\twithout\tsymptoms\tcan\tsometimes\tbe\tfollowed\tclosely\twithout\tthe\tneed\tfor\t\na\tpacemaker.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tThe\tmost\timportant\tmonitoring\tparameters\tinclude:\t(1)\tmortality\t(total\tand\tdue\tto\t\narrhythmic\tdeath),\t(2)\tarrhythmia\trecurrence\t(duration,\tfrequency,\tand\tsymptoms),\t\n(3)\themodynamic\tconsequences\t(rate,\tblood\tpressure,\tand\tsymptoms),\tand\t(4)\ttreat-\nment\tcomplications\t(side\teffects\tor\tneed\tfor\talternative\tor\tadditional\tdrugs,\tdevices,\t\nor\tsurgery).\nSee Chapter 8, The Arrhythmias, authored by Cynthia A. Sanoski and Jerry L.",
    "word_count": 464,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0121",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 121,
    "text": "Sanoski and Jerry L. Bauman, \nfor a more detailed discussion of this topic.",
    "word_count": 13,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0122",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 122,
    "text": "59\n•\tCardiac arrest \t involves\t cessation\t of\t cardiac\t mechanical\t activity\t as\t confirmed\t by\t\nabsence\tof\tsigns\tof\tcirculation\t(eg,\tdetectable\tpulse,\tunresponsiveness,\tand\tapnea).\nPATHOPHYSIOLOGY\n•\tCoronary\tartery\tdisease\tis\tthe\tmost\tcommon\tfinding\tin\tadults\twith\tcardiac\tarrest\tand\t\ncauses\t~80%\tof\tsudden\tcardiac\tdeaths.\tIn\tpediatric\tpatients,\tcardiac\tarrest\ttypically\t\nresults\tfrom\trespiratory\tfailure\tor\tprogressive\tshock.\n•\tTwo\tdifferent\tpathophysiologic\tconditions\tare\tassociated\twith\tcardiac\tarrest:\n✓\t\tPrimary:\tarterial\tblood\tis\ttypically\tfully\toxygenated\tat\tthe\ttime\tof\tarrest.\n✓\t\tSecondary:\t results\t from\t respiratory\t failure\t in\t which\t lack\t of\t ventilation\t leads\t to\t\nsevere\thypoxemia,\thypotension,\tand\tcardiac\tarrest.\n•\tCardiac\t arrest\t in\t adults\t usually\t results\t from\t arrhythmias.\t Historically,\t ventricular\t\nfibrillation\t (VF)\t and\t pulseless\t ventricular\t tachycardia\t (PVT)\t were\t most\t common.\t\nThe\t incidence\t of\t VF\t in\t out-of-hospital\t arrests\t is\t declining,\t which\t is\t of\t concern\t\nbecause\t survival\t rates\t are\t higher\t after\t VF/PVT\t than\t with\t cardiac\t arrest\t resulting\t\nfrom\tnonshockable\trhythms\tlike\tasystole\tor\tpulseless\telectrical\tactivity\t(PEA).\n•\tBecause\tin-hospital\tcardiac\tarrest\tis\ttypically\tpreceded\tby\thypoxia\tor\thypotension,\t\nasystole\tor\tPEA\toccurs\tmore\tcommonly\tthan\tVF\tor\tPVT .\n•\tOnly\t14%\tof\tpediatric\tpatients\twith\tin-hospital\tarrest\tpresent\twith\tVF\tor\tPFT\tas\tthe\t\ninitial\trhythm.\nCLINICAL PRESENTATION\n•\tCardiac\tarrest\tmay\tbe\tpreceded\tby\tanxiety,\tshortness\tof\tbreath,\tchest\tpain,\tnausea,\t\nvomiting,\tand\tdiaphoresis.\n•\tAfter\t an\t arrest,\t individuals\t are\t unresponsive,\t apneic,\t and\t hypotensive\t without\t a\t\ndetectable\tpulse.\tExtremities\tare\tcold\tand\tclammy,\tand\tcyanosis\tis\tcommon.\nDIAGNOSIS\n•\tRapid\tdiagnosis\tis\tvital\tto\tsuccess\tof\tcardiopulmonary\tresuscitation\t(CPR).\tPatients\t\nmust\t receive\tearly\tintervention\tto\tprevent\tcardiac\t rhythms\tfrom\tdegenerating\tinto\t\nless\ttreatable\tarrhythmias.\n•\tDiagnosis\tis\tmade\tby\tobservation\tof\tclinical\tmanifestations\tconsistent\twith\tcardiac\t\narrest.\tDiagnosis\tis\tconfirmed\tby\tvital\tsigns,\tespecially\theart\trate\tand\trespirations.\n•\tElectrocardiography\t(ECG)\tidentifies\tthe\tcardiac\trhythm,\twhich\tin\tturn\tdetermines\t\ndrug\ttherapy.\n✓\t\tVF\tis\telectrical\tanarchy\tof\tthe\tventricle\tresulting\tin\tno\tcardiac\toutput\tand\tcardio-\nvascular\tcollapse.\n✓\t\tPEA\tis\tabsence\tof\ta\tdetectable\tpulse\tand\tpresence\tof\tsome\ttype\tof\telectrical\tactivity\t\nother\tthan\tVF\tor\tPVT .\n✓\t\tAsystole\tis\tpresence\tof\ta\tflat\tline\ton\tthe\tECG.\nTREATMENT\n•\tGoals of Treatment: \t Resuscitation\t goals\t are\t to\t preserve\t life,\t restore\t health,\t relieve\t\nsuffering,\tlimit\tdisability,\tand\trespect\tthe\tindividual’ s\tdecisions,\trights,\tand\tprivacy.\t\nThis\tcan\tbe\taccomplished\tvia\tCPR\tby\treturn\tof\tspontaneous\tcirculation\t(ROSC)\twith\t\neffective\tventilation\tand\tperfusion\tas\tquickly\tas\tpossible\tto\tminimize\thypoxic\tdam-\nage\tto\tvital\torgans.\tAfter\tsuccessful\tresuscitation,\tprimary\tgoals\tinclude\toptimizing\t\t\nCardiac Arrest\n7\nC H A P T E R",
    "word_count": 426,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0123",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 123,
    "text": "60\nSECTION 2     Cardiovascular Disorders\ntissue\toxygenation,\tidentifying\tprecipitating\tcause(s)\tof\tarrest,\tand\tpreventing\tsub-\nsequent\tepisodes.\nGENERAL APPROACH\n•\tThe\t 2010\t American\t Heart\t Association\t (AHA)\t guidelines\t for\t CPR\t and\t emergency\t\ncardiovascular\tcare\t(ECC)\tstate\tthat\tthe\tlikelihood\tof\tsuccessful\toutcome\tis\tenhanced\t\nif\t five\t critical\t elements\t in\t the\t “chain\t of\t survival”\t are\t implemented\t promptly:\t (1)\t\nimmediate\t recognition\t of\t cardiac\t arrest\t and\t activation\t of\t the\t emergency\t response\t\nsystem,\t (2)\t early\t CPR\t with\t an\t emphasis\t on\t chest\t compressions,\t (3)\t rapid\t defibril-\nlation,\t (4)\t effective\tadvanced\tcardiac\t life\t support\t (ACLS),\t and\t (5)\tintegrated\tpost-\ncardiac\tarrest\tcare.\n•\tBasic\tlife\tsupport\tgiven\tby\thealthcare\tproviders\ttrained\tin\tCPR\tincludes\tthe\tfollowing\t\nactions\tperformed\tin\tthis\torder:\n✓\t\tFirst,\tdetermine\tpatient\tresponsiveness.\tIf\tunresponsive\twith\tno\tbreathing\tor\tno\t\nnormal\tbreathing\t(ie,\tonly\tgasping),\tactivate\tthe\temergency\tmedical\tresponse\tteam\t\nand\tobtain\tan\tautomated\texternal\tdefibrillator\t(AED)\tif\tavailable.\n✓\t\tCheck\tfor\tpulse,\tbut\tif\tnot\tdefinitely\tfelt\twithin\t10\tseconds,\tbegin\tCPR\tand\tuse\tthe\t\nAED\twhen\tavailable.\n✓\t\tBegin\tCPR\twith\t30\tchest\tcompressions\tat\ta\trate\tof\tat\tleast\t100/min\tand\ta\tcompres-\nsion\tdepth\tof\tat\tleast\t2\tin\t(5\tcm)\tin\tadults\tand\tat\tleast\tone\tthird\tof\tthe\tanteropos-\nterior\tchest\tdiameter\tin\tinfants\tand\tchildren\t(~1.5\tin\t[4\tcm]\tin\tinfants\tand\t2\tin\t[5\t\ncm]\tin\tchildren).\n✓\t\tOpen\tthe\tairway\tand\tdeliver\ttwo\trescue\tbreaths,\tthen\trepeat\tchest\tcompressions.\t\nFollow\teach\tcycle\tof\t30\tchest\tcompressions\tby\ttwo\trescue\tbreaths.\n✓\t\tContinue\tcycles\tof\t30\tcompressions/2\tbreaths\tuntil\tan\tAED\tarrives\tand\tis\tready\tfor\t\nuse\tor\temergency\tmedical\tservice\t(EMS)\tproviders\ttake\tover\tcare.\n✓\t\tIf\t AED\t is\t available,\t check\t rhythm\t to\t determine\t if\t defibrillation\t is\t advised.\t If\t so,\t\ndeliver\tone\tshock\twith\timmediate\tresumption\tof\tchest\tcompressions/rescue\tbreaths.\t\nAfter\tfive\tcycles,\treevaluate\tthe\trhythm\tto\tdetermine\tneed\tfor\tfurther\tdefibrillation.\t\nRepeat\tthis\tsequence\tuntil\thelp\tarrives\tor\tthe\trhythm\tis\tno\tlonger\tshockable.\n✓\t\tIf\trhythm\tis\tnot\tshockable,\tcontinue\tchest\tcompressions/rescue\tbreath\tcycles\tuntil\t\nhelp\t arrives\t or\t spontaneous\t circulation\t returns.\t If\t rhythm\t is\t not\t shockable,\t it\t is\t\nlikely\tto\tbe\teither\tasystole\tor\tPEA.\n•\tOnce\tACLS\tproviders\tarrive,\tfurther\tdefinitive\ttherapy\tis\tgiven\tfollowing\tthe\tACLS\t\nalgorithm\tshown\tin\tFig.",
    "word_count": 370,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0124",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 124,
    "text": "  Cardiovascular Disorders\ntissue\toxygenation,\tidentifying\tprecipitating\tcause(s)\tof\tarrest,\tand\tpreventing\tsub-\nsequent\tepisodes.\nGENERAL APPROACH\n•\tThe\t 2010\t American\t Heart\t Association\t (AHA)\t guidelines\t for\t CPR\t and\t emergency\t\ncardiovascular\tcare\t(ECC)\tstate\tthat\tthe\tlikelihood\tof\tsuccessful\toutcome\tis\tenhanced\t\nif\t five\t critical\t elements\t in\t the\t “chain\t of\t survival”\t are\t implemented\t promptly:\t (1)\t\nimmediate\t recognition\t of\t cardiac\t arrest\t and\t activation\t of\t the\t emergency\t response\t\nsystem,\t (2)\t early\t CPR\t with\t an\t emphasis\t on\t chest\t compressions,\t (3)\t rapid\t defibril-\nlation,\t (4)\t effective\tadvanced\tcardiac\t life\t support\t (ACLS),\t and\t (5)\tintegrated\tpost-\ncardiac\tarrest\tcare.\n•\tBasic\tlife\tsupport\tgiven\tby\thealthcare\tproviders\ttrained\tin\tCPR\tincludes\tthe\tfollowing\t\nactions\tperformed\tin\tthis\torder:\n✓\t\tFirst,\tdetermine\tpatient\tresponsiveness.\tIf\tunresponsive\twith\tno\tbreathing\tor\tno\t\nnormal\tbreathing\t(ie,\tonly\tgasping),\tactivate\tthe\temergency\tmedical\tresponse\tteam\t\nand\tobtain\tan\tautomated\texternal\tdefibrillator\t(AED)\tif\tavailable.\n✓\t\tCheck\tfor\tpulse,\tbut\tif\tnot\tdefinitely\tfelt\twithin\t10\tseconds,\tbegin\tCPR\tand\tuse\tthe\t\nAED\twhen\tavailable.\n✓\t\tBegin\tCPR\twith\t30\tchest\tcompressions\tat\ta\trate\tof\tat\tleast\t100/min\tand\ta\tcompres-\nsion\tdepth\tof\tat\tleast\t2\tin\t(5\tcm)\tin\tadults\tand\tat\tleast\tone\tthird\tof\tthe\tanteropos-\nterior\tchest\tdiameter\tin\tinfants\tand\tchildren\t(~1.5\tin\t[4\tcm]\tin\tinfants\tand\t2\tin\t[5\t\ncm]\tin\tchildren).\n✓\t\tOpen\tthe\tairway\tand\tdeliver\ttwo\trescue\tbreaths,\tthen\trepeat\tchest\tcompressions.\t\nFollow\teach\tcycle\tof\t30\tchest\tcompressions\tby\ttwo\trescue\tbreaths.\n✓\t\tContinue\tcycles\tof\t30\tcompressions/2\tbreaths\tuntil\tan\tAED\tarrives\tand\tis\tready\tfor\t\nuse\tor\temergency\tmedical\tservice\t(EMS)\tproviders\ttake\tover\tcare.\n✓\t\tIf\t AED\t is\t available,\t check\t rhythm\t to\t determine\t if\t defibrillation\t is\t advised.\t If\t so,\t\ndeliver\tone\tshock\twith\timmediate\tresumption\tof\tchest\tcompressions/rescue\tbreaths.\t\nAfter\tfive\tcycles,\treevaluate\tthe\trhythm\tto\tdetermine\tneed\tfor\tfurther\tdefibrillation.\t\nRepeat\tthis\tsequence\tuntil\thelp\tarrives\tor\tthe\trhythm\tis\tno\tlonger\tshockable.\n✓\t\tIf\trhythm\tis\tnot\tshockable,\tcontinue\tchest\tcompressions/rescue\tbreath\tcycles\tuntil\t\nhelp\t arrives\t or\t spontaneous\t circulation\t returns.\t If\t rhythm\t is\t not\t shockable,\t it\t is\t\nlikely\tto\tbe\teither\tasystole\tor\tPEA.\n•\tOnce\tACLS\tproviders\tarrive,\tfurther\tdefinitive\ttherapy\tis\tgiven\tfollowing\tthe\tACLS\t\nalgorithm\tshown\tin\tFig. 7–1.\n•\tCentral\t venous\t catheter\t access\t results\t in\t faster\t and\t higher\t peak\t drug\t concentrations\t\nthan\t peripheral\t venous\t administration,\t but\t central\t line\t access\t is\t not\t needed\t in\t most\t\nresuscitation\tattempts.\tHowever,\tif\ta\tcentral\tline\tis\talready\tpresent,\tit\tis\tthe\taccess\tsite\tof\t\nchoice.\tIf\tIV\taccess\t(either\tcentral\tor\tperipheral)\thas\tnot\tbeen\testablished,\tinsert\ta\tlarge\t\nperipheral\tvenous\tcatheter.\tIf\tthis\tis\tnot\tsuccessful,\tinsert\tan\tintraosseous\t(IO)\tdevice.\n•\tIf\t neither\t IV\t nor\t IO\t access\t can\t be\t established,\t lidocaine,\t epinephrine,\t naloxone,\t\nand\tvasopressin\tmay\tbe\tadministered\tendotracheally.\tThe\tendotracheal\tdose\tshould\t\ngenerally\tbe\t2\tto\t2.5\ttimes\tlarger\tthan\tthe\tIV/IO\tdose.\nTREATMENT OF VENTRICULAR FIBRILLATION AND  \nPULSELESS VENTRICULAR TACHYCARDIA\nNonpharmacologic Therapy\n•\tAdminister\telectrical\tdefibrillation\twith\tone\tshock\tusing\t360\tJ\t(monophasic\tdefibril-\nlator)\tor\t120\tto\t200\tJ\t(biphasic\tdefibrillator).\tAfter\tdefibrillation\tis\tattempted,\trestart\t\nCPR\timmediately\tand\tcontinue\tfor\tabout\tfive\tcycles\t(~2\tmin)\tbefore\tanalyzing\tthe\t\nrhythm\tor\tchecking\ta\tpulse.\tIf\tthere\tis\tstill\tevidence\tof\tVF/PVT\tafter\t2\tminutes,\tthen\t\ngive\tpharmacologic\ttherapy\twith\trepeat\tattempts\tat\tsingle-discharge\tdefibrillation.\n•\tObtain\tendotracheal\tintubation\tand\tIV\taccess\twhen\tfeasible,\tbut\tnot\tat\tthe\texpense\t\nof\tstopping\tchest\tcompressions.\tOnce\tan\tairway\tis\tachieved,\tventilate\tpatients\twith\t\n100%\toxygen.",
    "word_count": 573,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0125",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 125,
    "text": "61\nCardiac Arrest     CHAPTER 7\nAdult Cardiac Arrest\nShout for Help/Activate Emergency Response\nRhythm\nshockable?\nRhythm\nshockable?\nVF/VT Asystole/PEA\nStart CPR\n• Give oxygen\n• Attach monitor/defibrillator\n1\n2\n9\n10\n11\n12\n3\n5\n7\nNo\nNo\nNo\nYes\nYes\nNo\nShock\nYes\nShock\nYes\nYes No\nShock\n4\n6\n8\nCPR 2 min\n• Epinephrine every 3-5 min\n• Consider advanced airway ,\n capnography\nCPR 2 min\n• IV/IO access\n• Epinephrine every 3-5 min\n• Consider advanced airway ,\n capnography\nCPR 2 min\n• Amiodarone\n• T reat reversible causes\nCPR 2 min\n• T reat reversible causes\nCPR 2 min\n• IV/IO access\nGo to 5 or 7• If no signs of return of\n spontaneus circulation\n (ROSC), go to 10 or 11\n• If ROSC, go to\n P ost–Cardiac Arrest\n Care\nRhythm\nshockable? Rhythm\nshockable?\nRhythm\nshockable?\nCPR Quality\n• Push hard (≥2 inches\n [5 cm]) and fast\n (≥100/min) and allow\n complete chest recoil\n• Minimize interruptions in\n compressions\n• Avoid excessive ventilation\n• Rotate compressor every\n 2 min\n• If no advanced airway,\n 30:2 compression-\n v entilation ratio\n• Quantitative waveform\n capnograph y\n – If PETCO2 <10 mm Hg,\n  attempt to improve\n  CPR quality\n• Intra-arterial pressure\n – If relaxation phase\n  (diastolic) pressure\n  <20 mm Hg, attempt\n  to improve CPR quality\nReturn of Spontaneous\nCirculation (ROSC)\n• Pulse and blood pressure\n• Abrupt sustained\n increase in PETCO2\n (typically ≥40 mm Hg)\n• Spontaneous arterial\n pressure waves with\n intra-arterial monitoring\nShock Energy\n• Biphasic: Manufacturer\n recommendation\n (120-200 J); if unknown,\n use maximum available.\n Second and subsequent\n doses should be equivalent,\n and higher doses may be\n consider ed\n• Monophasic: 360 J\nDrug Therapy\n• Epinephrine IV/IO Dose:\n 1 mg every 3-5 min\n• Vasopressin IV/IO Dose:\n 40 units can replace\n first or second dose of\n epinephrine\n• Amiodarone IV/IO Dose:\n First dose: 300 mg bolus\n Second dose: 150 mg\nAdvanced Airway\n• Supraglottic advanced\n airway or endotracheal\n intubation\n• Waveform capnography\n to confirm and monitor\n ET tube placement\n• 8-10 breaths per minute\n with continuous chest\n compressions\nReversible Causes\n– Hypovolemia\n– Hypoxia\n– Hydrogen ion (acidosis)\n– Hypo-/hyperkalemia\n– Hypothermia\n– Tension pneumothorax\n– Tamponade, cardiac\n– Toxins\n– Thrombosis, pulmonary\n– Thrombosis, coronary \nFIGURE 7–1.  Advanced cardiac life support (ACLS) cardiac arrest algorithm.",
    "word_count": 379,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0126",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 126,
    "text": " Advanced cardiac life support (ACLS) cardiac arrest algorithm.  \n(CPR, cardiopulmonary resuscitation; PEA, pulseless electrical activity; VF, ventricular \nfibrillation; VT, ventricular tachycardia.) ( Reprinted with permission: 2010 American Heart \nAssociation Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular \nCare, Part 8: Adult Advanced Cardiovascular Life Support. Circulation 2010;122(Suppl \n3):S729–S767. © 2010 American Heart Association, Inc. )",
    "word_count": 54,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0127",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 127,
    "text": "62\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0128",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 128,
    "text": "62\nSECTION 2     Cardiovascular Disorders\nPharmacologic Therapy\nEPINEPHRINE\n•\tEpinephrine\tis\ta\tdrug\tof\tfirst\tchoice\tfor\ttreating\tVF ,\tPVT ,\tasystole,\tand\tPEA.\tIt\tis\t\nan\tagonist\tof\tboth\tα\tand\tβ\treceptors,\tbut\teffectiveness\tis\tprimarily\tdue\tto\tα\teffects.\t\nIt\t increases\t systemic\t arteriolar\t vasoconstriction,\t thereby\t improving\t coronary\t and\t\ncerebral\tperfusion\tpressure\tduring\tthe\tlow-flow\tstate\tassociated\twith\tCPR.\n•\tThe\t recommended\t adult\t dose\t of\t epinephrine\t is\t 1\t mg\t administered\t by\t IV\t or\t IO\t\ninjection\tevery\t3\tto\t 5\tminutes.\tHigher\tdoses\tmay\tbe\tadministered\tto\ttreat\tspecific\t\ndisorders\tsuch\tas\tβ-blocker\tand\tcalcium\tchannel\tblocker\toverdose.\nVASOPRESSIN\n•\tVasopressin\tis\ta\tpotent\tnonadrenergic\tvasoconstrictor\tthat\tincreases\tblood\tpressure\t\n(BP)\tand\tsystemic\tvascular\tresistance.\tIts\tvasoconstrictive\tproperties\tare\tdue\tprimar-\nily\t to\t effects\t on\t V1\t receptors.\t The\t 2010\t AHA\t guidelines\t indicate\t that\t vasopressin\t\n40\tunits\tIV/IO\tcan\treplace\tthe\tfirst\tor\tsecond\tdose\tof\tepinephrine.\nANTIARRHYTHMICS\n•\tThe\t purpose\t of\t antiarrhythmic\t drug\t therapy\t after\t unsuccessful\t defibrillation\t and\t\nvasopressor\t administration\t is\t to\t prevent\t development\t or\t recurrence\t of\t VF\t and\t\nPVT\tby\traising\tthe\tfibrillation\tthreshold.\tHowever,\tclinical\tevidence\tdemonstrating\t\nimproved\tsurvival\tto\thospital\tdischarge\tis\tlacking.\n•\tAmiodarone\tis\tthe\trecommended\tantiarrhythmic\tin\tpatients\twith\tVF/VT\tunrespon-\nsive\tto\tCPR,\tdefibrillation,\tand\tvasopressors.\tThe\tdose\tis\t300\tmg\tIV/IO\tfollowed\tby\t\na\tsecond\tdose\tof\t150\tmg.\n•\tLidocaine\tmay\tbe\tused\tif\tamiodarone\tis\tunavailable,\tbut\tit\thas\tnot\tbeen\tshown\tto\t\nimprove\trates\tof\tROSC,\tadmission\tto\tthe\thospital,\tor\tsurvival\tto\tdischarge\tcompared\t\nwith\tamiodarone.\tThe\tinitial\tdose\tis\t1\tto\t1.5\tmg/kg\tIV .\tAdditional\tdoses\tof\t0.5\tto\t0.75\t\nmg/kg\tcan\tbe\tadministered\tat\t5-\tto\t10-minute\tintervals\tto\ta\tmaximum\tdose\tof\t3\tmg/\nkg\tif\tVF/PVT\tpersists.\nMAGNESIUM\n•\tSevere\thypomagnesemia\thas\tbeen\tassociated\twith\tVF/PVT ,\tbut\troutine\tadministra-\ntion\t of\t magnesium\t during\t cardiac\t has\t not\t improved\t clinical\t outcomes.\t Two\t trials\t\nshowed\t improved\t ROSC\t in\t cardiac\t arrests\t associated\t with\t torsades\t de\t pointes.\t\nTherefore,\t limit\t magnesium\t administration\t to\t these\t patients.\t The\t dose\t is\t 1\t to\t 2\t g\t\ndiluted\tin\t10\tmL\tof\t5%\tdextrose\tin\twater\tadministered\tIV/IO\tpush\tover\t15\tminutes.\nTHROMBOLYTICS\n•\tThrombolytic\tuse\tduring\tCPR\thas\tbeen\tinvestigated\tbecause\tmost\tcardiac\tarrests\tare\t\nrelated\tto\teither\tmyocardial\tinfarction\t(MI)\tor\tpulmonary\tembolism\t(PE).\tAlthough\t\nseveral\tstudies\tdemonstrated\tsuccessful\tuse,\tfew\thave\tshown\timprovements\tto\thospi-\ntal\tdischarge,\tand\tan\tincrease\tin\tintracranial\themorrhage\twas\tnoted.\tTherefore,\tfibri-\nnolytic\ttherapy\tshould\tnot\tbe\tused\troutinely\tin\tcardiac\tarrest\tbut\tcan\tbe\tconsidered\t\nwhen\tPE\tis\tthe\tpresumed\tor\tknown\tcause\tof\tthe\tarrest.\nTREATMENT OF PULSELESS ELECTRICAL ACTIVITY AND ASYSTOLE\nNonpharmacologic Therapy\n•\tSuccessful\t treatment\t of\t PEA\t and\t asystole\t depends\t on\t diagnosis\t of\t the\t underlying\t\ncause.\tPotentially\treversible\tcauses\tinclude:\t(1)\thypovolemia,\t(2)\thypoxia,\t(3)\tacido-\nsis,\t (4)\t hyper-\t or\t hypokalemia,\t (5)\t hypothermia,\t (6)\t hypoglycemia,\t (7)\t drug\t over-\ndose,\t(8)\tcardiac\ttamponade,\t(9)\ttension\tpneumothorax,\t(10)\tcoronary\tthrombosis,\t\n(11)\tpulmonary\tthrombosis,\tand\t(12)\ttrauma.\n•\tPEA\t and\t asystole\t are\t treated\t the\t same\t way.\t Both\t conditions\t require\t CPR,\t airway\t\ncontrol,\t and\t IV\t access.\t Avoid\t defibrillation\t in\t asystole\t because\t the\t resulting\t para-\nsympathetic\tdischarge\tcan\treduce\tthe\tchance\tof\tROSC\tand\tdecrease\tthe\tlikelihood\tof\t\nsurvival.\tIf\tavailable,\ttranscutaneous\tpacing\tcan\tbe\tattempted.",
    "word_count": 532,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0129",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 129,
    "text": "63\nCardiac Arrest  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0130",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 130,
    "text": "63\nCardiac Arrest     CHAPTER 7\nPharmacologic Therapy\n•\tEpinephrine\t1\tmg\tadministered\tby\tIV\tor\tIO\tinjection\tevery\t3\tto\t5\tminutes.\n•\tVasopressin\t40\tunits\tIV/IO\tcan\treplace\tthe\tfirst\tor\tsecond\tdose\tof\tepinephrine.\n•\tAtropine\t should\t not\t be\t routinely\t administered\t for\t treatment\t of\t asystole\t or\t PEA\t\nbecause\t there\t are\t no\t prospective\t controlled\t trials\t showing\t benefit\t and\t there\t is\t\nconflicting\t evidence\t from\t retrospective\t and\t observational\t reports.\t The\t 2010\t AHA\t\nguidelines\tremoved\tatropine\tfrom\tthe\tACLS\tcardiac\tarrest\talgorithm.\nACID–BASE MANAGEMENT\n•\tAcidosis\toccurs\tduring\tcardiac\tarrest\tbecause\tof\tdecreased\tblood\tflow\tor\tinadequate\t\nventilation.\tChest\tcompressions\tgenerate\tonly\t~20%\tto\t30%\tof\tnormal\tcardiac\tout-\nput,\tleading\tto\tinadequate\torgan\tperfusion,\ttissue\thypoxia,\tand\tmetabolic\tacidosis.\t\nLack\tof\tventilation\tcauses\tCO2\tretention,\tleading\tto\trespiratory\tacidosis.\tThe\tcom-\nbined\tacidosis\treduces\tmyocardial\tcontractility\tand\tmay\tcause\tarrhythmias.\n•\tRoutine\t use\t of\t sodium\t bicarbonate\t in\t cardiac\t arrest\t is\t not\t recommended\t because\t\nthere\tare\tfew\tclinical\tdata\tsupporting\tits\tuse,\tand\tit\tmay\thave\tdetrimental\teffects.\tIt\t\ncan\tbe\tused\tin\tspecial\tcircumstances\t(eg,\tpreexisting\tmetabolic\tacidosis,\thyperkale-\nmia,\tand\ttricyclic\tantidepressant\toverdose).\tThe\tdosage\tshould\tbe\tguided\tby\tlabora-\ntory\tanalysis\tif\tpossible.\nPOSTRESUSCITATIVE CARE\n•\tROSC\tfrom\ta\tcardiac\tarrest\tmay\tbe\tfollowed\tby\ta\tpost-cardiac\tarrest\tsyndrome\tchar-\nacterized\t by\t brain\t injury,\t myocardial\t dysfunction,\t systemic\t ischemia/reperfusion\t\nresponse,\tand\tpersistent\tprecipitating\tpathology.\n•\tIt\t is\t imperative\t to\t ensure\t adequate\t airway\t and\t oxygenation.\t Raise\t the\t head\t of\t the\t\nbed\tto\t30\tdegrees\tto\treduce\trisk\tfor\taspiration,\tventilator-associated\tpneumonia,\tand\t\ncerebral\tedema.\tAfter\tuse\tof\t100%\toxygen\tduring\tthe\tresuscitation\teffort,\ttitrate\tthe\t\noxygen\tfraction\tdown\tas\ttolerated\tto\tavoid\toxygen\ttoxicity.\tOverventilation\tcan\tbe\t\navoided\tby\tusing\tend-tidal\t(ET)\tCO2\tmeasurements\ttargeting\tan\tETCO2\tof\t40–45\tmm\t\nHg\t[5.3–6.0\tkPa]).\n•\tEvaluate\tfor\tECG\tchanges\tconsistent\twith\tacute\tmyocardial\tinfarction\tas\tsoon\tas\tpos-\nsible\tand\tperform\trevascularization\tas\tappropriate.\n•\tHypothermia\t can\t protect\t from\t cerebral\t injury\t by\t suppressing\t chemical\t reactions\t\nthat\t occur\t after\t restoration\t of\t blood\t flow.\t The\t 2010\t AHA\t guidelines\t recommend\t\nthat\tunconscious\tadult\tpatients\twith\tROSC\tafter\tout-of-hospital\tVF\tcardiac\tarrest\tbe\t\ncooled\tto\t32–34°C\t(89.6–93.2°F)\tfor\t12\tto\t24\thours.\tCooling\tmay\talso\tbe\tconsidered\t\nfor\tcomatose\tadults\tpatients\twith\tROSC\tafter\tout-of-hospital\tarrests\twith\tan\tinitial\t\nrhythm\tof\tasystole\tor\tPEA\tor\tafter\tin-hospital\tcardiac\tarrest\tof\tany\tinitial\trhythm.\t\nThere\t is\t insufficient\t evidence\t to\trecommend\t therapeutic\thypothermia\t in\t children.\t\nPotential\tcomplications\tof\thypothermia\tinclude\tcoagulopathy,\tdysrhythmias,\thyper-\nglycemia,\tincreased\tincidence\tof\tpneumonia\tand\tsepsis,\tand\tprofound\teffects\ton\tdrug\t\ndistribution\tand\telimination.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tMonitoring\tshould\toccur\tboth\tduring\tthe\tresuscitation\tattempt\tand\tin\tthe\tpostresus-\ncitation\tphase.\tThe\toptimal\toutcome\tfollowing\tCPR\tis\tan\tawake,\tresponsive,\tspon-\ntaneously\tbreathing\tpatient.\tIdeally,\tpatients\tmust\tremain\tneurologically\tintact\twith\t\nminimal\tmorbidity\tafter\tthe\tresuscitation.\n•\tAssess\tand\tdocument\theart\trate,\tcardiac\trhythm,\tand\tBP\tthroughout\tthe\tresuscitation\t\nattempt\tand\tafter\teach\tintervention.\tDetermination\tof\tthe\tpresence\tor\tabsence\tof\ta\t\npulse\tis\tparamount\tto\tdeciding\twhich\tinterventions\tare\tappropriate.\n•\tCoronary\t perfusion\t pressure\t (CPP)\t and\t central\t venous\t oxygen\t saturation\t (ScvO2)\t\ncan\tprovide\tuseful\tinformation\ton\tthe\tpatient’ s\tresponse\tto\ttherapy.\n•\tETCO2\tmonitoring\tis\ta\tsafe\tand\teffective\tmethod\tto\tassess\tcardiac\toutput\tduring\tCPR\t\nand\thas\tbeen\tassociated\twith\tROSC.",
    "word_count": 542,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0131",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 131,
    "text": "64\nSECTION 2  |  Cardiovascular Disorders\n•\tConsider\tthe\tprecipitating\tcause\tof\tthe\tcardiac\tarrest\t(eg,\tMI,\telectrolyte\timbalance,\t\nprimary\tarrhythmia).\tReview\tprearrest\tstatus\tcarefully,\tparticularly\tif\tthe\tpatient\twas\t\nreceiving\tdrug\ttherapy.\n•\tAddress\t any\t altered\t cardiac,\t hepatic,\t and\t renal\t function\t resulting\t from\t ischemic\t\ndamage\tduring\tthe\tarrest.\n•\tAssess\tneurologic\tfunction\tby\tthe\tCerebral\tPerformance\tCategory\tand\tthe\tGlasgow\t\nComa\tScale.\nSee Chapter 2, Cardiac Arrest, authored by Jeffrey F. Barletta and Jeffrey L. Wilt, for a \nmore detailed discussion of this topic.",
    "word_count": 85,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0132",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 132,
    "text": "65\n•\tDyslipidemia\tis\televated\ttotal\tcholesterol,\tlow-density\tlipoprotein\t(LDL)\tcholesterol,\t\nor\ttriglycerides;\tlow\thigh-density\tlipoprotein\t(HDL)\tcholesterol;\tor\ta\tcombination\tof\t\nthese\tabnormalities.\nPATHOPHYSIOLOGY\n•\tCholesterol,\ttriglycerides,\tand\tphospholipids\tare\ttransported\tin\tblood\tas\tcomplexes\t\nof\tlipids\tand\tproteins\t(lipoproteins).\tElevated\ttotal\tand\tLDL\tcholesterol\tand\treduced\t\nHDL\tcholesterol\tare\tassociated\twith\tdevelopment\tof\tcoronary\theart\tdisease\t(CHD).\n•\tRisk\tfactors\tsuch\tas\toxidized\tLDL,\tmechanical\tinjury\tto\tendothelium,\tand\texcessive\t\nhomocysteine\tcan\tlead\tto\tendothelial\tdysfunction\tand\tcellular\tinteractions\tculminat-\ning\t in\t atherosclerosis.\t Eventual\t clinical\t outcomes\t may\t include\t angina,\t myocardial\t\ninfarction\t (MI),\t arrhythmias,\t stroke,\t peripheral\t arterial\t disease,\t abdominal\t aortic\t\naneurysm,\tand\tsudden\tdeath.\n•\tAtherosclerotic\tlesions\tarise\tfrom\ttransport\tand\tretention\tof\tplasma\tLDL\tthrough\tthe\t\nendothelial\tcell\tlayer\tinto\tthe\textracellular\tmatrix\tof\tthe\tsubendothelial\tspace.\tOnce\t\nin\tthe\tartery\twall,\tLDL\tis\tchemically\tmodified\tthrough\toxidation\tand\tnonenzymatic\t\nglycation.\tMildly\toxidized\tLDL\trecruits\tmonocytes\tinto\tthe\tartery\twall,\twhich\ttrans-\nform\t into\t macrophages\t that\t accelerate\t LDL\t oxidation.\t Oxidized\t LDL\t provokes\t an\t\ninflammatory\tresponse\tmediated\tby\tchemoattractants\tand\tcytokines.\n•\tRepeated\t injury\t and\t repair\t within\t an\t atherosclerotic\t plaque\t eventually\t lead\t to\t a\t\nfibrous\tcap\tprotecting\tthe\tunderlying\tcore\tof\tlipids,\tcollagen,\tcalcium,\tand\tinflam-\nmatory\tcells.\tMaintenance\tof\tthe\tfibrous\tplaque\tis\tcritical\tto\tprevent\tplaque\trupture\t\nand\tcoronary\tthrombosis.\n•\tPrimary\t or\t genetic\t lipoprotein\t disorders\t are\t classified\t into\t six\t categories:\t I\t (chylomi-\ncrons),\tIIa\t(LDL),\tIIb\t(LDL\t+\tvery-low-density\tlipoprotein\t[VLDL]),\tIII\t(intermediate-\ndensity\t lipoprotein),\t IV\t (VLDL),\t and\t V\t (VLDL\t +\t chylomicrons).\t Secondary\t forms\t of\t\ndyslipidemia\t also\t exist,\t and\t several\tdrug\t classes\tmay\t affect\t lipid\t levels\t (eg,\t progestins,\t\nthiazide\tdiuretics,\tglucocorticoids,\tβ-blockers,\tisotretinoin,\tprotease\tinhibitors,\tcyclospo-\nrine,\tmirtazapine,\tand\tsirolimus).\n•\tThe\tprimary\tdefect\tin\tfamilial\thypercholesterolemia\tis\tinability\tto\tbind\tLDL\tto\tthe\t\nLDL\treceptor\t(LDL-R).\tThis\tleads\tto\ta\tlack\tof\tLDL\tdegradation\tby\tcells\tand\tunregu-\nlated\tbiosynthesis\tof\tcholesterol.\nCLINICAL PRESENTATION\n•\tMost\tpatients\tare\tasymptomatic\tfor\tmany\tyears.\tSymptomatic\tpatients\tmay\tcomplain\t\nof\tchest\tpain,\tpalpitations,\tsweating,\tanxiety,\tshortness\tof\tbreath,\tabdominal\tpain,\tor\t\nloss\tof\tconsciousness\tor\tdifficulty\twith\tspeech\tor\tmovement.\n•\tDepending\t on\t the\t lipoprotein\t abnormality,\t signs\t on\t physical\t examination\t may\t\ninclude\tcutaneous\txanthomas,\tperipheral\tpolyneuropathy,\thigh\tblood\tpressure,\tand\t\nincreased\tbody\tmass\tindex\tor\twaist\tsize.\nDIAGNOSIS\n•\tMeasure\tfasting\tlipoprotein\tprofile\t(total\tcholesterol,\tLDL,\tHDL,\ttriglycerides)\tin\tall\t\nadults\t20\tyears\tof\tage\tor\tolder\tat\tleast\tonce\tevery\t5\tyears.\n•\tMeasure\tplasma\tcholesterol,\ttriglyceride,\tand\tHDL\tlevels\tafter\ta\t12-hour\tfast\tbecause\t\ntriglycerides\tmay\tbe\televated\tin\tnonfasting\tindividuals;\ttotal\tcholesterol\tis\tonly\tmod-\nestly\taffected\tby\tfasting.\n•\tTwo\t determinations,\t 1\t to\t 8\t weeks\t apart\t are\t recommended\t to\t minimize\t variability\t\nand\t obtain\t a\t reliable\t baseline.\t If\t the\t total\t cholesterol\t is\t greater\t than\t 200\t mg/dL\t\t\n(>5.17\t mmol/L),\t a\t second\t determination\t is\t recommended,\t and\t if\t the\t values\t are\t\ngreater\tthan\t30\tmg/dL\t(>0.78\tmmol/L)\tapart,\tuse\tthe\taverage\tof\tthree\tvalues.\nDyslipidemia\n8 \nC H A P T E R",
    "word_count": 485,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0133",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 133,
    "text": "66\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0134",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 134,
    "text": "66\nSECTION 2     Cardiovascular Disorders\n•\tHistory\t and\t physical\t examination\t should\t assess:\t (1)\t presence\t or\t absence\t of\t car-\ndiovascular\t risk\t factors\t or\t definite\t cardiovascular\t disease;\t (2)\t family\t history\t of\t\npremature\tcardiovascular\tdisease\tor\tlipid\tdisorders;\t(3)\tpresence\tor\tabsence\tof\tsec-\nondary\tcauses\tof\tdyslipidemia,\tincluding\tconcurrent\tmedications;\tand\t(4)\tpresence\t\nor\t absence\t of\t xanthomas,\t abdominal\t pain,\t or\thistory\t of\t pancreatitis,\t renal\tor\t liver\t\ndisease,\tperipheral\tvascular\tdisease,\tabdominal\taortic\taneurysm,\tor\tcerebral\tvascular\t\ndisease\t(carotid\tbruits,\tstroke,\tor\ttransient\tischemic\tattack).\n•\tDiabetes\tmellitus\tand\tthe\tmetabolic\tsyndrome\tare\tconsidered\tCHD\trisk\tequivalents;\t\ntheir\tpresence\tin\tpatients\twithout\tknown\tCHD\tis\tassociated\twith\tthe\tsame\tlevel\tof\t\nrisk\tas\tpatients\twithout\tthem\tbut\thaving\tconfirmed\tCHD.\n•\tLipoprotein\t electrophoresis\t is\t sometimes\t performed\t to\t determine\t which\t class\t of\t\nlipoproteins\tis\tinvolved.\tIf\tthe\ttriglycerides\tare\tless\tthan\t400\tmg/dL\t(4.52\tmmol/L),\t\nand\tneither\ttype\tIII\tdyslipidemia\tnor\tchylomicrons\tare\tdetected\tby\telectrophoresis,\t\nthen\tone\tcan\tcalculate\tVLDL\tand\tLDL\tconcentrations:\tVLDL\t=\ttriglycerides\t÷\t5;\tLDL\t\n=\ttotal\tcholesterol\t–\t(VLDL\t+\tHDL).\tInitial\ttesting\tuses\ttotal\tcholesterol\tfor\tcase\tfind-\ning,\tbut\tsubsequent\tmanagement\tdecisions\tshould\tbe\tbased\ton\tLDL.\nTREATMENT\n•\tGoals\t of\t Treatment:\t Lower\t total\t and\t LDL\t cholesterol\t to\t reduce\t the\t risk\t of\t first\t or\t\nrecurrent\t events\t such\t as\t MI,\t angina,\t heart\t failure,\t ischemic\t stroke,\t or\t peripheral\t\narterial\tdisease.\nGENERAL APPROACH\n•\tThe\tNational\tCholesterol\tEducation\tProgram\tAdult\tTreatment\tPanel\tIII\t(NCEP\tATP\t\nIII)\trecommends\tthat\tfasting\tlipoprotein\tprofile\tand\trisk\tfactor\tassessment\tbe\tused\t\nin\tinitial\tclassification\tof\tadults.\t\n•\tIf\t the\t total\t cholesterol\t is\t less\t than\t 200\t mg/dL\t (>5.17\t mmol/L),\t then\t the\t patient\t\nhas\ta\tdesirable\tblood\tcholesterol\tlevel\t(Table 8–1).\tIf\tthe\tHDL\tis\talso\tgreater\tthan\t\n40\tmg/dL\t(>1.03\tmmol/L),\tno\tfurther\tfollow-up\tis\trecommended\tfor\tpatients\twith-\nout\tknown\tCHD\tand\twho\thave\tfewer\tthan\ttwo\trisk\tfactors\t(Table 8–2).\tIn\tpatients\t\nwith\tborderline-high\tblood\tcholesterol\t(200–239\tmg/dL;\t5.17–6.18\tmmol/L),\tassess-\nment\tof\trisk\tfactors\tis\tneeded\tto\tmore\tclearly\tdefine\tdisease\trisk.\n TABLE 8–1  Classification of Total, LDL, and HDL Cholesterol and Triglycerides\nTotal cholesterol\n <200 mg/dL (<5.17 mmol/L)\n 200–239 mg/dL (5.17–6.20 mmol/L)\n ≥240 mg/dL (≥6.21 mmol/L)\nDesirable\nBorderline high\nHigh\nLDL cholesterol\n <100 mg/dL (<2.59 mmol/L)\n 100–129 mg/dL (2.59–3.35 mmol/L)\n 130–159 mg/dL (3.36–4.13 mmol/L)\n 160–189 mg/dL (4.14–4.90 mmol/L)\n ≥190 mg/dL (≥4.91 mmol/L)\nOptimal\nNear or above optimal\nBorderline high\nHigh\nVery high\nHDL cholesterol\n <40 mg/dL (<1.03 mmol/L)\n ≥60 mg/dL (≥1.55 mmol/L)\nLow\nHigh\nTriglycerides\n <150 mg/dL (<1.70 mmol/L)\n 150–199 mg/dL (1.70–2.25 mmol/L)\n 200–499 mg/dL (2.26–5.64 mmol/L)\n ≥500 mg/dL (≥5.65 mmol/L)\nNormal\nBorderline high\nHigh\nVery high\nHDL, high-density lipoprotein; LDL, low-density lipoprotein.",
    "word_count": 433,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0135",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 135,
    "text": "67\nDyslipidemia     CHAPTER 8 \n•\tDecisions\tregarding\tclassification\tand\tmanagement\tare\tbased\ton\tthe\tLDL\tcholesterol\t\nlevels\tlisted\tin\tTable 8–3.\n•\tFour\trisk\tcategories\tmodify\tthe\tgoals\tand\tmodalities\tof\tLDL-lowering\ttherapy:\n1.\t \tHighest\trisk\t=\tKnown\tCHD\tor\tCHD\trisk\tequivalents;\trisk\tfor\tcoronary\tevents\tis\t\nat\tleast\tas\thigh\tas\tfor\testablished\tCHD\t(ie,\t>20%\tper\t10\tyears,\tor\t2%\tper\tyear).\n2.\t \tModerately\thigh\trisk\t=\t2\tor\tmore\trisk\tfactors\tin\twhich\t10-year\trisk\tfor\tCHD\tis\t\n10%\tto\t20%.\n TABLE 8–2  Major Risk Factors (Exclusive of LDL Cholesterol) That Modify LDL Goalsa\nAge\n Men: ≥45 years\n Women: ≥55 years or premature menopause without estrogen replacement therapy\nFamily history of premature CHD (definite myocardial infarction or sudden death before 55 \nyears of age  \nin father or other male first-degree relative or before 65 years of age in mother or other \nfemale  \nfirst-degree relative)\nCigarette smoking\nHypertension (≥140/90 mm Hg or on antihypertensive medication)\nLow HDL cholesterol (<40 mg/dL [<1.03 mmol/L])b\nCHD, coronary heart disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.\na Diabetes is regarded as a CHD risk equivalent.\nb HDL cholesterol (≥60 mg/dL [≥1.55 mmol/L]) counts as a “negative”  risk factor; its presence removes \none risk factor from the total count.\n TABLE 8–3   LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLCs) and \nDrug Therapy in Different Risk Categories\nRisk Category\nLDL Goal, mg/\ndL (mmol/L)\nLDL Level \nat Which \nto Initiate \nTLC, mg/dL \n(mmol/L)\nLDL Level at Which to \nConsider Drug Therapy, \nmg/dL (mmol/L)\nHigh risk: CHD or CHD risk \nequivalents (10-year risk \n>20%)\n<100 (<2.59)\n(optional goal: \n<70 [<1.81])\n≥100 (≥2.59) ≥100 (≥2.59)\n(<100 [<2.59]: consider \ndrug options)a\nModerately high risk: 2+ \nrisk factors (10-year risk \n10–20%)\n<130 (<3.36) ≥130 (≥3.36) ≥130 (≥3.36)\n(100-129 [2.59–3.35):  \nconsider drug options)\nModerate risk: 2+ risk fac-\ntors (10-year risk <10%)\n<130 (<3.36) ≥130 (≥3.36) ≥160 (≥4.14)\nLower risk: 0 or 1 risk factor b <160 (<4.14) ≥160 (≥4.14) ≥190 (≥4.91)\n(160-189 [4.14–4.90]: LDL-\nlowering drug optional)\nCHD, coronary heart disease; LDL, low-density lipoprotein.\naSome authorities recommend use of LDL-lowering drugs in this category if LDL cholesterol <100 \nmg/dL (<2.59 mmol/L) cannot be achieved by TLC. Others prefer to use drugs that primarily \nmodify triglycerides and HDL (eg, nicotinic acid or fibrates).",
    "word_count": 377,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0136",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 136,
    "text": "Others prefer to use drugs that primarily \nmodify triglycerides and HDL (eg, nicotinic acid or fibrates). Clinical judgment also may call for \ndeferring drug therapy in this subcategory.\nbAlmost all people with zero or one risk factor have a 10-year risk less than 10%; thus, 10-year risk \nassessment in people with zero or 1 risk factor is not necessary.",
    "word_count": 59,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0137",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 137,
    "text": "68\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0138",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 138,
    "text": "68\nSECTION 2     Cardiovascular Disorders\n3.\t \tModerate\trisk\t=\t2\tor\tmore\trisk\tfactors\tand\ta\t10-year\trisk\tof\t10%\tor\tless.\n4.\t \tLowest\trisk\t=\t0\tto\t1\trisk\tfactor,\twhich\tis\tusually\tassociated\twith\ta\t10-year\tCHD\t\nrisk\tof\tless\tthan\t10%.\n•\tNote:\t New\t cholesterol\t treatment\t guidelines\t issued\t in\t late\t 2013\t are\t not\t considered\t\nhere.\nNONPHARMACOLOGIC THERAPY\n•\tBegin\ttherapeutic\tlifestyle\tchanges\t(TLCs)\ton\tthe\tfirst\tvisit,\tincluding\tdietary\ttherapy,\t\nweight\treduction,\tand\tincreased\tphysical\tactivity.\tAdvise\toverweight\tpatients\tto\tlose\t\n10%\tof\tbody\tweight.\tEncourage\tphysical\tactivity\tof\tmoderate\tintensity\t30\tminutes\ta\tday\t\nfor\t most\t days\t of\t the\t week.\t Assist\t patients\t with\t smoking\t cessation\t and\t control\t of\t\nhypertension.\n•\tThe\t objectives\t of\t dietary\t therapy\t are\t to\t progressively\t decrease\t intake\t of\t total\t fat,\t\nsaturated\tfat,\tand\tcholesterol\tand\tto\tachieve\ta\tdesirable\tbody\tweight\t(Table 8–4).\n•\tIncreased\t intake\t of\t soluble\tfiber\t(oat\tbran,\t pectins,\tpsyllium)\tcan\treduce\ttotal\tand\t\nLDL\tcholesterol\tby\t5%\tto\t20%.\tHowever,\tthey\thave\tlittle\teffect\ton\tHDL-C\tor\ttriglyc-\nerides.\tFiber\tproducts\tmay\talso\tbe\tuseful\tin\tmanaging\tconstipation\tassociated\twith\t\nbile\tacid\tresins\t(BARs).\n•\tFish\t oil\t supplementation\t reduces\t triglycerides\t and\t VLDL-C,\t but\t it\t either\t has\t no\t\neffect\ton\ttotal\tand\tLDL-C\tor\tmay\televate\tthese\tfractions.\tOther\tactions\tof\tfish\toil\tmay\t\naccount\tfor\tany\tcardioprotective\teffects.\n•\tIngestion\tof\t2\tto\t3\tg\tdaily\tof\tplant\tsterols\treduces\tLDL\tby\t6%\tto\t15%.\tThey\tare\tusually\t\navailable\tin\tcommercial\tmargarines.\n•\tIf\tall\trecommended\tdietary\tchanges\twere\tinstituted,\tthe\testimated\taverage\treduction\t\nin\tLDL\twould\trange\tfrom\t20%\tto\t30%.\nPHARMACOLOGIC THERAPY\n•\tThe\teffect\tof\tdrug\ttherapy\ton\tlipids\tand\tlipoproteins\tis\tshown\tin\tTable 8–5.\n•\tRecommended\tdrugs\tof\tchoice\tfor\teach\tlipoprotein\tphenotype\tare\tgiven\tin\tT able 8–6.\n•\tAvailable\tproducts\tand\ttheir\tdoses\tare\tprovided\tin\tTable 8–7.\nBile Acid Resins\n•\tBARs\t (cholestyramine,\t colestipol,\t colesevelam)\t bind\t bile\t acids\t in\t the\t intestinal\t\nlumen,\t with\t a\t concurrent\t interruption\t of\t enterohepatic\t circulation\t of\t bile\t acids,\t\nwhich\tdecreases\tthe\tbile\tacid\tpool\tsize\tand\tstimulates\thepatic\tsynthesis\tof\tbile\tacids\t\nfrom\tcholesterol.\tDepletion\tof\tthe\thepatic\tcholesterol\tpool\tincreases\tcholesterol\tbio-\nsynthesis\tand\tthe\tnumber\tof\tLDL-Rs\ton\thepatocyte\tmembranes,\twhich\tenhances\tthe\t\n TABLE 8–4  Macronutrient Recommendations for the Therapeutic Lifestyle Change (TLC) Diet\nComponenta Recommended Intake\nTotal fat 25–35% of total calories\nSaturated fat\n Polyunsaturated fat\n Monounsaturated fat\n<7% of total calories\nUp to 10% of total calories\nUp to 20% of total calories\nCarbohydratesb 50–60% of total calories\nCholesterol <200 mg/day\nDietary fiber 20–30 g/day\nPlant sterols 2 g/day\nProtein ~15% of total calories\nTotal calories To achieve and maintain desirable body weight\naCalories from alcohol not included.\nbCarbohydrates should derive from foods rich in complex carbohydrates, such as whole grains, fruits, \nand vegetables.",
    "word_count": 461,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0139",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 139,
    "text": "69\nDyslipidemia  |  CHAPTER 8 \n TABLE 8–5  Effects of Drug Therapy on Lipids and Lipoproteins\nDrug Mechanism of Action\nEffects on \nLipids\nEffects on \nLipoproteins\nCholestyramine, colestipol, \nand colesevelam\n↑ LDL catabolism\n↓ Cholesterol absorption\n↓ Cholesterol ↓ LDL\n↑ VLDL\nNiacin ↓ LDL and VLDL synthesis ↓ Triglyceride\n↓ Cholesterol\n↓ VLDL\n↓ LDL\n↑ HDL\nGemfibrozil, fenofibrate, \nand clofibrate\n↑ VLDL clearance\n↓ VLDL synthesis\n↓ Triglyceride\n↓ Cholesterol\n↓ VLDL\n↓ LDL\n↑ HDL\nLovastatin, pravastatin, \nsimvastatin, fluvastatin, \natorvastatin, and  \nrosuvastatin\n↑ LDL catabolism\n↓ LDL synthesis\n↓ Cholesterol ↓ LDL\nMipomersen Inhibits apolipoprotein \nB-100 synthesis\n↓ Cholesterol ↓ LDL, non-HDL\nLomitapide Inhibits microsomal \ntriglyceride transfer \nprotein\n↓ Cholesterol ↓ LDL, non-HDL\nEzetimibe Blocks cholesterol \nabsorption across the \nintestinal border\n↓ Cholesterol ↓ LDL\n↑, increased; ↓, decreased.\n TABLE 8–6  Lipoprotein Phenotype and Recommended Drug Treatment\nLipoprotein Type Drug of Choice Combination Therapy\nI Not indicated –\nIIa Statins\nCholestyramine or colestipol\nNiacin\nEzetimibe\nNiacin or BARs\nStatins or niacin\nStatins or BARs\nIIb Statins\nFibrates\nNiacin\nEzetimibe\nBARs, fibrates, or niacin\nStatins, niacin, or BARsa\nStatins or fibrates\nIII Fibrates\nNiacin\nEzetimibe\nStatins or niacin\nStatins or fibrates\nIV Fibrates\nNiacin\nNiacin\nFibrates\nV Fibrates\nNiacin\nNiacin\nFish oils\nBARs, bile acid resins; fibrates include gemfibrozil or fenofibrate.\na BARs are not used as first-line therapy if triglycerides are elevated at baseline because hypertriglyc-\neridemia may worsen with BARs alone.",
    "word_count": 234,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0140",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 140,
    "text": "70\nSECTION 2  |  Cardiovascular Disorders\n TABLE 8–7  Comparison of Drugs Used in the Treatment of Dyslipidemiaa\nDrug Dosage Forms\nUsual Daily \nDose\nMaximum \nDaily Dose\nCholestyramine \n(Questran)\nBulk powder/4 g packets 8 g three times \ndaily\n32 g\nCholestyramine \n(Cholybar)\n4 g resin per bar 8 g three times \ndaily\n32 g\nColestipol hydrochloride \n(Colestid)\nBulk powder/5 g packets 10 g twice daily 30 g\nColesevelam (Welchol) 625 mg tablets 1,875 mg twice \ndaily\n4,375 mg\nNiacin 50, 100, 250, and 500 mg tab -\nlets; 125, 250, and 500 mg \ncapsules\n0.5–1 g three \ntimes daily\n6 g\nExtended-release niacin \n(Niaspan)\n500, 750, and 1,000 mg tablets 1,000–2,000 mg \nonce daily\n2,000 mg\nExtended-release niacin \n+ lovastatin (Advicor)\nNiacin/lovastatin 500 mg/20 \nmg tablets\nNiacin/lovastatin 750 mg/20 \nmg tablets\nNiacin/lovastatin 1,000 mg/20 \nmg tablets\n500 mg/20 mg\n–\n–\n1,000 mg/20 \nmg\n–\n–\nFenofibrate (Tricor) 67, 134, and 200 mg capsules \n(micronized); 54 and 160 \nmg tablets; 40 and 120 mg \ntablets; 50 and 160 mg \ntablets\n54 mg or 67 mg 201 mg\nGemfibrozil (Lopid) 300 mg capsules 600 mg twice \ndaily\n1.5 g\nLovastatin (Mevacor) 20 and 40 mg tablets 20–40 mg 80 mg\nPravastatin (Pravachol) 10, 20, 40, and 80 mg tablets 10–20 mg 40 mg\nSimvastatin (Zocor) 5, 10, 20, 40, and 80 mg \ntablets\n10–20 mg 80 mg\nAtorvastatin (Lipitor) 10, 20, 40, and 80 mg tablets 10 mg 80 mg\nRosuvastatin (Crestor) 5, 10, 20, and 40 mg tablets 5 mg 40 mg\nPitavastatin (Livalo) 1, 2, and 4 mg tablets 2 mg 4 mg\nEzetimibe (Zetia) 10 mg tablet 10 mg 10 mg\nSimvastatin/ezetimibe \n(Vytorin)\nSimvastatin/ezetimibe 10 mg/ \n10 mg, 20 mg/10 mg,  \n40 mg/10 mg, and  \n80 mg/10 mg\nSimvastatin/ \nezetimibe  \n20 mg/10 mg\nSimvastatin/\nezetimibe 80 \nmg/10 mg\nLomitapide (Juxtapid) 5, 10, 20 mg capsules 5 mg initially, \nincreasing at  \n2 week \nintervals to \nresponse or \nmax dose\n60 mg\nMipomersen (Kynamro) 200 mg/mL for subcutaneous \ninjection\n200 mg subcuta-\nneously once \nweekly\n200 mg sub-\ncutaneously \nonce weekly\na This table does not include all drugs used for treating dyslipidemia.",
    "word_count": 352,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0141",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 141,
    "text": "71\nDyslipidemia  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0142",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 142,
    "text": "71\nDyslipidemia     CHAPTER 8 \nrate\tof\tcatabolism\tfrom\tplasma\tand\tlowers\tLDL\tlevels.\tIncreased\thepatic\tcholesterol\t\nbiosynthesis\tmay\tbe\tparalleled\tby\tincreased\thepatic\tVLDL\tproduction;\tconsequently,\t\nBARs\tmay\taggravate\thypertriglyceridemia\tin\tpatients\twith\tcombined\tdyslipidemia.\n•\tBARs\tare\tuseful\tin\ttreating\tprimary\thypercholesterolemia\t(familial\thypercholesterol-\nemia,\tfamilial\tcombined\tdyslipidemia,\tand\ttype\tIIa\thyperlipoproteinemia).\n•\tCommon\t GI\t complaints\t include\t constipation,\t bloating,\t epigastric\t fullness,\t nausea,\t\nand\tflatulence.\tThey\tcan\tbe\tmanaged\tby\tincreasing\tfluid\tintake,\tincreasing\tdietary\t\nbulk,\tand\tusing\tstool\tsofteners.\n•\tThe\t gritty\ttexture\tand\t bulk\tmay\t be\t minimized\t by\tmixing\tthe\tpowder\twith\t orange\t\ndrink\tor\tjuice.\tColestipol\tmay\thave\tbetter\tpalatability\tthan\tcholestyramine\tbecause\tit\t\nis\todorless\tand\ttasteless.\tTablet\tforms\tmay\thelp\timprove\tadherence.\n•\tOther\tpotential\tadverse\teffects\tinclude\timpaired\tabsorption\tof\tfat-soluble\tvitamins\tA,\tD,\t\nE,\tand\tK;\thypernatremia\tand\thyperchloremia;\tGI\tobstruction;\tand\treduced\tbioavail-\nability\t of\t acidic\t drugs\t such\t as\t warfarin,\t nicotinic\t acid,\t thyroxine,\t acetaminophen,\t\nhydrocortisone,\t hydrochlorothiazide,\t loperamide,\t and\t possibly\t iron.\t Drug\t interac-\ntions\tmay\tbe\tavoided\tby\talternating\tadministration\ttimes\twith\tan\tinterval\tof\t6\thours\t\nor\tmore\tbetween\tthe\tBARs\tand\tother\tdrugs.\nNiacin\n•\tNiacin\t (nicotinic\t acid)\t reduces\t hepatic\t synthesis\t of\t VLDL,\t which\t in\t turn\t reduces\t\nsynthesis\tof\tLDL.\tNiacin\talso\tincreases\tHDL\tby\treducing\tits\tcatabolism.\n•\tThe\t principal\t use\t of\t niacin\t is\t for\t mixed\t dyslipidemia\t or\t as\t a\t second-line\t agent\t in\t\ncombination\t therapy\tfor\thypercholesterolemia.\t It\t is\ta\tfirst-line\t agent\t or\t alternative\t\nfor\ttreatment\tof\thypertriglyceridemia\tand\tdiabetic\tdyslipidemia.\n•\tCutaneous\t flushing\t and\t itching\t appear\t to\t be\t prostaglandin\t mediated\t and\t can\t be\t\nreduced\tby\ttaking\taspirin\t325\tmg\tshortly\tbefore\tniacin\tingestion.\tTaking\tthe\tniacin\t\ndose\t with\t meals\t and\t slowly\t titrating\t the\t dose\t upward\t may\t minimize\t these\t effects.\t\nConcomitant\t alcohol\t and\t hot\t drinks\t may\t magnify\t the\t flushing\t and\t pruritus\t from\t\nniacin,\tand\tthey\tshould\tbe\tavoided\tat\tthe\ttime\tof\tingestion.\tGI\tintolerance\tis\talso\ta\t\ncommon\tproblem.\n•\tLaboratory\tabnormalities\t may\t include\t elevated\t liver\t function\t tests,\t hyperuricemia,\t\nand\t hyperglycemia.\t Niacin-associated\t hepatitis\t is\t more\t common\t with\t sustained-\nrelease\tpreparations,\tand\ttheir\tuse\tshould\tbe\trestricted\tto\tpatients\tintolerant\tof\treg-\nular-release\tproducts.\tNiacin\tis\tcontraindicated\tin\tpatients\twith\tactive\tliver\tdisease,\t\nand\tit\tmay\texacerbate\tpreexisting\tgout\tand\tdiabetes.\n•\tNiaspan\tis\ta\tprescription-only,\textended-release\tniacin\tformulation\twith\tpharmaco-\nkinetics\tintermediate\tbetween\tprompt-\tand\tsustained-release\tproducts.\tIt\thas\tfewer\t\ndermatologic\treactions\tand\ta\tlow\trisk\tof\thepatotoxicity.\tCombination\twith\tstatins\tcan\t\nproduce\tlarge\treductions\tin\tLDL\tand\tincreases\tin\tHDL.\n•\tNicotinamide\tshould\tnot\tbe\tused\tin\tthe\ttreatment\tof\tdyslipidemia\tbecause\tit\tdoes\tnot\t\neffectively\tlower\tcholesterol\tor\ttriglyceride\tlevels.\nHMG-CoA Reductase Inhibitors\n•\tStatins\t (atorvastatin,\t fluvastatin,\t lovastatin,\t pitavastatin,\t pravastatin,\t rosuvastatin,\t\nand\tsimvastatin)\tinhibit\t3-hydroxy-3-methylglutaryl\tcoenzyme\tA\t(HMG-CoA)\treduc-\ntase,\t interrupting\t conversion\t of\t HMG-CoA\t to\t mevalonate,\t the\t rate-limiting\t step\t in\t\ncholesterol\tbiosynthesis.\tReduced\tLD\tsynthesis\tand\tenhanced\tLDL\tcatabolism\tmediated\t\nthrough\tLDL-Rs\tappear\tto\tbe\tthe\tprincipal\tmechanisms\tfor\tlipid-lowering\teffects.\n•\tWhen\tused\tas\tmonotherapy,\tstatins\tare\tthe\tmost\tpotent\ttotal\tand\tLDL\tcholesterol–\nlowering\tagents\tand\tamong\tthe\tbest\ttolerated.\tT otal\tand\tLDL\tcholesterol\tare\treduced\t\nin\ta\tdose-related\tfashion\tby\t30%\tor\tmore\twhen\tadded\tto\tdietary\ttherapy.\n•\tCombination\ttherapy\twith\ta\tstatin\tand\ta\tBAR\tis\trational\tbecause\tthe\tnumbers\tof\tLDL-Rs\t\nare\tincreased,\tleading\tto\tgreater\tdegradation\tof\tLDL\tcholesterol;\tintracellular\tsynthesis\t\nof\tcholesterol\tis\tinhibited;\tand\tenterohepatic\trecycling\tof\tbile\tacids\tis\tinterrupted.\n•\tCombination\ttherapy\twith\ta\tstatin\tand\tezetimibe\tis\talso\trational\tbecause\tezetimibe\t\ninhibits\tcholesterol\tabsorption\tacross\tthe\tgut\tborder\tand\tadds\t12%\tto\t20%\tfurther\t\nreduction\twhen\tcombined\twith\ta\tstatin\tor\tother\tdrug.",
    "word_count": 589,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0143",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 143,
    "text": "72\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0144",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 144,
    "text": "72\nSECTION 2     Cardiovascular Disorders\n•\tConstipation\toccurs\tin\tless\tthan\t10%\tof\tpatients\ttaking\tstatins.\tOther\tadverse\teffects\t\ninclude\televated\talanine\taminotransferase,\televated\tcreatine\tkinase\tlevels,\tmyopathy,\t\nand,\trarely,\trhabdomyolysis.\nFibric Acids\n•\tFibrate\t monotherapy\t(gemfibrozil,\tfenofibrate,\tclofibrate)\tis\teffective\t in\treducing\t\nVLDL,\t but\t a\t reciprocal\t rise\t in\t LDL\t may\t occur,\t and\t total\t cholesterol\t values\t may\t\nremain\t relatively\tunchanged.\t Plasma\t HDL\tconcentrations\tmay\trise\t10%\tto\t15%\tor\t\nmore\twith\tfibrates.\n•\tGemfibrozil\t reduces\t synthesis\t of\t VLDL\t and,\t to\t a\t lesser\t extent,\t apolipoprotein\t B\t\nwith\t a\t concurrent\t increase\t in\t the\t rate\t of\t removal\t of\t triglyceride-rich\t lipoproteins\t\t\nfrom\tplasma.\tClofibrate\tis\tless\teffective\tthan\tgemfibrozil\tor\tniacin\tin\treducing\tVLDL\t\nproduction.\n•\tGI\tcomplaints\toccur\tin\t3%\tto\t5%\tof\tpatients.\tRash,\tdizziness,\tand\ttransient\televations\t\nin\t transaminase\t levels\t and\t alkaline\t phosphatase\t may\t also\t occur.\t Gemfibrozil\t and\t\nprobably\tfenofibrate\tenhance\tgallstone\tformation\trarely.\n•\tA\tmyositis\tsyndrome\tof\tmyalgia,\tweakness,\tstiffness,\tmalaise,\tand\televations\tin\tcre-\natine\tkinase\tand\taspartate\taminotransferase\tmay\toccur\tand\tseems\tto\tbe\tmore\tcom-\nmon\tin\tpatients\twith\trenal\tinsufficiency.\n•\tFibrates\tmay\tpotentiate\tthe\teffects\tof\toral\tanticoagulants,\tand\tthe\tinternational\tnor-\nmalized\tratio\t(INR)\tshould\tbe\tmonitored\tvery\tclosely\twith\tthis\tcombination.\nEzetimibe\n•\tEzetimibe\t interferes\t with\t absorption\t of\t cholesterol\t from\t the\t brush\t border\t of\t the\t\nintestine,\t making\t it\t a\t good\t choice\t for\t adjunctive\t therapy.\t It\t is\t approved\t as\t mono-\ntherapy\tand\tfor\tuse\twith\ta\tstatin.\tThe\tdose\tis\t10\tmg\tonce\tdaily,\tgiven\twith\tor\twithout\t\nfood.\t When\t used\t alone,\t it\t results\t in\t ~18%\t reduction\t in\t LDL\t cholesterol.\t When\t\nadded\tto\ta\tstatin,\tezetimibe\tlowers\tLDL\tby\tan\tadditional\t12%\tto\t20%.\tA\tcombina-\ntion\t product\t (Vytorin)\t containing\t ezetimibe\t 10\t mg\t and\t simvastatin\t 10,\t 20,\t 40,\t or\t\n80\tmg\tis\tavailable.\tEzetimibe\tis\twell\ttolerated;\t~4%\tof\tpatients\texperience\tGI\tupset.\t\nBecause\tcardiovascular\toutcomes\twith\tezetimibe\thave\tnot\tbeen\tevaluated,\tit\tshould\t\nbe\treserved\tfor\tpatients\tunable\tto\ttolerate\tstatin\ttherapy\tor\tthose\twho\tdo\tnot\tachieve\t\nsatisfactory\tlipid\tlowering\twith\ta\tstatin\talone.\nFish Oil Supplementation\n•\tDiets\thigh\tin\tomega-3\tpolyunsaturated\tfatty\tacids\t(from\tfish\toil),\tmost\tcommonly\t\neicosapentaenoic\tacid\t(EPA),\treduce\tcholesterol,\ttriglycerides,\tLDL,\tand\tVLDL\tand\t\nmay\televate\tHDL\tcholesterol.\n•\tFish\toil\tsupplementation\tmay\tbe\tmost\tuseful\tin\tpatients\twith\thypertriglyceridemia,\t\nbut\tits\trole\tin\ttreatment\tis\tnot\twell\tdefined.\n•\tLOV AZA\t(omega-3-acid ethyl esters)\tis\ta\tprescription\tform\tof\tconcentrated\tfish\toil\t\nEPA\t465\tmg\tand\tdocosahexaenoic\tacid\t375\tmg.\tThe\tdaily\tdose\tis\t4\tg,\twhich\tcan\tbe\t\ntaken\tas\tfour\t1-g\tcapsules\tonce\tdaily\tor\ttwo\t1-g\tcapsules\ttwice\tdaily.\tThis\tproduct\t\nlowers\ttriglycerides\tby\t14%\tto\t30%\tand\traises\tHDL\tby\t~10%.\n•\tComplications\tof\tfish\toil\tsupplementation\tsuch\tas\tthrombocytopenia\tand\tbleeding\t\ndisorders\thave\tbeen\tnoted,\tespecially\twith\thigh\tdoses\t(EPA\t15–30\tg/day).\nTREATMENT RECOMMENDATIONS\n•\tTreatment\tof\ttype\tI\thyperlipoproteinemia\tis\tdirected\ttoward\treduction\tof\tchylomi-\ncrons\tderived\tfrom\tdietary\tfat\twith\tthe\tsubsequent\treduction\tin\tplasma\ttriglycerides.\t\nT otal\tdaily\tfat\tintake\tshould\tbe\tno\tmore\tthan\t10\tto\t25\tg,\tor\t~15%\tof\ttotal\tcalories.\t\nSecondary\t causes\t of\t hypertriglyceridemia\t should\t be\t excluded,\t and,\t if\t present,\t the\t\nunderlying\tdisorder\tshould\tbe\ttreated\tappropriately.\n•\tPrimary\t hypercholesterolemia\t (familial\t hypercholesterolemia,\t familial\t combined\t\ndyslipidemia,\t and\t type\t IIa\t hyperlipoproteinemia)\t is\t treated\t with\t BARs,\t statins,\t\nniacin,\tor\tezetimibe.",
    "word_count": 545,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0145",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 145,
    "text": "73\nDyslipidemia  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0146",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 146,
    "text": "73\nDyslipidemia     CHAPTER 8 \n•\tCombined\t hyperlipoproteinemia\t (type\t IIb)\tmay\tbe\ttreated\t with\tstatins,\t niacin,\t or\t\ngemfibrozil to\tlower\tLDL-C\twithout\televating\tVLDL\tand\ttriglycerides.\tNiacin\tis\tthe\t\nmost\teffective\tagent\tand\tmay\tbe\tcombined\twith\ta\tBAR.\tA\tBAR\talone\tin\tthis\tdisorder\t\nmay\televate\tVLDL\tand\ttriglycerides,\tand\ttheir\tuse\tas\tsingle\tagents\tfor\ttreating\tcom-\nbined\thyperlipoproteinemia\tshould\tbe\tavoided.\n•\tType\t III\t hyperlipoproteinemia\t may\t be\t treated\t with\t fibrates\t or\t niacin.\t Although\t\nfibrates\thave\tbeen\tsuggested\tas\tthe\tdrugs\tof\tchoice,\tniacin\tis\ta\treasonable\talternative\t\nbecause\tof\tthe\tlack\tof\tdata\tsupporting\ta\tcardiovascular\tmortality\tbenefit\tfrom\tfibrates\t\nand\tbecause\tof\tpotentially\tserious\tadverse\teffects.\tFish\toil\tsupplementation\tmay\tbe\t\nan\talternative\ttherapy.\n•\tType\tV\thyperlipoproteinemia\trequires\tstringent\trestriction\tof\tdietary\tfat\tintake.\tDrug\t\ntherapy\twith\tfibrates\tor\tniacin\tis\tindicated\tif\tthe\tresponse\tto\tdiet\talone\tis\tinadequate.\t\nMedium-chain triglycerides,\twhich\tare\tabsorbed\twithout\tchylomicron\tformation\tmay\t\nbe\tused\tas\ta\tdietary\tsupplement\tfor\tcaloric\tintake\tif\tneeded\tfor\tboth\ttypes\tI\tand\tV .\nCombination Drug Therapy\n•\tCombination\ttherapy\t may\t be\tconsidered\t after\tadequate\t trials\tof\tmonotherapy\tand\t\nfor\t patients\t documented\t to\t be\t adherent\t to\t the\t prescribed\t regimen.\t Two\t or\t three\t\nlipoprotein\tprofiles\tat\t6-week\tintervals\tshould\tconfirm\tthe\tlack\tof\tresponse\tprior\tto\t\ninitiation\tof\tcombination\ttherapy.\n•\tScreen\tcarefully\tfor\tcontraindications\tand\tdrug\tinteractions\twith\tcombined\ttherapy,\t\nand\tconsider\tthe\textra\tcost\tof\tdrug\tproduct\tand\tmonitoring.\n•\tIn\tgeneral,\ta\tstatin\tplus\ta\tBAR\tor\tniacin\tplus\ta\tBAR\tprovides\tthe\tgreatest\treduction\t\nin\ttotal\tand\tLDL\tcholesterol.\n•\tRegimens\tintended\tto\tincrease\tHDL\tlevels\tshould\tinclude\teither\tgemfibrozil\tor\tnia-\ncin,\tbearing\tin\tmind\tthat\tstatins\tcombined\twith\teither\tof\tthese\tdrugs\tmay\tresult\tin\ta\t\ngreater\tincidence\tof\thepatotoxicity\tor\tmyositis.\n•\tFamilial\tcombined\tdyslipidemia\tmay\trespond\tbetter\tto\ta\tfibrate\tand\ta\tstatin\tthan\tto\t\na\tfibrate\tand\ta\tBAR.\nTREATMENT OF HYPERTRIGLYCERIDEMIA\n•\tLipoprotein\tpattern\ttypes\tI,\tIII,\tIV ,\tand\tV\tare\tassociated\twith\thypertriglyceridemia,\t\nand\tthese\tprimary\tlipoprotein\tdisorders\tshould\tbe\texcluded\tprior\tto\timplementing\t\ntherapy.\n•\tA\t family\t history\t positive\t for\t CHD\t is\t important\t in\t identifying\t patients\t at\t risk\t for\t\npremature\tatherosclerosis.\tIf\ta\tpatient\twith\tCHD\thas\televated\ttriglycerides,\tthe\tasso-\nciated\tabnormality\tis\tprobably\ta\tcontributing\tfactor\tto\tCHD\tand\tshould\tbe\ttreated.\n•\tHigh\t serum\t triglycerides\t (see\t Table 8–1 )\t should\t be\t treated\t by\t achieving\t desirable\t\nbody\tweight,\tconsumption\tof\ta\tlow\tsaturated\tfat\tand\tcholesterol\tdiet,\tregular\texercise,\t\nsmoking\tcessation,\tand\trestriction\tof\talcohol\t(in\tselect\tpatients).\n•\tThe\t sum\t of\t LDL\t and\t VLDL\t (termed\t non-HDL\t [total\t cholesterol\t –\t HDL])\t is\t a\t\nsecondary\t therapeutic\t target\t in\t persons\t with\t high\t triglycerides\t (≥200\t mg/dL\t\n[≥2.26\t mmol/L).\t The\t goal\t for\t non-HDL\t with\t high\t serum\t triglycerides\t is\t set\t at\t 30\t\nmg/dL\t(0.78\tmmol/L)\thigher\tthan\tthat\tfor\tLDL\ton\tthe\tpremise\tthat\ta\tVLDL\tlevel\tless\t\nthan\tor\tequal\tto\t30\tmg/dL\t(0.78\tmmol/L)\tis\tnormal.\n•\tDrug\t therapy\t with\t niacin\t should\t be\t considered\t in\t patients\t with\t borderline-high\t\ntriglycerides\t but\t with\t risk\tfactors\t of\t established\t CHD,\t family\t history\t of\t premature\t\nCHD,\t concomitant\t LDL\t elevation\t or\t low\tHDL,\t and\t genetic\t forms\t of\t hypertriglyc-\neridemia\t associated\t with\t CHD.\t Alternative\t therapies\t include\t gemfibrozil\t or\t feno-\nfibrate,\tstatins,\tand\tfish\toil.\tThe\tgoal\tof\ttherapy\tis\tto\tlower\ttriglycerides\tand\tVLDL\t\nparticles\tthat\tmay\tbe\tatherogenic,\tincrease\tHDL,\tand\treduce\tLDL.\n•\tV ery\t high\t triglycerides\t are\t associated\t with\t pancreatitis\t and\t other\t adverse\t conse-\nquences.\t Management\t includes\t dietary\t fat\t restriction\t (10–20%\t of\t calories\t as\t fat),\t\nweight\tloss,\talcohol\trestriction,\tand\ttreatment\tof\tcoexisting\tdisorders\t(eg,\tdiabetes).\t\nDrug\t therapy\t includes\t gemfibrozil\t or\t fenofibrate,\t niacin,\t and\t higher-potency\t\nstatins\t(atorvastatin,\tpitavastatin,\trosuvastatin,\tand\tsimvastatin).\tSuccessful\ttreat-\nment\tis\tdefined\tas\treduction\tin\ttriglycerides\tto\tless\tthan\t500\tmg/dL\t(5.65\tmmol/L).",
    "word_count": 621,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0147",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 147,
    "text": "74\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0148",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 148,
    "text": "74\nSECTION 2     Cardiovascular Disorders\nTREATMENT OF LOW HDL CHOLESTEROL\n•\tLow\tHDL\tcholesterol\tis\ta\tstrong\tindependent\trisk\tpredictor\tof\tCHD.\tATP\tIII\trede-\nfined\tlow\tHDL\tcholesterol\tas\tless\tthan\t40\tmg/dL\t(<1.03\tmmol/L)\tbut\tspecified\tno\t\ngoal\tfor\tHDL\traising.\tIn\tlow\tHDL,\tthe\tprimary\ttarget\tremains\tLDL,\tbut\ttreatment\t\nemphasis\tshifts\tto\tweight\treduction,\tincreased\tphysical\tactivity,\tand\tsmoking\tcessa-\ntion,\tand\tto\tfibrates\tand\tniacin\tif\tdrug\ttherapy\tis\trequired.\nTREATMENT OF DIABETIC DYSLIPIDEMIA\n•\tDiabetic\tdyslipidemia\tis\tcharacterized\tby\thypertriglyceridemia,\tlow\tHDL,\tand\tmini-\nmally\t elevated\t LDL.\t Small,\t dense\t LDL\t (pattern\t B)\t in\t diabetes\t is\t more\t atherogenic\t\nthan\tlarger,\tmore\tbuoyant\tforms\tof\tLDL\t(pattern\tA).\n•\tATP\tIII\tconsiders\tdiabetes\tto\tbe\ta\tCHD\trisk\tequivalent,\tand\tthe\tprimary\ttarget\tis\tto\t\nlower\tthe\tLDL\tto\tless\tthan\t100\tmg/dL\t(<2.59\tmmol/L).\tWhen\tLDL\tis\tgreater\tthan\t130\t\nmg/dL\t(>3.36\tmmol/L),\tmost\tpatients\trequire\tsimultaneous\tTLCs\tand\tdrug\ttherapy.\t\nWhen\tLDL\tis\tbetween\t100\tand\t129\tmg/dL\t(2.59\tand\t3.34\tmmol/L),\tintensifying\tgly-\ncemic\tcontrol,\tadding\tdrugs\tfor\tatherogenic\tdyslipidemia\t(fibrates\tand\tniacin)\tand\t\nintensifying\tLDL-lowering\ttherapy\tare\toptions.\tStatins\tare\tconsidered\tby\tmany\tto\tbe\t\nthe\tdrugs\tof\tchoice\tbecause\tthe\tprimary\ttarget\tis\tLDL.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tShort-term\tevaluation\tof\ttherapy\tfor\tdyslipidemia\tis\tbased\ton\tresponse\tto\tdiet\tand\t\ndrug\ttreatment\tas\tmeasured\tby\ttotal\tcholesterol,\tLDL-C,\tHDL-C,\tand\ttriglycerides.\n•\tMany\tpatients\ttreated\tfor\tprimary\tdyslipidemia\thave\tno\tsymptoms\tor\tclinical\tmani-\nfestations\tof\ta\tgenetic\tlipid\tdisorder\t(eg,\txanthomas),\tand\tmonitoring\tmay\tbe\tsolely\t\nlaboratory\tbased.\n•\tIn\tpatients\ttreated\tfor\tsecondary\tintervention,\tsymptoms\tof\tatherosclerotic\tcardio-\nvascular\t disease,\t such\t as\t angina\t and\t intermittent\t claudication,\t may\t improve\t over\t\nmonths\tto\tyears.\tXanthomas\tor\tother\texternal\tmanifestations\tof\tdyslipidemia\tshould\t\nregress\twith\ttherapy.\n•\tObtain\tlipid\tmeasurements\tin\tthe\tfasting\tstate\tto\tminimize\tinterference\tfrom\tchylo-\nmicrons.\tMonitoring\tis\tneeded\tevery\tfew\tmonths\tduring\tdosage\ttitration.\tOnce\tthe\t\npatient\tis\tstable,\tmonitoring\tat\tintervals\tof\t6\tmonths\tto\t1\tyear\tis\tsufficient.\n•\tPatients\ton\tBAR\ttherapy\tshould\thave\ta\tfasting\tpanel\tchecked\tevery\t4\tto\t8\tweeks\tuntil\t\na\tstable\tdose\tis\treached;\tcheck\ttriglycerides\tat\ta\tstable\tdose\tto\tensure\tthey\thave\tnot\t\nincreased.\n•\tNiacin\t requires\t baseline\t tests\t of\t liver\t function\t (alanine\t aminotransferase),\t uric\t\nacid,\t and\t glucose.\t Repeat\t tests\t are\t appropriate\t at\t doses\t of\t 1,000\t to\t 1,500\t mg/day.\t\nSymptoms\tof\tmyopathy\tor\tdiabetes\tshould\tbe\tinvestigated\tand\tmay\trequire\tcreatine\t\nkinase\tor\tglucose\tdeterminations.\tPatients\twith\tdiabetes\tmay\trequire\tmore\tfrequent\t\nmonitoring.\n•\tPatients\treceiving\tstatins\tshould\thave\ta\tfasting\tlipid\tpanel\t4\tto\t8\tweeks\tafter\tthe\tinitial\t\ndose\tor\tdose\tchanges.\tObtain\tliver\tfunction\ttests\tat\tbaseline\tand\tperiodically\tthere-\nafter.\tSome\texperts\tbelieve\tthat\tmonitoring\tfor\thepatotoxicity\tand\tmyopathy\tshould\t\nbe\ttriggered\tby\tsymptoms.\n•\tFor\t patients\t with\t multiple\t risk\t factors\t and\t established\t CHD,\t evaluate\t for\t progress\t\nin\tmanaging\tother\trisk\tfactors\tsuch\tas\tBP\tcontrol,\tsmoking\tcessation,\texercise\tand\t\nweight\tcontrol,\tand\tglycemic\tcontrol\t(if\tdiabetic).\n•\tEvaluation\tof\tdietary\ttherapy\twith\tdiet\tdiaries\tand\trecall\tsurvey\tinstruments\tallows\t\ninformation\t about\t diet\t to\t be\t collected\t in\t a\t systematic\t fashion\t and\t may\t improve\t\npatient\tadherence\tto\tdietary\trecommendations.\nSee Chapter 11, Dyslipidemia, authored by Robert L.",
    "word_count": 535,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0149",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 149,
    "text": "  Cardiovascular Disorders\nTREATMENT OF LOW HDL CHOLESTEROL\n•\tLow\tHDL\tcholesterol\tis\ta\tstrong\tindependent\trisk\tpredictor\tof\tCHD.\tATP\tIII\trede-\nfined\tlow\tHDL\tcholesterol\tas\tless\tthan\t40\tmg/dL\t(<1.03\tmmol/L)\tbut\tspecified\tno\t\ngoal\tfor\tHDL\traising.\tIn\tlow\tHDL,\tthe\tprimary\ttarget\tremains\tLDL,\tbut\ttreatment\t\nemphasis\tshifts\tto\tweight\treduction,\tincreased\tphysical\tactivity,\tand\tsmoking\tcessa-\ntion,\tand\tto\tfibrates\tand\tniacin\tif\tdrug\ttherapy\tis\trequired.\nTREATMENT OF DIABETIC DYSLIPIDEMIA\n•\tDiabetic\tdyslipidemia\tis\tcharacterized\tby\thypertriglyceridemia,\tlow\tHDL,\tand\tmini-\nmally\t elevated\t LDL.\t Small,\t dense\t LDL\t (pattern\t B)\t in\t diabetes\t is\t more\t atherogenic\t\nthan\tlarger,\tmore\tbuoyant\tforms\tof\tLDL\t(pattern\tA).\n•\tATP\tIII\tconsiders\tdiabetes\tto\tbe\ta\tCHD\trisk\tequivalent,\tand\tthe\tprimary\ttarget\tis\tto\t\nlower\tthe\tLDL\tto\tless\tthan\t100\tmg/dL\t(<2.59\tmmol/L).\tWhen\tLDL\tis\tgreater\tthan\t130\t\nmg/dL\t(>3.36\tmmol/L),\tmost\tpatients\trequire\tsimultaneous\tTLCs\tand\tdrug\ttherapy.\t\nWhen\tLDL\tis\tbetween\t100\tand\t129\tmg/dL\t(2.59\tand\t3.34\tmmol/L),\tintensifying\tgly-\ncemic\tcontrol,\tadding\tdrugs\tfor\tatherogenic\tdyslipidemia\t(fibrates\tand\tniacin)\tand\t\nintensifying\tLDL-lowering\ttherapy\tare\toptions.\tStatins\tare\tconsidered\tby\tmany\tto\tbe\t\nthe\tdrugs\tof\tchoice\tbecause\tthe\tprimary\ttarget\tis\tLDL.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tShort-term\tevaluation\tof\ttherapy\tfor\tdyslipidemia\tis\tbased\ton\tresponse\tto\tdiet\tand\t\ndrug\ttreatment\tas\tmeasured\tby\ttotal\tcholesterol,\tLDL-C,\tHDL-C,\tand\ttriglycerides.\n•\tMany\tpatients\ttreated\tfor\tprimary\tdyslipidemia\thave\tno\tsymptoms\tor\tclinical\tmani-\nfestations\tof\ta\tgenetic\tlipid\tdisorder\t(eg,\txanthomas),\tand\tmonitoring\tmay\tbe\tsolely\t\nlaboratory\tbased.\n•\tIn\tpatients\ttreated\tfor\tsecondary\tintervention,\tsymptoms\tof\tatherosclerotic\tcardio-\nvascular\t disease,\t such\t as\t angina\t and\t intermittent\t claudication,\t may\t improve\t over\t\nmonths\tto\tyears.\tXanthomas\tor\tother\texternal\tmanifestations\tof\tdyslipidemia\tshould\t\nregress\twith\ttherapy.\n•\tObtain\tlipid\tmeasurements\tin\tthe\tfasting\tstate\tto\tminimize\tinterference\tfrom\tchylo-\nmicrons.\tMonitoring\tis\tneeded\tevery\tfew\tmonths\tduring\tdosage\ttitration.\tOnce\tthe\t\npatient\tis\tstable,\tmonitoring\tat\tintervals\tof\t6\tmonths\tto\t1\tyear\tis\tsufficient.\n•\tPatients\ton\tBAR\ttherapy\tshould\thave\ta\tfasting\tpanel\tchecked\tevery\t4\tto\t8\tweeks\tuntil\t\na\tstable\tdose\tis\treached;\tcheck\ttriglycerides\tat\ta\tstable\tdose\tto\tensure\tthey\thave\tnot\t\nincreased.\n•\tNiacin\t requires\t baseline\t tests\t of\t liver\t function\t (alanine\t aminotransferase),\t uric\t\nacid,\t and\t glucose.\t Repeat\t tests\t are\t appropriate\t at\t doses\t of\t 1,000\t to\t 1,500\t mg/day.\t\nSymptoms\tof\tmyopathy\tor\tdiabetes\tshould\tbe\tinvestigated\tand\tmay\trequire\tcreatine\t\nkinase\tor\tglucose\tdeterminations.\tPatients\twith\tdiabetes\tmay\trequire\tmore\tfrequent\t\nmonitoring.\n•\tPatients\treceiving\tstatins\tshould\thave\ta\tfasting\tlipid\tpanel\t4\tto\t8\tweeks\tafter\tthe\tinitial\t\ndose\tor\tdose\tchanges.\tObtain\tliver\tfunction\ttests\tat\tbaseline\tand\tperiodically\tthere-\nafter.\tSome\texperts\tbelieve\tthat\tmonitoring\tfor\thepatotoxicity\tand\tmyopathy\tshould\t\nbe\ttriggered\tby\tsymptoms.\n•\tFor\t patients\t with\t multiple\t risk\t factors\t and\t established\t CHD,\t evaluate\t for\t progress\t\nin\tmanaging\tother\trisk\tfactors\tsuch\tas\tBP\tcontrol,\tsmoking\tcessation,\texercise\tand\t\nweight\tcontrol,\tand\tglycemic\tcontrol\t(if\tdiabetic).\n•\tEvaluation\tof\tdietary\ttherapy\twith\tdiet\tdiaries\tand\trecall\tsurvey\tinstruments\tallows\t\ninformation\t about\t diet\t to\t be\t collected\t in\t a\t systematic\t fashion\t and\t may\t improve\t\npatient\tadherence\tto\tdietary\trecommendations.\nSee Chapter 11, Dyslipidemia, authored by Robert L. Talbert, for a more detailed discus-\nsion of this topic.",
    "word_count": 542,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0150",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 150,
    "text": "75\n•\tHeart failure\t(HF)\tis\ta\tprogressive\tclinical\tsyndrome\tcaused\tby\tinability\tof\tthe\theart\t\nto\tpump\tsufficient\tblood\tto\tmeet\tthe\tbody’ s\tmetabolic\tneeds.\tHF\tcan\tresult\tfrom\tany\t\ndisorder\t that\t reduces\t ventricular\t filling\t (diastolic\t dysfunction)\t and/or\t myocardial\t\ncontractility\t(systolic\tdysfunction).\nPATHOPHYSIOLOGY\n•\tCauses\tof\tsystolic\tdysfunction\t(decreased\tcontractility)\tare\treduced\tmuscle\tmass\t(eg,\t\nmyocardial\tinfarction\t[MI]),\tdilated\tcardiomyopathies,\tand\tventricular\thypertrophy.\t\nV entricular\thypertrophy\tcan\tbe\tcaused\tby\tpressure\toverload\t(eg,\tsystemic\tor\tpulmo-\nnary\t hypertension\t and\t aortic\t or\t pulmonic\t valve\t stenosis)\t or\t volume\t overload\t (eg,\t\nvalvular\tregurgitation,\tshunts,\thigh-output\tstates).\n•\tCauses\tof\tdiastolic\tdysfunction\t(restriction\tin\tventricular\tfilling)\tare\tincreased\tven-\ntricular\t stiffness,\t ventricular\t hypertrophy,\t infiltrative\t myocardial\t diseases,\t myocar-\ndial\tischemia\tand\tMI,\tmitral\tor\ttricuspid\tvalve\tstenosis,\tand\tpericardial\tdisease\t(eg,\t\npericarditis\tand\tpericardial\ttamponade).\n•\tThe\tleading\tcauses\tof\tHF\tare\tcoronary\tartery\tdisease\tand\thypertension.\n•\tAs\tcardiac\tfunction\tdecreases\tafter\tmyocardial\tinjury,\tthe\theart\trelies\ton\tcompensa-\ntory\t mechanisms:\t (1)\t tachycardia\t and\t increased\t contractility\t through\t sympathetic\t\nnervous\t system\t activation;\t (2)\t the\t Frank–Starling\t mechanism,\t whereby\t increased\t\npreload\tincreases\tstroke\tvolume;\t(3)\tvasoconstriction;\tand\t(4)\tventricular\thypertro-\nphy\t and\t remodeling.\t Although\t these\t compensatory\t mechanisms\t initially\t maintain\t\ncardiac\t function,\t they\t are\t responsible\t for\t the\t symptoms\t of\t HF\t and\t contribute\t to\t\ndisease\tprogression.\n•\tIn\t the\t neurohormonal model \t of\t HF ,\t an\t initiating\t event\t (eg,\t acute\t MI)\t leads\t to\t\ndecreased\t cardiac\t output;\t the\t HF\t state\t then\t becomes\t a\t systemic\t disease\t whose\t\nprogression\tis\tmediated\tlargely\tby\tneurohormones\tand\tautocrine/paracrine\tfactors.\t\nThese\t substances\t include\t angiotensin\t II,\t norepinephrine,\t aldosterone,\t natriuretic\t\npeptides,\targinine\tvasopressin,\tendothelin\tpeptides,\tand\tother\tcirculating\tbiomarkers\t\n(eg,\tC-reactive\tprotein).\n•\tCommon\tprecipitating\tfactors\tthat\tmay\tcause\ta\tpreviously\tcompensated\tHF\tpatient\t\nto\tdecompensate\tinclude\tmyocardial\tischemia\tand\tMI,\tatrial\tfibrillation,\tpulmonary\t\ninfections,\t nonadherence\t with\t diet\t or\t drug\t therapy,\t and\t inappropriate\t medication\t\nuse.\t Drugs\t may\t precipitate\t or\t exacerbate\t HF\t because\t of\t their\t negative\t inotropic,\t\ncardiotoxic,\tor\tsodium-\tand\twater-retaining\tproperties.\nCLINICAL PRESENTATION\n•\tPatient\tpresentation\tmay\trange\tfrom\tasymptomatic\tto\tcardiogenic\tshock.\n•\tPrimary\t symptoms\t are\t dyspnea\t (particularly\t on\t exertion)\t and\t fatigue,\t which\t lead\t\nto\texercise\tintolerance.\tOther\tpulmonary\tsymptoms\tinclude\torthopnea,\tparoxysmal\t\nnocturnal\tdyspnea,\ttachypnea,\tand\tcough.\n•\tFluid\toverload\tcan\tresult\tin\tpulmonary\tcongestion\tand\tperipheral\tedema.\n•\tNonspecific\tsymptoms\tmay\tinclude\tfatigue,\tnocturia,\themoptysis,\tabdominal\tpain,\t\nanorexia,\tnausea,\tbloating,\tascites,\tpoor\tappetite,\tmental\tstatus\tchanges,\tand\tweight\t\ngain.\n•\tPhysical\t examination\t findings\t may\t include\t pulmonary\t crackles,\t S3\t gallop,\t cool\t\nextremities,\tCheyne–Stokes\trespiration,\ttachycardia,\tnarrow\tpulse\tpressure,\tcardio-\nmegaly,\tsymptoms\tof\tpulmonary\tedema\t(extreme\tbreathlessness\tand\tanxiety,\tsome-\ntimes\t with\t coughing\t and\t pink,\t frothy\t sputum),\t peripheral\t edema,\t jugular\t venous\t\ndistention,\thepatojugular\treflux,\tand\thepatomegaly.\nHeart Failure\n9 \nC H A P T E R",
    "word_count": 442,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0151",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 151,
    "text": "76\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0152",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 152,
    "text": "76\nSECTION 2     Cardiovascular Disorders\nDIAGNOSIS\n•\tConsider\t diagnosis\t of\t HF\t in\t patients\t with\t characteristic\t signs\t and\t symptoms.\t A\t\ncomplete\t history\t and\t physical\t examination\t with\t appropriate\t laboratory\t testing\t are\t\nessential\tin\tevaluating\tpatients\twith\tsuspected\tHF .\n•\tLaboratory\t tests\t for\t identifying\t disorders\t that\t may\t cause\t or\t worsen\t HF\t include\t\ncomplete\tblood\tcell\tcount;\tserum\telectrolytes\t(including\tcalcium\tand\tmagnesium);\t\nrenal,\thepatic,\tand\tthyroid\tfunction\ttests;\turinalysis;\tlipid\tprofile;\tand\tA1C.\tB-type\t\nnatriuretic\tpeptide\t(BNP)\twill\tgenerally\tbe\tgreater\tthan\t100\tpg/mL.\n•\tV entricular\thypertrophy\tcan\tbe\tdemonstrated\ton\tchest\tradiograph\tor\telectrocardio-\ngram\t(ECG).\tChest\tradiograph\tmay\talso\tshow\tpleural\teffusions\tor\tpulmonary\tedema.\n•\tEchocardiogram\t can\t identify\t abnormalities\t of\t the\t pericardium,\t myocardium,\t or\t\nheart\t valves\t and\t quantify\t left\t ventricular\t ejection\t fraction\t (LVEF)\t to\t determine\t if\t\nsystolic\tor\tdiastolic\tdysfunction\tis\tpresent.\n•\tThe\tNew\t Y ork\tHeart\tAssociation\tFunctional\tClassification\tSystem\tis\tintended\tpri-\nmarily\t to\t classify\t symptomatic\t HF\t patients\t according\t to\t the\t physician’ s\t subjective\t\nevaluation.\t Functional\t class\t (FC)-I\t patients\t have\t no\t limitation\t of\t physical\t activity,\t\nFC-II\t patients\t have\t slight\t limitation,\t FC-III\t patients\t have\t marked\t limitation,\t and\t\nFC-IV\tpatients\tare\tunable\tto\tcarry\ton\tphysical\tactivity\twithout\tdiscomfort.\n•\tThe\tAmerican\tCollege\tof\tCardiology/American\tHeart\tAssociation\t(ACC/AHA)\tstag-\ning\t system\t provides\t a\t more\t comprehensive\t framework\t for\t evaluating,\t preventing,\t\nand\ttreating\tHF\t(see\tfurther\tdiscussion\tbelow).\nTREATMENT OF CHRONIC HEART FAILURE\n•\tGoals\tof\tTreatment:\tImprove\tquality\tof\tlife,\trelieve\tor\treduce\tsymptoms,\tprevent\tor\t\nminimize\thospitalizations,\tslow\tdisease\tprogression,\tand\tprolong\tsurvival.\nGENERAL APPROACH\n•\tThe\t first\t step\t is\t to\t determine\t the\t etiology\t or\t precipitating\t factors.\t Treatment\t of\t\nunderlying\tdisorders\t(eg,\thyperthyroidism)\tmay\tobviate\tthe\tneed\tfor\ttreating\tHF .\n•\tNonpharmacologic\t interventions\t include\t cardiac\t rehabilitation\t and\t restriction\t of\t\nfluid\t intake\t (maximum\t 2\t L/day\t from\t all\t sources)\t and\t dietary\t sodium\t (<2–3\t g\t of\t\nsodium/day).\n•\tACC/AHA\tstage\tA:\tThese\tare\tpatients\tat\thigh\trisk\tfor\tdeveloping\theart\tfailure.\tThe\t\nemphasis\t is\t on\t identifying\t and\t modifying\t risk\t factors\t to\t prevent\t development\t of\t\nstructural\t heart\t disease\t and\t subsequent\t HF .\t Strategies\t include\t smoking\t cessation\t\nand\t control\t of\t hypertension,\t diabetes\t mellitus,\t and\t dyslipidemia.\t Although\t treat-\nment\t must\t be\t individualized,\t angiotensin-converting\t enzyme\t (ACE)\t inhibitors\t\nor\tangiotensin\treceptor blockers (ARBs) \tare\trecommended\tfor\tHF\tprevention\tin\t\npatients\twith\tmultiple\tvascular\trisk\tfactors.\n•\tACC/AHA stage B:\tIn\tthese\tpatients\twith\tstructural\theart\tdisease\tbut\tno\tHF\tsigns\t\nor\tsymptoms,\ttreatment\tis\ttargeted\tat\tminimizing\tadditional\tinjury\tand\tpreventing\t\nor\tslowing\tthe\tremodeling\tprocess.\tIn\taddition\tto\ttreatment\tmeasures\toutlined\tfor\t\nstage\tA,\tpatients\twith\ta\tprevious\tMI\tshould\treceive\tboth\tACE\tinhibitors\t(or\tARBs\t\nin\t patients\t intolerant\t of\t ACE\t inhibitors)\t and\t β -blockers\t regardless\t of\t the\t ejection\t\nfraction.\t Patients\t with\t reduced\t ejection\t fractions\t should\t also\t receive\t both\t agents,\t\nregardless\tof\twhether\tthey\thave\thad\tan\tMI.\n•\tACC/AHA stage C: \t These\t patients\t have\t structural\t heart\t disease\t and\t previous\t or\t\ncurrent\t HF\t symptoms.\t Most\t should\t receive\t the\t treatments\t for\t stages\t A\t and\t B,\t as\t\nwell\tas\tinitiation\tand\ttitration\tof\ta\tdiuretic\t(if\tclinical\tevidence\tof\tfluid\tretention),\t\nACE\tinhibitor,\tand\tβ -blocker\t(if\tnot\talready\treceiving\ta\tβ-blocker\tfor\tprevious\tMI,\t\nleft\t ventricular\t [LV]\t dysfunction,\t or\t other\t indication).\t If\t diuresis\t is\t initiated,\t and\t\nsymptoms\timprove\tonce\tthe\tpatient\tis\teuvolemic,\tlong-term\tmonitoring\tcan\tbegin.\t\nIf\t symptoms\t do\t not\t improve,\t an\t aldosterone\t receptor\t antagonist,\t ARB\t (in\t ACE\t\ninhibitor–intolerant\t patients),\t digoxin,\t and/or\t hydralazine/isosorbide dinitrate \t\n(ISDN)\t may\t be\t useful\t with\t carefully\t screened\t patients.\t Other\t general\t measures",
    "word_count": 562,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0153",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 153,
    "text": "77\nHeart Failure  |  CHAPTER 9 \ninclude\t moderate\t sodium\t restriction,\t daily\t weight\t measurement,\t immunization\t\nagainst\t influenza\t and\t pneumococcus,\t modest\t physical\t activity,\t and\t avoidance\t of\t\nmedications\tthat\tcan\texacerbate\tHF .\n•\tACC/AHA stage D: \t These\t are\t patients\t with\t refractory\t HF\t (ie,\t symptoms\t at\t rest\t\ndespite\tmaximal\tmedical\ttherapy).\tThey\tshould\tbe\tconsidered\tfor\tspecialized\tthera-\npies,\t including\t mechanical\t circulatory\t support,\t continuous\t IV\t positive\t inotropic\t\ntherapy,\tcardiac\ttransplantation,\tor\thospice\tcare\t(when\tno\tadditional\ttreatments\tare\t\nappropriate).\nPHARMACOLOGIC THERAPY\nDrug Therapies for Routine Use in Stage C Systolic Heart Failure\n(Fig. 9–1)\nDIURETICS\n•\tCompensatory\tmechanisms\tin\tHF\tstimulate\texcessive\tsodium\tand\twater\tretention,\t\noften\tleading\tto\tsystemic\tand\tpulmonary\tcongestion.\tConsequently,\tdiuretic\ttherapy\t\n(in\taddition\tto\tsodium\trestriction)\tis\trecommended\tfor\tall\tpatients\twith\tclinical\tevi-\ndence\tof\tfluid\tretention.\tHowever,\tbecause\tthey\tdo\tnot\talter\tdisease\tprogression\tor\t\nprolong\tsurvival,\tthey\tare\tnot\tmandatory\tfor\tpatients\twithout\tfluid\tretention.\n•\tThiazide\tdiuretics\t(eg,\thydrochlorothiazide)\tare\trelatively\tweak\tand\tare\tused\talone\t\ninfrequently\t in\t HF .\t However,\t thiazides\t or\t the\t thiazide-like\t diuretic\t metolazone\t\ncan\tbe\tused\tin\tcombination\twith\ta\tloop\tdiuretic\tto\tpromote\tvery\teffective\tdiuresis.\t\nThiazides\t may\t be\t preferred\t over\t loop\t diuretics\t in\t patients\t with\t only\t mild\t fluid\t\nStage C\nInitiate and titrate\nACE inhibitor and β-blockera\nARA‡      (Class I, Evidence B)\n    (Class IA, Evidence A if ACE inhibitor intolerant)\nInitiate and titrate diuretic\nSymptoms\nimprove once \neuvolemic?\nLong-term \nmonitoring \nAggressive diuretic therapy\nAny time during therapy . . .\nARB\nHydralazine/ISDN\nARA\nAmlodipine or felodipine\nNitrates\nAmlodipine or felodipine\nYes\nYes\nYes\nYes\nYes\nNo\nNo\nNo\n(Class IIa, Evidence A if already taking ARB for alternative indication)\n(Class IIb, Evidence B if persistently symptomatic on ACE inhibitor and BB)\nDigoxin   (Class IIa, Evidence B†)\nHydralazine/ISDN (Class I, Evidence B if African American and moderate-severe symptoms)\n                            (Class IIb, Evidence C if ACE inhibitor/ARB intolerant) \na If not already receiving this therapy for previous MI, LV dysfunction, or other indication.‡ If moderately severe to severe symptoms.† Indication is to reduce hospitalization. \nARB\nFluid retention\nPersistent volume overload?\nPersistent HTN?\nConcomitant angina\nFIGURE 9–1.  Treatment algorithm for patients with ACC/AHA stage C heart \nfailure. (ACE, angiotensin-converting enzyme; ARA, aldosterone receptor antagonist; \nARB, angiotensin receptor blocker; BB, β-blocker; HTN, hypertension; ISDN, isosorbide \ndinitrate; LV, left ventricular; MI, myocardial infarction.)",
    "word_count": 379,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0154",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 154,
    "text": "78\nSECTION 2  |  Cardiovascular Disorders\nretention\tand\televated\tblood\tpressure\t(BP)\tbecause\tof\ttheir\tmore\tpersistent\tantihy-\npertensive\teffects.\n•\tLoop\tdiuretics\t(furosemide,\tbumetanide,\tand\ttorsemide)\tare\tusually\tnecessary\tto\t\nrestore\tand\tmaintain\teuvolemia\tin\tHF .\tIn\taddition\tto\tacting\tin\tthe\tthick\tascending\t\nlimb\t of\t the\t loop\t of\t Henle,\t they\t induce\t a\t prostaglandin-mediated\t increase\t in\t renal\t\nblood\tflow\tthat\tcontributes\tto\ttheir\tnatriuretic\teffect.\tUnlike\tthiazides,\tloop\tdiuret-\nics\tmaintain\ttheir\teffectiveness\tin\tthe\tpresence\tof\timpaired\trenal\tfunction,\talthough\t\nhigher\tdoses\tmay\tbe\tnecessary.\n•\tRanges\tof\tdoses\tand\tceiling\tdoses\tfor\tloop\tdiuretics\tin\tpatients\twith\tvarying\tdegrees\t\nof\trenal\tfunction\tare\tlisted\tin\tTable 9–1.\nANGIOTENSIN -C ONv ERTING  ENz YME INHIb ITORS\n•\tACE\t inhibitors\t (Table 9–2 )\t decrease\t angiotensin\t II\t and\t aldosterone,\t attenuat-\ning\t many\t of\t their\t deleterious\t effects,\t including\t reducing\t ventricular\t remodeling,\t\n TABLE 9–1  Loop Diuretic Use in Heart Failure\nFurosemide Bumetanide Torsemide\nUsual daily dose (oral) 20–160 mg/day 0.5–4 mg/day 10–80 mg/day\nCeiling dosea\n Normal renal function\n CLcr 20–50 mL/min\n CLcr <20 mL/min\n80–160 mg\n160 mg\n400 mg\n1–2 mg\n2 mg\n8–10 mg\n20–40 mg\n40 mg\n100 mg\nBioavailability 10%–100%\nAverage: 50%\n80%–90% 80%–100%\nAffected by food Yes Yes No\nHalf-life 0.3–3.4 h 0.3–1.5 h 3–4 h\nCLcr, creatinine clearance.\naCeiling dose: single dose above which additional response is unlikely to be observed\n TABLE 9–2  ACE Inhibitors Routinely Used for Treatment of Heart Failure\nGeneric \nName\nBrand \nName Initial Dose\nTarget Dosing–\nSurvival Benefita Prodrug Eliminationb\nCaptopril Capoten 6.25 mg three \ntimes daily\n50 mg three times \ndaily\nNo Renal\nEnalapril Vasotec 2.5–5 mg twice \ndaily\n10 mg twice daily Yes Renal\nLisinopril Zestril, \nPrinivil\n2.5–5 mg daily 20–40 mg daily c No Renal\nQuinapril Accupril 5 mg twice daily 20–40 mg twice \ndailyd\nYes Renal\nRamipril Altace 1.25–2.5 mg twice \ndaily\n5 mg twice daily Yes Renal\nFosinopril Monopril 5–10 mg daily 40 mg dailyd Yes Renal/hepatic\nTrandolapril Mavik 0.5–1 mg daily 4 mg daily Yes Renal/hepatic\nPerindopril Aceon 2 mg daily 8–16 mg daily Yes Renal/hepatic\naTarget doses associated with survival benefits in clinical trials.\nbPrimary route of elimination.\ncNote that in the ATLAS trial (Circulation 1999;100:2312–2318), no significant difference in mortality \nwas found between low-dose (~5 mg/day) and high-dose (~35 mg/day) lisinopril therapy.\ndEffects on mortality have not been evaluated.",
    "word_count": 386,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0155",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 155,
    "text": "79\nHeart Failure  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0156",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 156,
    "text": "79\nHeart Failure     CHAPTER 9 \nmyocardial\tfibrosis,\tmyocyte\tapoptosis,\tcardiac\thypertrophy,\tnorepinephrine\trelease,\t\nvasoconstriction,\tand\tsodium\tand\twater\tretention.\n•\tClinical\t trials\t have\t produced\t unequivocal\t evidence\t that\t ACE\t inhibitors\t improve\t\nsymptoms,\t slow\t disease\t progression,\t and\t decrease\t mortality\t in\t patients\t with\t HF\t\nand\t reduced\t LVEF\t (stage\t C).\t These\t patients\t should\t receive\t ACE\t inhibitors\t unless\t\ncontraindications\t are\t present.\t ACE\t inhibitors\t should\t also\t be\t used\t to\t prevent\t the\t\ndevelopment\tof\tHF\tin\tat-risk\tpatients\t(ie,\tstages\tA\tand\tB).\nβ - bLOC k ERS\n•\tThere\t is\t overwhelming\t clinical\t trial\t evidence\t that\t certain\t β-blockers\t slow\t disease\t\nprogression,\tdecrease\thospitalizations,\tand\treduce\tmortality\tin\tpatients\twith\tsystolic\t\nHF .\n•\tThe\tACC/AHA\tguidelines\trecommend\tuse\tof\tβ-blockers\tin\tall\tstable\tpatients\twith\t\nHF\t and\t a\t reduced\t LVEF\t in\t the\t absence\t of\t contraindications\t or\t a\t clear\t history\t of\t\nβ-blocker\tintolerance.\tPatients\tshould\treceive\ta\tβ-blocker\teven\tif\tsymptoms\tare\tmild\t\nor\twell\tcontrolled\twith\tACE\tinhibitor\tand\tdiuretic\ttherapy.\tIt\tis\tnot\tessential\tthat\tACE\t\ninhibitor\tdoses\tbe\toptimized\tbefore\ta\tβ-blocker\tis\tstarted\tbecause\tthe\taddition\tof\ta\t\nβ-blocker\tis\tlikely\tto\tbe\tof\tgreater\tbenefit\tthan\tan\tincrease\tin\tACE\tinhibitor\tdose.\n•\tβ-Blockers\tare\talso\trecommended\tfor\tasymptomatic\tpatients\twith\ta\treduced\tLVEF\t\n(stage\tB)\tto\tdecrease\tthe\trisk\tof\tprogression\tto\tHF .\n•\tInitiate\tβ-blockers\tin\tstable\tpatients\twho\thave\tno\tor\tminimal\tevidence\tof\tfluid\tover-\nload.\tBecause\tof\ttheir\tnegative\tinotropic\teffects,\tstart\tβ-blockers\tin\tvery\tlow\tdoses\t\nwith\t slow\t upward\tdose\t titration\t to\tavoid\t symptomatic\tworsening\t or\t acute\t decom-\npensation.\tTitrate\tto\ttarget\tdoses\twhen\tpossible\tto\tprovide\tmaximal\tsurvival\tbenefits.\n•\tCarvedilol,\t metoprolol\t succinate\t (CR/XL),\t and\t bisoprolol\t are\t the\t only\t β-blockers\t\nshown\tto\treduce\tmortality\tin\tlarge\tHF\ttrials.\tBecause\tbisoprolol\tis\tnot\tavailable\tin\tthe\t\nnecessary\tstarting\tdose\tof\t1.25\tmg,\tthe\tchoice\tis\ttypically\tlimited\tto\teither\tcarvedilol\t\nor\t metoprolol\tsuccinate.\tOn\tthe\tbasis\t of\t regimens\tproven\t in\t large\tclinical\t trials\tto\t\nreduce\tmortality,\tinitial\tand\ttarget\toral\tdoses\tare\tas\tfollows:\n✓\t\tCarvedilol,\t3.125\tmg\ttwice\tdaily\tinitially;\ttarget\tdose\t25\tmg\ttwice\tdaily\t(the\ttarget\t\ndose\tfor\tpatients\tweighing\t>85\tkg\t[187\tlb]\tis\t50\tmg\ttwice\tdaily).\n✓\t\tCarvedilol\tCR,\t10\tmg\tonce\tdaily\tinitially;\ttarget\tdose\t80\tmg\tonce\tdaily.\tThis\tprod-\nuct\tshould\tbe\tconsidered\tin\tpatients\twith\tdifficulty\tmaintaining\tadherence\tto\tthe\t\nimmediate-release\tcarvedilol\tformulation.\n✓\t\tMetoprolol\tsuccinate\tCR/XL,\t12.5\tto\t25\tmg\tonce\tdaily\tinitially;\ttarget\tdose\t200\tmg\t\nonce\tdaily.\n✓\tBisoprolol,\t1.25\tmg\tonce\tdaily\tinitially;\ttarget\tdose\t10\tmg\tonce\tdaily.\n•\tDoses\tshould\tbe\tdoubled\tno\tmore\toften\tthan\tevery\t2\tweeks,\tas\ttolerated,\tuntil\tthe\t\ntarget\tdose\tor\tthe\tmaximally\ttolerated\tdose\tis\treached.\tPatients\tshould\tunderstand\t\nthat\tdose\tup-titration\tis\ta\tlong,\tgradual\tprocess\tand\tthat\tachieving\tthe\ttarget\tdose\tis\t\nimportant\tto\tmaximize\tbenefits.\tFurther,\tthe\tresponse\tto\ttherapy\tmay\tbe\tdelayed,\tand\t\nHF\tsymptoms\tmay\tactually\tworsen\tduring\tthe\tinitiation\tperiod.\nDrug Therapies to Consider for Select Patients\nANGIOTENSIN  II R ECEPTOR bLOC k ERS\n•\tThe\t angiotensin\t II\t receptor\t antagonists\t block\t the\t angiotensin\t II\t receptor\t subtype\t\nAT1,\tpreventing\tthe\tdeleterious\teffects\tof\tangiotensin\tII,\tregardless\tof\tits\torigin.\tThey\t\ndo\tnot\tappear\tto\taffect\tbradykinin\tand\tare\tnot\tassociated\twith\tthe\tside\teffect\tof\tcough\t\nthat\t sometimes\t results\t from\t ACE\t inhibitor–induced\t accumulation\t of\t bradykinin.\t\nAlso,\tdirect\tblockade\tof\tAT1\treceptors\tallows\tunopposed\tstimulation\tof\tAT2\trecep-\ntors,\tcausing\tvasodilation\tand\tinhibition\tof\tventricular\tremodeling.\n•\tAlthough\tsome\tdata\tsuggest\tthat\tARBs\tproduce\tequivalent\tmortality\tbenefits\twhen\t\ncompared\twith\tACE\tinhibitors,\tthe\tACC/AHA\tguidelines\trecommend\tuse\tof\tARBs\t\nonly\t in\t patients\t with\t stage\t A,\t B,\t or\t C\t HF\t who\t are\t intolerant\t of\t ACE\t inhibitors.\t\nAlthough\tthere\tare\t currently\tseven\tARBs\ton\t the\tmarket\tin\tthe\tUnited\tStates,\tonly",
    "word_count": 619,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0157",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 157,
    "text": "80\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0158",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 158,
    "text": "80\nSECTION 2     Cardiovascular Disorders\ncandesartan\t and\t valsartan\t are\t FDA-approved\t for\t the\t treatment\t of\t HF\t and\t are\t the\t\npreferred\tagents,\twhether\tused\talone\tor\tin\tcombination\twith\tACE\tinhibitors.\n•\tTherapy\tshould\tbe\tinitiated\tat\tlow\tdoses\tand\tthen\ttitrated\tto\ttarget\tdoses:\n✓\tCandesartan,\t4\tto\t8\tmg\tonce\tdaily\tinitially;\ttarget\tdose\t32\tmg\tonce\tdaily.\n✓\tValsartan,\t20\tto\t40\tmg\ttwice\tdaily\tinitially;\ttarget\tdose\t160\tmg\ttwice\tdaily.\n•\tAssess\t BP ,\t renal\t function,\t and\t serum\t potassium\t within\t 1\t to\t 2\t weeks\t after\t therapy\t\ninitiation\t and\t dose\t increases,\t with\t these\t endpoints\t used\t to\t guide\t subsequent\t dose\t\nchanges.\tIt\tis\tnot\tnecessary\tto\treach\ttarget\tARB\tdoses\tbefore\tadding\ta\tβ-blocker.\n•\tCough\tand\tangioedema\tare\tthe\tmost\tcommon\tcauses\tof\tACE\tinhibitor\tintolerance.\t\nCaution\tshould\tbe\texercised\twhen\tARBs\tare\tused\tin\tpatients\twith\tangioedema\tfrom\t\nACE\tinhibitors\tbecause\tcross-reactivity\thas\tbeen\treported.\tARBs\tare\tnot\talternatives\t\nin\tpatients\twith\thypotension,\thyperkalemia,\tor\trenal\tinsufficiency\tdue\tto\tACE\tinhibi-\ntors\tbecause\tthey\tare\tjust\tas\tlikely\tto\tcause\tthese\tadverse\teffects.\n•\tCombination\ttherapy\twith\tan\tARB\tand\tACE\tinhibitor\toffers\ta\ttheoretical\tadvantage\t\nover\teither\tagent\talone\tthrough\tmore\tcomplete\tblockade\tof\tthe\tdeleterious\teffects\tof\t\nangiotensin\tII.\tHowever,\tclinical\ttrial\tresults\tindicate\tthat\tthe\taddition\tof\tan\tARB\tto\t\noptimal\tHF\ttherapy\t(eg,\tACE\tinhibitors,\tβ-blockers,\tand\tdiuretics)\toffers\tmarginal\t\nbenefits\tat\tbest\twith\tincreased\trisk\tof\tadverse\teffects.\tThe\taddition\tof\tan\tARB\tmay\t\nbe\t considered\t with\t patients\t who\t remain\t symptomatic\t despite\t receiving\t optimal\t\nconventional\ttherapy.\nALDOSTERONE  ANTAGONISTS\n•\tSpironolactone\tand\teplerenone\tblock\tthe\tmineralocorticoid\treceptor,\tthe\ttarget\tsite\t\nfor\taldosterone.\tIn\tthe\tkidney,\taldosterone\tantagonists\tinhibit\tsodium\treabsorption\t\nand\tpotassium\texcretion.\tHowever,\tdiuretic\teffects\tare\tminimal,\tsuggesting\tthat\ttheir\t\ntherapeutic\tbenefits\tresult\tfrom\tother\tactions.\n•\tBased\ton\tclinical\ttrial\tresults\tdemonstrating\treduced\tmortality,\tlow-dose\taldosterone\t\nantagonists\tmay\tbe\tappropriate\tfor:\t(1)\tpatients\twith\tmild\tto\tmoderately\tsevere\tsys-\ntolic\tHF\twho\tare\treceiving\tstandard\ttherapy,\tand\t(2)\tthose\twith\tLV\tdysfunction\tand\t\neither\tacute\tHF\tor\tdiabetes\tearly\tafter\tMI.\n•\tAldosterone\t antagonists\t must\t be\t used\t cautiously\t and\t with\t careful\t monitoring\t of\t\nrenal\tfunction\tand\tpotassium\tconcentration.\tThey\tshould\tbe\tavoided\tin\tpatients\twith\t\nrenal\timpairment,\trecent\tworsening\tof\trenal\tfunction,\thigh-normal\tpotassium\tlevels,\t\nor\ta\thistory\tof\tsevere\thyperkalemia.\tSpironolactone\talso\tinteracts\twith\tandrogen\tand\t\nprogesterone\treceptors,\twhich\tmay\tlead\tto\tgynecomastia,\timpotence,\tand\tmenstrual\t\nirregularities\tin\tsome\tpatients.\n•\tInitial\t doses\t should\t be\t low\t (spironolactone\t 12.5\t mg/day;\t eplerenone\t 25\t mg/day),\t\nespecially\t in\t the\t elderly\t and\t those\t with\t diabetes\t or\t creatinine\t clearance\t less\t than\t\t\n50\tmL/min.\tA\tspironolactone\tdose\tof\t25\tmg/day\twas\tused\tin\tone\tmajor\tclinical\ttrial.\t\nThe\teplerenone\tdose\tshould\tbe\ttitrated\tto\tthe\ttarget\tdose\tof\t50\tmg\tonce\tdaily,\tprefer-\nably\twithin\t4\tweeks\tas\ttolerated\tby\tthe\tpatient.\nDIGOx IN\n•\tAlthough\tdigoxin\thas\tpositive\tinotropic\teffects,\tits\tbenefits\tin\tHF\tare\trelated\tto\tits\t\nneurohormonal\teffects.\tDigoxin\tdoes\tnot\timprove\tsurvival\tin\tpatients\twith\tHF\tbut\t\ndoes\tprovide\tsymptomatic\tbenefits.\n•\tIn\tpatients\twith\tchronic\tsystolic\tHF\tand\tsupraventricular\ttachyarrhythmias\tsuch\tas\tatrial\t\nfibrillation,\tconsider\tdigoxin\tearly\tin\ttherapy\tto\thelp\tcontrol\tventricular\tresponse\trate.\n•\tFor\tpatients\tin\tnormal\tsinus\trhythm,\teffects\ton\tsymptom\treduction\tand\tquality-of-\nlife\timprovement\tare\tevident\tin\tpatients\twith\tmild\tto\tsevere\tHF .\tTherefore,\tdigoxin\t\nshould\tbe\tused\ttogether\twith\tstandard\tHF\ttherapies\t(ACE\tinhibitors,\tβ-blockers,\tand\t\ndiuretics)\tin\tpatients\twith\tsymptomatic\tHF\tto\treduce\thospitalizations.\n•\tAdjust\tdoses\tto\tachieve\tplasma\tdigoxin\tconcentration\tof\t0.5\tto\t1\tng/mL\t(0.6–1.3\tnmol/\t\nL).\t Most\t patients\t with\t normal\t renal\t function\t can\t achieve\t this\t level\t with\t a\t dose\t of\t\t\n0.125\t mg/day.\t Patients\t with\t decreased\t renal\t function,\t the\t elderly,\t or\t those\t receiving\t\ninteracting\tdrugs\t(eg,\tamiodarone)\tshould\treceive\t0.125\tmg\tevery\tother\tday.",
    "word_count": 624,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0159",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 159,
    "text": "81\nHeart Failure  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0160",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 160,
    "text": "81\nHeart Failure     CHAPTER 9 \nNITRATES AND HYDRALA z INE\n•\tNitrates\t (eg,\t ISDN)\t and\t hydralazine\t have\t complementary\t hemodynamic\t actions.\t\nNitrates\t are\t primarily\t venodilators,\t producing\t reductions\t in\t preload.\t Hydralazine\t\nis\t a\t direct\t arterial\t vasodilator\t that\t reduces\t systemic\t vascular\t resistance\t (SVR)\t and\t\nincreases\tstroke\tvolume\tand\tcardiac\toutput.\n•\tThe\t combination\t of\t nitrates\t and\t hydralazine\t improves\t the\t composite\t endpoint\t of\t\nmortality,\t hospitalizations\t for\t HF ,\t and\t quality\t of\t life\t in\t African\t Americans\t who\t\nreceive\tstandard\ttherapy.\tA\tfixed-dose\tcombination\tproduct\tis\tavailable\tthat\tcontains\t\nISDN\t 20\t mg\t and\t hydralazine\t 37.5\t mg\t (BiDil).\t Guidelines\t recommend\t addition\t of\t\nhydralazine\tand\t nitrates\t to\tself-described\tAfrican\tAmericans\t with\tsystolic\t HF\t and\t\nmoderate\t to\t severe\t symptoms\t despite\t therapy\t with\t ACE\t inhibitors,\t diuretics,\t and\t\nβ-blockers.\tThe\tcombination\tmay\talso\tbe\treasonable\tfor\tpatients\tof\tother\tethnicities\t\nwith\tpersistent\tsymptoms\tdespite\toptimized\ttherapy\twith\tan\tACE\tinhibitor\t(or\tARB)\t\nand\tβ-blocker.\tThe\tcombination\tis\talso\tappropriate\tas\tfirst-line\ttherapy\tin\tpatients\t\nunable\tto\ttolerate\tACE\tinhibitors\tor\tARBs\tbecause\tof\trenal\tinsufficiency,\thyperkale-\nmia,\tor\tpossibly\thypotension.\n•\tObstacles\tto\tsuccessful\ttherapy\twith\tthis\tdrug\tcombination\tinclude\tthe\tneed\tfor\tfre-\nquent\tdosing\t(ie,\tthree\ttimes\tdaily\twith\tthe\tfixed-dose\tcombination\tproduct),\thigh\t\nfrequency\tof\tadverse\teffects\t(eg,\theadache,\tdizziness,\tGI\tdistress),\tand\tincreased\tcost\t\nfor\tthe\tfixed-dose\tcombination\tproduct.\nTREATMENT OF ACUTE DECOMPENSATED HEART FAILURE\nGENERAL APPROACH\n•\tAcute decompensated heart failure (ADHF) \t involves\t patients\t with\t new\t or\t worsen-\ning\t signs\t or\t symptoms\t (often\t resulting\t from\t volume\t overload\t and/or\t hypoperfu-\nsion)\t requiring\t additional\t medical\t care,\t such\t as\t emergency\t department\t visits\t and\t\nhospitalizations.\n•\tGoals\t of\t Treatment:\t Relieve\t congestive\t symptoms,\t optimize\t volume\t status,\t treat\t\nsymptoms\tof\tlow\tcardiac\toutput,\tand\tminimize\trisks\tof\tdrug\ttherapy\tso\tthe\tpatient\t\ncan\tbe\tdischarged\tin\ta\tcompensated\tstate\ton\toral\tdrug\ttherapy.\n•\tHospitalization\tis\trecommended\t or should be considered \tdepending\t on\t patient\t pre-\nsentation.\tAdmission\tto\tan\tintensive\tcare\tunit\t(ICU)\tmay\tbe\trequired\tif\tthe\tpatient\t\nexperiences\themodynamic\tinstability\trequiring\tfrequent\tmonitoring,\tinvasive\themo-\ndynamic\tmonitoring,\tor\trapid\ttitration\tof\tIV\tmedications\twith\tclose\tmonitoring.\n•\tAddress\tand\t correct\t reversible\t or\t treatable\tcauses\t of\t decompensation.\t Medications\t\nthat\tmay\taggravate\tHF\tshould\tbe\tevaluated\tcarefully\tand\tdiscontinued\twhen\tpossible.\n•\tThe\t first\t step\t in\t managing\t ADHF\t is\t to\t ascertain\t that\t optimal\t treatment\t with\t oral\t\nmedications\thas\tbeen\tachieved.\tIf\tfluid\tretention\tis\tevident,\taggressive\tdiuresis,\toften\t\nwith\tIV\tdiuretics,\tshould\tbe\taccomplished.\tStandard\ttreatment\tshould\tbe\toptimized\t\nwith\tan\tACE\tinhibitor\tand\tβ-blocker.\tβ-blockers\tshould\tgenerally\tbe\tcontinued\tdur-\ning\t hospitalization\tunless\trecent\t dose\t initiation\t or\t up-titration\t was\t responsible\t for\t\ndecompensation.\tIn\t such\t cases,\t β-blocker\ttherapy\t may\t be\t temporarily\twithheld\t or\t\ndose-reduced.\tMost\tpatients\tmay\tcontinue\tto\treceive\tdigoxin\tat\ta\tlow\tdose\ttargeting\t\na\ttrough\tserum\tconcentration\tof\t0.5–1\tng/mL\t(0.6–1.3\tnmol/L).\n•\tAppropriate\t management\t of\t ADHF\t is\t aided\t by\t determination\t of\t whether\t the\t patient\t\nhas\tsigns\tand\tsymptoms\tof\tfluid\toverload\t(“wet”\tHF)\tor\tlow\tcardiac\toutput\t(“ dry”\tHF)\t\n(Fig.",
    "word_count": 483,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0161",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 161,
    "text": "  CHAPTER 9 \nNITRATES AND HYDRALA z INE\n•\tNitrates\t (eg,\t ISDN)\t and\t hydralazine\t have\t complementary\t hemodynamic\t actions.\t\nNitrates\t are\t primarily\t venodilators,\t producing\t reductions\t in\t preload.\t Hydralazine\t\nis\t a\t direct\t arterial\t vasodilator\t that\t reduces\t systemic\t vascular\t resistance\t (SVR)\t and\t\nincreases\tstroke\tvolume\tand\tcardiac\toutput.\n•\tThe\t combination\t of\t nitrates\t and\t hydralazine\t improves\t the\t composite\t endpoint\t of\t\nmortality,\t hospitalizations\t for\t HF ,\t and\t quality\t of\t life\t in\t African\t Americans\t who\t\nreceive\tstandard\ttherapy.\tA\tfixed-dose\tcombination\tproduct\tis\tavailable\tthat\tcontains\t\nISDN\t 20\t mg\t and\t hydralazine\t 37.5\t mg\t (BiDil).\t Guidelines\t recommend\t addition\t of\t\nhydralazine\tand\t nitrates\t to\tself-described\tAfrican\tAmericans\t with\tsystolic\t HF\t and\t\nmoderate\t to\t severe\t symptoms\t despite\t therapy\t with\t ACE\t inhibitors,\t diuretics,\t and\t\nβ-blockers.\tThe\tcombination\tmay\talso\tbe\treasonable\tfor\tpatients\tof\tother\tethnicities\t\nwith\tpersistent\tsymptoms\tdespite\toptimized\ttherapy\twith\tan\tACE\tinhibitor\t(or\tARB)\t\nand\tβ-blocker.\tThe\tcombination\tis\talso\tappropriate\tas\tfirst-line\ttherapy\tin\tpatients\t\nunable\tto\ttolerate\tACE\tinhibitors\tor\tARBs\tbecause\tof\trenal\tinsufficiency,\thyperkale-\nmia,\tor\tpossibly\thypotension.\n•\tObstacles\tto\tsuccessful\ttherapy\twith\tthis\tdrug\tcombination\tinclude\tthe\tneed\tfor\tfre-\nquent\tdosing\t(ie,\tthree\ttimes\tdaily\twith\tthe\tfixed-dose\tcombination\tproduct),\thigh\t\nfrequency\tof\tadverse\teffects\t(eg,\theadache,\tdizziness,\tGI\tdistress),\tand\tincreased\tcost\t\nfor\tthe\tfixed-dose\tcombination\tproduct.\nTREATMENT OF ACUTE DECOMPENSATED HEART FAILURE\nGENERAL APPROACH\n•\tAcute decompensated heart failure (ADHF) \t involves\t patients\t with\t new\t or\t worsen-\ning\t signs\t or\t symptoms\t (often\t resulting\t from\t volume\t overload\t and/or\t hypoperfu-\nsion)\t requiring\t additional\t medical\t care,\t such\t as\t emergency\t department\t visits\t and\t\nhospitalizations.\n•\tGoals\t of\t Treatment:\t Relieve\t congestive\t symptoms,\t optimize\t volume\t status,\t treat\t\nsymptoms\tof\tlow\tcardiac\toutput,\tand\tminimize\trisks\tof\tdrug\ttherapy\tso\tthe\tpatient\t\ncan\tbe\tdischarged\tin\ta\tcompensated\tstate\ton\toral\tdrug\ttherapy.\n•\tHospitalization\tis\trecommended\t or should be considered \tdepending\t on\t patient\t pre-\nsentation.\tAdmission\tto\tan\tintensive\tcare\tunit\t(ICU)\tmay\tbe\trequired\tif\tthe\tpatient\t\nexperiences\themodynamic\tinstability\trequiring\tfrequent\tmonitoring,\tinvasive\themo-\ndynamic\tmonitoring,\tor\trapid\ttitration\tof\tIV\tmedications\twith\tclose\tmonitoring.\n•\tAddress\tand\t correct\t reversible\t or\t treatable\tcauses\t of\t decompensation.\t Medications\t\nthat\tmay\taggravate\tHF\tshould\tbe\tevaluated\tcarefully\tand\tdiscontinued\twhen\tpossible.\n•\tThe\t first\t step\t in\t managing\t ADHF\t is\t to\t ascertain\t that\t optimal\t treatment\t with\t oral\t\nmedications\thas\tbeen\tachieved.\tIf\tfluid\tretention\tis\tevident,\taggressive\tdiuresis,\toften\t\nwith\tIV\tdiuretics,\tshould\tbe\taccomplished.\tStandard\ttreatment\tshould\tbe\toptimized\t\nwith\tan\tACE\tinhibitor\tand\tβ-blocker.\tβ-blockers\tshould\tgenerally\tbe\tcontinued\tdur-\ning\t hospitalization\tunless\trecent\t dose\t initiation\t or\t up-titration\t was\t responsible\t for\t\ndecompensation.\tIn\t such\t cases,\t β-blocker\ttherapy\t may\t be\t temporarily\twithheld\t or\t\ndose-reduced.\tMost\tpatients\tmay\tcontinue\tto\treceive\tdigoxin\tat\ta\tlow\tdose\ttargeting\t\na\ttrough\tserum\tconcentration\tof\t0.5–1\tng/mL\t(0.6–1.3\tnmol/L).\n•\tAppropriate\t management\t of\t ADHF\t is\t aided\t by\t determination\t of\t whether\t the\t patient\t\nhas\tsigns\tand\tsymptoms\tof\tfluid\toverload\t(“wet”\tHF)\tor\tlow\tcardiac\toutput\t(“ dry”\tHF)\t\n(Fig. 9–2).\n•\tInvasive\themodynamic\tmonitoring\tin\tselect\tpatients\tmay\thelp\tguide\ttreatment\tand\t\nclassify\tpatients\tinto\tfour\tspecific\themodynamic\tsubsets\tbased\ton\tcardiac\tindex\tand\t\npulmonary\tartery\tocclusion\tpressure\t(PAOP).\nPHARMACOTHERAPY OF ACUTE DECOMPENSATED HEART FAILURE\nDiuretics\n•\tIV\tloop\tdiuretics,\tincluding\tfurosemide,\tbumetanide,\tand\ttorsemide,\tare\tused\tfor\t\nADHF ,\twith\tfurosemide\tbeing\tthe\tmost\twidely\tstudied\tand\tused\tagent.",
    "word_count": 541,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0162",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 162,
    "text": "82\nSECTION 2  |  Cardiovascular Disorders\nMAP >50 mm Hg\nNoYes\nSBP <90 mm Hg\nSymptomatic hypotension\nWorsening renal function\nDopamine\nNo\nIV Diuretics\n± IV Vasodilators\nYes\nIV Inotropes\n± PAC to guide therapy\n+ IV diuretics as tolerated\nSymptom relief\nIncrease IV loop diuretic dose\nor\nSwitch to IV loop diuretic continuous infusion\nor\nAdd a diuretic with a different mechanism\n(e.g. metolazone PO, HCTZ PO, or CTZ IV)\nor\nUltrafiltration\nSymptom relief\nYes No\nSee Subset I IV Inotrope\n± PAC to guide therapy\nYes No\nSee Subset I\nSubset I\n(Warm and Dry)\nOptimize chronic oral HF medications\nSubset II\n(Warm and Wet)\nIV Bolus Loop Diuretic ± Vasodilator\n(for acute symptomatic relief)\n(Goal:  PAOP 15–18 mm Hg)\nPAOP <15 mm Hg PAOP 15–18 mm Hg\nMAP >50 mm HgFluids until PAOP >15 mm Hg\nCI >2.2 L/min/m2 NoYes\nNo Yes\nSee Subset I\nDopamineSBP <90 mm Hg\nSymptomatic hypotension\nWorsening renal function\nIV Vasodilator IV Inotrope\n± PAC to guide therapy\nCI >2.2 L/min/m2 and/or\nsymptom relief\nYes No\nSee Subset I Add IV Inotrope\nSubset III\n(Cold and Dry)\nSubset IV\n(Cold and Wet)\nFIGURE 9–2.  General treatment algorithm for acute decompensated heart fail-\nure (ADHF) based on clinical presentation. IV vasodilators that may be used include \nnitroglycerin, nesiritide, and nitroprusside. Metolazone or spironolactone may be added \nif the patient fails to respond to loop diuretics and a second diuretic is required. IV \ninotropes that may be used include dobutamine and milrinone. (CI, cardiac index; CTZ, \nchlorothiazide; D/C, discontinue; HCTZ, hydrochlorothiazide; HF, heart failure; MAP , \nmean arterial pressure; PAC, pulmonary artery catheter; PAOP , pulmonary artery occlu-\nsion pressure; SBP , systolic blood pressure.)\n•\tBolus\t diuretic\t administration\t decreases\t preload\t by\t functional\t venodilation\t within\t\t\n5\tto\t15\tminutes\tand\tlater\t(>20\tmin)\tvia\tsodium\tand\twater\texcretion,\tthereby\timprov-\ning\tpulmonary\tcongestion.\tHowever,\tacute\treductions\tin\tvenous\treturn\tmay\tseverely\t\ncompromise\t effective\t preload\t in\t patients\t with\t significant\t diastolic\t dysfunction\t or\t\nintravascular\tdepletion.",
    "word_count": 329,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0163",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 163,
    "text": "83\nHeart Failure  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0164",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 164,
    "text": "83\nHeart Failure     CHAPTER 9 \n•\tBecause\t diuretics\t can\t cause\t excessive\t preload\t reduction,\t they\t must\t be\t used\t judi-\nciously\tto\tobtain\tthe\tdesired\timprovement\tin\tcongestive\tsymptoms\twhile\tavoiding\ta\t\nreduction\tin\tcardiac\toutput,\tsymptomatic\thypotension,\tor\tworsening\trenal\tfunction.\n•\tDiuretic\tresistance\tmay\tbe\tovercome\tby\tadministering\tlarger\tIV\tbolus\tdoses\tor\tcon-\ntinuous\tIV\tinfusions\tof\tloop\tdiuretics.\tDiuresis\tmay\talso\tbe\timproved\tby\tadding\ta\t\nsecond\tdiuretic\twith\ta\tdifferent\tmechanism\tof\taction\t(eg,\tcombining\ta\tloop\tdiuretic\t\nwith\ta\tdistal\ttubule\tblocker\tsuch\tas\tmetolazone\tor\thydrochlorothiazide).\tThe\tloop\t\ndiuretic–thiazide\tcombination\tshould\t generally\tbe\t reserved\tfor\tinpatients\twho\tcan\t\nbe\tmonitored\tclosely\tfor\tthe\tdevelopment\tof\tsevere\tsodium,\tpotassium,\tand\tvolume\t\ndepletion.\tV ery\tlow\tdoses\tof\tthe\tthiazide-type\tdiuretic\tshould\tbe\tused\tin\tthe\toutpa-\ntient\tsetting\tto\tavoid\tserious\tadverse\tevents.\nPositive Inotropic Agents\nDOb UTAMINE\n•\tDobutamine\tis\ta\tβ1-\tand\tβ2-receptor\tagonist\twith\tsome\tα1-agonist\teffects.\tThe\tnet\t\nvascular\t effect\t is\t usually\tvasodilation.\t It\t has\ta\tpotent\t inotropic\teffect\t without\t pro-\nducing\ta\tsignificant\tchange\tin\theart\trate.\tInitial\tdoses\tof\t2.5\tto\t5\tmcg/kg/min\tcan\tbe\t\nincreased\tprogressively\tto\t20\tmcg/kg/min\ton\tthe\tbasis\tof\tclinical\tand\themodynamic\t\nresponses.\n•\tDobutamine\t increases\t cardiac\t index\t because\t of\t inotropic\t stimulation,\t arterial\t\nvasodilation,\tand\ta\tvariable\tincrease\tin\theart\trate.\tIt\tcauses\trelatively\tlittle\tchange\tin\t\nmean\tarterial\tpressure\tcompared\twith\tthe\tmore\tconsistent\tincreases\tobserved\twith\t\ndopamine.\n•\tAlthough\tconcern\tover\tattenuation\tof\tdobutamine’ s\themodynamic\teffects\twith\tpro-\nlonged\tadministration\thas\tbeen\traised,\tsome\teffect\tis\tlikely\tretained.\tConsequently,\t\nthe\tdobutamine\tdose\tshould\tbe\ttapered\trather\tthan\tabruptly\tdiscontinued.\nMILRINONE\n•\tMilrinone\tinhibits\tphosphodiesterase\tIII\tand\tproduces\tpositive\tinotropic\tand\tarte-\nrial\t and\t venous\t vasodilating\t effects\t (an\t inodilator).\t It\t has\t supplanted\t use\t of\t amri-\nnone,\twhich\thas\ta\thigher\trate\tof\tthrombocytopenia.\n•\tDuring\tIV\tadministration,\tmilrinone\tincreases\tstroke\tvolume\t(and\tcardiac\toutput)\t\nwith\tminimal\tchange\tin\theart\trate.\tIt\talso\tlowers\tpulmonary\tcapillary\twedge\tpressure\t\n(PCWP)\t by\t venodilation\t and\t is\t particularly\t useful\t in\t patients\t with\t a\t low\t cardiac\t\nindex\t and\t elevated\t LV\t filling\t pressure.\t However,\t this\t decrease\t in\t preload\t can\t be\t\nhazardous\t for\tpatients\twithout\texcessive\tfilling\tpressure,\tleading\tto\tfurther\tdecline\t\nin\tcardiac\tindex.\n•\tUse\t milrinone\t cautiously\t as\t a\t single\t agent\t in\t severely\t hypotensive\t HF\t patients\t\nbecause\tit\twill\tnot\tincrease,\tand\tmay\teven\tdecrease,\tarterial\tBP .\n•\tThe\tusual\tloading\tdose\tof\tmilrinone\tis\t50\tmcg/kg\tover\t10\tminutes.\tIf\trapid\themo-\ndynamic\tchanges\tare\tunnecessary,\teliminate\tthe\tloading\tdose\tbecause\tof\tthe\trisk\tof\t\nhypotension.\tMost\tpatients\tare\tsimply\tstarted\ton\tthe\tmaintenance\tcontinuous\tinfu-\nsion\tof\t0.1\tto\t0.3\tmcg/kg/min\t(up\tto\t0.75\tmcg/kg/min).\n•\tThe\tmost\tnotable\tadverse\tevents\tare\tarrhythmia,\thypotension,\tand,\trarely,\tthrombo-\ncytopenia.\tMeasure\tplatelet\tcount\tbefore\tand\tduring\ttherapy.\n•\tRoutine\t use\t of\t milrinone\t (and\t perhaps\t other\t inotropes)\t should\t be\t discouraged\t\nbecause\t recent\t studies\t suggest\t a\t higher\t in-hospital\t mortality\t rate\t than\t with\t some\t\nother\tdrugs.\tHowever,\tinotropes\tmay\tbe\tneeded\twith\tcertain\tpatients,\tsuch\tas\tthose\t\nwith\t low\t cardiac\t output\t states\t with\t organ\t hypoperfusion\t and\t cardiogenic\t shock.\t\nMilrinone\t may\t be\t considered\t for\t patients\t receiving\t chronic\t β-blocker\t therapy\t\nbecause\tits\tpositive\tinotropic\teffect\tdoes\tnot\tinvolve\tstimulation\tof\tβ-receptors.\nDOPAMINE\n•\tDopamine\tshould\tgenerally\tbe\tavoided\tin\tADHF ,\tbut\tits\tpharmacologic\tactions\tmay\t\nbe\tpreferable\tto\tdobutamine\tor\tmilrinone\tin\tpatients\twith\tmarked\tsystemic\thypoten-\nsion\tor\tcardiogenic\tshock\tin\tthe\tface\tof\televated\tventricular\tfilling\tpressures,\twhere",
    "word_count": 568,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0165",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 165,
    "text": "84\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0166",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 166,
    "text": "84\nSECTION 2     Cardiovascular Disorders\ndopamine\t in\t doses\t greater\t than\t 5\t mcg/kg/min\t may\t be\t necessary\t to\t raise\t central\t\naortic\tpressure.\n•\tDopamine\t produces\t dose-dependent\t hemodynamic\t effects\t because\t of\t its\t relative\t\naffinity\tfor\tα1-,\tβ1-,\tβ2-,\tand\tD1-\t(vascular\tdopaminergic)\treceptors.\tPositive\tinotro-\npic\teffects\tmediated\tprimarily\tby\tβ1-receptors\tbecome\tmore\tprominent\twith\tdoses\t\nof\t 2\t to\t 5\t mcg/kg/min.\t At\t doses\t between\t 5\t and\t 10\t mcg/kg/min,\t chronotropic\t and\t\nα1-mediated\tvasoconstricting\teffects\tbecome\tmore\tprominent.\nVasodilators\n•\tArterial\tvasodilators\treduce\tafterload\tand\tcause\ta\treflex\tincrease\tin\tcardiac\toutput.\t\nV enodilators\treduce\tpreload\tby\tincreasing\tvenous\tcapacitance,\timproving\tsymptoms\t\nof\t pulmonary\t congestion\t in\t patients\t with\t high\t cardiac\t filling\t pressures.\t Mixed\t\nvasodilators\tact\ton\tboth\tarterial\tresistance\tand\tvenous\tcapacitance\tvessels,\treducing\t\ncongestive\tsymptoms\twhile\tincreasing\tcardiac\toutput.\nNITROPRUSSIDE\n•\tSodium\tnitroprusside\tis\ta\tmixed\tarteriovenous\tvasodilator\tthat\tacts\tdirectly\ton\tvas-\ncular\tsmooth\tmuscle\tto\tincrease\tcardiac\tindex\tand\tdecrease\tvenous\tpressure.\tDespite\t\nits\tlack\tof\tdirect\tinotropic\tactivity,\tnitroprusside\texerts\themodynamic\teffects\tthat\tare\t\nqualitatively\tsimilar\tto\tthose\tof\tdobutamine\tand\tmilrinone.\tHowever,\tnitroprusside\t\ngenerally\tdecreases\tPCWP ,\tSVR,\tand\tBP\tmore\tthan\tthose\tagents\tdo.\n•\tHypotension\tis\tan\timportant\tdose-limiting\tadverse\teffect\tof\tnitroprusside\tand\tother\t\nvasodilators.\t Therefore,\t nitroprusside\t is\t primarily\t used\t with\t patients\t who\t have\t a\t\nsignificantly\televated\tSVR\tand\toften\trequires\tinvasive\themodynamic\tmonitoring.\n•\tNitroprusside\tis\teffective\tin\tthe\tshort-term\tmanagement\tof\tsevere\tHF\tin\ta\tvariety\tof\t\nsettings\t(eg,\tacute\tMI,\tvalvular\tregurgitation,\tafter\tcoronary\tbypass\tsurgery,\tdecom-\npensated\tchronic\tHF).\tGenerally,\tit\twill\tnot\tworsen,\tand\tmay\timprove,\tthe\tbalance\t\nbetween\tmyocardial\toxygen\tdemand\tand\tsupply.\tHowever,\tan\texcessive\tdecrease\tin\t\nsystemic\tarterial\tpressure\tcan\tdecrease\tcoronary\tperfusion\tand\tworsen\tischemia.\n•\tNitroprusside\t has\t a\t rapid\t onset\t and\t a\t duration\t of\t action\t less\t than\t 10\t minutes,\t\nwhich\tnecessitates\tuse\tof\tcontinuous\tIV\tinfusions.\tInitiated\ttherapy\twith\ta\tlow\tdose\t\t\n(0.1–0.2\tmcg/kg/min)\tto\tavoid\texcessive\thypotension,\tand\tincrease\tby\tsmall\tincre-\nments\t(0.1–0.2\tmcg/kg/min)\tevery\t5\tto\t10\tminutes\tas\tneeded\tand\ttolerated.\tUsual\t\neffective\t doses\t range\t from\t 0.5\t to\t 3\t mcg/kg/min.\t Taper\t nitroprusside\t slowly\t when\t\nstopping\ttherapy\tbecause\tof\tpossible\trebound\tafter\tabrupt\twithdrawal.\tNitroprusside-\ninduced\tcyanide\tand\tthiocyanate\ttoxicity\tare\tunlikely\twhen\tdoses\tless\tthan\t3\tmcg/kg/\nmin\tare\tadministered\tfor\tless\tthan\t3\tdays,\texcept\tin\tpatients\twith\tserum\tcreatinine\t\nlevels\tgreater\tthan\t3\tmg/dL\t(>265\tμmol/L).\nNITROGLYCERIN\n•\tIV\t nitroglycerin\t decreases\t preload\t and\t PCWP\t because\t of\t functional\t venodilation\t\nand\tmild\tarterial\tvasodilation.\tIt\tis\toften\tthe\tpreferred\tagent\tfor\tpreload\treduction\tin\t\nADHF ,\tespecially\tin\tpatients\twith\tpulmonary\tcongestion.\tIn\thigher\tdoses,\tnitroglyc-\nerin\tdisplays\tpotent\tcoronary\tvasodilating\tproperties\tand\tbeneficial\teffects\ton\tmyo-\ncardial\toxygen\tdemand\tand\tsupply,\tmaking\tit\tthe\tvasodilator\tof\tchoice\tfor\tpatients\t\nwith\tsevere\tHF\tand\tischemic\theart\tdisease.\n•\tInitiate\tnitroglycerin\tat\t5\tto\t10\tmcg/min\t(0.1\tmcg/kg/min)\tand\tincrease\tevery\t5\tto\t\t\n10\tminutes\tas\tnecessary\tand\ttolerated.\tMaintenance\tdoses\tusually\trange\tfrom\t35\tto\t\n200\tmcg/min\t(0.5–3\tmcg/kg/min).\tHypotension\tand\tan\texcessive\tdecrease\tin\tPCWP\t\nare\timportant\tdose-limiting\tside\teffects.\tSome\ttolerance\tmay\tdevelop\tover\t12\tto\t72\t\nhours\tof\tcontinuous\tadministration.\nNESIRITIDE\n•\tNesiritide\tis\ta\trecombinant\tproduct\tthat\tis\tidentical\tto\tendogenous\tBNP\tsecreted\tby\t\nthe\tventricular\tmyocardium\tin\tresponse\tto\tvolume\toverload.\tNesiritide\tmimics\tthe\t\nvasodilatory\tand\tnatriuretic\tactions\tof\tthe\tendogenous\tpeptide,\tresulting\tin\tvenous\t\nand\t arterial\t vasodilation;\t increased\t cardiac\t output;\t natriuresis\t and\t diuresis;\t and",
    "word_count": 557,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0167",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 167,
    "text": "85\nHeart Failure  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0168",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 168,
    "text": "85\nHeart Failure     CHAPTER 9 \ndecreased\tcardiac\tfilling\tpressures,\tsympathetic\tnervous\tsystem\tactivity,\tand\trenin–\nangiotensin–aldosterone\tsystem\tactivity.\n•\tThe\trole\tof\tnesiritide\tin\tpharmacotherapy\tof\tADHF\tremains\tcontroversial.\tCompared\t\nwith\t nitroglycerin\t or\t nitroprusside,\t it\t produces\t marginal\t improvement\t in\t clinical\t\noutcomes\t and\t is\t substantially\t more\t expensive.\t Concerns\t about\t potential\t negative\t\neffects\ton\trenal\tfunction\tand\tincreased\tmorality\tare\talso\tunsettled.\n Vasopressin Receptor Antagonists\n•\tThe\t vasopressin\treceptor\tantagonists\tcurrently\tavailable\taffect\tone\tor\t two\t arginine\t\nvasopressin\t (A VP;\t antidiuretic\t hormone)\t receptors,\t V1A\t or\t V2.\t Stimulation\t of\t V1A\t\nreceptors\t (located\t in\t vascular\t smooth\t muscle\t cells\t and\t myocardium)\t results\t in\t\nvasoconstriction,\t myocyte\t hypertrophy,\t coronary\t vasoconstriction,\t and\t positive\t\ninotropic\teffects.\tV2\treceptors\tare\tlocated\tin\trenal\ttubules,\twhere\tthey\tregulate\twater\t\nreabsorption.\n✓\t\tTolvaptan\tselectively\tbinds\tto\tand\tinhibits\tthe\tV2\treceptor.\tIt\tis\tan\toral\tagent\tindi-\ncated\t for\t hypervolemic\t and\t euvolemic\t hyponatremia\t in\t patients\t with\t syndrome\t\nof\t inappropriate\t antidiuretic\t hormone\t (SIADH),\t cirrhosis,\t and\t HF .\t T olvaptan\t is\t\ntypically\tinitiated\tat\t15\tmg\torally\tdaily\tand\tthen\ttitrated\tto\t30\tor\t60\tmg\tdaily\tas\t\nneeded\tto\tresolve\thyponatremia.\tIt\tis\ta\tsubstrate\tof\tcytochrome\tP450-3A4\tand\tis\t\ncontraindicated\t with\t potent\t inhibitors\t of\t this\t enzyme.\t The\t most\t common\t side\t\neffects\tare\tdry\tmouth,\tthirst,\turinary\tfrequency,\tconstipation,\tand\thyperglycemia.\n✓\t\tConivaptan\tnonselectively\tinhibits\tboth\tthe\tV1A\tand\tV2\treceptors.\tIt\tis\tan\tIV\tagent\t\nindicated\tfor\thypervolemic\tand\teuvolemic\thyponatremia\tdue\tto\ta\tvariety\tof\tcauses;\t\nhowever,\tit\tis\tnot\tindicated\tfor\thyponatremia\tassociated\twith\tHF .\n•\tMonitor\tpatients\tclosely\tto\tavoid\texcessively\trapid\trise\tin\tserum\tsodium\tthat\tcould\t\ncause\thypotension\tor\thypovolemia;\tdiscontinue\ttherapy\tif\tthat\toccurs.\tTherapy\tmay\t\nbe\t restarted\t at\t a\t lower\t dose\t if\t hyponatremia\t recurs\t or\t persists\t and/or\t these\t side\t\neffects\tresolve.\n•\tThe\t role\t of\t vasopressin\t receptor\t antagonists\t in\t the\t long-term\t management\t of\t HF\t\nis\t unclear.\t In\t clinical\t trials,\t tolvaptan\t improved\t hyponatremia,\t diuresis,\t and\t signs/\nsymptoms\tof\tcongestion.\tHowever,\tone\tstudy\tfailed\tto\tdemonstrate\timprovement\tin\t\nglobal\tclinical\tstatus\tat\tdischarge\tor\ta\treduction\tin\t2-year\tall-cause\tmortality,\tcardio-\nvascular\tmortality,\tand\tHF\trehospitalization.\nMECHANICAL CIRCULATORY SUPPORT\n•\tThe\t intraaortic balloon pump (IABP) \t is\t typically\t employed\t in\t patients\t with\t\nadvanced\t HF\t who\t do\t not\t respond\t adequately\t to\t drug\t therapy,\t such\t as\t those\t with\t\nintractable\t myocardial\t ischemia\t or\t patients\t in\t cardiogenic\t shock.\t IV\t vasodilators\t\nand\tinotropic\tagents\tare\tgenerally\tused\tin\tconjunction\twith\tthe\tIABP\tto\tmaximize\t\nhemodynamic\tand\tclinical\tbenefits.\n•\tVentricular assist devices \t are\t surgically\t implanted\t and\t assist,\t or\t in\t some\t cases\t\nreplace,\tthe\tpumping\tfunctions\tof\tthe\tright\tand/or\tleft\tventricles.\tThey\tcan\tbe\tused\tin\t\nthe\tshort-term\t(days\tto\tseveral\tweeks)\tfor\ttemporary\tstabilization\tof\tpatients\tawaiting\t\nan\tintervention\tto\tcorrect\tunderlying\tcardiac\tdysfunction.\tThey\tcan\talso\tbe\tused\tlong\t\nterm\t(several\tmonths\tto\tyears)\tas\ta\tbridge\tto\theart\ttransplantation.\nSURGICAL THERAPY\n•\tOrthotopic\t cardiac\t transplantation\t is\t the\t best\t therapeutic\t option\t for\t patients\t with\t\nchronic\tirreversible\tNew\tY ork\tHeart\tAssociation\tclass\tIV\tHF ,\twith\ta\t10-year\tsurvival\t\nof\t~50%\tin\twell-selected\tpatients.\n Ev ALUATION OF THERAPEUTIC OUTCOMES\nCHRONIC HEART FAILURE\n•\tAsk\tpatients\tabout\tthe\tpresence\tand\tseverity\tof\tsymptoms\tand\thow\tsymptoms\taffect\t\ndaily\tactivities.",
    "word_count": 518,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0169",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 169,
    "text": "86\nSECTION 2  |  Cardiovascular Disorders\n•\tEvaluate\tefficacy\tof\tdiuretic\ttreatment\tby\tdisappearance\tof\tthe\tsigns\tand\tsymptoms\t\nof\texcess\tfluid\tretention.\tPhysical\texamination\tshould\tfocus\ton\tbody\tweight,\textent\tof\t\njugular\tvenous\tdistention,\tpresence\tof\thepatojugular\treflux,\tand\tpresence\tand\tsever-\nity\tof\tpulmonary\tcongestion\t(rales,\tdyspnea\ton\texertion,\torthopnea,\tand\tparoxysmal\t\nnocturnal\tdyspnea)\tand\tperipheral\tedema.\n•\tOther\toutcomes\tare\timprovement\tin\texercise\ttolerance\tand\tfatigue,\tdecreased\tnoctu-\nria,\tand\ta\tdecrease\tin\theart\trate.\n•\tMonitor\tBP\tto\tensure\tthat\tsymptomatic\thypotension\tdoes\tnot\tdevelop\tas\ta\tresult\tof\t\ndrug\ttherapy.\n•\tBody\tweight\tis\ta\tsensitive\tmarker\tof\tfluid\tloss\tor\tretention,\tand\tpatients\tshould\tweigh\t\nthemselves\tdaily\tand\treport\tchanges\tto\ttheir\thealthcare\tprovider\tso\tthat\tadjustments\t\ncan\tbe\tmade\tin\tdiuretic\tdoses.\n•\tSymptoms\t may\t worsen\t initially\t on\t β-blocker\t therapy,\t and\t it\t may\t take\t weeks\t to\t\nmonths\tbefore\tpatients\tnotice\tsymptomatic\timprovement.\n•\tRoutine\tmonitoring\tof\tserum\telectrolytes\tand\trenal\tfunction\tis\tmandatory\tin\tpatients\t\nwith\tHF .\n ACUTE DECOMPENSATED HEART FAILURE\n•\tInitial\tstabilization\trequires\tadequate\tarterial\toxygen\tsaturation,\tcardiac\tindex,\tand\t\nblood\t pressure.\t Functional\t end-organ\t perfusion\t may\t be\t assessed\t by\t mental\t status,\t\nrenal\t function\t sufficient\t to\t prevent\t metabolic\t complications,\t hepatic\t function\t\nadequate\tto\tmaintain\tsynthetic\tand\texcretory\tfunctions,\tstable\theart\trate\tand\trhythm,\t\nabsence\tof\tongoing\tmyocardial\tischemia\tor\tMI,\tskeletal\tmuscle\tand\tskin\tblood\tflow\t\nsufficient\tto\tprevent\tischemic\tinjury,\tand\tnormal\tarterial\tpH\t(7.34–7.47)\tand\tserum\t\nlactate\t concentration.\t These\t goals\t are\t most\t often\t achieved\t with\t a\t cardiac\t index\t\ngreater\t than\t 2.2\t L/min/m2,\t mean\t arterial\t BP\t greater\t than\t 60\t mm\t Hg,\t and\t PCWP\t\n15\tmm\tHg\tor\tgreater.\n•\tDaily\t monitoring\t should\t include\t weight,\t strict\t fluid\t intake\t and\t output\t measure-\nments,\t and\t HF\t signs/symptoms\t to\t assess\t the\t efficacy\t of\t drug\t therapy.\t Monitoring\t\nfor\telectrolyte\tdepletion,\tsymptomatic\thypotension,\tand\trenal\tdysfunction\tshould\tbe\t\nperformed\tfrequently.\tVital\tsigns\tshould\tbe\tassessed\tfrequently\tthroughout\tthe\tday.\n•\tDischarge\t from\t the\t ICU\t requires\t maintenance\t of\t the\t preceding\t parameters\t in\t the\t\nabsence\tof\tongoing\tIV\tinfusion\ttherapy,\tmechanical\tcirculatory\tsupport,\tor\tpositive-\npressure\tventilation.\nSee Chapter 4, Chronic Heart Failure, authored by Robert B. Parker, Jean M. Nappi, and \nLarisa H. Cavallari, and Chap. 5, Acute Decompensated Heart Failure, authored by \nJo E. Rodgers and Brent N. Reed, for a more detailed discussion of this topic.",
    "word_count": 381,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0170",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 170,
    "text": "87\n•\tHypertension\tis\tdefined\tas\tpersistently\televated\tarterial\tblood\tpressure\t(BP).\tThe\tsev-\nenth\treport\tof\tthe\tJoint\tNational\tCommittee\ton\tPrevention,\tDetection,\tEvaluation,\t\nand\tTreatment\tof\tHigh\tBlood\tPressure\t(JNC7)\tclassifies\tadult\tBP\tas\tshown\tin\tTable \n10–1.\n•\tIsolated\t systolic\t hypertension\t is\t diastolic\t blood\t pressure\t (DBP)\t values\t less\t than\t\t\n90\tmm\tHg\tand\tsystolic\tblood\tpressure\t(SBP)\tvalues\tof\t140\tmm\tHg\tor\tmore.\n•\tHypertensive\tcrisis\t(BP\t>180/120\tmm\tHg)\tmay\tbe\tcategorized\tas\thypertensive\temer-\ngency\t(extreme\tBP\televation\twith\tacute\tor\tprogressing\ttarget-organ\tdamage)\tor\thyper-\ntensive\turgency\t(high\tBP\televation\twithout\tacute\tor\tprogressing\ttarget-organ\tinjury).\nPATHOPHYSIOLOGY\n•\tHypertension\t may\t result\t from\t a\t specific\t cause\t (secondary\t hypertension)\t or\t from\t\nan\tunknown\tetiology\t(primary\tor\tessential\thypertension).\tSecondary\thypertension\t\n(<10%\tof\tcases)\tis\tusually\tcaused\tby\tchronic\tkidney\tdisease\t(CKD)\tor\trenovascular\t\ndisease.\tOther\tconditions\tare\tCushing\tsyndrome,\tcoarctation\tof\tthe\taorta,\tobstructive\t\nsleep\tapnea,\thyperparathyroidism,\tpheochromocytoma,\tprimary\taldosteronism,\tand\t\nhyperthyroidism.\t Some\t drugs\t that\t may\t increase\t BP\t include\t corticosteroids,\t estro-\ngens,\tnonsteroidal\tanti-inflammatory\tdrugs\t(NSAIDs),\tamphetamines,\tsibutramine,\t\ncyclosporine,\ttacrolimus,\terythropoietin,\tand\tvenlafaxine.\n•\tFactors\tcontributing\tto\tdevelopment\tof\tprimary\thypertension\tinclude:\n✓\t\tHumoral\t abnormalities\t involving\t the\t renin–angiotensin–aldosterone \t system\t\n(RAAS),\tnatriuretic\thormone,\tor\tinsulin\tresistance\tand\thyperinsulinemia;\n✓\t\tDisturbance\t in\t the\t CNS,\t autonomic\t nerve\t fibers,\t adrenergic\t receptors,\t or\t\nbaroreceptors;\n✓\t\tAbnormalities\t in\t renal\t or\t tissue\t autoregulatory\t processes\t for\t sodium\t excretion,\t\nplasma\tvolume,\tand\tarteriolar\tconstriction;\n✓\t\tDeficiency\t in\t synthesis\t of\t vasodilating\t substances\t in\t vascular\t endothelium\t\n(prostacyclin,\tbradykinin,\tand\tnitric\toxide)\tor\texcess\tvasoconstricting\tsubstances\t\n(angiotensin\tII,\tendothelin\tI);\n✓\t\tHigh\tsodium\tintake\tor\tlack\tof\tdietary\tcalcium.\n•\tMain\tcauses\tof\tdeath\tare\tcerebrovascular\taccidents,\tcardiovascular\t(CV)\tevents,\tand\t\nrenal\tfailure.\tProbability\tof\tpremature\tdeath\tcorrelates\twith\tthe\tseverity\tof\tBP\televation.\nCLINICAL PRESENTATION\n•\tPatients\twith\tuncomplicated\tprimary\thypertension\tare\tusually\tasymptomatic\tinitially.\n•\tPatients\twith\tsecondary\thypertension\tmay\thave\tsymptoms\tof\tthe\tunderlying\tdisor-\nder.\t Patients\t with\t pheochromocytoma\t may\t have\t headaches,\t sweating,\t tachycardia,\t\npalpitations,\t and\t orthostatic\t hypotension.\t In\t primary\t aldosteronism,\t hypokalemic\t\nsymptoms\t of\t muscle\t cramps\t and\t weakness\t may\t be\t present.\t Patients\t with\t Cushing\t\nsyndrome\tmay\thave\tweight\tgain,\tpolyuria,\tedema,\tmenstrual\tirregularities,\trecurrent\t\nacne,\tor\tmuscular\tweakness\tin\taddition\tto\tclassic\tfeatures\t(moon\tface,\tbuffalo\thump,\t\nand\thirsutism).\nDIAGNOSIS\n•\tElevated\tBP\tmay\tbe\tthe\tonly\tsign\tof\tprimary\thypertension\ton\tphysical\texamination.\t\nDiagnosis\tshould\tbe\tbased\ton\tthe\taverage\tof\ttwo\tor\tmore\treadings\ttaken\tat\teach\tof\t\ntwo\tor\tmore\tclinical\tencounters.\n•\tSigns\t of\t end-organ\t damage\t occur\t primarily\t in\t the\t eye,\t brain,\t heart,\t kidneys,\t and\t\nperipheral\tblood\tvessels.\nHypertension\n10C H A P T E R",
    "word_count": 426,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0171",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 171,
    "text": "88\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0172",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 172,
    "text": "88\nSECTION 2     Cardiovascular Disorders\n•\tFunduscopic\texamination\tmay\treveal\tarteriolar\tnarrowing,\tfocal\tarteriolar\tconstrictions,\t\narteriovenous\tnicking,\tretinal\themorrhages\tand\texudates,\tand\tdisk\tedema.\tPresence\tof\t\npapilledema\tusually\tindicates\ta\thypertensive\temergency\trequiring\trapid\ttreatment.\n•\tCardiopulmonary\texamination\tmay\treveal\tabnormal\theart\trate\tor\trhythm,\tleft\tven-\ntricular\t(LV)\thypertrophy,\tcoronary\theart\tdisease,\tor\theart\tfailure\t(HF).\n•\tPeripheral\t vascular\t examination\t may\t reveal\t aortic\t or\t abdominal\t bruits,\t distended\t\nveins,\tdiminished\tor\tabsent\tperipheral\tpulses,\tor\tlower\textremity\tedema.\n•\tPatients\twith\trenal\tartery\tstenosis\tmay\thave\tan\tabdominal\tsystolic-diastolic\tbruit.\n•\tBaseline\thypokalemia\tmay\tsuggest\tmineralocorticoid-induced\thypertension.\tProtein,\t\nblood\tcells,\tand\tcasts\tin\tthe\turine\tmay\tindicate\trenovascular\tdisease.\n•\tLaboratory tests:\t Blood\t urea\t nitrogen\t (BUN)/serum\t creatinine,\t fasting\t lipid\t panel,\t\nfasting\t blood\t glucose,\t serum\t electrolytes\t (sodium\t and\t potassium),\t spot\t urine\t\nalbumin-to-creatinine\tratio,\tand\testimated\tglomerular\tfiltration\trate\t(GFR,\tusing\tthe\t\nModification\tof\tDiet\tin\tRenal\tDisease\t[MDRD]\tequation).\tA\t12-lead\telectrocardio-\ngram\t(ECG)\tshould\talso\tbe\tobtained.\n•\tLaboratory tests to diagnose secondary hypertension:\tPlasma\tnorepinephrine\tand\turi-\nnary\t metanephrine\t levels\t for\t pheochromocytoma,\t plasma\tand\t urinary\taldosterone\t\nconcentrations\tfor\tprimary\taldosteronism,\tplasma\trenin\tactivity,\tcaptopril\tstimula-\ntion\ttest,\trenal\tvein\trenin,\tand\trenal\tartery\tangiography\tfor\trenovascular\tdisease.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\toverall\tgoal\tis\tto\treduce\tmorbidity\tand\tmortality\tby\tthe\tleast\t\nintrusive\tmeans\tpossible.\tJNC7\tguidelines\trecommend\tgoal\tBP\tless\tthan\t140/90\tmm\t\nHg\tfor\tmost\tpatients,\tless\tthan\t140/80\tmm\tHg\tfor\tpatients\twith\tdiabetes\tmellitus,\tand\t\nless\tthan\t130/80\tmm\tHg\tfor\tpatients\twith\tCKD\twho\thave\tpersistent\talbuminuria\t(>30\t\nmg\turine\talbumin\texcretion\tper\t24\thours).\nNONPHARMACOLOGIC THERAPY\n•\tLifestyle\t modifications:\t (1)\t weight\t loss\t if\t overweight,\t (2)\t adoption\t of\t the\t Dietary\t\nApproaches\t to\t Stop\t Hypertension\t (DASH)\t eating\t plan,\t (3)\t dietary\t sodium\t restriction\t\nideally\tto\t1.5\tg/day\t(3.8\tg/day\tsodium\tchloride),\t(4)\tregular\taerobic\tphysical\tactivity,\t(5)\t\nmoderate\talcohol\tconsumption\t(two\tor\tfewer\tdrinks\tper\tday),\tand\t(6)\tsmoking\tcessation.\n•\tLifestyle\t modification\t alone\t is\t sufficient\t for\t most\t patients\t with\t prehypertension\t\nbut\t inadequate\t for\t patients\t with\t hypertension\t and\t additional\t CV\t risk\t factors\t or\t\nhypertension-associated\ttarget-organ\tdamage.\nPHARMACOLOGIC THERAPY\n•\tInitial\tdrug\tselection\tdepends\ton\tthe\tdegree\tof\tBP\televation\tand\tpresence\tof\tcompel-\nling\tindications\tfor\tselected\tdrugs.\n•\tAngiotensin-converting enzyme (ACE) inhibitors,\tangiotensin II receptor block-\ners (ARBs),\tcalcium channel blockers (CCBs),\tand\tthiazide diuretics\tare\tacceptable\t\nfirst-line\toptions.\n•\tβ-Blockers \tare\tused\tto\teither\ttreat\ta\tspecific\tcompelling\tindication\tor\tas\tcombina-\ntion\ttherapy\twith\ta\tfirst-line\tantihypertensive\tagent\tfor\tpatients\twithout\ta\tcompelling\t\nindication\t(Table 10–2).\n•\tMost\tpatients\twith\tstage\t1\thypertension\tshould\tbe\ttreated\tinitially\twith\ta\tfirst-line\t\nantihypertensive\tdrug\tor\ta\ttwo-drug\tcombination\t(Fig.",
    "word_count": 436,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0173",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 173,
    "text": "  Cardiovascular Disorders\n•\tFunduscopic\texamination\tmay\treveal\tarteriolar\tnarrowing,\tfocal\tarteriolar\tconstrictions,\t\narteriovenous\tnicking,\tretinal\themorrhages\tand\texudates,\tand\tdisk\tedema.\tPresence\tof\t\npapilledema\tusually\tindicates\ta\thypertensive\temergency\trequiring\trapid\ttreatment.\n•\tCardiopulmonary\texamination\tmay\treveal\tabnormal\theart\trate\tor\trhythm,\tleft\tven-\ntricular\t(LV)\thypertrophy,\tcoronary\theart\tdisease,\tor\theart\tfailure\t(HF).\n•\tPeripheral\t vascular\t examination\t may\t reveal\t aortic\t or\t abdominal\t bruits,\t distended\t\nveins,\tdiminished\tor\tabsent\tperipheral\tpulses,\tor\tlower\textremity\tedema.\n•\tPatients\twith\trenal\tartery\tstenosis\tmay\thave\tan\tabdominal\tsystolic-diastolic\tbruit.\n•\tBaseline\thypokalemia\tmay\tsuggest\tmineralocorticoid-induced\thypertension.\tProtein,\t\nblood\tcells,\tand\tcasts\tin\tthe\turine\tmay\tindicate\trenovascular\tdisease.\n•\tLaboratory tests:\t Blood\t urea\t nitrogen\t (BUN)/serum\t creatinine,\t fasting\t lipid\t panel,\t\nfasting\t blood\t glucose,\t serum\t electrolytes\t (sodium\t and\t potassium),\t spot\t urine\t\nalbumin-to-creatinine\tratio,\tand\testimated\tglomerular\tfiltration\trate\t(GFR,\tusing\tthe\t\nModification\tof\tDiet\tin\tRenal\tDisease\t[MDRD]\tequation).\tA\t12-lead\telectrocardio-\ngram\t(ECG)\tshould\talso\tbe\tobtained.\n•\tLaboratory tests to diagnose secondary hypertension:\tPlasma\tnorepinephrine\tand\turi-\nnary\t metanephrine\t levels\t for\t pheochromocytoma,\t plasma\tand\t urinary\taldosterone\t\nconcentrations\tfor\tprimary\taldosteronism,\tplasma\trenin\tactivity,\tcaptopril\tstimula-\ntion\ttest,\trenal\tvein\trenin,\tand\trenal\tartery\tangiography\tfor\trenovascular\tdisease.\nTREATMENT\n•\tGoals\tof\tTreatment:\tThe\toverall\tgoal\tis\tto\treduce\tmorbidity\tand\tmortality\tby\tthe\tleast\t\nintrusive\tmeans\tpossible.\tJNC7\tguidelines\trecommend\tgoal\tBP\tless\tthan\t140/90\tmm\t\nHg\tfor\tmost\tpatients,\tless\tthan\t140/80\tmm\tHg\tfor\tpatients\twith\tdiabetes\tmellitus,\tand\t\nless\tthan\t130/80\tmm\tHg\tfor\tpatients\twith\tCKD\twho\thave\tpersistent\talbuminuria\t(>30\t\nmg\turine\talbumin\texcretion\tper\t24\thours).\nNONPHARMACOLOGIC THERAPY\n•\tLifestyle\t modifications:\t (1)\t weight\t loss\t if\t overweight,\t (2)\t adoption\t of\t the\t Dietary\t\nApproaches\t to\t Stop\t Hypertension\t (DASH)\t eating\t plan,\t (3)\t dietary\t sodium\t restriction\t\nideally\tto\t1.5\tg/day\t(3.8\tg/day\tsodium\tchloride),\t(4)\tregular\taerobic\tphysical\tactivity,\t(5)\t\nmoderate\talcohol\tconsumption\t(two\tor\tfewer\tdrinks\tper\tday),\tand\t(6)\tsmoking\tcessation.\n•\tLifestyle\t modification\t alone\t is\t sufficient\t for\t most\t patients\t with\t prehypertension\t\nbut\t inadequate\t for\t patients\t with\t hypertension\t and\t additional\t CV\t risk\t factors\t or\t\nhypertension-associated\ttarget-organ\tdamage.\nPHARMACOLOGIC THERAPY\n•\tInitial\tdrug\tselection\tdepends\ton\tthe\tdegree\tof\tBP\televation\tand\tpresence\tof\tcompel-\nling\tindications\tfor\tselected\tdrugs.\n•\tAngiotensin-converting enzyme (ACE) inhibitors,\tangiotensin II receptor block-\ners (ARBs),\tcalcium channel blockers (CCBs),\tand\tthiazide diuretics\tare\tacceptable\t\nfirst-line\toptions.\n•\tβ-Blockers \tare\tused\tto\teither\ttreat\ta\tspecific\tcompelling\tindication\tor\tas\tcombina-\ntion\ttherapy\twith\ta\tfirst-line\tantihypertensive\tagent\tfor\tpatients\twithout\ta\tcompelling\t\nindication\t(Table 10–2).\n•\tMost\tpatients\twith\tstage\t1\thypertension\tshould\tbe\ttreated\tinitially\twith\ta\tfirst-line\t\nantihypertensive\tdrug\tor\ta\ttwo-drug\tcombination\t(Fig. 10–1).\tCombination\ttherapy\t\n TABLE 10–1  Classification of Blood Pressure in Adults\nClassification Systolic (mm Hg) Diastolic (mm Hg)\nNormal <120 and <80\nPrehypertension 120–139 or 80–89\nStage 1 hypertension 140–159 or 90–99\nStage 2 hypertension ≥160 or ≥100",
    "word_count": 471,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0174",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 174,
    "text": "89\nHypertension  |  CHAPTER 10\n TABLE 10–2  First-Line and Other Common Antihypertensive Agents\nClass/Subclass/Drug (brand name)\nUsual Dose \nRange (mg/\nday) Daily Frequency\nAngiotensin-converting enzyme inhibitors\n Benazepril (Lotensin)\n Captopril (Capoten)\n Enalapril (Vasotec)\n Fosinopril (Monopril)\n Lisinopril (Prinivil, Zestril)\n Moexipril (Univasc)\n Perindopril (Aceon)\n Quinapril (Accupril)\n Ramipril (Altace)\n Trandolapril (Mavik)\n10–40\n12.5–150\n5–40\n10–40\n10–40\n7.5–30\n4–16\n10–80\n2.5–10\n1–4\n1 or 2\n2 or 3\n1 or 2\n1\n1\n1 or 2\n1\n1 or 2\n1 or 2\n1\nAngiotensin II receptor blockers\n Azilsartan (Edarbi)\n Candesartan (Atacand)\n Eprosartan (Teveten)\n Irbesartan (Avapro)\n Losartan (Cozaar)\n Olmesartan (Benicar)\n Telmisartan (Micardis)\n Valsartan (Diovan)\n40–80\n8–32\n600–800\n150–300\n50–100\n20–40\n20–80\n80–320\n1\n1 or 2\n1 or 2\n1\n1 or 2\n1\n1\n1\nCalcium channel blockers\n Dihydropyridines\n  Amlodipine (Norvasc)\n  Felodipine (Plendil)\n  Isradipine (DynaCirc)\n  Isradipine SR (DynaCirc SR)\n  Nicardipine sustained-release (Cardene SR)\n  Nifedipine long-acting (Adalat CC, Procardia XL)\n  Nisoldipine (Sular)\n2.5–10\n5–20\n5–10\n5–20\n60–120\n30–90\n10–40\n1\n1\n2\n1\n2\n1\n1\n Nondihydropyridines\n  Diltiazem sustained-release (Cardizem SR)\n   Diltiazem sustained-release (Cardizem CD,  \n Cartia XT, Dilacor XR, Diltia XT, Tiazac, Taztia XT)\n  Diltiazem extended-release (Cardizem LA)\n  Verapamil sustained-release (Calan SR, Isoptin  \n  SR, Verelan)\n  Verapamil controlled-onset extended-release  \n  (Covera HS)\n  Verapamil chronotherapeutic oral drug \n  absorption system (Verelan PM)\n180–360\n120–480\n120–540\n180–480\n180–420\n100–400\n2\n1\n1 (morning or evening)\n1 or 2\n1 (in the evening)\n1 (in the evening)\nDiuretics\n Thiazides\n Chlorthalidone (Hygroton)\n Hydrochlorothiazide (Esidrix, HydroDiuril,  \n Microzide, Oretic)\n Indapamide (Lozol)\n Metolazone (Mykrox)\n Metolazone (Zaroxolyn)\n12.5–25\n12.5–50\n1.25–2.5\n0.5–1\n2.5–10\n1\n1\n1\n1\n1\n(continued )",
    "word_count": 253,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0175",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 175,
    "text": "90\nSECTION 2  |  Cardiovascular Disorders\n TABLE 10–2  First-Line and Other Common Antihypertensive Agents\nClass/Subclass/Drug (brand name)\nUsual Dose \nRange (mg/\nday) Daily Frequency\n Triamterene (Dyrenium)\n Triamterene/hydrochlorothiazide (Dyazide)\n50–100\n37.5–75/25–50\n1 or 2\n1\nLoops\n Bumetanide (Bumex)\n Furosemide (Lasix)\n Torsemide (Demadex)\n0.5–4\n20–80\n5–10\n2\n2\n1\nPotassium sparing\n Amiloride (Midamor)\n Amiloride/hydrochlorothiazide (Moduretic)\n5–10\n5–10/50–100\n1 or 2\n1\nβ-Blockers\n Cardioselective\n  Atenolol (Tenormin)\n  Betaxolol (Kerlone)\n  Bisoprolol (Zebeta)\n  Metoprolol tartrate (Lopressor)\n  Metoprolol succinate extended-release (Toprol \nXL)\n25–100\n5–20\n2.5–10\n100–400\n50–200\n1\n1\n1\n2\n1\n Nonselective\n  Nadolol (Corgard)\n  Propranolol (Inderal)\n  Propranolol long-acting (Inderal LA, InnoPran \nXL)\n  Timolol (Blocadren)\n40–120\n160–480\n80–320\n10–40\n1\n2\n1\n1\n Intrinsic sympathomimetic activity\n  Acebutolol (Sectral)\n  Carteolol (Cartrol)\n  Penbutolol (Levatol)\n  Pindolol (Visken)\n200–800\n2.5–10\n10–40\n10–60\n2\n1\n1\n2\n Mixed α- and β-blockers\n  Carvedilol (Coreg)\n  Carvedilol phosphate (Coreg CR)\n  Labetalol (Normodyne, Trandate)\n12.5–50\n20–80\n200–800\n2\n1\n2\n Cardioselective and vasodilatory\n  Nebivolol (Bystolic) 5–20 1\n(Continued )\nis\trecommended\tfor\tpatients\twith\tstage\t2\thypertension,\tpreferably\twith\ttwo\tfirst-line\t\nagents.\n•\tThere\t are\t six\t compelling\t indications\t where\t specific\t antihypertensive\t drug\t classes\t\nprovide\tunique\tbenefits\t(Fig. 10–2).\n•\tOther\t antihypertensive\t drug\t classes\t (α1-blockers,\t direct\t renin\t inhibitors,\t central\t\nα2-agonists,\t peripheral\t adrenergic\t antagonists,\t and\t direct\t arterial\t vasodilators)\t are\t\nalternatives\tthat\tmay\tbe\tused\tfor\tselect\tpatients\tafter\tfirst-line\tagents\t(Table 10–3).\nAngiotensin-Converting Enzyme Inhibitors\n•\tACE\tinhibitors\tare\ta\tfirst-line\toption,\tand\tif\tthey\tare\tnot\tthe\tfirst\tagent\tused,\tthey\t\nshould\tbe\tthe\tsecond\tagent\ttried\tin\tmost\tpatients.\n•\tACE\t inhibitors\t block\t conversion\t of\t angiotensin\t I\t to\t angiotensin\t II,\t a\t potent\t vaso-\nconstrictor\t and\t stimulator\t of\t aldosterone\t secretion.\t ACE\t inhibitors\t also\t block",
    "word_count": 267,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0176",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 176,
    "text": "91\nHypertension  |  CHAPTER 10\ndegradation\tof\tbradykinin\tand\tstimulate\tsynthesis\tof\tother\tvasodilating\tsubstances,\t\nincluding\tprostaglandin\tE2\tand\tprostacyclin.\t\n•\tStarting\tdoses\tshould\tbe\tlow\twith\tslow\tdose\ttitration.\tAcute\thypotension\tmay\toccur\t\nat\tthe\tonset\tof\ttherapy,\tespecially\tin\tpatients\twho\tare\tsodium-\tor\tvolume-depleted,\t\nin\t HF\t exacerbation,\t very\t elderly,\t or\t on\t concurrent\t vasodilators\t or\t diuretics.\t Start\t\nadministering\t doses\t in\t such\t patients,\t using\t half\t the\t normal\t dose\tfollowed\tby\t slow\t\ndose\ttitration.\n•\tACE\tinhibitors\tdecrease\taldosterone\tand\tcan\tincrease\tserum\tpotassium\tconcentrations.\t\nHyperkalemia\toccurs\tprimarily\tin\tpatients\twith\tCKD\tor\tthose\talso\ttaking\tpotassium\t\nsupplements,\tpotassium-sparing\tdiuretics,\tARBs,\tor\ta\tdirect\trenin\tinhibitor.\n•\tAcute\t renal\t failure\t is\t a\t rare\t but\t serious\t side\t effect;\t preexisting\t kidney\t disease\t\nincreases\t risk.\t Bilateral\t renal\t artery\t stenosis\t or\t unilateral\t stenosis\t of\t a\t solitary\t\nfunctioning\t kidney\t renders\t patients\t dependent\t on\t the\t vasoconstrictive\t effect\t of\t\nangiotensin\t II\t on\t efferent\t arterioles,\t making\t these\t patients\t particularly\t susceptible\t\nto\tacute\trenal\tfailure.\n•\tGFR\tdeclines\tin\tpatients\treceiving\tACE\tinhibitors\tbecause\tof\tinhibition\tof\tangioten-\nsin\tII\tvasoconstriction\ton\tefferent\tarterioles.\tSerum\tcreatinine\tconcentrations\toften\t\nincrease,\tbut\tmodest\televations\t(eg,\tabsolute\tincreases\t<1\tmg/dL\t[88\tμmol/L])\tdo\tnot\t\nwarrant\t treatment\t changes.\t Discontinue\t therapy\t or\t reduce\t dose\t if\t larger\t increases\t\noccur.\nInitial Drug Therapy\nChoices\nNo Compelling Indications Compelling Indication(s)\n(see Fig.10-2)\nStage 1 Hypertension\n(SBP 140–159 or DBP 90–99 mm Hg)\nStage 2 Hypertension\n(SBP ≥160 or DBP ≥100 mm Hg)\n• ACE Inhibitor [A-1], ARB [A-2],\n CCB [A-1], or thiazide-type\n diuretic [A-1];\nTwo-drug combination [B-2]\nMonotherapy using:\nor\n• ACE Inhibitor or ARB with a\n thiazide-type diuretic [B-2]; or\n• ACE Inhibitor or ARB with a CCB [A-2]\nTwo-drug combination for most\n[A-1], preferably using:\nFIGURE 10–1.  Algorithm for treatment of hypertension.  Drug therapy recom-\nmendations are graded with strength of recommendation and quality of evidence \nin brackets. Strength of recommendations: A, B, C are good, moderate, and poor \nevidence to support recommendation, respectively. Quality of evidence: (1) evidence \nfrom more than one properly randomized, controlled trial; (2) evidence from at least \none well-designed clinical trial with randomization, from cohort or case-controlled \nstudies, or dramatic results from uncontrolled experiments or subgroup analyses;  \n(3) evidence from opinions of respected authorities, based on clinical experience, \ndescriptive studies, or reports of expert communities. (ACE, angiotensin-converting \nenzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DBP , diastolic \nblood pressure; SBP , systolic blood pressure.)",
    "word_count": 396,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0177",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 177,
    "text": "92\nSECTION 2  |  Cardiovascular Disorders\nCompelling\nindication(s)\nHeart failure\nwith reduced\nejection fraction\nDiuretic with\nACE inhibitor or \nARB \n[A-1];\nthen add\nβ-Blocker\n[A-1]\nCCB [A-1]\nThiazide diuretic\n[A-1],\nβ-Blocker\n[B-2]\nCCB [B-1]\nThiazide diuretic\n[B-2]\nAldosterone\nantagonist\n[A-1]\nβ-Blocker\n[A-1];\nthen add\nACE inhibitor\n[A-1] or\nARB [A-2]\nβ-Blocker\n[A-1];\nthen add\nACE inhibitor\n[A-1] or ARB\n[B-2]\nStandard\nPharmacotherapy\nAdd-on\nPharmacotherapy\nPost–\nmyocardial\ninfarction\nCoronary\nartery\ndisease\nChronic\nkidney\ndisease\nRecurrent\nstroke\nprevention\nDiabetes\nmellitus\nACE inhibitor\n[A-1],\nor\nARB [A-1]\nThiazide diuretic \n[A-2] or \nThiazide diuretic \nwith\nACE inhibitor\n[A-2]\nACE inhibitor\n[A-1],\nor\nARB [A-1]\nFIGURE 10–2.  Compelling indications for individual drug classes.  Compelling indications for specific drugs are \nevidence-based recommendations from outcome studies or existing clinical guidelines. (ACE, angiotensin-converting \nenzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.)",
    "word_count": 134,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0178",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 178,
    "text": "93\nHypertension  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0179",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 179,
    "text": "93\nHypertension     CHAPTER 10\n•\tAngioedema\toccurs\tin\tfewer\tthan\t1%\tof\tpatients.\tDrug\twithdrawal\tis\tnecessary,\tand\t\nsome\tpatients\tmay\trequire\tdrug\ttreatment\tand/or\temergent\tintubation.\tAn\tARB\tcan\t\ngenerally\tbe\tused\tin\tpatients\twith\ta\thistory\tof\tACE\tinhibitor–induced\tangioedema,\t\nwith\tcareful\tmonitoring.\n•\tA\tpersistent\tdry\tcough\toccurs\tin\tup\tto\t20%\tof\tpatients\tand\tis\tthought\tto\tbe\tdue\tto\t\ninhibition\tof\tbradykinin\tbreakdown.\n•\tACE\tinhibitors\t(as\twell\tas\tARBs\tand\tdirect\trenin\tinhibitors)\tare\tcontraindicated\tin\t\npregnancy.\nAngiotensin II Receptor Blockers\n•\tAngiotensin\tII\tis\tgenerated\tby\tthe\trenin–angiotensin\tpathway\t(which\tinvolves\tACE)\t\nand\tan\talternative\tpathway\tthat\tuses\tother\tenzymes\tsuch\tas\tchymases.\tACE\tinhibitors\t\nblock\tonly\tthe\trenin–angiotensin\tpathway,\twhereas\tARBs\tantagonize\tangiotensin\tII\t\ngenerated\tby\teither\tpathway.\tThe\tARBs\tdirectly\tblock\tthe\tangiotensin\tII\ttype\t1\trecep-\ntor\tthat\tmediates\tthe\teffects\tof\tangiotensin\tII.\n•\tUnlike\t ACE\t inhibitors,\t ARBs\t do\t not\t block\t bradykinin\t breakdown.\t Although\t this\t\naccounts\tfor\tthe\tlack\tof\tcough\tas\ta\tside\teffect,\tthere\tmay\tbe\tnegative\tconsequences\t\nbecause\t some\t of\t the\t antihypertensive\t effect\t of\t ACE\t inhibitors\t may\t be\t due\t to\t\nincreased\tlevels\tof\tbradykinin.\n•\tAll\tARBs\thave\tsimilar\tantihypertensive\tefficacy\tand\tfairly\tflat\tdose-response\tcurves.\t\nAddition\t of\t a\t CCB\t or\t thiazide\t diuretic\t significantly\t increases\t antihypertensive\t\nefficacy.\n•\tARBs\thave\ta\tlow\tincidence\tof\tside\teffects.\tLike\tACE\tinhibitors,\tthey\tmay\tcause\trenal\t\ninsufficiency,\thyperkalemia,\tand\torthostatic\thypotension.\tARBs\tare\tcontraindicated\t\nin\tpregnancy.\nCalcium Channel Blockers\n•\tCalcium\tchannel\tblockers\t(CCBs)\tcause\trelaxation\tof\tcardiac\tand\tsmooth\tmuscle\tby\t\nblocking\tvoltage-sensitive\tcalcium\tchannels,\tthereby\treducing\tentry\tof\textracellular\t\ncalcium\tinto\tcells.\tThis\tleads\tto\tvasodilation\tand\ta\tcorresponding\treduction\tin\tBP .\t\nDihydropyridine\tcalcium\tchannel\tantagonists\tmay\tcause\treflex\tsympathetic\tactiva-\ntion,\tand\tall\tagents\t(except\tamlodipine\tand\tfelodipine)\tmay\thave\tnegative\tinotropic\t\neffects.\n•\tVerapamil\t decreases\t heart\t rate,\t slows\t atrioventricular\t (A V)\t nodal\t conduction,\t\nand\t produces\t a\t negative\t inotropic\t effect\t that\t may\t precipitate\t HF\t in\t patients\t with\t\n TABLE 10–3  Alternative Antihypertensive Agents\nClass Drug (Brand Name) Usual Dose Range (mg/\nday)\nDaily Frequency\nα1-Blockers\n Doxazosin (Cardura)\n Prazosin (Minipress)\n Terazosin (Hytrin)\n1–8\n2–20\n1–20\n1\n2 or 3\n1 or 2\nDirect renin inhibitor\n Aliskiren (Tekturna) 150–300 1\nCentral α2-agonists\n Clonidine (Catapres)\n Clonidine patch (Catapres-TTS)\n Methyldopa (Aldomet)\n0.1–0.8\n0.1–0.3\n250–1,000\n2\n1 weekly\n2\nPeripheral adrenergic antagonist\n Reserpine (generic only) 0.05–0.25 1\nDirect arterial vasodilators\n Minoxidil (Loniten)\n Hydralazine (Apresoline)\n10–40\n20–100\n1 or 2\n2 to 4",
    "word_count": 401,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0180",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 180,
    "text": "94\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0181",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 181,
    "text": "94\nSECTION 2     Cardiovascular Disorders\nborderline\tcardiac\treserve.\tDiltiazem\tdecreases\tA V\tconduction\tand\theart\trate\tto\ta\t\nlesser\textent\tthan\tverapamil.\n•\tDiltiazem\tand\tverapamil\tcan\tcause\tcardiac\tconduction\tabnormalities\tsuch\tas\tbrady-\ncardia,\tA V\tblock,\tand\tHF .\tBoth\tcan\tcause\tanorexia,\tnausea,\tperipheral\tedema,\tand\t\nhypotension.\tV erapamil\tcauses\tconstipation\tin\t~7%\tof\tpatients.\n•\tDihydropyridines\tcause\ta\tbaroreceptor-mediated\treflex\tincrease\tin\theart\trate\tbecause\t\nof\tpotent\tperipheral\tvasodilating\teffects.\tDihydropyridines\tdo\tnot\tdecrease\tA V\tnode\t\nconduction\tand\tare\tnot\teffective\tfor\ttreating\tsupraventricular\ttachyarrhythmias.\n•\tShort-acting\t nifedipine\t may\t rarely\t increase\t frequency,\t intensity,\t and\t duration\t of\t\nangina\tin\tassociation\twith\tacute\thypotension.\tThis\teffect\tmay\tbe\tobviated\tby\tusing\t\nsustained-release\t formulations\t of\t nifedipine\t or\t other\t dihydropyridines.\t Other\t side\t\neffects\t of\t dihydropyridines\t are\t dizziness,\t flushing,\t headache,\t gingival\t hyperplasia,\t\nand\tperipheral\tedema.\nDiuretics\n•\tAcutely,\tdiuretics\tlower\tBP\tby\tcausing\tdiuresis.\tThe\treduction\tin\tplasma\tvolume\tand\t\nstroke\tvolume\tassociated\twith\tdiuresis\tdecreases\tcardiac\toutput\tand\tBP .\tThe\tinitial\tdrop\t\nin\t cardiac\t output\t causes\t a\t compensatory\t increase\t in\t peripheral\t vascular\t resistance.\t\nWith\t chronic\t therapy,\t extracellular\t fluid\t volume\t and\t plasma\t volume\t return\t to\t near\t\npretreatment\t levels,\t and\t peripheral\t vascular\t resistance\t falls\t below\t baseline.\t Reduced\t\nperipheral\tvascular\tresistance\tis\tresponsible\tfor\tthe\tlong-term\thypotensive\teffects.\t\n•\tThiazide diuretics\tare\tthe\tpreferred\ttype\tof\tdiuretic\tfor\tmost\thypertensive\tpatients.\t\nThey\t mobilize\t sodium\t and\t water\t from\t arteriolar\t walls,\t which\t may\t contribute\t to\t\ndecreased\tperipheral\tvascular\tresistance\tand\tlowered\tBP .\n•\tLoop diuretics\tare\tmore\tpotent\tfor\tinducing\tdiuresis\tbut\tare\tnot\tideal\tantihyperten-\nsives\tunless\trelief\tof\tedema\tis\talso\tneeded.\tLoops\tare\toften\tpreferred\tover\tthiazides\tin\t\npatients\twith\tCKD\twhen\testimated\tGFR\tis\tless\tthan\t30\tmL/min/1.73\tm2.\n•\tPotassium-sparing diuretics\tare\tweak\tantihypertensives\twhen\tused\talone\tand\tpro-\nvide\tminimal\tadditive\teffect\twhen\tcombined\twith\ta\tthiazide\tor\tloop\tdiuretic.\tTheir\t\nprimary\tuse\tis\tin\tcombination\twith\tanother\tdiuretic\tto\tcounteract\tpotassium-wasting\t\nproperties.\n•\tAldosterone antagonists (spironolactone \t and\t eplerenone)\t are\t also\t potassium-\nsparing\tdiuretics\tbut\tare\tmore\tpotent\tantihypertensives\twith\ta\tslow\tonset\tof\taction\t\n(up\tto\t6\tweeks\twith\tspironolactone).\n•\tWhen\tdiuretics\tare\tcombined\twith\tother\tantihypertensive\tagents,\tan\tadditive\thypo-\ntensive\t effect\t is\t usually\t observed\t because\t of\t independent\t mechanisms\t of\t action.\t\nFurthermore,\t many\t nondiuretic\t antihypertensive\t agents\t induce\t sodium\t and\t water\t\nretention,\twhich\tis\tcounteracted\tby\tconcurrent\tdiuretic\tuse.\n•\tSide\t effects\t of\t thiazides\t include\t hypokalemia,\t hypomagnesemia,\t hypercalcemia,\t\nhyperuricemia,\thyperglycemia,\tdyslipidemia,\tand\tsexual\tdysfunction.\tLoop\tdiuretics\t\nhave\tless\teffect\ton\tserum\tlipids\tand\tglucose,\tbut\thypokalemia\tis\tmore\tpronounced,\t\nand\thypocalcemia\tmay\toccur.\n•\tHypokalemia\tand\thypomagnesemia\tmay\tresult\tin\tcardiac\tarrhythmias,\tespecially\tin\t\npatients\t receiving\t digoxin,\t patients\t with\t LV\t hypertrophy,\t and\t those\t with\t ischemic\t\nheart\tdisease.\tLow-dose\ttherapy\t(eg,\t25\tmg\thydrochlorothiazide\tor\t12.5\tmg\tchlortha-\nlidone\tdaily)\tcauses\tsmall\telectrolyte\tdisturbances.\n•\tPotassium-sparing\t diuretics\t may\t cause\t hyperkalemia,\t especially\t in\t patients\t with\t\nCKD\t or\t diabetes\t and\t in\t patients\t receiving\t concurrent\t treatment\t with\t an\t ACE\t\ninhibitor,\tARB,\tdirect\trenin\tinhibitor,\tor\tpotassium\tsupplement.\tEplerenone\thas\tan\t\nincreased\t risk\t for\t hyperkalemia\t and\t is\t contraindicated\t in\t patients\t with\t impaired\t\nrenal\tfunction\tor\ttype\t2\tdiabetes\twith\tproteinuria.\tSpironolactone\tmay\tcause\tgyneco-\nmastia\tin\tup\tto\t10%\tof\tpatients;\tthis\teffect\toccurs\trarely\twith\teplerenone.\nβ-Blockers\n•\tβ-Blockers\tare\tonly\tconsidered\tappropriate\tfirst-line\tagents\tto\ttreat\tspecific\tcompel-\nling\tindications\t(eg,\tpost-MI\t[myocardial\tinfarction],\tcoronary\tartery\tdisease).\tTheir\t\nhypotensive\t mechanism\t may\t involve\t decreased\t cardiac\t output\t through\t negative",
    "word_count": 560,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0182",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 182,
    "text": "95\nHypertension  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0183",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 183,
    "text": "95\nHypertension     CHAPTER 10\nchronotropic\tand\tinotropic\teffects\ton\tthe\theart\tand\tinhibition\tof\trenin\trelease\tfrom\t\nthe\tkidney.\n•\tAtenolol,\tbetaxolol,\tbisoprolol,\tand\tmetoprolol\tare\tcardioselective\tat\tlow\tdoses\tand\t\nbind\tmore\tavidly\tto\tβ1-receptors\tthan\tto\tβ2-receptors.\tAs\ta\tresult,\tthey\tare\tless\tlikely\t\nto\tprovoke\tbronchospasm\tand\tvasoconstriction\tand\tmay\tbe\tsafer\tthan\tnonselective\t\nβ-blockers\tin\tpatients\twith\tasthma,\tchronic\tobstructive\tpulmonary\tdisease\t(COPD),\t\ndiabetes,\tand\tperipheral\tarterial\tdisease\t(PAD).\tCardioselectivity\tis\ta\tdose-dependent\t\nphenomenon,\tand\tthe\teffect\tis\tlost\tat\thigher\tdoses.\n•\tAcebutolol,\t carteolol,\t penbutolol,\t and\t pindolol\t possess\t intrinsic\t sympathomimetic\t\nactivity\t(ISA)\tor\tpartial\tβ-receptor\tagonist\tactivity.\tWhen\tsympathetic\ttone\tis\tlow,\tas\tin\t\nresting\tstates,\tβ-receptors\tare\tpartially\tstimulated,\tso\tresting\theart\trate,\tcardiac\toutput,\tand\t\nperipheral\tblood\tflow\tare\tnot\treduced\twhen\treceptors\tare\tblocked.\tTheoretically,\tthese\t\ndrugs\tmay\thave\tadvantages\tin\tpatients\twith\tHF\tor\tsinus\tbradycardia.\tUnfortunately,\tthey\t\ndo\tnot\treduce\tCV\tevents\tas\twell\tas\tother\tβ-blockers\tand\tmay\tincrease\trisk\tafter\tMI\tor\tin\t\nthose\twith\thigh\tcoronary\tdisease\trisk.\tThus,\tagents\twith\tISA\tare\trarely\tneeded.\n•\tAtenolol\tand\tnadolol\thave\trelatively\tlong\thalf-lives\tand\tare\texcreted\trenally;\tthe\tdosage\t\nmay\tneed\tto\tbe\treduced\tin\tpatients\twith\trenal\tinsufficiency.\tEven\tthough\tthe\thalf-lives\tof\t\nother\tβ-blockers\tare\tshorter,\tonce-daily\tadministration\tstill\tmay\tbe\teffective.\t\n•\tMyocardial\tside\teffects\tinclude\tbradycardia,\tA V\tconduction\tabnormalities,\tand\tacute\t\nHF .\t Blocking\t β2-receptors\t in\t arteriolar\t smooth\t muscle\t may\t cause\t cold\t extremities\t\nand\taggravate\tPAD\tor\tRaynaud\tphenomenon\tbecause\tof\tdecreased\tperipheral\tblood\t\nflow.\tIncreases\tin\tserum\tlipids\tand\tglucose\tappear\tto\tbe\ttransient\tand\tof\tlittle\tclinical\t\nimportance.\n•\tAbrupt\t cessation\t of\t β-blocker\t therapy\t may\t produce\t unstable\t angina,\t MI,\t or\t even\t\ndeath\t in\t patients\t with\t coronary\t disease.\t In\t patients\t without\t heart\t disease,\t abrupt\t\ndiscontinuation\t of\t β-blockers\t may\t be\t associated\t with\t tachycardia,\t sweating,\t and\t\ngeneralized\tmalaise\tin\taddition\tto\tincreased\tBP .\tFor\tthese\treasons,\tthe\tdose\tshould\t\nalways\tbe\ttapered\tgradually\tover\t1\tto\t2\tweeks\tbefore\tdiscontinuation.\nα 1-Receptor Blockers\n•\tPrazosin,\t terazosin,\t and\t doxazosin\t are\t selective\t α1-receptor\t blockers\t that\t inhibit\t\ncatecholamine\tuptake\tin\tsmooth\tmuscle\tcells\tof\tperipheral\tvasculature,\tresulting\tin\t\nvasodilation.\n•\tA\tfirst-dose\tphenomenon\tcharacterized\tby\torthostatic\thypotension\taccompanied\tby\t\ntransient\tdizziness\tor\tfaintness,\tpalpitations,\tand\teven\tsyncope\tmay\toccur\twithin\t1\tto\t\n3\thours\tof\tthe\tfirst\tdose\tor\tafter\tlater\tdosage\tincreases.\tThe\tpatient\tshould\ttake\tthe\t\nfirst\tdose\t(and\tsubsequent\tfirst\tincreased\tdoses)\tat\tbedtime.\tOccasionally,\torthostatic\t\ndizziness\tpersists\twith\tchronic\tadministration.\n•\tSodium\tand\twater\tretention\tcan\toccur;\tthese\tagents\tare\tmost\teffective\twhen\tgiven\t\nwith\ta\tdiuretic\tto\tmaintain\tantihypertensive\tefficacy\tand\tminimize\tedema.\n•\tBecause\tdoxazosin\t(and\tprobably\tother\tα1-receptor\tblockers)\tmay\tnot\tbe\tas\tprotec-\ntive\t against\t CV\t events\t as\t other\t therapies,\t they\t should\t be\t reserved\t as\t alternative\t\nagents\tfor\tunique\tsituations,\tsuch\tas\tmen\twith\tbenign\tprostatic\thyperplasia.\tIf\tused\t\nto\tlower\tBP\tin\tthis\tsituation,\tthey\tshould\tonly\tbe\tused\tin\tcombination\twith\tfirst-line\t\nantihypertensives.\nDirect Renin Inhibitor\n•\tAliskiren\t blocks\t the\t RAAS\t at\t its\t point\t of\t activation,\t resulting\t in\t reduced\t plasma\t\nrenin\tactivity\tand\t BP .\tBP\treductions\t are\tcomparable\t to\t an\tACE\t inhibitor,\tARB,\t or\t\nCCB.\tAliskiren\t is\t approved\t for\t monotherapy\tor\tin\tcombination\t with\tother\t agents.\t\nIt\tshould\tnot\tbe\tused\tin\tcombination\twith\tan\tACE\tinhibitor\tor\tan\tARB\tbecause\tof\ta\t\nhigher\trisk\tof\tadverse\teffects\twithout\tadditional\treduction\tin\tCV\tevents.\n•\tMany\tof\tthe\tcautions\tand\tadverse\teffects\tseen\twith\tACE\tinhibitors\tand\tARBs\tapply\t\nto\taliskiren.\tIt\tis\tcontraindicated\tin\tpregnancy.\n•\tUse\t aliskiren\t only\t as\t an\t alternative\t therapy\t because\t of\t lack\t of\t long-term\t studies\t\nevaluating\tCV\tevent\treduction\tand\tits\tsignificant\tcost\tcompared\twith\tgeneric\tagents\t\nthat\thave\toutcomes\tdata.",
    "word_count": 612,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0184",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 184,
    "text": "96\nSECTION 2     Cardiovascular Disorders\nCentral α 2-Agonists\n•\tClonidine, guanabenz, guanfacine,\tand\tmethyldopa\tlower\tBP\tprimarily\tby\tstimulat-\ning\t α2-adrenergic\t receptors\tin\t the\t brain,\t which\t reduces\tsympathetic\t outflow\t from\tthe\t\nvasomotor\t center\t and\t increases\t vagal\t tone.\t Stimulation\t of\t presynaptic\t α2-receptors\t\nperipherally\tmay\t contribute\tto\treduced\tsympathetic\t tone.\tConsequently,\t there\tmay\tbe\t\ndecreases\tin\theart\trate,\tcardiac\toutput,\ttotal\tperipheral\tresistance,\tplasma\trenin\tactivity,\t\nand\tbaroreceptor\treflexes.\n•\tChronic\tuse\tresults\tin\tsodium\tand\tfluid\tretention.\tOther\tside\teffects\tinclude\tdepres-\nsion,\torthostatic\thypotension,\tdizziness,\tand\tanticholinergic\teffects.\n•\tAbrupt\t cessation\t may\t lead\t to\t rebound\t hypertension,\t perhaps\t from\t a\t compensa-\ntory\t increase\tin\t norepinephrine\trelease\tthat\tfollows\t discontinuation\tof\t presynaptic\t\nα-receptor\tstimulation.\n•\tMethyldopa\t rarely\t causes\t hepatitis\t or\t hemolytic\t anemia.\t A\t transient\t elevation\t\nin\t hepatic\t transaminases\t occasionally\t occurs.\t Discontinue\t therapy\t if\t persistent\t\nincreases\t in\tliver\tfunction\ttests\toccur,\tbecause\tthis\tmay\therald\t onset\tof\tfulminant,\t\nlife-threatening\thepatitis.\tCoombs-positive\themolytic\tanemia\toccurs\trarely,\tand\t20%\t\nof\tpatients\texhibit\ta\tpositive\tdirect\tCoombs\ttest\twithout\tanemia.\tFor\tthese\treasons,\t\nmethyldopa\thas\tlimited\tusefulness\texcept\tin\tpregnancy.\nReserpine\n•\tReserpine\t depletes\t norepinephrine\t from\t sympathetic\t nerve\t endings\t and\t blocks\t\ntransport\tof\tnorepinephrine\tinto\tstorage\tgranules.\tWhen\tthe\tnerve\tis\tstimulated,\tless\t\nthan\tthe\tusual\tamount\tof\tnorepinephrine\tis\treleased\tinto\tthe\tsynapse.\tThis\treduces\t\nsympathetic\ttone,\tdecreasing\tperipheral\tvascular\tresistance\tand\tBP .\n•\tReserpine\thas\ta\tlong\thalf-life\tthat\tallows\tfor\tonce-daily\tdosing,\tbut\tit\tmay\ttake\t2\tto\t\t\n6\tweeks\tbefore\tthe\tmaximal\tantihypertensive\teffect\tis\tseen.\n•\tReserpine\tcan\tcause\tsignificant\tsodium\tand\tfluid\tretention,\tand\tit\tshould\tbe\tgiven\t\nwith\ta\tdiuretic\t(preferably\ta\tthiazide).\n•\tReserpine’ s\tstrong\tinhibition\tof\tsympathetic\tactivity\tresults\tin\tparasympathetic\tactiv-\nity,\t which\t is\t responsible\t for\t side\t effects\t of\t nasal\t stuffiness,\t increased\t gastric\t acid\t\nsecretion,\tdiarrhea,\tand\tbradycardia.\n•\tDose-related\tdepression\tcan\tbe\tminimized\tby\tnot\texceeding\t0.25\tmg\tdaily.\nDirect Arterial Vasodilators\n•\tHydralazine \t and\t minoxidil \t cause\t direct \t arteriolar \t smooth \t muscle \t relaxation. \t\nCompensatory \t activation \t of\t baroreceptor \t reflexes \t results \t in\t increased \t sympa-\nthetic \toutflow \tfrom\tthe\tvasomotor \tcenter,\tincreasing \theart \trate,\tcardiac \toutput,\t\nand\trenin\trelease.",
    "word_count": 342,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0185",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 185,
    "text": "\t\nCompensatory \t activation \t of\t baroreceptor \t reflexes \t results \t in\t increased \t sympa-\nthetic \toutflow \tfrom\tthe\tvasomotor \tcenter,\tincreasing \theart \trate,\tcardiac \toutput,\t\nand\trenin\trelease. \tConsequently, \thypotensive \teffectiveness \tof\tdirect \tvasodilators \t\ndiminishes \t over\t time\t unless \t the\t patient \t is\t also\t taking \t a\t sympathetic \t inhibitor \t\nand\ta\tdiuretic.\n•\tPatients\ttaking\tthese\tdrugs\tfor\tlong-term\thypertension\ttherapy\tshould\tfirst\treceive\t\nboth\ta\tdiuretic\tand\ta\tβ-blocker.\tThe\tdiuretic\tminimizes\tthe\tside\teffect\tof\tsodium\tand\t\nwater\tretention.\tDirect\tvasodilators\tcan\tprecipitate\tangina\tin\tpatients\twith\tunderly-\ning\tcoronary\tartery\tdisease\tunless\tthe\tbaroreceptor\treflex\tmechanism\tis\tcompletely\t\nblocked\twith\ta\tβ-blocker.\tNondihydropyridine\tCCBs\tcan\tbe\tused\tas\tan\talternative\tto\t\nβ-blockers\tin\tpatients\twith\tcontraindications\tto\tβ-blockers.\n•\tHydralazine\tmay\tcause\tdose-related,\treversible\tlupus-like\tsyndrome,\twhich\tis\tmore\t\ncommon\t in\t slow\t acetylators.\t Lupus-like\t reactions\t can\t usually\t be\t avoided\t by\t using\t\ntotal\t daily\t doses\t less\t than\t 200\t mg.\t Because\t of\t side\t effects,\t hydralazine\t has\t limited\t\nusefulness\tfor\tchronic\thypertension\tmanagement.\n•\tMinoxidil\tis\ta\tmore\tpotent\tvasodilator\tthan\thydralazine,\tand\tcompensatory\tincreases\t\nin\theart\trate,\tcardiac\toutput,\trenin\trelease,\tand\tsodium\tretention\tare\tmore\tdramatic.\t\nSevere\t sodium\t and\t water\t retention\t may\t precipitate\t congestive\t HF .\t Minoxidil\t also\t\ncauses\treversible\thypertrichosis\ton\tthe\tface,\tarms,\tback,\tand\tchest.\tReserve\tminoxidil\t\nfor\tvery\tdifficult\tto\tcontrol\thypertension\tand\tfor\tpatients\trequiring\thydralazine\twho\t\nexperience\tdrug-induced\tlupus.",
    "word_count": 219,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0186",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 186,
    "text": "97\nHypertension     CHAPTER 10\nCOMPELLING INDICATIONS\n•\tSix\tcompelling\tindications\trepresent\tspecific\tcomorbid\tconditions\tfor\twhich\tclinical\t\ntrial\tdata\tsupport\tusing\tspecific\tantihypertensive\tdrug\tclasses\tto\ttreat\tboth\thyperten-\nsion\tand\tthe\tcompelling\tindication\t(see\tFig.",
    "word_count": 36,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0187",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 187,
    "text": "  CHAPTER 10\nCOMPELLING INDICATIONS\n•\tSix\tcompelling\tindications\trepresent\tspecific\tcomorbid\tconditions\tfor\twhich\tclinical\t\ntrial\tdata\tsupport\tusing\tspecific\tantihypertensive\tdrug\tclasses\tto\ttreat\tboth\thyperten-\nsion\tand\tthe\tcompelling\tindication\t(see\tFig. 10–2).\nLeft Ventricular Dysfunction (Systolic Heart Failure)\n•\tStandard\t pharmacotherapy\t consists\t of\t three\t to\t four\t drugs:\t ACE\t inhibitor\t or\t ARB\t\nplus\tdiuretic\ttherapy,\tfollowed\tby\taddition\tof\tan\tappropriate\tβ-blocker\tand\tpossibly\t\nan\taldosterone\treceptor\tantagonist.\n•\tStart\tan\tACE\tinhibitor\tor\tARB\tin\tlow\tdoses\tto\tavoid\torthostatic\thypotension\tbecause\t\nof\tthe\thigh\trenin\tstate\tin\tHF .\n•\tDiuretics\tprovide\tsymptomatic\trelief\tof\tedema\tby\tinducing\tdiuresis.\tLoop\tdiuretics\t\nare\toften\tneeded,\tespecially\tin\tpatients\twith\tmore\tadvanced\tdisease.\n•\tβ-Blocker\t therapy\t is\t appropriate\t to\t further\t modify\t disease\t and\t is\t a\t component\t of\t\nstandard\ttherapy.\tBecause\tof\tthe\trisk\tof\texacerbating\tHF ,\tβ-blockers\tmust\tbe\tstarted\t\nin\tvery\tlow\tdoses\tand\ttitrated\tslowly\tto\thigh\tdoses\tbased\ton\ttolerability.\tBisoprolol,\t\ncarvedilol,\tand\tsustained-release\tmetoprolol\tsuccinate\tare\tthe\tonly\tβ-blockers\tproven\t\nto\tbe\tbeneficial\tin\tLV\tdysfunction.\n•\tAfter\t implementation\tof\ta\t standard\tthree-drug\tregimen,\tan\taldosterone\tantagonist\t\nmay\tbe\tconsidered.\nPostmyocardial Infarction\n•\tβ-Blockers\t (without\t ISA)\t and\t ACE\t inhibitor\t or\t ARB\t therapy\t are\t recommended.\t\nβ-Blockers\t decrease\t cardiac\t adrenergic\t stimulation\t and\t reduce\t risk\t of\t subsequent\t\nMI\t or\t sudden\t cardiac\t death.\t ACE\t inhibitors\t improve\t cardiac\t function\t and\t reduce\t\nCV\tevents\tafter\tMI.\tARBs\tare\talternatives\tto\tACE\tinhibitors\tin\tpost-MI\tpatients\twith\t\nLV\tdysfunction.\nCoronary Artery Disease\n•\tβ-Blockers\t(without\tISA)\tare\tfirst-line\ttherapy\tin\tchronic\tstable\tangina\tand\treduce\t\nBP ,\timprove\tmyocardial\tconsumption,\tand\tdecrease\tdemand.\tLong-acting\tCCBs\tare\t\neither\talternatives\t(verapamil\tand\tdiltiazem)\tor\tadd-on\ttherapy\t(dihydropyridines)\t\nto\tβ-blockers\tin\tchronic\tstable\tangina.\tOnce\tischemic\tsymptoms\tare\tcontrolled\twith\t\nβ-blocker\tand/or\tCCB\ttherapy,\tother\tantihypertensives\t(eg,\tACE\tinhibitor\tor\tARB)\t\ncan\t be\t added\t to\t provide\t additional\t CV\t risk\t reduction.\t Thiazide\t diuretics\t may\t be\t\nadded\tthereafter\tto\tprovide\tadditional\tBP\tlowering\tand\tfurther\treduce\tCV\trisk.\n•\tFor\t acute\t coronary\t syndromes,\t first-line\t therapy\t includes\t a\t β-blocker\t and\t ACE\t\ninhibitor\t(or\tARB);\tthe\tcombination\tlowers\tBP ,\tcontrols\tacute\tischemia,\tand\treduces\t\nCV\trisk.\nDiabetes Mellitus\n•\tTreat\tall\tpatients\twith\tdiabetes\tand\thypertension\twith\tan\tACE\tinhibitor\tor\tARB.\tBoth\t\nclasses\tprovide\tnephroprotection\tand\treduced\tCV\trisk.\n•\tCCBs\tare\tthe\tmost\tappropriate\tadd-on\tagents\tfor\tBP\tcontrol\tin\tpatients\twith\tdiabetes.\t\nThe\tcombination\tof\tan\tACE\tinhibitor\twith\ta\tCCB\tis\tmore\teffective\tin\treducing\tCV\t\nevents\tthan\tan\tACE\tinhibitor\tplus\ta\tthiazide\tdiuretic.\n•\tA\tthiazide\tdiuretic\tis\trecommended\tas\tan\tadd-on\tto\tthe\tprevious\tagents\tto\tlower\tBP\t\nand\tprovide\tadditional\tCV\trisk\treduction.\n•\tβ-Blockers,\t similar\t to\t CCBs,\t are\t useful\t add-on\t agents\t for\t BP\t control\t in\t patients\t\nwith\tdiabetes.\tThey\tshould\talso\tbe\tused\tto\ttreat\tanother\tcompelling\tindication\t(eg,\t\npost-MI).\tHowever,\tthey\tmay\tmask\tsymptoms\tof\thypoglycemia\t(tremor,\ttachycardia,\t\nand\tpalpitations\tbut\tnot\tsweating)\tin\ttightly\tcontrolled\tpatients,\tdelay\trecovery\tfrom\t\nhypoglycemia,\tand\tproduce\televations\tin\tBP\tdue\tto\tvasoconstriction\tcaused\tby\tunop-\nposed\tβ-receptor\tstimulation\tduring\tthe\thypoglycemic\trecovery\tphase.\tDespite\tthese\t\npotential\tproblems,\tβ-blockers\tcan\tbe\tused\tsafely\tin\tpatients\twith\tdiabetes.",
    "word_count": 517,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0188",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 188,
    "text": "98\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0189",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 189,
    "text": "98\nSECTION 2     Cardiovascular Disorders\nChronic Kidney Disease\n•\tEither\tan\tACE\tinhibitor\tor\tan\tARB\tis\tfirst-line\ttherapy\tto\tcontrol\tBP\tand\tpreserve\t\nkidney\tfunction\tin\tCKD.\tTreat\tpatients\twith\tmoderately\tor\tseverely\tincreased\talbu-\nminuria\tto\tgoal\tBP\tof\t130/80\tmm\tHg.\n•\tBecause\t these\t patients\t usually\t require\t multiple-drug\t therapy,\t diuretics\t and\t a\t third\t\nantihypertensive\tdrug\tclass\t(eg,\tβ-blocker\tor\tCCB)\tare\toften\tneeded.\nRecurrent Stroke Prevention\n•\tA\t thiazide\t diuretic,\t either\t as\t monotherapy\t or\t combined\t with\t an\t ACE\t inhibitor,\t\nis\t recommended\t for\t patients\t with\t history\t of\t stroke\t or\t transient\t ischemic\t attack.\t\nImplement\tantihypertensive\tdrug\ttherapy\tonly\tafter\tpatients\thave\tstabilized\tafter\tan\t\nacute\tcerebrovascular\tevent.\nSPECIAL POPULATIONS\nOlder People\n•\tElderly\tpatients\tmay\tpresent\twith\teither\tisolated\tsystolic\thypertension\tor\televation\tin\t\nboth\tSBP\tand\tDBP .\tCV\tmorbidity\tand\tmortality\tare\tmore\tclosely\trelated\tto\tSBP\tthan\t\nto\tDBP\tin\tpatients\t50\tyears\tof\tage\tand\tolder.\n•\tDiuretics,\t ACE\t inhibitors,\t and\t ARBs\t provide\t significant\t benefits\t and\t can\t be\t used\t\nsafely\t in\t the\t elderly,\t but\t smaller-than-usual\t initial\t doses\t must\t be\t used\t for\t initial\t\ntherapy.\nChildren and Adolescents\n•\tSecondary\thypertension\tis\tmore\tcommon\tin\tchildren\tand\tadolescents\tthan\tin\tadults.\t\nMedical\tor\tsurgical\tmanagement\tof\tthe\tunderlying\tdisorder\tusually\tnormalizes\tBP .\n•\tNonpharmacologic\ttreatment\t(particularly\tweight\tloss\tin\tobese\tchildren)\tis\tthe\tcor-\nnerstone\tof\ttherapy\tof\tprimary\thypertension.\n•\tACE\t inhibitors,\t ARBs,\t β-blockers,\t CCBs,\t and\t thiazide\t diuretics\t are\t all\t acceptable\t\ndrug\ttherapy\tchoices.\n•\tACE\t inhibitors,\t ARBs,\t and\t direct\t renin\t inhibitors\t are\t contraindicated\t in\t sexually\t\nactive\tgirls\tbecause\tof\tpotential\tteratogenic\teffects.\nPregnancy\n•\tPreeclampsia,\tdefined\tas\tBP\t\tof\t140/90\tmm\tHg\tor\tmore\tthat\tappears\tafter\t20\tweeks’\t\ngestation\t accompanied\t by\t new-onset\t proteinuria\t (≥300\t mg/24\t h),\t can\t lead\t to\t life-\nthreatening\tcomplications\tfor\tboth\tmother\tand\tfetus.\tEclampsia, the\tonset\tof\tconvul-\nsions\tin\tpreeclampsia,\tis\ta\tmedical\temergency.\n•\tDefinitive\ttreatment\tof\tpreeclampsia\tis\tdelivery,\tand\tthis\tis\tindicated\tif\tpending\tor\t\nfrank\t eclampsia\t is\t present.\t Otherwise,\t management\t consists\t of\t restricting\t activity,\t\nbedrest,\tand\tclose\tmonitoring.\tSalt\trestriction\tor\tother\tmeasures\tthat\tcontract\tblood\t\nvolume\t should\t be\t avoided.\t Antihypertensives\t are\t used\t prior\t to\t induction\t of\t labor\t\nif\tthe\tDBP\tis\tgreater\tthan\t105\tmm\tHg,\twith\ta\ttarget\tDBP\tof\t95\tto\t105\tmm\tHg.\tIV\t\nhydralazine\tis\tmost\tcommonly\tused;\tIV\tlabetalol\tis\talso\teffective.\n•\tChronic\t hypertension\t is\t defined\t as\t elevated\t BP\t that\t was\t noted\t before\t pregnancy\t\nbegan.\tMethyldopa\tis\tconsidered\tthe\tdrug\tof\tchoice\tbecause\tof\texperience\twith\tits\t\nuse.\tβ-Blockers\t(other\tthan\tatenolol),\tlabetalol,\tand\tCCBs\tare\talso\treasonable\talterna-\ntives.\tACE\tinhibitors,\tARBs,\tand\tthe\tdirect\trenin\tinhibitor\taliskiren\tare\tcontraindi-\ncated\tin\tpregnancy.\nAfrican Americans\n•\tHypertension\tis\tmore\tcommon\tand\tmore\tsevere\tin\tAfrican\tAmericans\tthan\tin\tthose\t\nof\t other\t races.\t Differences\t in\t electrolyte\t homeostasis,\t glomerular\t filtration\t rate,\t\nsodium\texcretion\tand\ttransport\tmechanisms,\tplasma\trenin\tactivity,\tand\tBP\tresponse\t\nto\tplasma\tvolume\texpansion\thave\tbeen\tnoted.\n•\tAfrican\tAmericans\thave\tan\tincreased\tneed\tfor\tcombination\ttherapy\tto\tachieve\tand\t\nmaintain\tBP\tgoals.\tStart\ttherapy\twith\ttwo\tdrugs\tin\tpatients\twith\tSBP\tvalues\tgreater\t\nthan\tor\tequal\tto\t15\tmm\tHg\tabove\tgoal.",
    "word_count": 517,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0190",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 190,
    "text": "99\nHypertension  ",
    "word_count": 2,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0191",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 191,
    "text": "99\nHypertension     CHAPTER 10\n•\tThiazides\t and\t CCBs\t are\t most\t effective\t in\t African\t Americans.\t Antihypertensive\t\nresponse\t is\tsignificantly\t increased\t when\t either\t class\t is\t combined\t with\t a\tβ-blocker,\t\nACE\tinhibitor,\tor\tARB.\nPulmonary Disease and Peripheral Arterial Disease\n•\tAlthough\tβ-blockers\t(especially\tnonselective\tagents)\thave\tgenerally\tbeen\tavoided\tin\t\nhypertensive\tpatients\twith\tasthma\tand\tCOPD\tbecause\tof\tfear\tof\tinducing\tbroncho-\nspasm,\tdata\tsuggest\tthat\tcardioselective\tβ-blockers\tcan\tbe\tused\tsafely.\tConsequently,\t\ncardioselective\tagents\tshould\tbe\tused\tto\ttreat\ta\tcompelling\tindication\t(ie,\tpost-MI,\t\ncoronary\tdisease,\tor\tHF)\tin\tpatients\twith\treactive\tairway\tdisease.\n•\tPAD\tis\tconsidered\ta\tcoronary\tartery\tdisease\trisk\tequivalent.\tβ-Blockers\tcan\ttheoreti-\ncally\tbe\tproblematic\tbecause\tof\tpossible\tdecreased\tperipheral\tblood\tflow\tsecondary\t\nto\tunopposed\tstimulation\tof\tα-receptors\tthat\tresults\tin\tvasoconstriction.\tThis\tcan\tbe\t\nmitigated\tby\tusing\ta\tβ-blocker\twith\tα-blocking\tproperties\t(eg,\tcarvedilol).\tHowever,\t\nβ-blockers\t are\t not\t contraindicated\t in\t PAD\t and\t have\t not\t been\t shown\t to\t adversely\t\naffect\twalking\tcapacity.\nHYPERTENSIVE URGENCIES AND EMERGENCIES\n•\tHypertensive urgencies\t are\t ideally\t managed\t by\t adjusting\t maintenance\t therapy\t by\t\nadding\ta\tnew\tantihypertensive\tand/or\tincreasing\tthe\tdose\tof\ta\tpresent\tmedication.\n•\tAcute\tadministration\tof\ta\tshort-acting\toral\tdrug\t(captopril,\tclonidine,\tor\tlabetalol)\t\nfollowed\tby\tcareful\tobservation\tfor\tseveral\thours\tto\tensure\ta\tgradual\tBP\treduction\t\nis\tan\toption.\n✓\t\tOral\tcaptopril\tdoses\tof\t25\tto\t50\tmg\tmay\tbe\tgiven\tat\t1-\tto\t2-hour\tintervals.\tThe\t\nonset\tof\taction\tis\t15\tto\t30\tminutes.\n✓\t\tFor\t treatment\t of\t hypertensive\t rebound\t after\t withdrawal\t of\t clonidine,\t 0.2\t mg\t is\t\ngiven\tinitially,\tfollowed\tby\t0.2\tmg\thourly\tuntil\tthe\tDBP\tfalls\tbelow\t110\tmm\tHg\tor\t\na\ttotal\tof\t0.7\tmg\thas\tbeen\tadministered;\ta\tsingle\tdose\tmay\tbe\tsufficient.\n✓\t\tLabetalol\tcan\tbe\tgiven\tin\ta\tdose\tof\t200\tto\t400\tmg,\tfollowed\tby\tadditional\tdoses\t\nevery\t2\tto\t3\thours.\n•\tHypertensive emergencies\trequire\timmediate\tBP\treduction\tto\tlimit\tnew\tor\tprogress-\ning\ttarget-organ\tdamage.\tThe\tgoal\tis\tnot\tto\tlower\tBP\tto\tnormal;\tinstead,\tthe\tinitial\t\ntarget\tis\ta\treduction\tin\tmean\tarterial\tpressure\tof\tup\tto\t25%\twithin\tminutes\tto\thours.\t\nIf\tBP\tis\tthen\tstable,\tit\tcan\tbe\treduced\ttoward\t160/100\tto\t110\tmm\tHg\twithin\tthe\tnext\t\n2\tto\t6\thours.\tPrecipitous\tdrops\tin\tBP\tmay\tcause\tend-organ\tischemia\tor\tinfarction.\tIf\t\nBP\treduction\tis\twell\ttolerated,\tadditional\tgradual\tdecrease\ttoward\tthe\tgoal\tBP\tcan\tbe\t\nattempted\tafter\t24\tto\t48\thours.\n✓\t\tNitroprusside\tis\tthe\tagent\tof\tchoice\tfor\tminute-to-minute\tcontrol\tin\tmost\tcases.\t\nIt\tis\tusually\tgiven\tas\ta\tcontinuous\tIV\tinfusion\tat\ta\trate\tof\t0.25\tto\t10\tmcg/kg/min.\t\nOnset\t of\t hypotensive\t action\t is\t immediate\t and\t disappears\t within\t 1\t to\t 2\t minutes\t\nof\tdiscontinuation.\tWhen\tthe\tinfusion\tmust\tbe\tcontinued\tlonger\tthan\t72\thours,\t\nmeasure\tserum\tthiocyanate\tlevels,\tand\tdiscontinue\tthe\tinfusion\tif\tthe\tlevel\texceeds\t\n12\tmg/dL\t(~2.0\tmmol/L).\tThe\trisk\tof\tthiocyanate\ttoxicity\tis\tincreased\tin\tpatients\t\nwith\timpaired\tkidney\tfunction.\tOther\tadverse\teffects\tare\tnausea,\tvomiting,\tmuscle\t\ntwitching,\tand\tsweating.\n✓\t\tDosing\tguidelines\tand\tadverse\teffects\tof\tparenteral\tagents\tfor\ttreating\thypertensive\t\nemergency\tare\tlisted\tin\tTable 10–4.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tEvaluate\tBP\tresponse\t2\tto\t4\tweeks\tafter\tinitiating\tor\tmaking\tchanges\tin\ttherapy.\tOnce\t\ngoals\tBP\tvalues\tare\tobtained,\tmonitor\tBP\tevery\t3\tto\t6\tmonths,\tassuming\tno\tsigns\tor\t\nsymptoms\tof\tacute\ttarget-organ\tdisease.\tEvaluate\tmore\tfrequently\tin\tpatients\twith\ta\t\nhistory\t of\t poor\t control,\t nonadherence,\t progressive\t target-organ\t damage,\t or\t symp-\ntoms\tof\tadverse\tdrug\teffects.",
    "word_count": 573,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0192",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 192,
    "text": "100\nSECTION 2  |  Cardiovascular Disorders\n TABLE 10–4  Parenteral Antihypertensive Agents for Hypertensive Emergency\nDrug Dose\nOnset \n(min)\nDuration \n(min) Adverse Effects\nClevidipine 1–2 mg/h (32 mg/h max) 2–4 5–15 Headache, nau-\nsea, tachycar-\ndia, hypertri-\nglyceridemia\nEnalaprilat 1.25–5 mg IV every 6 h 15–30 360–720 Precipitous \nfall in BP in \nhigh-renin \nstates; variable \nresponse\nEsmolol  \nhydrochloride\n250–500 mcg/kg/min IV \nbolus, then 50–100 mcg/\nkg/min IV infusion; may \nrepeat bolus after 5 min \nor increase infusion to 300 \nmcg/min\n1–2 10–20 Hypotension, \nnausea, \nasthma, first-\ndegree heart \nblock, heart \nfailure\nFenoldopam  \nmesylate\n0.1–0.3 mcg/kg/min IV infu-\nsion\n<5 30 Tachycardia, \nheadache, \nnausea,  \nflushing\nHydralazine  \nhydrochloride\n12–20 mg IV\n10–50 mg IM\n10–20\n20–30\n60–240\n240–360\nTachycardia, \nflushing, head-\nache, vomiting, \naggravation of \nangina\nLabetalol hydro-\nchloride\n20–80 mg IV bolus every \n10 min; 0.5–2 mg/min IV \ninfusion\n5–10 180–360 Vomiting, scalp \ntingling, bron-\nchoconstric-\ntion, dizziness, \nnausea, heart \nblock, ortho-\nstatic hypoten-\nsion\nNicardipine  \nhydrochloride\n5–15 mg/h IV 5–10 15–30; may \nexceed \n240\nTachycardia, \nheadache, \nflushing, local \nphlebitis\nNitroglycerin 5–100 mcg/min IV infusion 2–5 5–10 Headache, vomit-\ning, methemo-\nglobinemia, \ntolerance with \nprolonged use\nSodium nitro-\nprusside\n0.25–10 mcg/kg/min IV \ninfusion (requires special \ndelivery system)\nImmediate 1–2 Nausea, vomiting, \nmuscle twitch-\ning, sweating, \nthiocyanate \nand cyanide  \nintoxication\nBP , blood pressure; IM, intramuscular; IV, intravenous.",
    "word_count": 215,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0193",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 193,
    "text": "101\nHypertension  |  CHAPTER 10\n•\tSelf-measurements\tof\tBP\tor\tautomatic\tambulatory\tBP\tmonitoring\tcan\tbe\tuseful\tto\t\nestablish\t effective\t 24-hour\t control.\t These\t techniques\t are\t currently\t recommended\t\nonly\tfor\tselect\tsituations\tsuch\tas\tsuspected\twhite\tcoat\thypertension.\n•\tMonitor\tpatients\tfor\tsigns\tand\tsymptoms\tof\tprogressive\ttarget-organ\tdisease.\tTake\ta\t\ncareful\thistory\tfor\tchest\tpain\t(or\tpressure),\tpalpitations,\tdizziness,\tdyspnea,\torthop-\nnea,\theadache,\tsudden\tchange\tin\tvision,\tone-sided\tweakness,\tslurred\tspeech,\tand\tloss\t\nof\tbalance\tto\tassess\tfor\tthe\tpresence\tof\tcomplications.\n•\tMonitor\tfunduscopic\tchanges\ton\teye\texamination,\tLV\thypertrophy\ton\tECG,\tprotein-\nuria,\tand\tchanges\tin\tkidney\tfunction\tperiodically.\n•\tMonitor\t for\t adverse\t drug\t effects\t 2\t to\t 4\t weeks\t after\t starting\t a\t new\t agent\t or\t dose\t\nincreases,\tthen\tevery\t6\tto\t12\tmonths\tin\tstable\tpatients.\tFor\tpatients\ttaking\taldoste-\nrone\tantagonists,\tassess\tpotassium\tconcentration\tand\tkidney\tfunction\twithin\t3\tdays\t\nand\tagain\tat\t1\tweek\tafter\tinitiation\tto\tdetect\tpotential\thyperkalemia.\n•\tAssess\tpatient\tadherence\twith\tthe\tregimen\tregularly.\tAsk\tpatients\tabout\tchanges\tin\t\ntheir\tgeneral\thealth\tperception,\tenergy\tlevel,\tphysical\tfunctioning,\tand\toverall\tsatis-\nfaction\twith\ttreatment.\nSee Chapter 3, Hypertension, authored by Joseph J. Saseen and Eric J. MacLaughlin, for a \nmore detailed discussion of this topic.",
    "word_count": 202,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0194",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 194,
    "text": "102\n•\tIschemic heart disease\t(IHD)\tis\tdefined\tas\tlack\tof\toxygen\tand\tdecreased\tor\tno\tblood\t\nflow\t to\t the\t myocardium\t resulting\t from\t coronary\t artery\t narrowing\t or\t obstruction.\t\nIt\tmay\tpresent\tas\tacute\tcoronary\tsyndrome\t(ACS),\twhich\tincludes\tunstable\tangina\t\nand\t non–ST-segment\t elevation\t (NSTE)\t or\t ST-segment\t elevation\t (STE)\t myocardial\t\ninfarction\t (MI),\t chronic\t stable\t exertional\t angina,\t ischemia\t without\t symptoms,\t or\t\nischemia\tdue\tto\tcoronary\tartery\tvasospasm\t(variant\tor\tPrinzmetal\tangina).\nPATHOPHYSIOLOGY\n•\tMajor\tdeterminants\tof\tmyocardial\toxygen\tdemand\t(MVo2)\tare\theart\trate\t(HR),\tcon-\ntractility,\tand\tintramyocardial\twall\ttension\tduring\tsystole.\tBecause\tthe\tconsequences\t\nof\tIHD\tusually\tresult\tfrom\tincreased\tdemand\twith\ta\tfixed\toxygen\tsupply,\talterations\t\nin\t MVo2\t are\t important\t in\t producing\t ischemia\t and\t for\t interventions\t intended\t to\t\nalleviate\tit.\n•\tThe\tdouble\tproduct\t(DP)\tis\tthe\theart\trate\tmultiplied\tby\tthe\tsystolic\tblood\tpressure\t\n(DP\t=\tHR\t×\tSBP)\tand\tserves\tas\tan\tindirect\testimate\tof\tMVo2.\n•\tThe\tcaliber\tof\tresistance\tvessels\tdelivering\tblood\tto\tthe\tmyocardium\tand\tMVo2\tare\t\nthe\tprimary\tdeterminants\tin\tthe\toccurrence\tof\tischemia.\n•\tLarge\tepicardial\tor\tsurface\tcoronary\tvessels\t(R1)\toffer\tlittle\tresistance\tto\tmyocardial\t\nflow\t and\t intramyocardial\t arteries\t and\t arterioles\t (R2),\t which\t branch\t into\t a\t dense\t\ncapillary\tnetwork\tto\tsupply\tbasal\tblood\tflow.\tUnder\tnormal\tcircumstances,\tresistance\t\nin\tR2\tis\tmuch\tgreater\tthan\tthat\tin\tR1.\tMyocardial\tblood\tflow\tis\tinversely\trelated\tto\t\narteriolar\tresistance\tand\tdirectly\trelated\tto\tcoronary\tdriving\tpressure.\n•\tAtherosclerotic\tlesions\toccluding\tR1\tincrease\tarteriolar\tresistance,\tand\tR2\tcan\tvaso-\ndilate\t to\t maintain\t coronary\t blood\t flow.\t With\t greater\t degrees\t of\t obstruction,\t this\t\nresponse\tis\tinadequate,\tand\tthe\tcoronary\tflow\treserve\tafforded\tby\tR2\tvasodilation\tis\t\ninsufficient\tto\tmeet\toxygen\tdemand.\t\n•\tThe\t diameter\tand\tlength\tof\tobstructing\t lesions\tand\t the\tinfluence\t of\tpressure\tdrop\t\nacross\tan\tarea\tof\tstenosis\talso\taffect\tcoronary\tblood\tflow.\tDynamic\tcoronary\tobstruc-\ntion\tcan\toccur\tin\tnormal\tvessels\tand\tvessels\twith\tstenosis\tin\twhich\tvasomotion\tor\ta\t\nspasm\tmay\tbe\tsuperimposed\ton\ta\tfixed\tstenosis.\tPersisting\tischemia\tmay\tpromote\t\ngrowth\tof\tcollateral\tblood\tflow.\n•\tRelatively\t severe\t stenosis\t (>70%)\t may\t provoke\t ischemia\t and\t symptoms\t at\t rest.\t\nLesions\t creating\t obstruction\t of\t 50%\t to\t 70%\t may\t reduce\t blood\t flow,\t but\t these\t\nobstructions\tare\tnot\tconsistent,\tand\tvasospasm\tand\tthrombosis\tsuperimposed\ton\ta\t\n“noncritical”\tlesion\tmay\tlead\tto\tclinical\tevents\tsuch\tas\tMI.\n•\tRegional\tloss\tof\tventricular\tcontractility\tmay\timpose\ta\tburden\ton\tremaining\tmyo-\ncardial\t tissue,\tresulting\tin\t heart\t failure\t(HF),\tincreased\t MVo2,\tand\t rapid\tdepletion\t\nof\t blood\t flow\t reserve.\t Zones\t of\t tissue\t with\t marginal\t blood\t flow\t may\t develop\t that\t\nare\tat\trisk\tfor\tmore\tsevere\tdamage\tif\tthe\tischemic\tepisode\tpersists\tor\tbecomes\tmore\t\nsevere.\t Nonischemic\t areas\t of\t myocardium\t may\t compensate\t for\t severely\t ischemic\t\nand\tborder\tzones\tof\tischemia\tby\tdeveloping\tmore\ttension\tthan\tusual\tin\tattempt\tto\t\nmaintain\tcardiac\toutput.\tThe\tleft\tor\tright\tventricular\tdysfunction\tthat\tensues\tmay\tbe\t\nassociated\twith\tan\tS3\tgallop,\tdyspnea,\torthopnea,\ttachycardia,\tfluctuating\tblood\tpres-\nsure,\ttransient\tmurmurs,\tand\tmitral\tor\ttricuspid\tregurgitation.\tImpaired\tdiastolic\tand\t\nsystolic\tfunction\tleads\tto\televated\tleft\tventricular\tfilling\tpressure.\nCLINICAL PRESENTATION\n•\tMany\t ischemic\t episodes\t are\t asymptomatic\t (silent\t ischemia).\t Patients\t often\t have\t a\t\nreproducible\tpattern\tof\tpain\tor\tother\tsymptoms\tthat\tappear\tafter\ta\tspecific\tamount\tof\t\nexertion.\tIncreased\tsymptom\tfrequency,\tseverity,\tor\tduration,\tand\tsymptoms\tat\trest\t\nsuggest\tan\tunstable\tpattern\tthat\trequires\timmediate\tmedical\tevaluation.\nIschemic Heart Disease\n11\nC H A P T E R",
    "word_count": 559,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0195",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 195,
    "text": "103\nIschemic Heart Disease  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0196",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 196,
    "text": "103\nIschemic Heart Disease     CHAPTER 11\n•\tSymptoms\t may\t include\t a\t sensation\t of\t pressure\t or\t burning\t over\t the\t sternum\t or\t\nnear\tit,\twhich\toften\tradiates\tto\tthe\tleft\tjaw,\tshoulder,\tand\tarm.\tChest\ttightness\tand\t\nshortness\tof\tbreath\tmay\talso\toccur.\tThe\tsensation\tusually\tlasts\tfrom\t30\tseconds\tto\t\n30\tminutes.\n•\tPrecipitating\tfactors\tinclude\texercise,\tcold\tenvironment,\twalking\tafter\ta\tmeal,\temo-\ntional\tupset,\tfright,\tanger,\tand\tcoitus.\tRelief\toccurs\twith\trest\tand\twithin\t45\tseconds\t\nto\t5\tminutes\tof\ttaking\tnitroglycerin.\n•\tPatients\t with\t variant\t (Prinzmetal)\t angina\t secondary\t to\t coronary\t spasm\t are\t more\t\nlikely\tto\texperience\tpain\tat\trest\tand\tin\tthe\tearly\tmorning\thours.\tPain\tis\tnot\tusually\t\nbrought\ton\tby\texertion\tor\temotional\tstress\tor\trelieved\tby\trest;\tthe\telectrocardiogram\t\n(ECG)\t pattern\t demonstrates\t current\t injury\t with\t ST-segment\t elevation\t rather\t than\t\ndepression.\n•\tUnstable\t angina\t is\t stratified\t into\t categories\t of\t low,\t intermediate,\t or\t high\t risk\t for\t\nshort-term \tdeath\tor\tnonfatal \tMI.\tFeatures \tof\thigh-risk \tunstable \tangina \tinclude: \t\n(1)\t accelerating\t tempo\t of\t ischemic\t symptoms\t in\t the\t preceding\t 48\t hours;\t (2)\t pain\t\nat\t rest\t lasting\t more\t than\t 20\t minutes;\t (3)\t age\t older\t than\t 75\t years;\t (4)\t ST-segment\t\nchanges;\tand\t(5)\tclinical\tfindings\tof\tpulmonary\tedema,\tmitral\tregurgitation,\tS3,\trales,\t\nhypotension,\tbradycardia,\tor\ttachycardia.\n•\tEpisodes\tof\tischemia\tmay\talso\tbe\tpainless,\tor\t“silent, ”\tperhaps\tdue\tto\ta\thigher\tthresh-\nold\tand\ttolerance\tfor\tpain\tthan\tin\tpatients\twho\thave\tpain\tmore\tfrequently.\nDIAGNOSIS\n•\tObtain\tmedical\thistory\tto\tidentify\tthe\tnature\tor\tquality\tof\tchest\tpain,\tprecipitating\t\nfactors,\tduration,\tpain\tradiation,\tand\tresponse\tto\tnitroglycerin\tor\trest.\tIschemic\tchest\t\npain\tmay\tresemble\tpain\tfrom\tnoncardiac\tsources,\tand\tdiagnosis\tof\tanginal\tpain\tmay\t\nbe\tdifficult\tbased\ton\thistory\talone.\n•\tAsk\tthe\tpatient\tabout\tpersonal\trisk\tfactors\tfor\tcoronary\theart\tdisease\t(CHD),\tinclud-\ning\tsmoking,\thypertension,\tand\tdiabetes\tmellitus.\n•\tObtain\t family\t history\t that\t includes\t information\t about\t premature\t CHD,\t hyperten-\nsion,\tlipid\tdisorders,\tand\tdiabetes\tmellitus.\n•\tFindings\t on\t cardiac\t examination\t may\t include\t abnormal\t precordial\t systolic\t bulge,\t\ndecreased\tintensity\tof\tS1,\tparadoxical\tsplitting\tof\tS2,\tpresence\tof\tS3\tor\tS4,\tapical\tsystolic\t\nmurmur,\tand\tdiastolic\tmurmur.\t\n•\tLaboratory tests:\themoglobin,\tfasting\tglucose\t(to\texclude\tdiabetes),\tand\tfasting\tlipid\t\npanel.\tHigh-sensitivity\tC-reactive\tprotein\t(hsCRP);\thomocysteine\tlevel;\tevidence\tof\t\nChlamydia\tinfection;\tand\televations\tin\tlipoprotein\t(a),\tfibrinogen,\tand\tplasminogen\t\nactivator\t inhibitor\t may\t be\t helpful.\t Cardiac\t enzymes\t are\t normal\t in\t stable\t angina.\t\nTroponin\tT\tor\tI,\tmyoglobin,\tand\tcreatinine\tkinase\tmyocardial\tband\t(CK-MB)\tmay\t\nbe\televated\tin\tunstable\tangina.\n•\tResting\tECG\tis\tnormal\tin\tabout\thalf\tof\tpatients\twith\tangina\twho\tare\tnot\texperienc-\ning\tacute\tischemia.\tTypical\tST–T-wave\tchanges\tinclude\tdepression,\tT-wave\tinversion,\t\nand\t ST-segment\televation.\t V ariant\tangina\tis\tassociated\t with\t ST-segment\televation,\t\nwhereas\tsilent\tischemia\tmay\tproduce\televation\tor\tdepression.\tSignificant\tischemia\tis\t\nassociated\twith\tST-segment\tdepression\tgreater\tthan\t2\tmm,\texertional\thypotension,\t\nand\treduced\texercise\ttolerance.\n•\tExercise\ttolerance\t(stress)\ttesting\t(ETT),\tthallium\tmyocardial\tperfusion\tscintigraphy,\t\nradionuclide\t angiocardiography,\t ultrarapid\t computed\t tomography,\t and\t coronary\t\nangiography\tmay\tbe\tperformed\tin\tcertain\tcircumstances.\tObtain\ta\tchest\tradiograph\t\nif\tthe\tpatient\thas\tHF\tsymptoms.\nTREATMENT\n•\tGoals\tof\tTreatment:\tShort-term\tgoals\tare\tto\treduce\tor\tprevent\tanginal\tsymptoms\tthat\t\nlimit\t exercise\t capability\t and\t impair\t quality\t of\t life.\t Long-term\t goals\t are\t to\t prevent\t\nCHD\tevents\tsuch\tas\tMI,\tarrhythmias,\tand\tHF\tand\tto\textend\tthe\tpatient’ s\tlife.",
    "word_count": 546,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0197",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 197,
    "text": "104\nSECTION 2  ",
    "word_count": 3,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0198",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 198,
    "text": "104\nSECTION 2     Cardiovascular Disorders\nNONPHARMACOLOGIC THERAPY\n•\tPrimary\t prevention\t through\t modification\t of\t risk\t factors\t should\t reduce\t prevalence\t of\t\nIHD.\tSecondary\tintervention\tis\teffective\tin\treducing\tsubsequent\tmorbidity\tand\tmortality.\n•\tRisk\t factors\t for\t IHD\t are\t additive\t and\t can\t be\t classified\t as\t alterable\t or\t unalterable.\t\nUnalterable\trisk\tfactors\tinclude\tgender,\tage,\tfamily\thistory\tor\tgenetic\tcomposition,\t\nenvironmental\t influences,\t and,\t to\t some\t extent,\t diabetes\t mellitus.\t Alterable\t risk\t\nfactors\t include\t smoking,\t hypertension,\t hyperlipidemia,\t obesity,\t sedentary\t lifestyle,\t\nhyperuricemia,\t psychosocial\t factors\t such\t as\t stress,\t and\t use\t of\t drugs\t that\t may\t be\t\ndetrimental\t(eg,\tprogestins,\tcorticosteroids,\tcalcineurin\tinhibitors).\nPHARMACOLOGIC THERAPY\nβ-Adrenergic Blockers\n•\tDecreased\tHR,\tcontractility,\tand\tblood\tpressure\treduce\tMVo2\tand\toxygen\tdemand\t\nin\t patients\t with\t effort-induced\t angina.\t β-Blockers\t do\t not\t improve\t oxygen\t supply,\t\nand,\tin\tcertain\tinstances,\tunopposed\tα-adrenergic\tstimulation\tmay\tlead\tto\tcoronary\t\nvasoconstriction.\n•\tβ-Blockers\timprove\tsymptoms\tin\tapproximately\t80%\tof\tpatients\twith\tchronic\texertional\t\nstable\tangina,\tand\tobjective\tmeasures\tof\tefficacy\tdemonstrate\timproved\texercise\tdura-\ntion\tand\tdelay\tin\tthe\ttime\tat\twhich\tST-segment\tchanges\tand\tinitial\tor\tlimiting\tsymptoms\t\noccur.\tβ-Blockade\tmay\tallow\tangina\tpatients\tpreviously\tlimited\tby\tsymptoms\tto\tperform\t\nmore\texercise\tand\timprove\tcardiovascular\tperformance\tthrough\ta\ttraining\teffect.\n•\tIdeal\tcandidates\tfor\tβ-blockers\tinclude\tpatients\tin\twhom\tphysical\tactivity\tis\ta\tpromi-\nnent\tcause\tof\tattacks;\tthose\twith\tcoexisting\thypertension,\tsupraventricular\tarrhyth-\nmias,\t or\t post-MI\t angina;\t and\t those\t with\t anxiety\t associated\t with\t anginal\t episodes.\t\nβ-Blockers\tmay\tbe\tused\tsafely\tin\tangina\tand\tHF .\n•\tβ-Blockade\tis\teffective\tin\tchronic\texertional\tangina\tas\tmonotherapy\tand\tin\tcombina-\ntion\twith\tnitrates\tand/or\tcalcium\tchannel\tblockers\t(CCBs).\tβ-Blockers\tare\tfirst\tline\tin\t\nchronic\tangina\trequiring\tdaily\tmaintenance\ttherapy\tbecause\tthey\tare\tmore\teffective\t\nin\treducing\tepisodes\tof\tsilent\tischemia\tand\tearly-morning\tpeak\tof\tischemic\tactivity\t\nand\timproving\tmortality\tafter\tQ-wave\tMI\tthan\tnitrates\tor\tCCBs.\n•\tIf\tβ-blockers\tare\tineffective\tor\tnot\ttolerated,\tmonotherapy\twith\ta\tCCB\tor\tcombina-\ntion\ttherapy\tmay\tbe\tinstituted.\tReflex\ttachycardia\tfrom\tnitrates\tcan\tbe\tblunted\twith\t\nβ-blocker\ttherapy,\tmaking\tthis\ta\tuseful\tcombination.\n•\tInitial\tdoses\tof\tβ-blockers\tshould\tbe\tat\tthe\tlower\tend\tof\tthe\tusual\tdosing\trange\tand\t\ntitrated\tto\tresponse.\tTreatment\tobjectives\tinclude\tlowering\tthe\tresting\tHR\tto\t50\tto\t60\t\nbeats/min\tand\tlimiting\tmaximal\texercise\tHR\tto\tapproximately\t100\tbeats/min\tor\tless.\t\nHR\twith\tmodest\texercise\tshould\tbe\tno\tmore\tthan\tapproximately\t20\tbeats/min\tabove\t\nresting\tHR\t(or\ta\t10%\tincrement\tover\tresting\tHR).\n•\tThere\t is\t little\t evidence\t to\t suggest\t superiority\t of\t any\t particular\t β-blocker.\t Those\t with\t\nlonger\thalf-lives\tmay\tbe\tadministered\tless\tfrequently,\tbut\teven\tpropranolol\tmay\tbe\tgiven\t\ntwice\tdaily\tin\tmost\tpatients.\tMembrane-stabilizing\tactivity\tis\tirrelevant\tin\tangina\ttreat-\nment.\tIntrinsic\tsympathomimetic\tactivity\tappears\tto\tbe\tdetrimental\tin\tpatients\twith\trest\t\nor\tsevere\tangina\tbecause\tthe\treduction\tin\tHR\twould\tbe\tminimized,\tlimiting\treduction\t\nin\t MVo2.\t Cardioselective\t β-blockers\t may\t minimize\t adverse\t effects\t such\t as\t broncho-\nspasm,\tintermittent\tclaudication,\tand\tsexual\tdysfunction.\tCombined\tnonselective\tβ-\tand\t\nα-blockade\twith\tlabetalol\tmay\tbe\tuseful\tin\tpatients\twith\tmarginal\tleft\tventricular\t(L V)\t\nreserve.\n•\tAdverse\teffects\tof\tβ-blockade\tinclude\thypotension,\tdecompensated\tHF ,\tbradycardia,\t\nheart\tblock,\tbronchospasm,\taltered\tglucose\tmetabolism,\tfatigue,\tmalaise,\tand\tdepres-\nsion.\tAbrupt\twithdrawal\thas\tbeen\tassociated\twith\tincreased\tseverity\tand\tnumber\tof\t\nanginal\tepisodes\tand\tMI.\tTapering\tof\ttherapy\tover\tseveral\tdays\tshould\tminimize\trisk\t\nof\twithdrawal\treactions\tif\ttherapy\tis\tto\tbe\tdiscontinued.\nNitrates\n•\tNitrates\t reduce\t MVo2\t secondary\t to\t venodilation\t and\t arterial-arteriolar\t dilation,\t\nleading\tto\ta\treduction\tin\twall\tstress\tfrom\treduced\tventricular\tvolume\tand\tpressure.",
    "word_count": 575,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0199",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 199,
    "text": "105\nIschemic Heart Disease  ",
    "word_count": 4,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0200",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 200,
    "text": "105\nIschemic Heart Disease     CHAPTER 11\nDirect\tactions\ton\tcoronary\tcirculation\tinclude\tdilation\tof\tlarge\tand\tsmall\tintramural\t\ncoronary\t arteries,\t collateral\t dilation,\t coronary\t artery\t stenosis\t dilation,\t abolition\t of\t\nnormal\ttone\tin\tnarrowed\tvessels,\tand\trelief\tof\tspasm.\n•\tPharmacokinetic\tcharacteristics\tcommon\tto\tnitrates\tinclude\tlarge\tfirst-pass\thepatic\t\nmetabolism,\t short\t half-lives\t (except\t for\t isosorbide mononitrate \t [ISMN]),\t large\t\nvolumes\t of\t distribution,\t high\t clearance\t rates,\t and\t large\t interindividual\t variations\t\nin\tplasma\tconcentrations.\tThe\thalf-life\tof\tnitroglycerin\tis\t1\tto\t5\tminutes\tregardless\t\nof\t the\t route,\t hence\t the\t potential\t advantage\t of\t sustained-release\t and\t transdermal\t\nproducts.\tIsosorbide dinitrate\t(ISDN)\tis\tmetabolized\tto\tISMN.\tISMN\thas\ta\thalf-life\t\nof\t approximately\t5\t hours\t and\t may\t be\t given\tonce\t or\t twice\tdaily,\t depending\t on\t the\t\nproduct\tchosen.\n•\tNitrate\ttherapy\tmay\tbe\tused\tto\tterminate\tan\tacute\tanginal\tattack,\tto\tprevent\teffort-\t\nor\tstress-induced\tattacks,\tor\tfor\tlong-term\tprophylaxis,\tusually\tin\tcombination\twith\t\nβ-blockers\tor\tCCBs.\tSublingual,\tbuccal,\tor\tspray\tnitroglycerin\tproducts\tare\tpreferred\t\nfor\talleviation\tof\tanginal\tattacks\tbecause\tof\trapid\tabsorption\t(Table 11−1).\tSymptoms\t\nmay\tbe\tprevented\tby\tprophylactic\toral\tor\ttransdermal\tproducts\t(usually\tin\tcombina-\ntion\twith\tβ-blockers\tor\tCCBs),\tbut\tdevelopment\tof\ttolerance\tmay\tbe\tproblematic.\n•\tSublingual nitroglycerin ,\t 0.3\t to\t 0.4\t mg,\t relieves\t pain\t in\t approximately\t 75%\t of\t\npatients\twithin\t3\tminutes,\twith\tanother\t15%\tbecoming\tpain\tfree\tin\t5\tto\t15\tminutes.\t\nPain\tpersisting\tbeyond\t20\tto\t30\tminutes\tafter\tuse\tof\ttwo\tor\tthree\tnitroglycerin\ttablets\t\nsuggests\tACS,\tand\tthe\tpatient\tshould\tbe\tinstructed\tto\tseek\temergency\taid.\n•\tChewable,\toral,\tand\ttransdermal\tproducts\tare\tacceptable\tfor\tlong-term\tprophylaxis.\t\nDosing\t of\t long-acting\t preparations\t should\t be\t adjusted\t to\t provide\t a\t hemodynamic\t\nresponse.\t This\t may\t require\toral\tISDN\t doses\t of\t 10\t to\t 60\t mg\t as\t often\t as\t every\t 3\t to\t\t\n4\thours\tbecause\tof\ttolerance\tor\tfirst-pass\tmetabolism.\tIntermittent\t(10−12\thours\ton,\t\n12−14\thours\toff\t)\ttransdermal\tnitroglycerin\ttherapy\tmay\tproduce\tmodest\tbut\tsignifi-\ncant\timprovement\tin\texercise\ttime\tin\tchronic\tstable\tangina.\n•\tAdverse\teffects\tinclude\tpostural\thypotension\twith\tassociated\tcentral\tnervous\tsystem\t\n(CNS)\tsymptoms,\treflex\ttachycardia,\theadaches\tand\tflushing,\tand\toccasional\tnausea.\t\nExcessive\thypotension\tmay\tresult\tin\tMI\tor\tstroke.\tNoncardiovascular\tadverse\teffects\t\ninclude\t rash\t (especially\t with\t transdermal\t nitroglycerin),\t methemoglobinemia\t with\t\nhigh\tdoses\tgiven\tfor\textended\tperiods,\tand\tmeasurable\tethanol\tand\tpropylene\tglycol\t\nconcentrations\twith\tIV\tnitroglycerin.\n•\tBecause\tboth\tthe\tonset\tand\toffset\tof\ttolerance\tto\tnitrates\toccur\tquickly,\tone\tstrategy\t\nto\tcircumvent\ttolerance\tis\tto\tprovide\ta\tdaily\tnitrate-free\tinterval\tof\t8\tto\t12\thours.\tFor\t\nexample,\tISDN\tshould\tnot\tbe\tused\tmore\toften\tthan\tthree\ttimes\tdaily\tto\tavoid\ttolerance.\n TABLE 11–1  Nitrate Products\nProduct Onset \n(min)\nDuration Initial Dose\nNitroglycerin\n IV\n Sublingual/lingual\n Oral\n Ointment\n Patch\n1–2\n1–3\n40\n20–60\n40–60\n3–5 min\n30–60 min\n3–6 h\n2–8 h\n>8 h\n5 mcg/min\n0.3 mg\n2.5–9 mg 3 times daily\n½–1 in\n1 patch\nErythritol tetranitrate 5–30 4–6 h 5–10 mg 3 times daily\nPentaerythritol tetranitrate 30 4–8 h 10–20 mg 3 times daily\nIsosorbide dinitrate\n Sublingual/chewable\n Oral\n2–5\n20–40\n1–2 h\n4–6 h\n2.5–5 mg 3 times daily\n5–20 mg 3 times daily\nIsosorbide mononitrate \n(ISMN)\n30–60 6–8 h 20 mg once or twice daily  \ndepending on the product",
    "word_count": 523,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0201",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 201,
    "text": "106\nSECTION 2     Cardiovascular Disorders\n•\tNitrates \tmay\tbe\tcombined \twith\tother\tdrugs \twith\tcomplementary \tmechanisms \tof\t\naction \tfor\tchronic \tprophylaxis.",
    "word_count": 21,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0202",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 202,
    "text": "  Cardiovascular Disorders\n•\tNitrates \tmay\tbe\tcombined \twith\tother\tdrugs \twith\tcomplementary \tmechanisms \tof\t\naction \tfor\tchronic \tprophylaxis. \tCombination \ttherapy \tis\tgenerally \tused\tin\tpatients \t\nwith\t more\t frequent \t symptoms \t or\t symptoms \t that\t do\t not\t respond \t to\t β-blockers \t\nalone\t (nitrates \t plus\t β-blockers \t or\t CCBs), \t in\t patients \t intolerant \t of\t β-blockers \t\nor\t CCBs, \t and\t in\t patients \t with\t vasospasm \t leading \t to\t decreased \t supply\t (nitrates \t\t\nplus\tCCBs).\nCalcium Channel Blockers\n•\tDirect\tactions\tinclude\tvasodilation\tof\tsystemic\tarterioles\tand\tcoronary\tarteries,\tlead-\ning\tto\treduced\tarterial\tpressure\tand\tcoronary\tvascular\tresistance,\tas\twell\tas\tdepres-\nsion\t of\t myocardial\tcontractility\t and\tconduction\tvelocity\tof\tthe\tsinoatrial\t(SA)\tand\t\natrioventricular\t(A V)\tnodes.\tReflex\tβ-adrenergic\tstimulation\tovercomes\tmuch\tof\tthe\t\nnegative\tinotropic\teffect,\tand\tdepression\tof\tcontractility\tbecomes\tclinically\tapparent\t\nonly\tin\tthe\tpresence\tof\tLV\tdysfunction\tand\twhen\tother\tnegative\tinotropic\tdrugs\tare\t\nused\tconcurrently.\n•\tVerapamil\t and\tdiltiazem\t cause\tless\t peripheral\tvasodilation\tthan\t dihydropyridines\t\nsuch\tas\tnifedipine\tbut\tgreater\tdecreases\tin\tA V\tnode\tconduction.\tThey\tmust\tbe\tused\t\nwith\tcaution\tin\tpatients\twith\tpreexisting\tconduction\tabnormalities\tand\tthose\ttaking\t\nother\tdrugs\twith\tnegative\tchronotropic\tproperties.\n•\tMVo2\tis\treduced\twith\tall\tCCBs\tprimarily\tbecause\tof\treduced\twall\ttension\tsecond-\nary\tto\treduced\tarterial\tpressure.\tOverall,\tthe\tbenefit\tprovided\tby\tCCBs\tis\trelated\tto\t\nreduced\tMVo2\trather\tthan\timproved\toxygen\tsupply.\n•\tIn\tcontrast \tto\tβ-blockers, \tCCBs\tmay\timprove\tcoronary \tblood \tflow\tthrough \tareas\t\nof\t fixed \t coronary \t obstruction \t by\t inhibiting \t coronary \t artery \t vasomotion \t and\t\nvasospasm.\n•\tGood\tcandidates\tfor\tCCBs\tinclude\tpatients\twith\tcontraindications\tor\tintolerance\tto\t\nβ-blockers,\t coexisting\t conduction\t system\t disease\t (except\t for\t verapamil\t and\t diltia-\nzem),\tPrinzmetal\tangina,\tperipheral\tarterial\tdisease,\tsevere\tventricular\tdysfunction,\t\nand\tconcurrent\thypertension.\tAmlodipine\tis\tprobably\tthe\tCCB\tof\tchoice\tin\tsevere\t\nventricular\tdysfunction,\tand\tthe\tothers\tshould\tbe\tused\twith\tcaution\tif\tthe\tEF\tis\tless\t\nthan\t40%.\nRanolazine\n•\tRanolazine\t reduces\t calcium\t overload\t in\t ischemic\t myocytes\t through\t inhibition\t of\t\nthe\tlate\tsodium\tcurrent.\tIt\tdoes\tnot\taffect\tHR,\tinotropic\tor\themodynamic\tstate,\tor\t\nincrease\tcoronary\tblood\tflow.\n•\tRanolazine\t is\t indicated\t for\t treatment\t of\t chronic\t angina.\t In\t controlled\t trials,\t it\t\nmodestly\timproved\texercise\ttime\tby\t15\tto\tapproximately\t45\tseconds\tcompared\twith\t\nplacebo.\t In\t a\t large\t ACS\t trial,\t ranolazine\t reduced\t recurrent\t ischemia\t but\t did\t not\t\nimprove\t the\t primary\t efficacy\t composite\t end\t point\t of\t cardiovascular\t death,\t MI,\t or\t\nrecurrent\tischemia.\n•\tBecause\t it\t prolongs\t the\t QT\t interval,\t reserve\t ranolazine\t for\t patients\t who\t have\t not\t\nachieved\tan\tadequate\tresponse\tto\tother\tantianginal\tdrugs.\tIt\tshould\tbe\tused\tin\tcom-\nbination\twith\tamlodipine,\tβ-blockers,\tor\tnitrates.\n•\tStart\tranolazine\tat\t500\tmg\ttwice\tdaily\tand\tincrease\tto\t1000\tmg\ttwice\tdaily\tif\tneeded\t\nbased\ton\tsymptoms.\tObtain\tbaseline\tand\tfollow-up\tECGs\tto\tevaluate\teffects\ton\tthe\t\nQT\tinterval.\tThe\tmost\tcommon\tadverse\teffects\tinclude\tdizziness,\theadache,\tconstipa-\ntion,\tand\tnausea.\nTREATMENT OF STABLE ISCHEMIC HEART DISEASE\n•\tTable 11−2 \t lists\t select\t evidence-based\t drug\t therapy\t recommendations\t of\t the\t\nAmerican\t College\t of\t Cardiology\t Foundation\t and\t American\t Heart\t Association.\t A\t\ntreatment\talgorithm\tis\tshown\tin\tFig.",
    "word_count": 493,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0203",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 203,
    "text": "\tCombination \ttherapy \tis\tgenerally \tused\tin\tpatients \t\nwith\t more\t frequent \t symptoms \t or\t symptoms \t that\t do\t not\t respond \t to\t β-blockers \t\nalone\t (nitrates \t plus\t β-blockers \t or\t CCBs), \t in\t patients \t intolerant \t of\t β-blockers \t\nor\t CCBs, \t and\t in\t patients \t with\t vasospasm \t leading \t to\t decreased \t supply\t (nitrates \t\t\nplus\tCCBs).\nCalcium Channel Blockers\n•\tDirect\tactions\tinclude\tvasodilation\tof\tsystemic\tarterioles\tand\tcoronary\tarteries,\tlead-\ning\tto\treduced\tarterial\tpressure\tand\tcoronary\tvascular\tresistance,\tas\twell\tas\tdepres-\nsion\t of\t myocardial\tcontractility\t and\tconduction\tvelocity\tof\tthe\tsinoatrial\t(SA)\tand\t\natrioventricular\t(A V)\tnodes.\tReflex\tβ-adrenergic\tstimulation\tovercomes\tmuch\tof\tthe\t\nnegative\tinotropic\teffect,\tand\tdepression\tof\tcontractility\tbecomes\tclinically\tapparent\t\nonly\tin\tthe\tpresence\tof\tLV\tdysfunction\tand\twhen\tother\tnegative\tinotropic\tdrugs\tare\t\nused\tconcurrently.\n•\tVerapamil\t and\tdiltiazem\t cause\tless\t peripheral\tvasodilation\tthan\t dihydropyridines\t\nsuch\tas\tnifedipine\tbut\tgreater\tdecreases\tin\tA V\tnode\tconduction.\tThey\tmust\tbe\tused\t\nwith\tcaution\tin\tpatients\twith\tpreexisting\tconduction\tabnormalities\tand\tthose\ttaking\t\nother\tdrugs\twith\tnegative\tchronotropic\tproperties.\n•\tMVo2\tis\treduced\twith\tall\tCCBs\tprimarily\tbecause\tof\treduced\twall\ttension\tsecond-\nary\tto\treduced\tarterial\tpressure.\tOverall,\tthe\tbenefit\tprovided\tby\tCCBs\tis\trelated\tto\t\nreduced\tMVo2\trather\tthan\timproved\toxygen\tsupply.\n•\tIn\tcontrast \tto\tβ-blockers, \tCCBs\tmay\timprove\tcoronary \tblood \tflow\tthrough \tareas\t\nof\t fixed \t coronary \t obstruction \t by\t inhibiting \t coronary \t artery \t vasomotion \t and\t\nvasospasm.\n•\tGood\tcandidates\tfor\tCCBs\tinclude\tpatients\twith\tcontraindications\tor\tintolerance\tto\t\nβ-blockers,\t coexisting\t conduction\t system\t disease\t (except\t for\t verapamil\t and\t diltia-\nzem),\tPrinzmetal\tangina,\tperipheral\tarterial\tdisease,\tsevere\tventricular\tdysfunction,\t\nand\tconcurrent\thypertension.\tAmlodipine\tis\tprobably\tthe\tCCB\tof\tchoice\tin\tsevere\t\nventricular\tdysfunction,\tand\tthe\tothers\tshould\tbe\tused\twith\tcaution\tif\tthe\tEF\tis\tless\t\nthan\t40%.\nRanolazine\n•\tRanolazine\t reduces\t calcium\t overload\t in\t ischemic\t myocytes\t through\t inhibition\t of\t\nthe\tlate\tsodium\tcurrent.\tIt\tdoes\tnot\taffect\tHR,\tinotropic\tor\themodynamic\tstate,\tor\t\nincrease\tcoronary\tblood\tflow.\n•\tRanolazine\t is\t indicated\t for\t treatment\t of\t chronic\t angina.\t In\t controlled\t trials,\t it\t\nmodestly\timproved\texercise\ttime\tby\t15\tto\tapproximately\t45\tseconds\tcompared\twith\t\nplacebo.\t In\t a\t large\t ACS\t trial,\t ranolazine\t reduced\t recurrent\t ischemia\t but\t did\t not\t\nimprove\t the\t primary\t efficacy\t composite\t end\t point\t of\t cardiovascular\t death,\t MI,\t or\t\nrecurrent\tischemia.\n•\tBecause\t it\t prolongs\t the\t QT\t interval,\t reserve\t ranolazine\t for\t patients\t who\t have\t not\t\nachieved\tan\tadequate\tresponse\tto\tother\tantianginal\tdrugs.\tIt\tshould\tbe\tused\tin\tcom-\nbination\twith\tamlodipine,\tβ-blockers,\tor\tnitrates.\n•\tStart\tranolazine\tat\t500\tmg\ttwice\tdaily\tand\tincrease\tto\t1000\tmg\ttwice\tdaily\tif\tneeded\t\nbased\ton\tsymptoms.\tObtain\tbaseline\tand\tfollow-up\tECGs\tto\tevaluate\teffects\ton\tthe\t\nQT\tinterval.\tThe\tmost\tcommon\tadverse\teffects\tinclude\tdizziness,\theadache,\tconstipa-\ntion,\tand\tnausea.\nTREATMENT OF STABLE ISCHEMIC HEART DISEASE\n•\tTable 11−2 \t lists\t select\t evidence-based\t drug\t therapy\t recommendations\t of\t the\t\nAmerican\t College\t of\t Cardiology\t Foundation\t and\t American\t Heart\t Association.\t A\t\ntreatment\talgorithm\tis\tshown\tin\tFig. 11−1 .\n•\tGuideline-directed\t medical\t therapy\t (GDMT)\t places\t a\t strong\t emphasis\t on\t patient\t\neducation.\t Lifestyle\t modifications\t include\t daily\t physical\t activity,\t weight\t manage-\nment,\tdietary\ttherapy,\tsmoking\tcessation,\tpsychological\tinterventions,\tlimitation\tof\t\nalcohol\tintake,\tand\tmanagement\tof\tblood\tpressure\tand\tdiabetes.",
    "word_count": 515,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0204",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 204,
    "text": "107\nIschemic Heart Disease     CHAPTER 11\n TABLE 11–2   Selected Evidence-Based Recommendations for Treatment of Stable Exertional \nAngina Pectoris\nRecommendations\nRecommendation \nGradesa\nRisk Factor Modification\n Moderate- or high-dose statin therapy in the absence of  \n  contraindications or adverse effects, in addition to lifestyle \nchanges.\n For patients who do not tolerate statins, a bile acid sequestrant,   \n niacin, or both is reasonable.\n If blood pressure is 140/90 mm Hg or higher, drug therapy should  \n be instituted in addition to or after lifestyle modifications.\n For patients with DM, pharmacotherapy to achieve a target A1C  \n might be reasonable.\nClass I, level A\nClass IIa, level B\nClass I, level A\nClass IIb, level A\nMedical Therapy to Prevent MI and Death\n Aspirin 75–162 mg/day daily continued indefinitely in the absence  \n of contraindication. \n Clopidogrel is a reasonable alternative when aspirin is \ncontraindicated.\n β-Blocker therapy started and continued for 3 years in patients with \n normal LV function after MI or ACS.\n β-Blocker (carvedilol, metoprolol succinate, or bisoprolol) in \n  patients with LV systolic dysfunction (LVEF ≤40%) with HF or MI, \nunless contraindicated.\n ACE inhibitor in patients with HTN, DM, LVEF ≤40%, or CKD, unless  \n  contraindicated. ARBs are recommended if intolerant of ACE \ninhibitors.\nClass I, level A\nClass I, level B\nClass I, level B\nClass I, level A\nClass I, level A\nMedical Therapy for Relief of Symptoms\n Sublingual nitroglycerin or nitroglycerin spray for immediate relief \nof angina.\n β-Blockers as initial therapy for relief of symptoms. \n CCBs or long-acting nitrates for relief of symptoms when β-blockers \n are contraindicated or cause unacceptable side effects.\n CCBs or long-acting nitrates, in combination with β-blockers, when \n initial treatment with β-blockers is unsuccessful.\n Long-acting nondihydropyridine calcium antagonists (verapamil,   \n diltiazem) instead of a β-blocker as initial therapy.\n Ranolazine can be useful as a substitute for β-blockers if initial \n treatment with β-blockers causes unacceptable adverse effects \n or is ineffective or contraindicated.",
    "word_count": 306,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0205",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 205,
    "text": "\n CCBs or long-acting nitrates for relief of symptoms when β-blockers \n are contraindicated or cause unacceptable side effects.\n CCBs or long-acting nitrates, in combination with β-blockers, when \n initial treatment with β-blockers is unsuccessful.\n Long-acting nondihydropyridine calcium antagonists (verapamil,   \n diltiazem) instead of a β-blocker as initial therapy.\n Ranolazine can be useful as a substitute for β-blockers if initial \n treatment with β-blockers causes unacceptable adverse effects \n or is ineffective or contraindicated. \n Ranolazine combined with a β-blocker can be useful when initial \n β-blocker treatment is unsuccessful.\nClass I, level B\nClass I, level B\nClass I, level B\nClass I, level B\nClass IIa, level B\nClass IIa, level B\nClass IIa, level B\nACE, angiotensin-converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin receptor \nblocker; CCBs, calcium channel blockers; CKD, chronic kidney disease, DM, diabetes mellitus; EF , \nejection fraction; HF , heart failure; HTN, hypertension, LV, left ventricular; LVEF , left ventricular ejec-\ntion fraction; MI, myocardial infarction.\naAmerican College of Cardiology and American Heart Association Evidence Grading System \nRecommendation Class:\nI = Conditions for which there is evidence or general agreement that a given procedure or treat -\nment is useful and effective.\nII = Conditions for which there is conflicting evidence or a divergence of opinion about the use -\nfulness/efficacy of a given procedure or treatment.\nIIa = Weight of evidence/opinion is in favor of usefulness or efficacy.\n(continued )",
    "word_count": 230,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0206",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 206,
    "text": "108\nSECTION 2     Cardiovascular Disorders\nConsider\nrevascularization\nto improve\nsymptoms\nGo to Figure 5\nStable Ischemic Heart Disease\nPersistent symptoms\ndespite adequate trial\nof Guideline-Directed\nMedical Therapy\nGuideline-Directed Medical\nTherapy with ongoing\npatient education\nAnginal symptoms?\nASA\n75–162 mg\ndaily\nSublingual\nNTG\nCigarette Smoking?\nHypertension?\nBP ≥140/90\nmm Hg after diet,\nphysical activity\nprogram?\nDiabetes?\nModerate- to\nhigh-dose\nstatin\nβ-blocker\nif no contraindication\n(Espec. if prior MI,\nheart failure or\nother indication)\nLifestyle\nmodification including\ndiet, weight loss,\nphysical activity\nClopidogrel\n75 mg dailyor ASA\ndesensitization\nConsider\nadding bile-\nsequestrant† or\nniacin‡ \nDrug\ntherapy to achieve\nBP <140/90 mm Hg\nconsider ACEI/ARB if LV\ndysfunction,\ndiabetes,\nCKD\nSmoking\ncessation\nprogram\nAdd/substitute\nCCB and/or\nlong-acting nitrate if\nno contraindication\nAdd/substitute\nranolazine\nSuccessful\nTreatment?\nSuccessful\nTreatment?\nSuccessful\nTreatment?\nSerious\nContraindication\nNo\nNo\nSerious\nContraindication\nYes\nYes\nYes\nYes\nYes\nNo\nNo\nYes\nYes\nYes\nYes\nSee AHA/ACCF\nCardiovascular Risk\nReduction Guideline\nSee NHLBI ATP III\nPrevention\nGuideline\nSee JNC VII\nGuidelines\nSerious adverse effect\nor contraindication\nContraindicated\nor adverse effect\nAppropriate\nglycemic\ncontrol\nAlgorithm for guideline-directed medical therapy for patients with SIHD.*\nThe algorithms do not represent a comprehensive list of recommendations.\n†The use of bile acid sequestrant is relatively contraindicated when triglycerides are ≥200 mg/dL and is contraindicated when triglycerides are ≥500 mg/dL.\n‡Dietary supplement niacin must not be used as a substitute for prescription niacin. ACCF indicates American College of Cardiology Foundation; ACEI,\nangiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin-receptor blocker; ASA, aspirin; ATP III, Adult Treatment Panel\n3; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; JNC VII, Seventh Report of\nthe Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low-density lipoprotein cholesterol; LV,\nleft ventricular; MI, myocardial infarction; NHLBI, National Heart, Lung, and Blood Institute; and NTG, nitroglycerin.\nYes\nYesYes\nFIGURE 11–1.",
    "word_count": 309,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0207",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 207,
    "text": "ACCF indicates American College of Cardiology Foundation; ACEI,\nangiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin-receptor blocker; ASA, aspirin; ATP III, Adult Treatment Panel\n3; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; HDL-C, high-density lipoprotein cholesterol; JNC VII, Seventh Report of\nthe Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; LDL-C, low-density lipoprotein cholesterol; LV,\nleft ventricular; MI, myocardial infarction; NHLBI, National Heart, Lung, and Blood Institute; and NTG, nitroglycerin.\nYes\nYesYes\nFIGURE 11–1.  Algorithm for guideline-directed medical therapy for patients \nwith stable ischemic heart disease (IHD).\n TABLE 11–2   Selected Evidence-Based Recommendations for Treatment of Stable Exertional \nAngina Pectoris (Continued )\nIIb = Usefulness/efficacy is less well established by evidence/opinion.\nIII = Conditions for which there is evidence or general agreement that a given procedure or treat -\nment is not useful/effective and in some cases may be harmful.\nLevel of Evidence:\nA = Data derived from multiple randomized clinical trials with large numbers of patients.\nB = Data derived from a limited number of randomized trials with small numbers of patients, \ncareful analyses of nonrandomized studies, or observational registries.\nC = Expert consensus was the primary basis for the recommendation.",
    "word_count": 201,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0208",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 208,
    "text": "109\nIschemic Heart Disease     CHAPTER 11\n•\tβ-Blockers \tmay\tbe\tpreferable\tfor\tchronic\tprophylaxis\tbecause\tof\tless\tfrequent\tdosing\t\nand\tother\tdesirable\tproperties\t(eg,\tpotential\tcardioprotective\teffects,\tantiarrhythmic\t\neffects,\t lack\t of\t tolerance,\t and\t antihypertensive\t efficacy).\t Patients\t most\t likely\t to\t\nrespond\twell\tto\tβ-blockade\tare\tthose\twith\ta\thigh\tresting\tHR\tand\tthose\twith\ta\trela-\ntively\tfixed\tanginal\tthreshold.\n•\tCCBs\t are\t as\t effective\t as\t β-blockers\t and\t are\t most\t useful\t in\t patients\t who\t have\t a\t\nvariable\t threshold\t for\t exertional\t angina.\t Calcium\t antagonists\t may\t provide\t better\t\nskeletal\tmuscle\toxygenation,\tresulting\tin\tdecreased\tfatigue\tand\tbetter\texercise\ttoler-\nance.\tThey\tcan\tbe\tused\tsafely\tin\tmany\tpatients\twith\tcontraindications\tto\tβ-blockers.\t\nPatients\twith\tconduction\tabnormalities\tand\tmoderate\tto\tsevere\tLV\tdysfunction\t(EF\t\n<35%)\tshould\tnot\tbe\ttreated\twith\tverapamil\tor\tdiltiazem,\twhereas\tamlodipine\tmay\t\nbe\tused\tsafely\tin\tmany\tof\tthese\tpatients.\tDiltiazem\thas\tsignificant\teffects\ton\tthe\tA V\t\nnode\tand\tcan\tproduce\theart\tblock\tin\tpatients\twith\tpreexisting\tconduction\tdisease\tor\t\nwhen\tother\tdrugs\twith\teffects\ton\tconduction\t(eg,\tdigoxin\tand\tβ-blockers)\tare\tused\t\nconcurrently.\tNifedipine\tmay\tcause\texcessive\tHR\televation,\tespecially\tif\tthe\tpatient\t\nis\tnot\t receiving\ta\tβ-blocker,\tand\tthis\tmay\toffset\tits\tbeneficial\teffect\ton\tMVo2.\tThe\t\ncombination\tof\tCCBs\tand\tβ-blockers\tis\trational\tbecause\tthe\themodynamic\teffect\tof\t\ncalcium\tantagonists\tis\tcomplementary\tto\tβ-blockade.\tHowever,\tcombination\ttherapy\t\nmay\tnot\talways\tbe\tmore\teffective\tthan\tsingle-agent\ttherapy.\n•\tChronic\tprophylaxis\twith\tlong-acting\tforms\tof\tnitroglycerin\t(oral\tor\ttransdermal),\t\nISDN,\tISMN,\tand\tpentaerythritol tetranitrate\tmay\tbe\teffective,\tbut\tdevelopment\tof\t\ntolerance\tis\ta\tlimitation.\tMonotherapy\twith\tnitrates\tshould\tnot\tbe\tfirst-line\ttherapy\t\nunless\tβ-blockers\tand\tCCBs\tare\tcontraindicated\tor\tnot\ttolerated.\tA\tnitrate-free\tinter-\nval\tof\t8\thours\tper\tday\tor\tlonger\tshould\tbe\tprovided\tto\tmaintain\tefficacy.\t\n•\tFor\tprophylaxis \twhen\tundertaking \tactivities \tthat\tpredictably \tprecipitate \tattacks, \t\nnitroglycerin \t 0.3\t to\t 0.4\t mg\t sublingually \t may\t be\t used\t approximately \t 5\t minutes\t\nprior\t to\t the\t time\t of\t the\t activity.",
    "word_count": 319,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0209",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 209,
    "text": "  CHAPTER 11\n•\tβ-Blockers \tmay\tbe\tpreferable\tfor\tchronic\tprophylaxis\tbecause\tof\tless\tfrequent\tdosing\t\nand\tother\tdesirable\tproperties\t(eg,\tpotential\tcardioprotective\teffects,\tantiarrhythmic\t\neffects,\t lack\t of\t tolerance,\t and\t antihypertensive\t efficacy).\t Patients\t most\t likely\t to\t\nrespond\twell\tto\tβ-blockade\tare\tthose\twith\ta\thigh\tresting\tHR\tand\tthose\twith\ta\trela-\ntively\tfixed\tanginal\tthreshold.\n•\tCCBs\t are\t as\t effective\t as\t β-blockers\t and\t are\t most\t useful\t in\t patients\t who\t have\t a\t\nvariable\t threshold\t for\t exertional\t angina.\t Calcium\t antagonists\t may\t provide\t better\t\nskeletal\tmuscle\toxygenation,\tresulting\tin\tdecreased\tfatigue\tand\tbetter\texercise\ttoler-\nance.\tThey\tcan\tbe\tused\tsafely\tin\tmany\tpatients\twith\tcontraindications\tto\tβ-blockers.\t\nPatients\twith\tconduction\tabnormalities\tand\tmoderate\tto\tsevere\tLV\tdysfunction\t(EF\t\n<35%)\tshould\tnot\tbe\ttreated\twith\tverapamil\tor\tdiltiazem,\twhereas\tamlodipine\tmay\t\nbe\tused\tsafely\tin\tmany\tof\tthese\tpatients.\tDiltiazem\thas\tsignificant\teffects\ton\tthe\tA V\t\nnode\tand\tcan\tproduce\theart\tblock\tin\tpatients\twith\tpreexisting\tconduction\tdisease\tor\t\nwhen\tother\tdrugs\twith\teffects\ton\tconduction\t(eg,\tdigoxin\tand\tβ-blockers)\tare\tused\t\nconcurrently.\tNifedipine\tmay\tcause\texcessive\tHR\televation,\tespecially\tif\tthe\tpatient\t\nis\tnot\t receiving\ta\tβ-blocker,\tand\tthis\tmay\toffset\tits\tbeneficial\teffect\ton\tMVo2.\tThe\t\ncombination\tof\tCCBs\tand\tβ-blockers\tis\trational\tbecause\tthe\themodynamic\teffect\tof\t\ncalcium\tantagonists\tis\tcomplementary\tto\tβ-blockade.\tHowever,\tcombination\ttherapy\t\nmay\tnot\talways\tbe\tmore\teffective\tthan\tsingle-agent\ttherapy.\n•\tChronic\tprophylaxis\twith\tlong-acting\tforms\tof\tnitroglycerin\t(oral\tor\ttransdermal),\t\nISDN,\tISMN,\tand\tpentaerythritol tetranitrate\tmay\tbe\teffective,\tbut\tdevelopment\tof\t\ntolerance\tis\ta\tlimitation.\tMonotherapy\twith\tnitrates\tshould\tnot\tbe\tfirst-line\ttherapy\t\nunless\tβ-blockers\tand\tCCBs\tare\tcontraindicated\tor\tnot\ttolerated.\tA\tnitrate-free\tinter-\nval\tof\t8\thours\tper\tday\tor\tlonger\tshould\tbe\tprovided\tto\tmaintain\tefficacy.\t\n•\tFor\tprophylaxis \twhen\tundertaking \tactivities \tthat\tpredictably \tprecipitate \tattacks, \t\nnitroglycerin \t 0.3\t to\t 0.4\t mg\t sublingually \t may\t be\t used\t approximately \t 5\t minutes\t\nprior\t to\t the\t time\t of\t the\t activity. \t Nitroglycerin \t spray\t may\t be\t useful \t when\t inad-\nequate\t saliva \t is\t produced \t to\t rapidly \t dissolve \t sublingual \t nitroglycerin \t or\t if\t a\t\npatient \t has\t difficulty \t opening \t the\t tablet \t container.\t The\t response \t usually \t lasts\t\napproximately \t30\tminutes.\nTREATMENT OF CORONARY ARTERY SPASM  \nAND VARIANT ANGINA PECTORIS\n•\tAll\tpatients\tshould\tbe\ttreated\tfor\tacute\tattacks\tand\tmaintained\ton\tprophylactic\ttreat-\nment\tfor\t6\tto\t12\tmonths\tafter\tthe\tinitial\tepisode.\tAggravating\tfactors\tsuch\tas\talcohol\t\nor\tcocaine\tuse\tand\tcigarette\tsmoking\tshould\tbe\tstopped.\n•\tNitrates\tare\tthe\tmainstay\tof\ttherapy,\tand\tmost\tpatients\trespond\trapidly\tto\tsublingual\t\nnitroglycerin\tor\tISDN.\tIV\tand\tintracoronary\tnitroglycerin\tmay\tbe\tuseful\tfor\tpatients\t\nnot\tresponding\tto\tsublingual\tpreparations.\n•\tBecause\t CCBs\t may\t be\t more\t effective,\t have\t few\t serious\t adverse\t effects,\t and\t can\t\nbe\t given\t less\t frequently\t than\t nitrates,\t some\t authorities\t consider\t them\t the\t agents\t\nof\t choice\t for\t variant\t angina.\t Nifedipine,\t verapamil,\t and\t diltiazem\t are\t all\t equally\t\neffective\t as\t single\t agents\t for\t initial\t management.\t Patients\t unresponsive\t to\t CCBs\t\nalone\tmay\thave\tnitrates\tadded.\tCombination\ttherapy\twith\tnifedipine\tplus\tdiltiazem\t\nor\tnifedipine\tplus\tverapamil\tmay\tbe\tuseful\tin\tpatients\tunresponsive\tto\tsingle-drug\t\nregimens.\n•\tβ-Blockers\thave\tlittle\tor\tno\trole\tin\tthe\tmanagement\tof\tvariant\tangina\tbecause\tthey\t\nmay\tinduce\tcoronary\tvasoconstriction\tand\tprolong\tischemia.\nEVALUATION OF THERAPEUTIC OUTCOMES\n•\tSubjective\tmeasures\tof\tdrug\tresponse\tinclude\tnumber\tof\tpainful\tepisodes,\tamount\t\nof\trapid-acting\tnitroglycerin\tconsumed,\tand\tsymptomatic\timprovement\tin\texercise\t\ncapacity\t (ie,\t longer\t duration\t of\t exercise\t or\t fewer\t symptoms\t at\t the\t same\t exercise",
    "word_count": 559,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "dcb90cee_0210",
    "doc_id": "dcb90cee",
    "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Pharmacotherapy ",
    "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
    "chunk_index": 210,
    "text": "[Truncated PDF extraction: processed first 120 of 976 pages]",
    "word_count": 9,
    "metadata": {
      "doc_id": "dcb90cee",
      "filename": "Pharmacotherapy Handbook, 9th Ed.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Pharmacotherapy ",
      "drug_name": "Pharmacotherapy Handbook, 9Th Ed",
      "source": "medical_document",
      "word_count": 55223,
      "char_count": 363801
    }
  },
  {
    "chunk_id": "50556800_0000",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 0,
    "text": "Principles of Pharmacology - Study Guide\n\nPrinciples of Pharmacology - Study Guide \nEdited by Dr. Esam El-Fakahan y and Becky Merk ey, MEd\n\nPrinciples of Pharmacology - Study Guide by Edited by Dr. Esam El-Fakahany and Becky Merkey, MEd is licensed under a Creative \nCommons Attribution-NonCommercial 4.0 International License, except where otherwise noted.\n\nContents \n1. Introduction to Pharmacology 1 \n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics 5 \n3. Factors Contributing to Drug Effect 9 \n4. Pharmacological Descriptors of Drug-Receptor Interactions 13 \n5. Drug Action vs. Drug Effect 15 \n6. Characteristics of Drug-Receptor Interactions: 17 \n7. Response to Excessive and Reduced Stimulation of Receptors: 19 \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists 21 \n9. Receptor Allosteric Modulators 29 \n10. Competitive Antagonist vs. Negative Allosteric Modulator 31 \n11. Types of Drug-Drug Interactions 33 \n12. Introduction to Signal Transduction 35 \n13. Enzyme-Linked Receptors 41 \n15. Nuclear Receptors 47 \n16. Receptor Regulation 57 \n17. Ion Channels 65 \n21. Agents and Actions of the Autonomic Nervous System: Parasympathetic Nervous System 75 \n22. Agents and Actions of the Autonomic Nervous System: Sympathetic Nervous System 79\n\n1. Introduction to Pharmacology \nPharmacology: the study of interaction of drugs with living systems. \nSub-Disciplines of Pharmacology \n• Pharmacodynamics: effects and mechanisms of drug action \n◦ Drug-Receptor Interactions \n◦ Dose-Response Relationships \n◦ Signal Transduction \n• Pharmacokinetics: movement of drug throughout the body including: \n◦ Absorption \n◦ Distribution \n◦ Metabolism \n◦ Excretion \n• Pharmacogenetics: genetic factors play a role in the following: \n◦ Rate of Drug Metabolism \n◦ Drug-Induced Toxicity \n◦ Drug-Induced Allergies \n1\n\nPharmacology and the Pharmacist \nKey Questions you should be asking as a Pharmacist: \n• Where is the molecular site of action? \n• What are the body function changes caused by a drug (pharmacodynamics)? \n• What is the relationship between the Dose vs. Effect? \n• How does a drug produce its effect? \n2   Principles of Pharmacology - Study Guide",
    "word_count": 315,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0001",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 1,
    "text": "• What is the fate of the drug once it enters the body (pharmacokinetics)? \n• What is the interplay between genetic makeup and drug response? \nExample: Beta 1 Blocker: Metoprolol Succinate (oral) \nDrug Action:  selective binding to cardiac muscle beta 1 adrener gic receptors that respond to \nnorepinephrine (at higher doses, also inhibits bronchial and vascular smooth muscle by acting on beta 2 \nadrenergic receptors) to inhibit the binding of norepinephrine. \nDrug Effect: reduced inotropic effect (contractility) and chronotropic effect (heart rate) \nFate of the Drug (pharmacokinetics): 12% protein binding and distribution 5.6 L/kg: hepatic metabolism \n(CYP2D6 mainly): <5% renal excretion: t1/23-7 hours \n1. Introduction to Pharmacology   3\n\n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics \nReceptors: protein molecules including enzymes, transporters and ion channels where a ligand (specific \nendogenous neurotransmitter/hormone or an external pharmacological agent (drug)) binds to, resulting in a \ncellular response. \n• Unique Exception: Orphan Receptors are receptors for which the ligand remains unknown. \n• Reminder: Ligand is an ion or molecule that forms a complex with a biomolecule to serve a specific \nbiological purpose \nExamples of Endogenous Ligands: \n◦ Neurotransmitters[NT]: chemical messengers signaling across a synaptic cleft \n▪ Acetylcholine [Ach] \n▪ Epinephrine [EPI] \n▪ Norepinephrine [NE] \n5\n\n◦ Hormones (peptide): secreted from neuroendocrine cells into the blood to signal at distant \ncells and tissues. \n▪ Aldosterone \n▪ Insulin \n▪ Nerve growth factor [NGF] \n▪ Thyroid hormone [TH] \n6   Principles of Pharmacology - Study Guide\n\n• Insulin is synthesized and released by pancreatic beta cells. It is transported through the blood to a \nvariety of cells to stimulate those cells to express glucose transporters allowing those cells to bring \nglucose into the cell for energy utilization. \nDRUG: A chemical agent that selectively interacts with specific tar get molecules (i.e. receptors) to alter their \nspecific physiological functions. \n• Agonist: drug that activates receptors to result in either stimulation or inhibition of the function of \nvarious types of cells and organs. \n• Antagonist: drug that prevents receptor activation by agonists. \n2. Introduction to Drug-Receptor Interactions and Pharmacodynamics   7\n\nDrug-Receptor Binding:  drugs bind to their respective receptor in a variety of ways depending on their \ncharacteristics. \n• Ionic interaction: cation & anion \n• Hydrogen bonding \n• Lipophilic interaction \n• Covalent bond: irreversible \n8   Principles of Pharmacology - Study Guide",
    "word_count": 378,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0002",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 2,
    "text": "3. Factors Contributing to Drug Effect \nThe Effect a Drug may have is Dependent on a Variety of Factors: \n1. Drug dosage: effect of drug increases with increased amount of drug up to the POINT OF \nRECEPTOR SATURATION \n2. Number of Receptors: receptors may be differentially expressed in one tissue to the next and, \ntherefore, mediate different levels of biological responses. \n◦ Example: Beta-1 receptors are most concentrated in the heart; therefore, beta-1 agonists \nproduce the greatest effects in the heart. Beta-2 receptors are most expressed in the \nbronchioles of the lungs and the arteries of skeletal muscle; therefore, beta-2 agonists \nproduce the greatest effects in these tissues and organs. \n3. Disease states: disease states can effect drug pharmacology \n◦ Example: pharmacokinetics of a drug change dramatically in a patient with chronic kidney \ndisease \n▪ Digoxin’s volume of distribution decreases when one has chronic kidney disease \n[CKD]. Clearance also decreases causing digoxin’s half-life to increase, meaning \nthat patient with CKD actually needs a lower dose than a patient with normal \nfunctioning kidney to achieve safe and effective digoxin levels. \n4. Drug Efficacy/Intrinsic activity: ability to activate or block a receptor: maximum effect a drug can \nproduce regardless of the dose \n9\n\n5. Drug Potency/Affinity: rate of drug-receptor binding and drug-receptor release: amount of drug \nneeded to produce a particular effect: drug affinity for receptor: \nSee below: the more potent the drug the quicker it binds its receptor (forward rate) and the slower it \nreleases from its receptor (reverse rate). \nEfficacy vs Potency: As drug efficacy increases, so does the maximal biological response it can produce. Efficacy \ncannot be changed by increasing the dose beyond that which elicits a maximal response, since it is an inherent \ncharacteristic of the drug. While potency is also an intrinsic property of a given drug, ef fects of the drug may \nbe increased by using higher doses because potency refers to the rate of drug-receptor binding and dissociation \nwhereas efficacy refers to the resultant biological response. \nEFFICACY of a drug is therefore more important clinically than \nPOTENCY since one could manipulate the drug dose to produce the desirable response in case of a drug with \nlow potency but a drug with low efficacy could not be manipulated in the same way. \n10   Principles of Pharmacology - Study Guide",
    "word_count": 383,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0003",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 3,
    "text": "Spare Receptors: often times occupation of only a fraction of receptors is necessary for obtaining a maximal \nresponse. In this case the remaining unbound receptors are known as spare receptors. This means that there can \nbe a reduction in receptors (up to a limit!!!) without a corresponding decrease in the maximal response. \n3. Factors Contributing to Drug Effect   11\n\n12   Principles of Pharmacology - Study Guide\n\n4. Pharmacological Descriptors of Drug-Receptor Interactions \nPharmacological Descriptors of Drug-Receptor Interactions  are used to describe and compare potency of \ndrugs \n• KD [equilibrium dissociation constant]: indicates drug concentration at which 50% of the receptors \nare occupied by the drug \nFYI: This is constant for a given drug-receptor system \n• Bmax [maximal specific binding]: represents the total number of receptors present in a cell or tissue \nReminder: a drug does not have to bind all available receptors in order to achieve the maximal effect \n(see spare receptors) \n13\n\n5. Drug Action vs. Drug Effect \nDrug Action:  drug-receptor interaction that results in a change in the tertiary structure of the receptor \n(conformational change) by agonists \n• See right: Norepinephrine [NE] acts as an agonist, activating its receptor to initiate a cascade of \ncellular events. \nDrug/Pharmacological Effect: specific changes in physiological function as a result of  drug interaction with a \nparticular receptor. \n• See right: the drug-receptor interaction leads to a cascade of events ultimately causing the heart to \ncontract. \n15\n\n16   Principles of Pharmacology - Study Guide",
    "word_count": 241,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0004",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 4,
    "text": "6. Characteristics of Drug-Receptor Interactions: \n1. Follow Mass-Action Law: rate of reaction is DIRECTLY proportional to the concentration of the \nreactants, however, there is a limit. This limit is called the point of saturation \n◦ There are only so many receptors on each cell to which a drug can bind. Point of saturation \nrefers to the point at which every receptor is bound. \n2. Selectivity: every drug has a preferred receptor; however, it may bind to others with the same or \nlesser affinity than its preferred receptor. Side effects of drugs are a direct result of low selectivity \nbecause one drug can bind multiple receptors producing undesired biological responses. \n◦ Not to be confused with “specificity” meaning drug can only bind to one type of receptor, \nregardless of the drug dose: drugs that are “specific” are unheard of at this point \n3. Response is Proportional to Drug Dose [Concentration] up to the point of saturation \n4. Binding Changes the Receptor: when a drug binds a receptor it results in one of two changes as \noutlined below: \nAGONIST: results in an active receptor conformation to produce desired biological effect, \ni.e. intracellular signaling or changes in organ function \n17\n\nANTAGONIST: a simple occupancy by the antagonist of the receptor to hinder access of an agonist \nto its binding site on the receptor, therefore, obliterating the response to the agonist. \n18   Principles of Pharmacology - Study Guide",
    "word_count": 234,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0005",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 5,
    "text": "7. Response to Excessive and Reduced Stimulation of Receptors: \nExcessive Receptor Activation can result in desensitization or down regulation. \nDesensitization: receptor becomes less responsive when exposed to a high concentration of an agonist drug for a \nlong duration (several minutes). \nWhat is an example of receptor desensitization? \nUnder normal physiological conditions acetylcholine stimulates nicotinic acetylcholine receptors on skeletal \nmuscle to open an ion channel that allows calcium influx to cause muscle contraction. Acetylcholine is hydrolyzed \nrapidly by acetylcholinesterase; the channel closes and is ready to be opened again upon the arrival of new \nacetylcholine molecules. Pharmacological inhibitors of acetylcholine esterase cause accumulation of high \nconcentrations of acetylcholine in the synaptic cleft. The ion channel on the receptor becomes insensitive to \nacetylcholine in attempt to protect the muscle from being overly activated. \nDown Regulation: the number of receptors decreases (by proteolysis) upon exposure to a high concentration of \nagonist for a very long time (hours), making the cell less responsive to the same agonist or others that work at the \nsame receptor. \nWhat is an example of downregulation? \n19\n\nType 2 Diabetes: chronic increased levels of glucose leads to increased production of insulin. Over time, insulin \nreceptors downregulate making the individual less sensitive to insulin. \nReduced Receptor stimulation: can result in receptor supersensitivity and upregulation. \nSupersensitivity and Upregulation: occurs when a cell is deprived of its natural ligand for a long time, resulting \nin increased receptor expression over time and making the cell more sensitive to its ligand \nWhat is an example of supersensitivity? \nReserpine depletes stores of catecholamines (e.g. norepinephrine) in neurons. Catecholamine receptors \ncompensate by becoming more abundant and therefore more responsive to exogenous catecholamine-like drugs. \n20   Principles of Pharmacology - Study Guide\n\n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & \nAntagonists \nAgonists: tend to be smaller molecules that effect activation of receptors. \nNote: This may result in stimulation or inhibition of cell and organ function \nFull agonists: produces maximal biological response \n• Has maximal POSITIVE INTRINSIC activity (EFFICACY) \nPartial agonists: produces partial maximal biological response as compared to full agonist \n• has lower POSITIVE INTRINSIC activity \n• may COMPETITIVELY INHIBIT full agonist preventing maximal biological response \n◦ If the partial agonist is bound to the receptor, the full agonist cannot bind \n• may have higher, lower or the same affinity (potency) for the receptor as the full agonist \n21",
    "word_count": 394,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0006",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 6,
    "text": "Why use a partial agonist? Full agonist may cause too much activation resulting in toxicity or receptor \nadaptation on prolonged use (desensitization, downregulation). The lower ef ficacy of partial agonists \nminimizes these complications. \nInverse agonists:  produces opposite biological response to that of the endogenous agonist/\nneurotransmitter \n• has NEGATIVE INTRINSIC activity (EFFICACY) \nExample: GABAA receptor: agonists (benzodiazepines) produce a sedative effect whereas inverse \nagonists (i.e. Rho15-4513 — originally designed as alcohol antidote) produce anxiety-like effects. \nAntagonists: tend to be larger molecules producing INHIBITORY effect. \n• there are antagonists that act at the receptor, also known as receptor antagonists, \n22   Principles of Pharmacology - Study Guide\n\n**Antagonists DO NOT  have INTRINSIC ACTIVITY (EFFICACY) : reminder: antagonist simply \nblock the agonist from binding. Furthermore, keep in mind that just because antagonists do not have \nintrinsic activity does not mean they do not have physiological consequences. \nExample: While the beta-1 antagonist DOES NOT  have INTRINSIC activity on its own, it still \nhas pharmacological ef fects in vivo. Under normal circumstances, when a person is exercising \nnorepinephrine is released binds to beta-1 receptors resulting in increased cardiac inotropy \n(contractility) as well as increased chronotropy (heart rate) to accommodate the increased demand \nfor oxygen. If an individual were using a beta-1 antagonist (a.k.a. beta blocker), it would prevent \nnorepinephrine from binding to beta-1 receptors thus causing reduced contractility and lower heart \nrate compared to someone who is not using a beta-1 antagonist. Labetalol is an example of a beta-1 \nantagonist used in individuals who have angina (chest pain) associated with increased heart rate. This \ndrug enables them to exercise, while maintaining a lower heart rate so as to avoid chest pain. \nCompetitive Antagonist/Inhibitor: REVERSIBLE or SURMMOUNTABLE \n◦ Binds to a receptor at the same site as an endogenous or pharmacological agonist, blocking \nagonist binding and therefore receptor activation. \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists   23",
    "word_count": 316,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0007",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 7,
    "text": "• Antagonism is reversed by increasing the amount/dose of agonist (surmountable). While competitive \nantagonists do not affect agonist efficacy (maximal response), they do decrease AFFINITY and \nPOTENCY. Thus, a normal maximal response to the agonist may be attained in the presence of a \ncompetitive antagonist, albeit at higher agonist concentrations. Thus, agonist dose-response curve is \ntherefore SHIFTED TO THE RIGHT (more agonist needed to produce the same response) in the \npresence of a competitive antagonist (REFER TO GRAPH). \nIn this graph: \n◦ A: agonist \n◦ A + B: agonist + competitive antagonist \n24   Principles of Pharmacology - Study Guide\n\nThe receptor can interact with the agonist OR the competitive antagonist, but not both, i.e. binding is mutually \nexclusive. \nSee above: When the agonist concentration/dose is gradually increased, the equilibrium shifts towards formation \nof agonist-receptor complex [B]. The opposite is true when the antagonist concentration is increased [A]. \n• Competitive antagonists have an affinity (potency) for a receptor, however, do not have intrinsic \nactivity: REMINDER: antagonists lack intrinsic activity \nNon-Competitive Receptor Antagonists: UNSRUMMOUNTABLE \nTwo class: \nA. IRREVERSIBLE \nB. ALLOSTERIC \nA. Irreversible Non-Competitive Antagonists: \n◦ Usually bind to the same site as the agonist, however, it is not readily displaced like \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists   25\n\ncompetitive antagonists. \n◦ Generally irreversible due to the formation of a covalent bond between the antagonist and \nthe receptor, in essence reducing the number of receptors available to the agonist. \n◦ In the ABSENCE of SPARE RECEPTORS: The agonist dose-response curve will exhibit \na lower maximum that is proportional to the dose of the non-competitive antagoinst. \n• See above: Unlike competitive antagonists, non-competitive antagonists reduce the actual number of \nreceptors available to be activated, therefore, EFFICACY is REDUCED. The agonist exhibits a lower \nmaximum response in the presence of the non-competitive inhibitor. \n◦ A agonist \n◦ A + B agonist with irreversible non-competitive antagonist \nIn the pr esence of spar e r eceptors: Agonist dose-response curve will exhibit unaltered maximal \nresponse with increasing doses of the irreversible antagonist, until all spare receptors are exhausted. At \nthis point, higher doses of the antagonist will cause dose-dependent reduction in the maximal response \n(reduced efficacy). \n26   Principles of Pharmacology - Study Guide",
    "word_count": 371,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0008",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 8,
    "text": "• See above: A, agonist alone exhibits maximal response (efficacy) and affinity (potency) for the \nreceptor. B, agonist plus non-competitive antagonist: the agonist still exhibits maximal response \nbecause there are spare receptors, however, its affinity for the receptor is reduced. It is not until D, \nagonist plus higher concentration of non-competitive antagonist, that the agonist starts to exhibit a \nlower maximal response as all spare receptors have been eliminated by the irreversible antagonist. \nB. Allosteric Non-Competitive Antagonists:  A drug may bind to a site (allosteric site) on the receptor \ndifferent from that where an agonist binds (primary or classical binding site). Binding to the allosteric \nsite modifies the conformation of the primary site. In case of (negative) allosteric antagonists the altered \nconformation is less responsive to the agonist. Increasing agonist concentration does not displace the \nallosteric antagonist from the receptors since the two drugs bind to dif ferent sites, i.e. this type of \nantagonism is non-competitive and unsurmountable. See other types of allosteric modulators below. \nPhysiological Antagonist \n• Molecules that do NOT bind the same receptor as the endogenous or a pharmacological agonist, but \nproduce an effect that is opposite to the agonist effect. \nExample: epinephrine is a physiological antagonist to histamine, even though they bind to their \nown specific receptors. When histamine binds to its receptor , arterial pressure decreases through \nvasodilation. However, when epinephrine binds to its receptor , arterial pressure increases through \nvasoconstriction, thus counteracting histamine or producing an antihistamine effect. \nChemical Antagonists: \n8. Two Main Classes of Receptor Ligands in Pharmacology: Agonists & Antagonists   27\n\n• Drugs that do not interact with the agonist receptor but rather reduce the concentration of an agonist by \nforming a chemical complex; also known as chelating agents. \nExample: Phosphate binders are used to prevent hyperphosphatemia in patients who have chronic \nkidney disease. Phosphate binders can act as a chemical antagonist with a number of  medications \nincluding quinolone. Phosphate binders from a complex with quinolone reducing its ef fectiveness. \nPatients should be counseled to take a phosphate binder 3 hours before or after taking quinolone. \n28   Principles of Pharmacology - Study Guide",
    "word_count": 351,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0009",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 9,
    "text": "9. Receptor Allosteric Modulators \nAllosteric modulators interact with sites on the receptor dif ferent from the primary agonist binding site. This \nresults in modulation of the conformation of the agonist binding site to impart higher (allosteric enhancers) \nor lower (allosteric inhibitors) af finity for the agonist. Some allosteric modulators are able to  induce an active \nconformation of the receptor primary binding site to result in receptor activation in the absence of an agonist. \nThree Classes of Allosteric Modulators: \n1. Allosteric Agonists: agonist by itself in absence of any other agonist \n2. Allosteric Enhancer (Agonist): enhances (potentiates) agonist biological response \n3. Allosteric Inhibitors (Antagonist): inhibits agonist biological response \nAs you can see in this image, allosteric modulators bind to an area/domain on the receptor that is topographically \nDISTINCT from the PRIMARY AGONIST BINDING SITE . Binding to this area results in modifications to \nthe conformation of the primary site to either make it more or less favorable  to bind the agonist (increase or \ndecrease agonist affinity, respectively). This causes enhancement or dampening of agonist response. \n29\n\n10. Competitive Antagonist vs. Negative Allosteric Modulator \nA competitive antagonist directly and physically blocks access of the agonist to the receptor , whereas a negative \nallosteric modulator indirectly changes agonist binding by interacting at a secondary site on the receptor to \ndiminish the ability of the agonist to bind to the primary site. While a competitive antagonist shifts the dose-\nresponse curve of an agonist indefinitely by increasing antagonist dose, the shift caused by an allosteric antagonist \n(negative allosteric modulator) reaches a limit. This limit is dictated by the cooperatively factor that represents \nthe maximal magnitude of interaction between the allosteric and primary binding sites. This limit makes negative \nallosteric modulators safer and more amenable to producing fine tuning of receptor unction. This ceiling ef fect \nalso ensures achieving the same response to a maximal dose of the antagonist regardless of dif ferent blood \nconcentrations, e.g. due to differences in metabolism in one patient versus another. Another advantage of negative \nallosteric modulators is their higher or gan selectivity as compared with competitive antagonists. This is because \nof uniqueness of the chemical nature of the allosteric site on the same receptor expressed in dif ferent tissues and \norgans. This is in contrast to the well conserved nature of the primary binding site. This results in better selectivity \nand less side effects of allosteric modulators. \n31",
    "word_count": 399,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0010",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 10,
    "text": "This image above demonstrates the ceiling effect of a negative allosteric modulator/antagonist. The antagonist \nreduces the agonist response in a dose-dependent manner . However, this antagonism reaches a plateau even at \nhigher doses. This is in contrast to complete inhibition of the agonist response by a competitive antagonist. \nWhy does this matter ? There is need to reduce certain biological responses without completely shutting them \ndown. For example, a person who has gastrointestinal spasms needs a modulator that returns the hyperactive state \nof gastric and intestinal muscles to normal, without causing complete paralysis of the gastrointestinal tract. \nTo summarize, ADVANTAGES of negative allosteric modulators over competitive antagonists include: \nCeiling Effect:  can only inhibit agonist response to a certain point, protecting patient from excessive \ninhibition that could have serious consequences. \nFine-Tune ability:  allosteric modulators have greater potential for receptor subtype selectivity than do \ncompetitive antagonists, and this minimizes side effects. \n32   Principles of Pharmacology - Study Guide\n\n11. Types of Drug-Drug Interactions \nAdditivity: when the effect of two drugs given in combination equals the mathematical summation of their effects \nwhen given alone. \nSynergism: when the combine effect of two drugs is greater than the sum of their effects when given separately. \nPotentiation: when one drug does not elicit a response on its own but enhances the response to another drug. \nExamples of Drug-Drug Interactions: given responses to 4 drugs \n• Drug A = 0 units response \n• Drug B = 3 units response \n• Drug C = 5 units response \n• Drug D = 10 units response \nSee Below \nDrug A + Drug B = 5 units >> potentiation \nDrug B + Drug C = 8 unites >> additivity \nDrug C + Drug D = 20 units >> synergism \n33\n\n34   Principles of Pharmacology - Study Guide",
    "word_count": 296,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0011",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 11,
    "text": "12. Introduction to Signal Transduction \nSignal Transduction • transmission of molecular signals from outside the cell into the cell via cell-surface \nreceptors. Signal transmission is caused either by: \n• a cascade of events or biochemical changes within the cell \n◦ o receptors that initiate biochemical changes accomplish this either by intrinsic enzymatic \nactivities (within the receptor itself) or by activating intracellular messenger molecules \n• modification of the cell membrane potential initiated by the movement of ions into or out of the cell \nWhy is this important ? Identifying the cellular events that take place upon receptor activation is necessary for \ndesigning pharmacological agents that potentiate (increase) or diminish (decrease) signaling. For example, certain \nsignaling pathways become overly active in cancerous cells. Suppression of these exaggerated signals may be one \nway to reduce cell proliferation in cancer. \nPurpose of Signal Transduction \n• Signal amplification • increasing a signal so that minimal receptor occupation by small amounts of \nneurotransmitters in the synapse produces significant cellular responses. \nhttps://highered.mheducation.com/olcweb/cgi/pluginpop.cgi?it=swf::535::535::/sites/dl/free/0072437316/\n120069/bio08.swf::Signal%20Amplification \n35\n\n• Signal dampening • decreasing an abnormally high signal to maintain physiological homeostasis. An \nexample is how receptors on the presynaptic nerve ending respond to high levels of a neurotransmitter \nin the synapse by decreasing further neurotransmitter release (auto receptors) \n◦ Feedback inhibition: \nOutput of signal transduction is used as a signal to decrease the signaling process itself \n(which will usually limit the production of intracellular messengers) \nTypes of Signal Transduction \n• Autocrine \n• Paracrine \n• Endocrine \n36   Principles of Pharmacology - Study Guide\n\nAutocrine • cell secretes chemical messenger or hormone that will then activate receptors on that same cell. \nParacrine • cell secretes chemical messenger or hormone that will then activate cell-surface receptors on a cell \nnearby. \n• A good example is synaptic transmission, which is how neurons communicate through \nneurotransmitters. \n12. Introduction to Signal Transduction   37",
    "word_count": 306,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0012",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 12,
    "text": "Endocrine • cell secretes chemical messenger or hormone that needs to be transported via the blood stream to \nreach a distant target cell. \n• Neuroendocrine cells receive neuronal input (neurotransmitters released by nerve cells or \nneurosecretory cells) and, as a consequence of this input, release message molecules (hormones) to the \nbloodstream. \nExample • insulin is synthesized and secreted by pancreatic beta cells, released into the blood and transported to \ncells all over the body. Insulin then stimulates its receptors on these cells to initiate a cascade of events leading to \nexpression of glucose transporters to allow cells to take glucose in for energy utilization. \nSignal Transduction Pathways are not always linear. \n• Convergence • when signals from a variety of unrelated receptors can converge and activate common \neffectors. \n• Divergence • when a signal from a single receptor can activate multiple effectors. \n38   Principles of Pharmacology - Study Guide\n\n• Crosstalk • when different signals increase or decrease the production of other signals \nEffector • The eventual target of signaling.  For example, the heart is an effector of norepinephrine released from \nnerve terminals. \nTypes of Signal Transducing Messengers \n1. First Messengers •agonists(i.e. hormones, neurotransmitters, pharmacological agonists) \n2. Second Messengers • molecules that transmit signals received at receptors (i.e., cAMP, cGMP, DNA \nbinding, ions) \n3. Third Messengers • (i.e., ions, protein kinases) \nTypes of Receptors \n1. Carriers (Transporters) \n2. Signal Transduction Receptors \n1. Enzyme-linked \n2. G-protein-coupled \n3. Ligand-gated channels \n4. Intracellular \n3. Enzymes \nReceptors Responsible for Signal Transduction \nThere are 4 Classes of Signal Transducing Receptors: \n1. Enzyme-Linked Receptors (Receptor Kinases) • have intrinsic enzymatic activity or are associated with an \nintracellular enzyme \n2. GPCRs (G-Protein-Coupled Receptors) • couple to GTP binding proteins (G-proteins) inside the cell to activate \nthem. Active G proteins modulate the activity of various ion channels and enzymes. \n3. Ligand-Gated Ion Channels  • allow specific ions to flow into or out of the cell in response to binding of a \nchemical messenger \n4. Intracellular Receptors (Cytoplasmic & Nuclear Receptors) • activation of these receptors located within a \ncell results in directly altered gene transcription \n12. Introduction to Signal Transduction   39",
    "word_count": 353,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0013",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 13,
    "text": "13. Enzyme-Linked Receptors \nEnzyme-Linked Receptors  • have intrinsic enzymatic activity or are associated with an enzyme (usually a \nkinase) • play a role in apoptosis, cell dif ferentiation, cell division, cell growth, immune response, inflammation, \nand tissue repair. \nKinases (Protein Kinases [PKs]) • enzymes that catalyze the phosphorylation of tar get molecules to cause their \nactivation.  In other words, they add a phosphate group to a molecule/protein/another kinase. \n• Protein Kinase Inhibitors (PKIs): stop kinase activity, important class of molecules used for cancer \ntreatment \nPhosphatases • enzymes that catalyze the dephosphorylation of target molecules. This dephosphorylation usually \ninactivates the target molecule (effector). Phosphatases act in opposition to kinases. \nIt is the balanced activity of kinases and phosphatases that results in ef fective, and fast, signaling events to allow \nfor the desired biological effect and enable our bodies to maintain homeostasis. \nEnzyme Linked Receptor Structure • composed of three key domains \n• Ligand-Binding Domain • often has a large EXTRACELLULAR ligand-binding domain allowing \nfor easy access and activation to the receptor. \n• Transmembrane Domain • composed of a series of hydrophobic amino acids (reminder: inner \nmembrane is lipophilic/hydrophobic) that tethers the receptor to the cell membrane. \n• Intracellular “Active Enzyme” Domain • either intrinsic to the receptor or \n41\n\ntightly bound to the transmembrane domain. The majority of the “active \nenzyme” domains are kinases that phosphorylate the amino acids serine, \nthreonine and tyrosine of proteins. \nExample • Insulin Receptor • ligand is insulin, which stimulates carbohydrate (glucose) utilization and protein \nsynthesis. \nLigand-binding domain = alpha domain \nTransmembrane domain = runs through the membrane anchoring it to the membrane \n“Active enzyme” domain = tyrosine kinase domain (intracellular component) activated by phosphorylation \n42   Principles of Pharmacology - Study Guide",
    "word_count": 286,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0014",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 14,
    "text": "Once activated, the insulin receptor leads to a cascade of events eventually resulting in expression of glucose \ntransporters (GLUTs) on the surface of a cell to allow it to bring in glucose for energy utilization. \nSignal Transduction by Enzyme-Linked Receptors \n1. Ligand binding leads to dimerization of two neighboring receptors. \n2. Neighboring dimerized receptors auto phosphorylate one another \n3. SH2-domain proteins bind to the phosphorylated receptors and are then phosphorylated enabling the \ncontinuation of the signal eventually leading to gene transcription. \n• SH2-domain [Scr homology 2] • protein domain composed of about 100 amino acid residues. \nSH2-domains most commonly play a role in the signal transduction by receptor tyrosine kinase \npathways as you will see later on in this section. They interact with specific target molecules (peptides) \nwith a phosphorylated tyrosine residue. \n 3 Main Types of Enzyme-Linked Receptors • \n13. Enzyme-Linked Receptors   43",
    "word_count": 143,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0015",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 15,
    "text": "• Receptor Tyrosine Kinases [RTK] • make up the majority of enzyme-linked receptors. Signal \ntransduction through RTK results in specific phosphorylation of tyrosine residues on target proteins \nand subsequent increase in gene transcription and regulation of cell growth, differentiation and \nsurvival. \n• Serine/Threonine Kinases • specifically phosphorylate the hydroxyl side chains of serine or \nthreonine amino acid residues. These kinases may have a role in cell proliferation, differentiation, \napoptosis and even embryonic development. \n• Tyrosine Kinase-Associated Receptors [“mixed”] • do not have a tyrosine kinase domain, rather act \nthrough cytoplasmic tyrosine kinases. \nReceptor Tyrosine Kinases [RTK] • This class of receptors are also considered enzymes that have intrinsic \nenzymatic activity. When RTK agonists bind to these receptors, their intrinsic enzymatic activity is stimulated. \nRTKs bind growth factors to signal processes that result in the regulation of cell growth, dif ferentiation and \nsurvival through gene transcription. Subclasses include: \n• Epidermal Growth Factor Receptors [EGFR, ErbB1, HER1] • This RTK subclass is activated by \nepidermal growth factor resulting in cell division that leads to cell growth, proliferation and \ndifferentiation. These receptors are found in abnormally high levels on the surface of a number of \ntypes of cancer cells allowing these cells to multiply excessively. \n• Nerve Growth Factor Receptors [NGF] • This RTK subclass is activated by nerve growth factors, \nmore specifically neurotropins; a family of proteins involved with development, survival and function \nof neurons. \n• Insulin Receptors • This RTK subclass is activated by insulin resulting in expression of glucose \ntransporters [GLUT] and allow cells to accumulate glucose from the blood. \n• Toll Like Receptors [TLRs]• This RTK subclass is activated by pathogen-derived molecules allowing \nthe body to detect unwanted pathogens early on as well as sense “danger” signals leading to the \neventual destruction of those pathogens. \nWhen RTKs are activated by an agonist, they form cross-linked dimers resulting in the activation of the tyrosine \nkinase by phosphorylation. Remember , kinases specifically act to catalyze the phosphorylation of a tar get \nmolecule, which in this case is a neighboring RTK. The dimerized RTKs phosphorylate each other multiple times \nto result in signal amplification. This process is known as cross-phosphorylation. RTK cross-phosphorylation then \nleads to the phosphorylation of other proteins that will eventually result in modulation of gene transcription. \n44   Principles of Pharmacology - Study Guide",
    "word_count": 384,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0016",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 16,
    "text": "Key Pathway • Ras/RAF/Mitogen-Activated Protein [MAP] Kinase Pathway \nRas = G-protein specific to this pathway                    RAF = proto-oncogene serine/threonine kinase \nMEK = mitogen-activated protein kinase                   MAPK = mitogen-activated protein kinase \nRas • a small G protein (GTPase) involved in signal transduction leading to cell division and proliferation. If not \nregulated properly, Ras proteins can lead to uncontrolled cell division that eventually results in tumor formation. \nRAF [Rapidly Accelerated Fibr osarcoma] • family of protein kinases that are involved with retroviral \noncogenes (genes that can potentially cause cancer). \nTyrosine-Kinase Associated Receptors • associate with intracellular proteins that have tyrosine kinase activity . \nThese receptors lack the tyrosine kinase domain that was discussed earlier and, therefore, accomplish tyrosine \nphosphorylation by cytoplasmic tyrosine kinases instead. \nCytokine receptors make up the largest family of receptors that relay signals into the cell by cytoplasmic tyrosine \nkinases. These particular receptors are associated with the cytoplasmic kinase, Jak (Janus kinase). Jak will go on \nto activate a gene regulatory protein called STAT (signal transducers and activators of transcription). The pathway \nis described and depicted below: \n13. Enzyme-Linked Receptors   45\n\nKey Pathway • Jak/Stat pathway (Janus kinase/signal transducers and activators of transcription) • The Jak/\nStat pathway is the principal pathway for cytokines and growth factors in humans. This pathway is activated by \na number of cytokines (most commonly interferons) and growth factors. Activation stimulates cell proliferation, \ndifferentiation, migration and apoptosis. Furthermore, cytokines control the synthesis and release of a number \nof inflammatory mediators. When a cytokine binds to its enzyme-linked receptor it results in a conformational \nchange leading to phosphorylation of the intracellular active-enzyme domain, eventually leading to the \ntranscription of inflammatory mediators. As with all signal transduction mechanisms, homeostasis is reliant on \nproper regulation of all these dif ferent pathways. Lack of proper regulation of the JAK pathway can cause \ninflammatory disease, erythrocytosis, gigantism and leukemias. \n**For more information on enzyme-linked receptors, see this link below: \nhttps://www.ncbi.nlm.nih.gov/books/NBK26822/ \n46   Principles of Pharmacology - Study Guide",
    "word_count": 328,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0017",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 17,
    "text": "15. Nuclear Receptors \nNuclear receptors are receptors located inside the cell. These receptors are found either in the cytoplasm (T ype I) \nor the nucleus (Type II) of a cell. Examples include:   estrogen, glucocorticoids, thyroid hormone T3 or vitamins \nD and A. Receptor stimulation of any intracellular receptor primarily results in altered gene transcription. \n• Type I • intracellular receptors located in the cytoplasm of a cell. These receptors are translocated to \nthe nucleus after stimulation by an agonist. \n◦ o Examples androgen [AR], glucocorticoid [GRa], mineralocorticoid [MR], and \nprogesterone receptors [PR]. \n• Type II • intracellular receptors located in the nucleus of a cell, even in the absence of agonists. \n◦ Examples • peroxidsome proliferator [PPAR a,ß,g, sigma], retinoic acid \n[RAR a,ß,g], thyroid receptors [TR a,ß]. \nNuclear Receptors • a subtype (Type II) of intracellular receptors that directly alter gene transcription. Nuclear \nreceptors [NR] are a superfamily of transcription factors. They are modulated by and bind small lipophilic \nmolecules (partial or mixed agonists) with low af finity. Some NRs do not have a known ligand at this point in \ntime and are therefore known as Orphan Receptors. \n47",
    "word_count": 189,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0018",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 18,
    "text": "Structure • monomeric proteins with similar general structure \n• N-terminal Domain • Activation function 1 [AF1] site binds other transcription factors to modify the \nbinding or activity of the receptor itself. These transcription factors are specific to a given cell. \n• Core Domain • It is at this domain that DNA recognition and binding of hormone response elements \n[HREs] occur. The domain is made of two zinc fingers (cysteine/histidine rich loops in the amino acid \nchain that are held in a particular conformation by zinc ions). \n◦ o HREs • portion of gene regulated by NRs that also result in receptor dimerization. \nThere are a number of nuclear receptors that produce a wide range of physiological functions. These receptors and \ntheir resultant functions will be discussed throughout the curriculum. \nType I Nuclear Receptors \n• Androgen Receptors [AR] Endogenous AR agonists include testosterone and dihydrotestosterone \n[DHT]. These ligands bind AR in the cytosol of a cell and then translocate to the nucleus in order to \nalter transcription leading to protein synthesis, cell growth, formation of gonads, development of \nsecondary sex characteristics and more. \n• Glucocorticoid Receptors [GR] Cortisol is one of the most a common pharmaceutical targets as a \nendogenous GR agonist. Cortisol and other glucocorticoid hormones are stress hormones essential to \nmaintaining homeostasis for a number of physiological processes such as metabolism, immune \nfunction, skeletal growth, cardiovascular function, reproduction and cognition. Upon binding, GR \nagonists can result in either activation or repression of transcription (depending on the particular \nisoform). For more details, see the link below:https://www.ncbi.nlm.nih.gov/pmc/articles/\nPMC4084612/ \n• Progesterone Receptors [PR] Upon binding PR in the cytosol, progesterone \nresults in activation of transcription affecting a number of biological processes \n48   Principles of Pharmacology - Study Guide",
    "word_count": 286,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0019",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 19,
    "text": "including the menstrual cycle. \nType II Nuclear Receptors \n• Peroxisome Proliferator-Activated Receptor Alpha Receptors [PPAR]. Upon stimulation, these \nreceptors lead to an increase in lipoprotein lipase (an enzyme that catalyzes the breakdown of \nlipoproteins) resulting in decreased hepatic triglyceride [TG] production. Fibrates, a drug class that \ntargets these receptors, are PPARa agonists. \nTheir primary action is to decrease TG blood levels, however, they also help increase HDL (“good \nfat”), lower LDL (“bad fat”), improving a patient’s lipid profile and providing improved \ncardiovascular protection. \nRXR • Retinoid X Receptor \nPPRE • Peroxisome Proliferator Response Element \n• Thyroid Hormone Receptors [THR a,ß] Upon stimulation, these receptors play \na role in the rate of metabolism, neural development and cholesterol metabolism. \nHypothyroidism, reduced TR stimulation, leads to slowed metabolism and \npresents as general fatigue and lethargy, weight gain, slowed heart rate, feeling \ncold and more. Conversely, hyperthyroidism, increases TR stimulation, leads to \nincreased metabolism and presents as weight loss, increased heart rate, feeling \nhot and more. Nuclear Receptor-mediated transcriptional regulation can be \n15. Nuclear Receptors   49\n\nmodulated by several signaling pathways; this is a great example of\nconvergence. Convergence is when multiple pathways lead to the same effect \nand in the case of nuclear receptors the effect is transcription. These pathways \ncan be initiated by either both external and internal signals involving GPCRs, \nion channels, TRKs as well as several other receptors. \n50   Principles of Pharmacology - Study Guide\n\nOverview of Receptor Types \n15. Nuclear Receptors   51\n\nEnzyme-Linked Receptors G-Pr\nLocation cell membrane cell membrane \nEffector protein kinases channel or enzyme \nCoupling \ndirect \n \nG-protein \n52   Principles of Pharmacology - Study Guide\n\nStructure single transmembrane helix linking extracellular receptor domain to intracellular enzyme (often kinases) domain. \n7 trans-membrane helices with intracellular G-protein-coupling domain \n15. Nuclear Receptors   53\n\n54   Principles of Pharmacology - Study Guide\n\nHormones bind to a receptor dimer to result in activation. \nExamples insulin, growth factors, cytokine receptors muscarinic acetylcholine receptors, adrenoceptors \n15. Nuclear Receptors   55",
    "word_count": 323,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0020",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 20,
    "text": "16. Receptor Regulation \nOverview \n• Intrinsic Regulation • receptors initiate regulation of a variety of events and are themselves subject to \nregulatory and homeostatic controls. \n• Disease States • disease states can alter the number, function, and/or activity of receptors. \n• Drugs • drugs can act as agonist, antagonists and allosteric modulators all of \nwhich can alter receptor function and number. \nIntrinsic Regulation \nIntrinsic Regulation • receptors are subject to regulation and homeostatic control. Left unregulated, receptors \nmay be over stimulated, which may lead to pathological changes, including apoptosis. Therefore, regulation helps \nprotect cells. There are times when an increased response is needed and others when a decreased response is \npreferred. \nCellular mechanisms of Increased Response \n• Super/Hyper Sensitivity \n• Synergism \n• Upregulation \nSuper/Hypersensitivity • Super or hypersensitivity refers to an enhanced response to an agonist. Hypersensitivity \nmay occur as a result of unmasking of receptors or accentuation of signal amplification. \n• Unmasking of Receptors • some receptors have a masking protein covering the intracellular portion \nof a receptor, like the GPCR seen below for example. This masking protein prevents signal \ntransduction and leads to decreased activity. When a masking protein in removed, activity increases. \n57\n\n• Accentuation of Signal Amplification • this may occur with an increase in receptor phosphorylation \nor increased enzymatic activity. As was discussed earlier, phosphorylation can lead to the activation of \na chain of second messengers and signal amplification. Therefore, as phosphorylation increases, so \ndoes signal transduction and amplification. Likewise, there are enzymes that catalyze components in a \nsignal transduction pathway leading to increased signal transduction and amplification as well.The \nimage below shows how signal amplification can be initiated by a single molecule. This particular \nexample leads to the activation of protein kinases, which goes on to phosphorylate specific target \nmolecules. As the signal is amplified, so is the amount of phosphorylation leading to an accentuation \nof signal amplification. If these kinases are not balanced by phosphatases, enzymes that reverse \nphosphorylation, phosphorylation can predominate and lead to further accentuation of the original \nsignal. \n58   Principles of Pharmacology - Study Guide",
    "word_count": 345,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0021",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 21,
    "text": "Synergism • when two receptors produce a combined effect that is greater than the sum of their individual effect. \nExample • Glucocorticoids stimulate glucocorticoid r eceptors [GR], a type of nuclear receptor , resulting in \nincreased erythroid cell (series of cell leading to red blood cells) production. When peroxisome proliferator-\nactivated r eceptor alpha  [PPARa] and GRs are stimulated simultaneously by their respective agonists, the \nresultant erythroid cell production is greater than the sum of production by each receptor individually . Together, \nPPARa and GR stimulation result in an enhanced response. \n16. Receptor Regulation   59\n\nUpregulation • Upregulation refers to an increase in the number of receptors due to prolonged deprivation of \nreceptors of interacting with their physiological neurotransmitter (e.g. by denervation of chronic use of a receptor \nantagonist). By expressing more receptors, there is a greater probability that a hormone will bump into and \nstimulate its receptor. \nCellular mechanisms of Decreased Response \n• Desensitization \n• Downregulation \n• Tachyphylaxis \n• Tolerance \nDesensitization • Desensitization refers to a reduced response to an agonist drug due to over activation of \na receptor (high doses, prolonged exposure to agonist). There is a number of mechanisms of desensitization \nincluding: loss of receptor function through a decrease in receptor -coupled signaling components (e.g., G-\nproteins). Receptor desensitization may occur in the absence of significant changes in the number of receptors. \n60   Principles of Pharmacology - Study Guide\n\nThis example here demonstrates loss of receptor function; one of several types of desensitization. As you can \nsee on the far right, the agonist is bound to the receptor, however, this does not result in the channel opening. \nDownregulation • Downregulation specifically refers to a reduction in the total number \nof receptors available to be stimulated due to prolonged receptor activation (e.g. by \nchronic treatment with a pharmacological agonist drug or prolonged inhibition of \nmetabolism of a neurotransmitter). This reduction in receptors in turn will decrease the \ncell’s sensitivity to an agonist or drug. Downregulation occurs through endocytosis. \nInternalized receptors may either be degraded in the lysosomes or recycled back to the \nmembrane surface later. \n16. Receptor Regulation   61",
    "word_count": 351,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0022",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 22,
    "text": "As the image shows, endocytosis involved the internalization of a receptor preventing it from carrying out signal \ntransduction. A receptor may either go to the endosome then lysosome to be degraded or recycled back to the \nmembrane surface to once again carry out signal transduction. \nTachyphylaxis • T achyphylaxis is a rapid decr ease in response to an agonist drug following repeated \nadministration within a brief period; an acute form of desensitization. This can occur without a change in the \nnumber of receptors or the ability of a receptor to affect the downstream signaling molecules. Increasing the dose \nof the drug will not improve the response. \n62   Principles of Pharmacology - Study Guide",
    "word_count": 113,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0023",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 23,
    "text": "Tolerance • Tolerance refers to a gradual decreased response to a drug, requiring a higher dose of drug to achieve \nthe same initial response. Tolerance is different from tachyphylaxis because it develops over a long period of time, \nwhereas, tachyphylaxis is an acute event. In addition, tolerance can be overcome by increasing the dose, unlike \ntachyphylaxis. \n Example • A great example of tolerance is in the story of Brett Favre, a Hall of Fame quarterback who played for \nthe Green Bay Packers 1991-2010. In the midst of his career he developed an addiction to V icodin (an analgesic \nmedication that contains hydrocodone, an agonist of opiate receptors). He started taking two tablets to treat his \nsports-related injuries/pain and eventually worked his way up to 15 tablets due to a development of tolerance \nto Vicodin. At his worst, he was taking 14-days’ worth of V icodin each day in order to achieve the same ef fect \nhe originally had with 2 tablets, which contributed to his streak of 297 consecutive games played; currently the \nlongest streak in NFL history by 27 games. You may read more about it at the link below: \nhttp://www.cbssports.com/nfl/news/brett-favre-says-he-used-to-take-a-months-worth-of-painkillers-in-two-days/ \nChanges in receptor response by disease states \nDisease states may alter the number of available r eceptors, which can alter the sensitivity and response of a \ngiven cell or tissue. Disease states may therefore alter the actual function or activity  of those receptors; either \nthrough loss or gain of function. \nExample • Loss of Receptors \nMyasthenia Gravis is an autoimmune disorder in which antibodies destroy nicotinic acetylcholine receptors \n[nAChR] located in skeletal muscle. nAChRs help communicate signals resulting in muscle contraction. Thus, \nMyasthenia Gravis causes muscle weakness, droopy eyes and even difficulty in swallowing. \n16. Receptor Regulation   63",
    "word_count": 290,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0024",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 24,
    "text": "Myasthenia Gravis is treated with immunosuppressants to decrease the production of antibodies that destroy \nnAChRs as well as with acetylcholine esterase inhibitors [AChEIs] that prevent the breakdown of acetylcholine, \na nAChR agonist, to increase its level in the synapse. \nExample • Loss of Function • Androgen Receptors [AR] \nAndrogen receptors have variants caused by genetic mutations. These variants have varied levels of function, \nranging from partial to complete loss of function. Individuals who have complete AR insensitivity exhibit \nComplete Androgen Insensitivity Syndrome [CAIS], and those who have partial AR insensitivity suf fer from \nPartial Androgen Insensitivity Syndrome [PAIS]. Both syndromes cause a loss of receptor function. \nTreatment for these syndromes includes hormone therapy; testosterone and/or dihydrotestosterone [DHT]. One \ngreat advantage of DHT over testosterone is that cannot be aromatized to estrogen, eliminating possible side \neffects associated with estrogen exposure. \nExample • Gain-of-Function •A number of endocrine diseases are caused by gain-of-function mutations of \nGPCRs. \nType 2 Diabetes Mellitus  [DM2] •  DM2 can be associated with a gain-of-function mutation, resulting in \nincreased expression of the a2A-adrenergic receptor; a GPCR that prevents or suppresses the secretion of \ninsulin. As you can imagine, a patient with this gain-of-function mutation will have elevated blood glucose, \npotentially leading to type II diabetes mellitus. \nFamilial Hypocalcemia Hypocalciuria  • This disease involves a gain-of-function \nmutation of the calcium-sensing r eceptor [CaSR]; a GPCR that allows the body to \nmonitor and regulate the amount of calcium in the blood. This gain-of-function leads \nto increased sensitivity to calcium. Because CaSR maintains calcium homeostasis, its \nexaggerated response to calcium tells the body to excrete more calcium. This leads to \ndecreased calcium levels in the blood (hypocalcemia) by suppressing the secretion of \nparathyroid hormone and increased renal excretion of calcium (hypercalciuria). \n64   Principles of Pharmacology - Study Guide\n\n17. Ion Channels \npore-forming membrane proteins that allow ions to pass through a channel pore \n• Ligan-Gated Ion Channels (aka iontropic) \n◦ Ion channels that open in response to specific ligand molecule(s) binding to the receptor \nprotein \n• Voltage-Gated Ion Channels \n◦ Ion channels that open and close in response to changes in membrane potential \n65",
    "word_count": 353,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0025",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 25,
    "text": "Ligand-Gated Ion Channels \nLigand-Gated Ion Channels – allow ions to flow into or out of the cell in response to the binding of a chemical \nmessenger to their respective receptors. \n• Acetylcholine Receptors (nicotinic) \n• GABAA Receptors \n• Glutamate Receptors (NMDAA, AMPA) \nReceptor Stimulation – Ligand binds to the receptor –>> causes receptor conformational change –>> channel \nopens allowing SPECIFIC ions to pass through. \n66   Principles of Pharmacology - Study Guide\n\nIONOTROPIC vs METABOTROPIC Receptors \nIonotropic Receptor Metabotropic Receptor \nReceptor \nType ligand-gated transmembrane protein ligand-gated transmembrane protein \nReceptor \nStructure ion channel no ion channel \nTime to \nAction fast acting slow acting \nResult of \nLigand \nBinding \nligand directly opens ion channel ligand activates G-protein leading to a cascade of events \nthat may eventually result in opening an ion channel \nACETYLCHOLINE RECEPTORS \nAcetylcholine Receptors – There are two families of acetylcholine receptors; muscarinic and nicotinic. Both \nfamilies are found pre-synaptically (ndurons that send neurotransmitter signals) as well as post-synpatically \n(neurons that receive neurotransmitter signals). They are widely distributed throughout the central nervous system \n(CNS) and peripheral organs. Certain neurodegenerative diseases, especially Alzheimer’s dementia, are associated \nwith reduction in the number of cholinergic neurons (neurons that synthesize and release acetylcholine). \nNicotinic Acetylcholine Receptors [nAChR] – these channels are pentamers composed of multiple \nsubunits, these channels are directly coupled to cation channels and mediate FAST EXCIT ATORY \nsynaptic transmission at the NEUROMUSCULAR junction, autonomic ganglia and various sites in the \nCNS. \n• nAChR has 5 subunits and requires two molecules of acetylcholine [ACh] to bind to open the channel \n(see below). \n17. Ion Channels   67\n\nMuscarinic Acetylcholine Receptors [mAChRs] – mAChRs are G protein coupled receptors [GPCRs] and, \ntherefore, will not be discussed in detail in this section. \nnAChR Synapse – nAChRs are found in neuromuscular and ganglionic synapses. Reminder – a synapse is \nthe gap through which electrical or chemical signals are transmitted from a nerve to a muscle or another nerve. \nPresynaptic nAChRs facilitate ACh release during synaptic activity . Excess neurotransmitter is recycled and \nbroken down by an enzyme called acetylcholinesterase [AChE], rendering ACh inactive as a neurotransmitter. \n68   Principles of Pharmacology - Study Guide",
    "word_count": 354,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0026",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 26,
    "text": "ACh (seen in the synaptic cleft above) is an important drug target. By inhibiting AChE, ACh is not broken down, \nthe amount of ACh in the synaptic cleft increases, allowing for increased stimulation of synaptic receptors by \nACh. \nThe autonomic system is responsible for controlling those functions we do not consciously control such as \nbreathing, food digestion, heart rate, etc. The autonomic nervous system can be divided into two branches: \nthe sympathetic nervous system [SNS] and the parasympathetic nervous system [PNS]. Nicotinic acetylcholine \nreceptors play an important role in both the SNS as well as the PNS. \nBelow – In this image, the nicotinic acetylcholine receptor [nAChR] functions to regulate the release of the \nneurotransmitters [NT] norepinephrine [NE]. T wo acetylcholine [ACh] molecules bind the nAChR resulting in \nthe release of NE from the postganglionic fiber . NE will bind to alpha and beta receptors [GPCRs] located on \nperipheral tissues producing a number of ef fects associated with a “fight or flight” response such as increased \nheart rate and contractility, and bronchiole dilation. \n17. Ion Channels   69\n\nBelow – In this image, the nAChR also functions to regulate the release of the NT Ach from the postganglionic \nfiber. ACh goes on to stimulate muscarinic acetylcholine receptors [mAChR; GPCR] located on peripheral tissues \nproducing a number of effects associated with “resting and digesting” such as reduced heart rate and contractility \nand increased intestinal activity. \n70   Principles of Pharmacology - Study Guide\n\nGABA (gamma aminobutyric acid) RECEPTORS \nGABAA Receptors – these receptors are pentamers (i.e. five subunits) that include a GABA binding site, a \nchannel through which ions (chloride) can travel, as well as a variety of modulatory sites. \nGABA is an endogenous agonist synthesized from glutamate \nGABA is the main INHIBITORY transmitter in the brain. It acts on both GABAA receptors \n(GPCRs). \nGABAA receptors are ionotropic receptors that allow for chloride ions to flow into a cell upon agonist (GABA) \nbinding. Chloride ions moving into a cell typically decrease second messenger signaling and produce inhibitory \neffects. \n17. Ion Channels   71",
    "word_count": 339,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0027",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 27,
    "text": "Pharmacological modulators of GABAA receptors include alcohol, barbiturates, benzodiazepines, and \nneurosteroids (steroids that alter neuronal activity). \nExample – Endogenous neurosteroids are synthesized in the brain, adrenals and gonads. These \nneurosteroids are metabolites of steroids such as progesterone and testosterone; some are positive \nmodulators (agonists) and others are negative modulators (antagonists) of GABAA receptors. \nGABAA receptors provide one of the best examples of the application of allosteric modulators. For \nexample, benzodiazepines (e.g., valium) bind to a receptor subunit dif ferent from (i.e., allosteric) that \nwhere GABA binds. This binding results in altering the conformation of the GABA binding site to a \nstate that has higher af finity for GABA (positive allosteric modulation). This results in potentiating the \nCNS suppression induced by GABA and explains the effectiveness of benzodiazepines in the treatment of \nanxiety. \nGABAA Antagonists – Decrease central nervous system activity , sometimes used with anesthesia in an \ninpatient setting. Sedatives, hypnotics, muscle relaxants and anti-convulsants. \nGLUTAMATE RECEPTORS \nGlutamate Receptors – composed of homo- or hetero-tetramers (four subunits). Found in the CNS on presynaptic \nneurons that control the release of neurotransmitters. Some glutamate receptors are couple to G proteins \n(metabotropic) while others are coupled to ion channels (ionotropic). \nTypes of ionotropic Glutamate Receptors \n• AMPA Receptors – Expressed on astrocytes as well on neurons and mediate fast excitatory synaptic \ntransmission. \n• Kainate Receptors – Expressed on presynaptic neurons as well as nerve terminals. No known drug \ntargets currently available for this particular receptor. \n• NMDA Receptors – Expressed on presynaptic and postsynaptic neurons as well as nerve terminals. \nNMDA RECEPTORS \nNMDA [N-methyl-D-aspartate] receptors are glutamate-gated cation channels. Once activated, these receptors are \n72   Principles of Pharmacology - Study Guide",
    "word_count": 278,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0028",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 28,
    "text": "highly permeable to sodium and calcium. As mentioned above, NMDA receptors are expressed on presynaptic \nand postsynaptic neurons as well as nerve terminals. It is at these nerve terminals that glutamate acts on NMDA \nreceptors to alter neurotransmitter release; mainly enhancing it. Furthermore, postsynaptic receptors contribute a \nslow component to the excitatory synaptic potential. \nNMDA receptors have a number of important roles such as in the development of the CNS, rhythmic breathing as \nwell as learning and memory. \nAgonists –  NMDA receptors need both glutamate and glycine to bind to the receptor in order to produce a \nbiological effect. \nActions – increased NA+ and Ca2+ influx \nStructure –  each subunit of the NMDA Receptor has an extracellular N-terminus  with 3 transmembrane \ndomains, an intramembrane reentrant “p-loop” between the 1 st and 3 rd transmemrane domains and an \nintracellular C-terminus. \n• Active Site – site at which agonist (glutamate) binds to stimulate a biological effect or response \n• Glycine Binding Site – a specific modulatory site at which glycine binds to the receptor. \n◦ Glycine is a co-agonist. This means that both glutamate and glycine must simultaneously \nbind and stimulate the receptor in order to produce a physiological effect. \n• Allosteric Site – secondary site at which drugs bind to modulate the binding of the agonist to the \nreceptor primary binding site to either enhance (positive allosterism) or reduce (negative allosterism) \nits effects. \n• Channel-blocking Site – site at which drugs bind to block the movement of Na+ and CA2+ ions into \nthe cell \nNMDA Antagonists – \n• Competitive NMDA Antagonists – block glutamate from binding to the active site \n• Glycine Antagonists – bind to the glycine site to block glycine binding, which is necessary for \nreceptor activation \n• Noncompetitive Antagonists – inhibit glutamate binding indirectly by binding at negative allosteric \nsites \n• Uncompetitive Antagonists – bind inside the channel pore to block the ion channel and prevent ion \nmovement into and out of a cell \n17. Ion Channels   73",
    "word_count": 330,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0029",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 29,
    "text": "Examples – drugs and their indications \n◦ Anesthetics – dizoclipine (MK801 ®), ketamine (Ketaject ®), phencyclidine \n▪ Ketamine is an anesthetic adjunct. It is indicated for surgical or diagnostic \nprocedures; ideally short procedures. Ketamine is a noncompetitive NMDA \nreceptor antagonist, which means this drug acts at an allosteric site (site other than \nligand-binding site) to inhibit receptor function. \n◦ Anti-tussives (cough suppressants) – dextromethorphan/dextrophan is a noncompetitive \nNMDA receptor antagonist. It is the main active ingredient in Robitussin ®, a widely used \ncough suppressant \n◦ Alzheimer’s Disease – memantine (Namenda ®) \n▪ Neurodegenerative disorders such as Alzheimer’s disease are caused by \nabnormally high neuronal excitation (excitotoxicity). Meamantine is a \nnoncompetitive NMDA receptor antagonist that binds to the NMDA receptor \ncation channel to prevent Ca2+ influx. It is therefore indicated for Alzheimer’s \ndisease. \n74   Principles of Pharmacology - Study Guide\n\n21. Agents and Actions of the Autonomic Nervous System: Parasympathetic \nNervous System \nParasympathetic Nervous System \nParasympathetic Nervous System [PNS] – “rest and digest” \nThe PNS can also be thought of as the “D” division – defecation, digestion, and diuresis \nMost organs are innervated with parasympathetic nerve ganglions. \nEXCEPTION – the ciliary smooth muscle of the eye only has parasympathetic innervation \nWhat does your body need when at rest? \n• Decreased cardiac output (compared to sympathetic) – lower oxygen demand when at rest \n• Energy storage (glycogenesis, lipogenesis) – lower energy demand at rest \n• Increased digestion – increased GI motility and secretions \n• Waste elimination – defecation and urination \nParasympathetic Neurons \nPre-ganglionic and post-ganglionic parasympathetic neurons release acetylcholine [ACh]. \n75\n\nAcetylcholine \nAcetylcholine interacts with two types of receptors: \n1. Nicotinic receptors – located on ganglion \n2. Muscarinic receptors – located on effector organ/tissue \n1. M1 – \n2. M2 – \n3. M3 – \n4. M4 – \n5. M5 – \n76   Principles of Pharmacology - Study Guide",
    "word_count": 304,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0030",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 30,
    "text": "Physiological Effects of PNS on Organs/Tissue & Respective Receptors \nOrgan/Tissue Receptor \nSubtype Physiological Effect \nBLADDER – detrusor M3 contracts promotes urination \nBLADDER – sphincter M3 relaxes promotes urination \nEYE – ciliary muscle M3 contracts improves near-sighted vision \nEYE – pupil M3 contracts \nGASTROINTESTINAL – glands M3 promotes secretion enhances digestion \nGASTROINTESTINAL – smooth \nmuscle M3 contracts enhances digestion & motility \nGASTROINTESTINAL – \nsphincter M3 relaxes promotes defecation \nHEART – AV node M2 decreases \nconduction \nHEART – cardiac muscle M2 decreases \ncontractility negative ionotropic effect [atria only] \nHEART – cardiac output M2 decreases decreases blood delivery \nHEART – SV node M2 decreased heart rate negative chronotropic effect – decreases \noxygen delivery \nLUNG – smooth muscle \n(bronchioles & trachea) M3 contracts \nSALIVARY GLAND M3 stimulates watery \nsecretions enhances digestion \nVASCULATURE – smooth muscle no PNS \ninnervation \n21. Agents and Actions of the Autonomic Nervous System: Parasympathetic Nervous System   77\n\n22. Agents and Actions of the Autonomic Nervous System: Sympathetic \nNervous System \nSympathetic Nervous System \nSympathetic Nervous System [SNS] – “fight or flight” \nThe SNS can also be thought of as the “E division” – embarrassment, emergency, exercise, excitement \nWhat do you want your body to do when in fight or flight situation? \n• Alertness \n• Bronchodilation – increased oxygen necessary for brain and muscles to function well \n• Blood shunted to organs and muscles – need organs and muscles to function well \n• Decreased digestion – body does not need to exert energy on digestion in emergency \n• Increased cardiac output – improved blood and oxygen delivery \n• Production of energy (fatty acid release, glycogenolysis) – important for muscles to perform \n• Prevention of waste elimination – body does not need to exert energy on elimination in emergency \n• Sweat – help maintain homeostasis \nEXCEPTIONS – most blood vessels and all sweat glands only have sympathetic innervation \n79",
    "word_count": 306,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "50556800_0031",
    "doc_id": "50556800",
    "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Principles of Pharmacology - Study Guide",
    "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
    "chunk_index": 31,
    "text": "Sympathetic Neurons \nPre-ganglionic sympathetic neurons release acetylcholine [ACh] and post-ganglionic sympathetic neurons \nrelease norepinephrine [NE]. ACh will then go onto stimulate the post-ganglion sympathetic neurons at \nmuscarinic receptors releasing NE and then NE will go onto stimulate adrenoceptors located on a variety of \neffector organs and tissue such as cardiac muscle, smooth muscle, and glands. \nEXCEPTIONS – acetylcholine [ACh] is released by post-ganglionic sympathetic neurons innervating sweat \nglands, which means ACh receptors (as opposed to adrenoceptors) have to be blocked in order to decrease \nsweating as \nNorepinephrine \nNorepinephrine [NE] interacts with two types of receptors: \n1. Alpha-adrenergic receptors [alpha adrenoceptors] \n1. Alpha-1 – blood vessels \n2. Alpha-2 – CNS (presynaptic) \n2. Beta-adrenergic receptors [beta adrenoceptors] \n1. Beta-1 – heart \n2. Beta-2 – lungs \n3. Beta-3 – bladder \n80   Principles of Pharmacology - Study Guide\n\nPhysiological Effects of SNS on Organs/Tissue & Respective Receptors \nOrgan/Tissue Receptor \nSubtype \nPhysiological \nEffect \nBLADDER – smooth muscle Beta-3 relaxes prevents urination \nBLADDER – sphincter Beta-3 contracts prevents urination \nEYE – ciliary muscle no SNS \ninnervation relaxes improves far-sighted vision \nEYE – pupil Beta- dilation/relaxation mydriasis \nGASTROINTESTINAL – \nglands Beta-2 inhibits secretion prevents digestion \nGASTROINTESTINAL – \nsmooth muscle \nAlpha-2 \nBeta-2 \nrelaxes smooth \nmuscle prevents digestion \nGASTROINTESTINAL – \nsphincter Alpha-1 contracts prevents defecation \nHEART – AV node Beta-1 increased \nconduction \nHeart – cardiac muscle Beta-1 increased \ncontractility \npositive ionotropic effect – enhances blood \ndelivery \nHeart – cardiac output Beta-1 increases enhances blood delivery \nHeart – SV node Beta-1 increased heart rate positive chronotropic effect – increases oxygen \ndelivery \nLung – smooth muscle \n(bronchioles & trachea) Beta-2 dilation/relaxation enhances breathing \nSalivary Gland Beta-2 stimulates viscous \nsecretions \nSweat Gland stimulates sweat \nsecretion regulates body temperature \nVasculature – smooth muscle Alpha-1 \nBeta-2 \ncontracts \nrelaxes coronary \narteries \nshunt blood to vital organs (brain, heart, etc), \nenhance cardiac output \n22. Agents and Actions of the Autonomic Nervous System: Sympathetic Nervous System   81",
    "word_count": 310,
    "metadata": {
      "doc_id": "50556800",
      "filename": "Principles-of-Pharmacology-Study-Guide-1580928012.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Principles of Pharmacology - Study Guide",
      "drug_name": "Principles Of Pharmacology Study Guide 1580928012",
      "source": "medical_document",
      "word_count": 9949,
      "char_count": 69000
    }
  },
  {
    "chunk_id": "1500f74c_0000",
    "doc_id": "1500f74c",
    "filename": "projectPlan.md",
    "source_folder": "docx",
    "file_type": ".md",
    "title": "HealthDose Project Plan",
    "drug_name": "Projectplan",
    "chunk_index": 0,
    "text": "HealthDose Project Plan\nPhase 1: Project Setup & Foundation\n\n<!-- • Initialize monorepo (PNPM Workspaces + Turborepo). -->\n<!-- • Set up React (Vite) frontend with Tailwind CSS and shadcn/ui. -->\n<!-- • Configure Firebase (Auth, Firestore, Storage). -->\n<!-- • Implement authentication system (patient, pharmacist, clinician roles). -->\n<!-- • Set up Google Cloud Functions (Node.js + TypeScript strict mode). -->\n\n• Configure CI/CD pipeline.\n• Basic UI scaffolding and layout structure.\nMilestone 1\n• User authentication working, architecture finalized, base UI ready.  \nPhase 2: Core Database & API Implementation\n\n<!-- • Design Firestore schema (Users, Medications, Interactions, Advice). #Martha -->\n\n<!-- • Populate medication database. #Lemmy -->\n\n<!-- • Implement tRPC API layer.  -->\n\n<!-- • Create medication search functionality. #Martha -->\n\n<!-- • Build drug interaction checker.#Lemmy -->\n\n<!-- • Add role-based access control (RBAC). -->\n\nMilestone 2\n• Medication search and interaction checker functional with role restrictions.\nPhase 3: RAG Engine Integration\n\n<!-- • Set up Vertex AI embedding pipeline. -->\n\n<!-- • Chunk and embed authoritative medical documents. -->\n\n• Configure Vector Database.\n• Integrate Gemini API for grounded generation.\n\n<!-- • Build backend RAG orchestration logic. -->\n\n• Display retrieved sources with AI responses.\nMilestone 3\n• End-to-end RAG pipeline operational with grounded responses.\nPhase 4: Safety, Compliance & UX Enhancements\n• Implement medical disclaimers and policies.\n• Add AI response feedback system.\n• Improve UI/UX and accessibility.\n• Add query history tracking.\n• Implement rate limiting and security hardening.\nMilestone 4\n• Application meets safety standards with stable UX and audit tracking.\nPhase 5: Testing & Optimization (Weeks 9–10)\n• Unit testing with Vitest.\n• Component testing with Testing Library.\n• End-to-end testing with Playwright.\n• Performance optimization and caching.\n• Security testing and validation.\n• Final production deployment.\nMilestone 5\n• Production-ready HealthDose platform deployed with full testing coverage.",
    "word_count": 307,
    "metadata": {
      "doc_id": "1500f74c",
      "filename": "projectPlan.md",
      "source_folder": "docx",
      "file_type": ".md",
      "title": "HealthDose Project Plan",
      "drug_name": "Projectplan",
      "source": "medical_document",
      "word_count": 307,
      "char_count": 2111
    }
  },
  {
    "chunk_id": "049ae0cd_0000",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 0,
    "text": "Lecture Notes: Retrieval-Augmented Generation \n(RAG) \n1. What is RAG? \nDefinition \nRetrieval-Augmented Generation (RAG) is the process of enhancing and optimizing the output of a large language model \n(LLM) by providing it with additional context retrieved from external data sources, ensuring more accurate, relevant, and \ngrounded responses. \nWhy Do We Need RAG? \nStandard LLMs are trained on a massive, but static, dataset. This leads to two major limitations: \n1. Stale Knowledge: The model has no information about anything that happened after its training data was collected. \n2. Hallucinations: The model can confidently \"make up\" facts or source citations that are plausible-sounding but \nincorrect. \n3. Lack of Specificity: The model has no access to private, proprietary, or domain-specific information (e.g., your \ncompany's internal policies, a user's personal documents, or real-time financial data). \nRAG solves this by connecting the LLM to a live, external knowledge source and \"grounding\" its answers in facts. \n2. The Core RAG Workflow \nAt its core, a RAG system performs three steps in response to a user's prompt: \n1. Retrieve: The user's prompt (e.g., \"What is our company's policy on remote work?\") is transformed into a query. \nThe system searches an external data source (the \"corpus\") for relevant information. \n2. Augment: The relevant information (e.g., the text from the \"Remote Work Policy.pdf\" document) is retrieved and \ncombined with the original prompt. This new, \"augmented\" prompt now contains both the user's question and the \nfactual context. \n3. Generate: This augmented prompt is fed to the LLM. The LLM is instructed to generate an answer based only on \nthe provided context. This forces the model to stick to the facts, effectively using it as a reasoning and \nsummarization engine rather than a knowledge recall engine. \n3. Methods of Retrieving External Information \nThe \"retrieval\" step is what makes RAG powerful. This external information can come from several sources. \nA. The RAG Corpus (The Knowledge Base) \nThis is the most common method. The corpus is the private, curated set of documents that you want the LLM to have \naccess to. \n● What is a Corpus? \nA corpus is a large, organized collection of text and data used as the \"knowledge library\" for the RAG system. It is \nthe \"ground truth\" that the LLM will consult. \n● Role in RAG: \nThe corpus serves as the long-term memory for the LLM.",
    "word_count": 386,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0001",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 1,
    "text": "\n● Role in RAG: \nThe corpus serves as the long-term memory for the LLM. Instead of retraining the entire model (which is slow and \nexpensive), you simply add new information to the corpus (e.g., add a new policy PDF). \n● Composition (How it's built):",
    "word_count": 44,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0002",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 2,
    "text": "A RAG corpus is not just a folder of files. It's a highly optimized, searchable index, typically built using a Vector \nDatabase. \n1. Ingestion: You load your raw data (e.g., PDFs, .txt files, Markdown, database entries, scraped web pages). \n2. Chunking: The documents are broken down into smaller, manageable \"chunks\" (e.g., paragraphs or sentences). \nThis is critical because you can't fit an entire 100-page document into the LLM's context window. \n3. Embedding: Each chunk is passed through an embedding model, which converts the text into a numerical \nrepresentation (a \"vector\"). This vector captures the semantic meaning of the text. \n4. Indexing: These vectors are stored in a Vector Database. This database is optimized to find vectors (and their \ncorresponding text chunks) that are \"semantically similar\" to the user's query vector. \nB. Web Scraping \nThis is a method for building a corpus by pulling data directly from the public web. \n● How it Works: \nWeb scraping is an automated process that fetches web pages and extracts specific data from them. A \"scraper\" bot \nvisits a URL, downloads the HTML, and then parses that HTML to pull out the desired text (e.g., blog post content, \nproduct descriptions, news articles). \n● Using Python for RAG: \nPython is the most common language for this. The workflow for building a RAG corpus from scraped data often \nlooks like this: \n1. Fetch: Use libraries like requests to download the web page. \n2. Parse: Use libraries like BeautifulSoup or Scrapy to navigate the HTML and extract the main text content, \nstripping away ads, navigation bars, and footers. \n3. Clean: Convert the extracted content into clean text or Markdown. \n4. Ingest: Feed this clean text into your RAG corpus pipeline (chunking, embedding, indexing) as described in \nsection 3A. \n5. Frameworks like LlamaIndex and LangChain have built-in \"Web Readers\" (ScrapflyReader, RAGScraper) that \ncan simplify this process into a few lines of code. \nC. APIs (Application Programming Interfaces) \nThis method is used to retrieve highly dynamic, real-time, or structured data. \n● Role in RAG: \nInstead of just searching a static database, the RAG system can be given \"tools,\" and one of those tools can be an \nAPI. This is essential when an answer depends on live data.",
    "word_count": 367,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0003",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 3,
    "text": "This is essential when an answer depends on live data. \n● How APIs Contribute: \n○ Free & Open Data Sources: Imagine a user asks, \"What's the weather in San Francisco and what's the top \nnews story about AI?\" A RAG system can be configured to: \n1. Parse the prompt into two sub-questions. \n2. Call a free Weather API for the San Francisco data. \n3. Call a free News API (like GNews) for the AI story. \n4. Combine both API responses (which are usually in a structured JSON format) into the \"context.\" \n5. Feed this context to the LLM to generate a single, natural-language answer. \n○ Internal/Proprietary APIs: A chatbot for an e-commerce store could use an internal API to check a user's \n\"order status\" or \"product availability\" from the company's live database. \n4. Real-World Use Cases \nRAG is not theoretical; it's already powering many applications you use. \n● Customer Support Chatbots (e.g., Shopify, DoorDash): When you ask a chatbot a question, it retrieves",
    "word_count": 163,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0004",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 4,
    "text": "information from the company's actual help center articles, product manuals, and internal FAQs to give you a \ncorrect, specific answer instead of a generic guess. \n● Healthcare (e.g., IBM Watson Health): A RAG system can assist doctors by taking a patient's symptoms (the \nprompt) and retrieving the most relevant, up-to-date research papers, clinical trial data, and treatment guidelines (the \ncorpus) to support a diagnosis. \n● Finance (e.g., Bloomberg): An analyst can ask, \"Summarize the key risks from Apple's latest quarterly earnings \nreport.\" The RAG system retrieves the actual 10-Q report (which was just released) and provides it to the LLM for \nsummarization, ensuring the answer is based on real-time, factual data. \n● Internal Knowledge Management (e.g., Assembly, Bell): Employees at a large company can use an internal \"Ask \nHR\" bot. This bot uses RAG to search all internal documents (employee handbooks, policy PDFs, intranet sites) to \nanswer questions like \"How do I submit an expense report?\" \n5. Building a RAG System with Vertex AI (Google Cloud) \nGoogle Cloud provides a powerful, managed platform to build and scale RAG systems using Vertex AI. \nKey Components \nVertex AI simplifies the RAG process by integrating all the necessary components: \n1. Vertex AI RAG Engine: This is the overarching service that manages the entire workflow, from data ingestion to \ngeneration. \n2. Data Ingestion & Connectors: You don't have to build complex data pipelines. You can point Vertex AI to your \ndata sources, including: \n○ Google Cloud Storage (for PDFs, .txt, etc.) \n○ Google Drive \n○ Third-party sources like Jira, Slack, or Salesforce. \n3. RagCorpus: This is the Vertex AI-managed service that automatically handles the data processing. When you add a \ndocument, it automatically performs chunking and parsing. \n4. Vertex AI Vector Search: This is the underlying vector database that creates the embeddings and performs the \nultra-fast semantic search. \n5. Generative Models (Gemini): The retrieved context is automatically fed to a Google Gemini model for the final, \ngrounded answer generation. \nThe Vertex AI Workflow (Simplified) \nWhile the console provides a \"clicks-not-code\" interface, you can also build this system programmatically using the \nPython SDK. \n1. Initialize Vertex AI: Connect to the Vertex AI platform. \nimport vertexai \nvertexai.init(project=\"your-project-id\", location=\"us-central1\") \n \n2. Create a Corpus: Create a RagCorpus to hold your data. \nfrom vertexai.preview import rag \nrag_corpus = rag.create_corpus(display_name=\"my-company-corpus\") \n \n3. Import Files: Upload your files (e.g., from a Google Cloud Storage bucket) into the corpus.",
    "word_count": 396,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0005",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 5,
    "text": "Import Files: Upload your files (e.g., from a Google Cloud Storage bucket) into the corpus. Vertex AI handles the \nchunking and embedding automatically. \nrag.import_files( \n    rag_corpus.name, \n    [\"gs://my-bucket/my-policy-doc.pdf\"],",
    "word_count": 26,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  },
  {
    "chunk_id": "049ae0cd_0006",
    "doc_id": "049ae0cd",
    "filename": "RAG.pdf",
    "source_folder": "docx",
    "file_type": ".pdf",
    "title": "Lecture Notes: Retrieval-Augmented Generation ",
    "drug_name": "Rag",
    "chunk_index": 6,
    "text": "chunk_size=1024 \n) \n \n4. Set up the RAG Tool: Create a RAG retrieval \"tool\" that the LLM can use. \nfrom vertexai.preview.generative_models import GenerativeModel, Tool \n \nrag_retrieval_tool = Tool.from_retrieval( \n    rag.Retrieval(source=rag.VertexRagStore(rag_corpora=[rag_corpus.name])) \n) \n \n5. Generate a Grounded Answer: Initialize a Gemini model and give it the RAG tool. Now, when you ask a question, \nthe model will automatically use the tool to find context from your corpus before answering. \nmodel = GenerativeModel( \n    \"gemini-1.5-flash-001\", \n    tools=[rag_retrieval_tool] \n) \n \nprompt = \"What is the company policy on remote work?\" \nresponse = model.generate_content(prompt) \n \nprint(response.text)  \n# This output will be grounded in the \"my-policy-doc.pdf\"",
    "word_count": 93,
    "metadata": {
      "doc_id": "049ae0cd",
      "filename": "RAG.pdf",
      "source_folder": "docx",
      "file_type": ".pdf",
      "title": "Lecture Notes: Retrieval-Augmented Generation ",
      "drug_name": "Rag",
      "source": "medical_document",
      "word_count": 1436,
      "char_count": 9425
    }
  }
]
